

Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION



Proteomics Identifies Thymidine Phosphorylase As a Key Regulator of the Angiogenic Potential of Colony-Forming Units and Endothelial Progenitor Cell Cultures

Giordano Pula, Ursula Mayr, Colin Evans, Marianna Prokopi, Dina S. Vara, Xiaoke Yin, Zoe Astroulakis, Qingzhong Xiao, Jonathan Hill, Qingbo Xu and Manuel Mayr
Circ. Res. 2009;104;32-40; originally published online Nov 20, 2008;

DOI: 10.1161/CIRCRESAHA.108.182261

Circulation Research is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75214

Copyright © 2009 American Heart Association. All rights reserved. Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circres.ahajournals.org/cgi/content/full/104/1/32>

Data Supplement (unedited) at:

<http://circres.ahajournals.org/cgi/content/full/CIRCRESAHA.108.182261/DC1>

Subscriptions: Information about subscribing to Circulation Research is online at
<http://circres.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail:
jurnalpermissions@lww.com

Reprints: Information about reprints can be found online at
<http://www.lww.com/reprints>

Proteomics Identifies Thymidine Phosphorylase As a Key Regulator of the Angiogenic Potential of Colony-Forming Units and Endothelial Progenitor Cell Cultures

Giordano Pula,* Ursula Mayr,* Colin Evans, Marianna Prokopi, Dina S. Vara, Xiaoke Yin, Zoe Astroulakis, Qingzhong Xiao, Jonathan Hill, Qingbo Xu, Manuel Mayr

Abstract—Endothelial progenitor cell (EPC) cultures and colony-forming units (CFUs) have been extensively studied for their therapeutic and diagnostic potential. Recent data suggest a role for EPCs in the release of proangiogenic factors. To identify factors secreted by EPCs, conditioned medium from EPC cultures and CFUs was analyzed using a matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometer combined with offline peptide separation by nanoflow liquid chromatography. Results were verified by RT-PCR and multiplex cytokine assays and complemented by a cellular proteomic analysis of cultured EPCs and CFUs using difference in-gel electrophoresis. This extensive proteomic analysis revealed the presence of the proangiogenic factor thymidine phosphorylase (TP). Functional experiments demonstrated that inhibition of TP by 5-bromo-6-amino-uracil or gene silencing resulted in a significant increase in basal and oxidative stress-induced apoptosis, whereas supplementation with 2-deoxy-D-ribose-1-phosphate (dRP), the enzymatic product of TP, abrogated this effect. Moreover, dRP produced in EPC cultures stimulated endothelial cell migration in a paracrine manner, as demonstrated by gene-silencing experiments in transmigration and wound repair assays. RGD peptides and inhibitory antibodies to integrin $\alpha v\beta 3$ attenuated the effect of conditioned medium from EPC cultures on endothelial migration. Finally, the effect of TP on angiogenesis was investigated by implantation of Matrigel plugs in mice. In these *in vivo* experiments, dRP strongly promoted neovascularization. Our data support the concept that EPCs exert their proangiogenic activity in a paracrine manner and demonstrate a key role of TP activity in their survival and proangiogenic potential. (*Circ Res.* 2009;104:32-40.)

Key Words: angiogenesis ■ endothelium ■ progenitor cells ■ proteomics ■ vascular biology

Human endothelial progenitor cells (EPCs) are attracting considerable attention in cardiovascular research,^{1,2} but multiple culture methods from peripheral blood mononuclear cells (PB-MNCs) have been described³⁻⁷ and studied for their clinical relevance.^{6,8-12} EPCs are commonly identified by cell surface antigen expression of CD133, CD34, and the vascular endothelial growth factor receptor-2 (VEGFR-2) (KDR).¹³ CD34 and VEGFR-2, however, are also expressed in hematopoietic stem cells¹⁴; thus, EPCs cannot yet be unambiguously defined. One alternative approach to flow cytometry has used the colony-forming unit (CFU) assay as a surrogate marker for EPCs.¹⁵ This method has been fundamental to many of the clinical studies published on EPCs to date, which predominantly reported low numbers of CFUs to be correlated to cardiovascular disease risk. Nonetheless, recent publications have cast doubts about the origin of CFUs by demonstrating that they may be clonally derived from the hematopoietic system, possess myeloid progenitor cell activity, and differentiate into phagocytic macrophages.¹⁶ Thus, there is an urgent need to provide a

mechanistic underpinning for the correlation between CFUs and cardiovascular disease^{6,15} and for the beneficial effects of endothelial progenitor transplantation *in vivo*.^{11,16}

Although it is commonly accepted that circulating progenitors may play an important role in revascularization and angiogenesis, the mechanisms by which they act remain unclear. Currently, there is little evidence of permanent engraftment of EPCs into blood vessels.^{8,17,18} It has therefore been suggested that EPCs stimulate endothelial repair by exerting a local paracrine effect.^{3,4,7,19} EPC-secreted factors, however, have not yet been fully characterized at the protein level. Although transcriptome analysis can generate a cell-specific signature,¹⁹ it cannot detail true cell phenotypes because of translational regulation and protein degradation. The addition of a proteome analysis offers an opportunity to characterize progenitor cells more comprehensively, leading to a better understanding of their role in vascular biology.²⁰⁻²²

In the present study, we use state-of-the-art proteomic techniques to analyze the secretome of EPC cultures and

Original received June 26, 2008; revision received November 7, 2008; accepted November 12, 2008.

From the Cardiovascular Division, King's College London School of Medicine, King's College London, United Kingdom.

*Both authors contributed equally to this work.

Correspondence to Manuel Mayr, Cardiovascular Division, BHF Centre, King's College, London, 125 Coldharbour Lane, London SE5 9NU, UK.
E-mail manuel.mayr@kcl.ac.uk

© 2009 American Heart Association, Inc.

Circulation Research is available at <http://circres.ahajournals.org>

DOI: 10.1161/CIRCRESAHA.108.182261




Figure 1. EPC cultures and CFUs. A and B, Morphology of CFUs (A) and endocytosis of acLDL (red fluorescence) (B). C, EPC cultures endocytose acLDL (red fluorescence) and bind to the lectin *Ulex europaeus* agglutinin (green fluorescence). Arrows indicate double positive cells. Blue labeling represents nuclear staining by DAPI. D, Assessment of mRNA levels for EPC cultures and CFUs by RT-PCR, including von Willebrand factor (vWF), CD31, CD14, CD133, and KDR (from top to bottom). The results shown are representative of at least 3 independent experiments.

CFUs by performing a nanoflow liquid chromatography matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF) analysis on culture media conditioned by EPCs. This approach was complemented by difference in-gel electrophoresis (DIGE) and cytokine antibody multiplex array analysis. Among the angiogenic factors revealed by proteomics, was thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor (PD-ECGF). This growth factor and deoxyribose phosphate (dRP), the product of its enzymatic activity, were shown to be essential for EPC survival and paracrine effects on endothelial cell migration and angiogenesis.

Materials and Methods

An expanded Material and Methods section is available in the online data supplement at <http://circres.ahajournals.org>. Key techniques involved adaptations of previously published protocols, including those for difference in-gel electrophoresis (DIGE)²³ and tandem mass spectrometry,²⁴ which are also available on our web site at <http://www.vascular-proteomics.com>.

CFUs and EPC Culture

Human blood was drawn from healthy volunteers. Informed consent was obtained and the study was approved by the ethics review board of King's College London. The CFU assay was performed as described previously.¹⁵ In brief, PB-MNCs were resuspended in growth medium 199 with 20% FBS on human

fibronectin-coated 6-well plates. After 48 hours, nonadherent cells were replated on human fibronectin-coated plates. For isolation of EPCs, PB-MNCs were separated onto Lymphoprep solution. EPC cultures were obtained using endothelial basal medium (EBM, Clonetics cc-3121, Lonza) containing human VEGF (10 ng/mL), as previously described.⁶ For secretome analysis, cells were incubated with serum-free culture medium for 24 hours before collection of the conditioned medium on day 7.

Matrix-Assisted Laser Desorption/Ionization Tandem Time-of-Flight Mass Spectrometry

For CFUs and EPCs, conditioned medium was concentrated using a Microcon Ultracel YM-10. A total volume of 1.5 mL conditioned medium was concentrated approximately 50-fold. The samples were digested overnight with trypsin, and the tryptic peptides were separated by nano liquid chromatography on a C18 column (PepMap) with a mobile phase formed from (1) high-performance liquid chromatography (HPLC)-grade water containing 5% acetonitrile and 0.1% TFA and (2) HPLC-grade acetonitrile containing 20% H₂O and 0.1% TFA. The HPLC was interfaced to a spotting robot (Dionex Probot). Several hundred fractions per sample were collected on MALDI target plates and mixed with matrix.

Peptides were subsequently analyzed using a TOF/TOF analyzer (4800 ToF/ToF, Applied Biosystems). Results were filtered using ProteinPilot software (Applied Biosystems). Assignments were accepted when the total score was ≥ 2.0 (corresponding to a 99% confidence of the protein identification). Results were further filtered for a minimum of ≥ 2 peptides per protein identification.

Table. Secretome of EPC Cultures and CFUs

Protein Name	Swiss Protein Accession No.	CFU		EPC	
		Total Ion Score	No. of Peptides	Total Ion Score	No. of Peptides
Angiogenic factors					
MMP-9	P14780	1262	24	ND	ND
IL-8	P10145	242	5	ND	ND
Pre-B cell-enhancing factor (PBEF)	P43490	233	6	216	6
Macrophage migration inhibitory factor (MIF)	P14174	168	3	89	2
Cathepsins					
Cathepsin B	P07858	598	11	567	11
Cathepsin S	P25774	374	6	325	6
Cathepsin Z	Q9UBR2	358	6	114	4
Cathepsin C	P53634	286	6	166	4
Cathepsin D	P07339	214	6	276	5
Cathepsin L	P07711	83	2	55	2
Protease inhibitors					
Inter- α -trypsin inhibitor complex component II	P19823	308	5	221	4
Metalloproteinase inhibitor 1 precursor (TIMP-1)	P01033	154	2	ND	ND
Cystatin-C	P01034	112	2	321	6
Serpin B9	P50453	95	3	101	3
α -2-Macroglobulin	P01023	92	3	88	3
Cystatin-B	P04080	82	1	75	2
S100 proteins					
Protein S100-A11	P31949	167	3	151	3
Protein S100-A8	P05109	71	2	65	2
Protein S100-A4	P26447	60	1	ND	ND
Miscellaneous					
Plasminogen activator inhibitor 2	P05120	739	11	466	10
Secretory granule proteoglycan core protein	P10124	239	5	26	1
Apolipoprotein E	P02649	202	6	985	22

Identifications were obtained by proteomic analysis of the conditioned medium of CFUs and EPC cultures by MALDI-TOF/TOF mass spectrometry. The average number of tryptic peptides and total ion scores are reported. The table highlights proteins that were chosen for their potential importance in the physiological activity of EPCs. The complete list of identified proteins is available in supplemental Table I. All peptide identifications are provided in supplemental Table II. ND indicates not detected.

Results

The Secretome of CFUs and EPC Cultures

CFUs consisted of a central cluster of rounded cells surrounded by multiple thin cells (Figure 1A), which showed endocytosis of acetylated LDL (red fluorescence) (Figure 1B). EPC cultures were characterized by single spindle-shaped cells positive for lectin staining and acetylated LDL uptake (Figure 1C). Both cell types express markers consistent with existing definitions of an EPC phenotype, such as von Willebrand factor, CD31 (platelet endothelial cell adhesion molecule-1), CD133, and VEGFR-2 (KDR) (Figure 1D). Analyses of the secretome of CFUs from 3 independent preparations resulted in the identification of 272 nonredundant proteins present in at least 2 samples (Table I in the online data supplement), of which 124 were also found in cultured EPCs. All identified peptides are provided in supplemental Table II. Secreted factors considered of potential relevance for the function of EPCs in the vascular system are

highlighted in the Table. Although some of the factors, such as cathepsins, have previously been reported to contribute to the angiogenic potential of EPCs,²⁵ others, such as the protein S100 family have not been implicated so far. A semiquantitative comparison based on the peptide count indicated that different members of the cathepsin family were present at similar concentrations under both culture conditions, whereas matrix metalloproteinase (MMP)-9 and interleukin (IL)-8 were secreted at higher levels by CFUs than cultured EPCs.

To further characterize cultured EPCs and CFUs, cellular protein extracts were labeled with Cy-dyes and separated by DIGE (Figure 2A and 2B). Overall, the proteome of CFUs was similar to EPC cultures and showed surprisingly little interindividual variability (supplemental Figure I). The analysis of 53 differentially expressed protein spots ($P<0.05$, 1-way ANOVA) by ion trap tandem mass spectrometry resulted in the identification of 37 nonredundant proteins (supplemental Table III). Notably, the proangiogenic factor




Figure 2. Difference in-gel electrophoresis. A, The proteins from CFUs are stained in green, whereas the proteins from EPC cultures are stained in red. B, Results are reproduced with different biological replicates using reverse-labeling (red for CFUs and green for EPCs). The protein corresponding to TP is highlighted with a box. Differentially expressed proteins ($P < 0.05$; 1-way ANOVA, SameSpot software, Nonlinear Dynamics) are numbered and listed in supplemental Table III.

TP,²⁶ although present in both EPC cultures and CFUs, was expressed at higher levels in cellular extracts of CFUs.

Validation of the Proteomic Findings

Cytokine concentrations in the conditioned media of CFUs ($n=15$) and EPC cultures ($n=13$) were quantified using a multiplex assay (supplemental Table IV). IL-8, as indicated by the proteomic analysis (Table), was confirmed to be the most abundant cytokine in the secretome of CFUs (76.1 ± 6.4 ng/mL) and cultured EPCs (1.4 ± 0.4 ng/mL). Its expression, along with other angiogenic factors, was verified by RT-PCR (Figure 3A). TP was further investigated by immunoblotting. This proangiogenic factor was predominantly present in CFUs, but also in EPC cultures and PB-MNCs, but not in human umbilical vein endothelial cells (HUVECs) (Figure 3B and 3C). Immunofluorescence experiments revealed the presence of TP in the cytosol and nucleus (Figure 3D), possibly because of its role in nucleotide metabolism.²⁶

TP Is a Survival Factor

To evaluate the functional role of TP in EPCs, cells were treated with 5-bromo-6-amino-uracil (5Br-6Am-U), an inhibitor of TP. Inhibition of TP resulted in a significant increase in baseline apoptosis as quantified by histone protein release (Figure 4A) and flow cytometric analysis of annexin V/propidium iodide staining (supplemental Figure II, A). Supplementation with deoxyribose phosphate (dRP), the product of TP, abrogated this effect. dRP also protected EPCs against apoptosis in response to diethyl maleate, a sulfhydryl-reactive agent, which induces oxidative stress by depleting intracellular glutathione levels. In contrast, inhibition of TP by 5Br-6Am-U aggravated the proapoptotic effect of diethyl maleate. These findings were replicated by ablation of TP expression using small interfering (si)RNA-mediated gene silencing (Figure 4B and supplemental Figure II, B). Again, dRP reversed the effect of gene silencing of TP by siRNA on constitutive and stress-induced apoptosis. Knockdown efficiency was assessed by immunoblotting (supplemental Figure III, A). The proapoptotic effect of TP gene silencing was independent of VEGF (supplemental Figure III, B). On the other hand, inhibition of TP by 5Br-6Am-U or treatment with dRP did not alter apoptosis in HUVECs (supplemental Figure III, C), whereas prolonged inhibition (7 days, supplemental Figure III, D) or genetic ablation of TP (supplemental Figure III, E) significantly reduced EPC numbers in culture. Interestingly, dRP increased the expression of Bcl-2 in response to oxidative stress, which mitigates the proapoptotic effects of Bax but had no effect on redox-sensitive p38 mitogen-activated protein kinase (MAPK) signaling (Figure 5 and supplemental Figure IV).

Deoxyribose Phosphate Stimulates Focal Adhesion Formation and Enhances Integrin $\beta 3$ Expression

Besides its antiapoptotic effect, TP has been shown to stimulate endothelial cell motility,^{27,28} providing a likely explanation for its angiogenic activity. Therefore, we analyzed the formation of focal adhesions in HUVECs in response to the conditioned medium from EPCs. The conditioned medium of EPCs significantly increased the




Figure 3. Expression of TP among other angiogenic factors. A, mRNA expression of TP, IL-8, MMP-9, MCP-1, pre-B cell-enhancing factor 4 (PB-EF), and apolipoprotein E (ApoE) in EPC cultures and CFUs as assessed by RT-PCR. GAPDH was used as loading control. B, Protein expression of TP in EPC cultures and CFUs as assessed by immunoblotting. C, Levels of TP in EPCs, PB-MNCs, and HUVECs. Actin was used as loading control. The RT-PCR and immunoblot results are representative of 3 independent experiments. D, The cellular distribution of TP was visualized by immunofluorescence. Nuclei were counterstained with DAPI. To confirm the specificity of the antibody, immunostaining was repeated in the presence of 10 ng/mL recombinant human TP (rhTP).

number and dimension of focal adhesions (Figure 6A and supplemental Figure V, A). Untreated HUVECs and HUVECs treated with the conditioned medium from TP knockdown EPCs (TP KD) served as controls. Supplementing the conditioned medium from TP knockdown EPCs with dRP restored its ability to enhance focal adhesion formation in HUVECs, confirming that TP-derived dRP is the active compound in the conditioned medium. Notably, treatment with dRP increased endothelial expression of integrin $\beta 3$, but not integrin $\beta 1$ or αv , whereas other focal adhesion-associated proteins, such as vinculin and vasodilator stimulated phosphoprotein, were not affected (Figure 6B and supplemental Figure V, B).

TP Stimulates Endothelial Cell Migration

Next, we assessed the effect of TP on endothelial cell motility in a modified Boyden chamber. The presence of EPCs in the bottom compartment stimulated the migration of HUVECs migrating from the top insert (Figure 7A), confirming the importance of paracrine factors in EPC–endothelial cell interactions. The genetic ablation of TP in

EPCs by siRNA transfection significantly reduced the number of transmigrating HUVECs. The addition of 50 μ mol/L dRP in the bottom chamber, but not in the insert, reversed this effect, suggesting that the product of TP in the conditioned medium of EPCs acts as a chemoattractant stimulus on HUVECs. Moreover, the presence of RGD peptides or an anti-integrin $\alpha v \beta 3$ inhibitory antibody attenuated the chemotactic activity, suggesting that dRP acts via integrins, in particular $\alpha v \beta 3$ (Figure 7B).

TP Enhances Wound Healing In Vitro and Angiogenesis In Vivo

The contribution of TP to the stimulatory activity of conditioned medium on endothelial motility was further investigated in a wound-healing assay. The process of endothelial wound-healing was attenuated in the presence of conditioned medium from TP-ablated EPC cultures compared to cultures treated with scrambled siRNA, suggesting that the activity of TP in EPCs promotes HUVEC motility in a paracrine manner (Figure 7C and supplemental Figure VI, A). The presence of an anti-integrin $\alpha v \beta 3$




Figure 4. TP protects against apoptosis. A, Apoptosis in EPC cultures following treatment with 5Br-6Am-U (100 $\mu\text{mol/L}$) was assessed by ELISA. Where indicated, apoptosis was induced by diethyl maleate (5 mmol/L, 12 hours). B, Apoptosis following knockdown of TP in EPC cultures by siRNA (TP KD) in the presence or absence of dRP (50 $\mu\text{mol/L}$) as quantified by ELISA. Controls were transfected with scrambled siRNA (CTRL KD). Flow cytometric analyses of annexin V and propidium iodide staining are shown in supplemental Figure II.

inhibitory antibody (supplemental Figure VI, B) or RGD peptides (supplemental Figure VI, C) abolished the difference between conditioned medium from TP-ablated and control EPCs. Finally, the angiogenic effect of TP and its product dRP was investigated by implanting Matrigel plugs into healthy mice and assessing the vascularization of the plugs over the implantation period. Whereas both control plugs and plugs treated with 5Br-6Am-U showed cell invasion, dRP facilitated vessel formation (Figure 7D and supplemental Figure VII).

Discussion

This study is the first to use state-of-the art proteomic techniques to better characterize CFUs and EPC cultures. Although it has become apparent that the markers currently used for defining EPCs are insufficient,¹⁴ EPCs have never been studied comprehensively at the protein level. By analyzing their secretome, we provide additional support to the concept that exogenously administered EPCs may augment neovascularization and endothelial repair via paracrine mechanisms.^{4,19}

Paracrine Effects of EPCs

Despite the controversy regarding the origin of EPCs, a contribution of circulating progenitors to blood vessel growth has been shown in different animal models^{3,11,16,29–31} and administration of bone marrow cells appears to be beneficial in some,^{32–34} but not all clinical trials conducted so far.³⁵




Figure 5. dRP enhances Bcl-2 expression under oxidative stress. EPC cultures with and without supplementation of dRP (50 $\mu\text{mol/L}$) were subjected to treatment with diethyl maleate (5 mmol/L) and probed for Bcl-2, Bax, p38 MAPK, and phospho-p38 MAPK by immunoblotting. Actin served as loading control. Protein expression was quantified by densitometry (means \pm SEM, n=3; supplemental Figure IV).

Although it is commonly accepted that EPCs have potential for use in angiogenic therapies, the mechanisms by which they improve revascularization remain unsettled.³⁶ Their baseline incorporation rate is low and there is currently limited evidence of long-term engraftment of EPCs into newly formed blood vessels.^{37,38} Additionally, it has been shown that EPCs can cause neovascularization without physically building endothelial structures,³⁹ supporting the concept of a paracrine effect on the vasculature. Therefore, further investigations are required to characterize paracrine factors that could mediate their proangiogenic effects. Our proteomic analysis revealed that CFUs secrete high levels of MMP-9, IL-8, and cathepsins, previously described as characteristics of EPCs.^{7,25} In addition, we found novel factors, in particular TP, which was further characterized for its functional relevance in the biology of EPCs.

TP Improves EPC Survival

TP is an angiogenic enzyme catalyzing the reversible phosphorolysis of 2'-deoxythymidine to dRP and thymine. The antiapoptotic role of TP has been investigated in cancer cells.^{40,41} The proposed mechanism of action is not clear, but it has been suggested that the protective effect of TP is mediated by 2-deoxy-D-ribose, a product of dephosphorylation of the primary TP product dRP.⁴⁰ In this study, we report the presence of TP in CFUs and EPC cultures. Whereas apoptosis of mature endothelial cells was not influenced by dRP, the activity of TP correlated with levels of basal and oxidative stress-induced apoptosis in EPC cultures. Notably, dRP enhances the expression of the antiapoptotic protein Bcl-2, which heterodimerizes with Bax and thereby antagonizes its proapoptotic effect.^{42,43} Thus, it is likely that dRP conveys resistance to oxidative stress and apoptosis by increasing the Bcl-2/Bax ratio.




Figure 6. TP expression and release of dRP by EPCs stimulates focal adhesion formation and integrin $\beta 3$ expression in HUVECs. A, HUVECs were cultured for 24 hours in the presence of conditioned medium from EPC cultures (ratio 1:2) treated with either siRNA directed toward TP (TP KD) (top right) or scrambled controls (CTRL KD) (top left). dRP (50 μ mol/L) was added where indicated (bottom left). HUVECs cultured in growth medium supplemented with nonconditioned EPC medium served as a reference (bottom right). Focal adhesions were visualized by the colocalization (yellow) of anti-integrin $\beta 3$ (FITC, green) and anti-vinculin (TRITC, red) staining. Two areas are magnified in the adjacent boxes (area 1 and 2), and the intensity of staining was quantified by densitometry (supplemental Figure V, A). The images are representative of 3 independent experiments. B, HUVECs were treated with 50 μ mol/L dRP for 24 hours and protein extracts were probed for expression of integrin $\beta 3$, integrin $\beta 1$, integrin αv , vasodilator stimulated phosphoprotein (VASP), and vinculin. Untreated HUVECs served as controls. The densitometric data were normalized to actin (means \pm SEM, n=3; supplemental Figure V, B).

TP Mediates Paracrine Effects on Endothelial Cells

It has long been suspected that EPCs may release paracrine factors to enhance endothelial repair. Our proteomic experiments revealed TP to be involved: First, the presence of EPC cultures in the bottom of a Boyden chamber markedly stimulated migration of HUVECs across the membrane, demonstrating the former cell type is able to induce endothelial migration in a paracrine manner. Second, downregulation of TP by siRNA attenuated this paracrine effect, suggesting that TP expression in EPC cultures plays a key role in the stimulation of endothelial migration. This is in agreement with previous observations that supplementation of dRP or TP-expressing tumor cells induce HUVEC chemotaxis.²⁷ Third, the addition of dRP to the bottom of a Boyden chamber with EPCs, but not to the top insert with HUVECs, restored the effect on HUVEC migration. Thus, the product of TP, not the enzyme itself, is the chemotactic agent that stimulates HUVEC migration in the conditioned medium of EPCs. Fourth, the expression of TP was also responsible for the enhanced regeneration of a wounded endothelial monolayer in the presence of conditioned medium from EPCs. The upregulation of integrin $\beta 3$ and enhanced focal adhesion formation provide a potential mechanism of how dRP regulates endothelial cell motility.²⁸ In summary, although the proangiogenic potential of TP and dRP has previously been established,^{28,44} our observations demonstrate for the first time that dRP is among the major proangiogenic factors in the conditioned medium of CFUs and EPC cultures. Therefore, the release of dRP at sites of vascular


injury is likely to promote endothelial cell migration from intact neighboring regions, which could represent an important mechanism by which EPCs enhance vascular repair. In agreement with this model, the effect of dRP on angiogenesis and neovascularization was further confirmed by our *in vivo* experiments.

Clinical Implications

The number of CFUs is widely used as a measure of EPC function⁴⁵ and has been shown to correlate negatively with cardiovascular disease risk factors and positively with vascular function. However, recent evidence casts doubts over the identity of the cells that form the colonies, suggesting they may be derived from hematopoietic rather than endothelial cell precursors.⁴⁵ This raises an important question: if CFUs do not directly reflect numbers of circulating EPCs, why do they correlate with cardiovascular disease risk? Our data demonstrate that CFUs express and secrete proangiogenic factors. Thus, although CFUs may not represent endothelial precursors per se, the cellular aggregates forming the colonies could still be involved in vascular homeostasis, ie, CFUs may represent a surrogate marker for the proangiogenic potential among PB-MNCs. This alternative explanation would help to reconcile literature documenting the beneficial effects of circulating EPCs on cardiovascular function with the recent finding that CFUs may be hematopoietic rather than endothelial precursors.

Limitations of the Study

There is currently no consensus on which culture conditions are most successful in isolating the effective EPC popula-



tions. In the present study, we used 2 of the most commonly used methods, but we cannot rule out that culture conditions used by other investigators may alter protein expression and secretion. In this respect, the present proteomic dataset could serve as a reference and contribute to standardizing EPC cultures. Although mass spectrometry has proven a valuable tool to array secreted proteins, it is important to note that minor components can remain undetected, especially in the presence of intracellular proteins released during cell death in culture.

Conclusion

In summary, the proteomic analysis reported in this study identified TP to be among the main proangiogenic factors in EPC cultures and CFUs, which might facilitate the development of new therapeutic strategies.

Acknowledgments

We thank Dr Dietrich Merkel (Applied Biosystems) for technical assistance.

Figure 7. TP stimulates endothelial cell migration. The motility of HUVECs in response to paracrine factors released by EPCs was investigated in a modified Boyden chamber. The bottom chamber was either empty or seeded with EPCs treated with TP siRNA (TP KD) or scrambled control siRNA (CTRL KD). A and B, dRP (50 µmol/L), anti- α v β 3 inhibitory antibody (Ab) (10 µg/mL), or RGD peptide (10 µmol/L) was added where indicated. The number of transmigrated cells was counted in 3 independent experiments and presented as means \pm SEM. Statistical significance was tested by 1-way ANOVA with Bonferroni post test (* P <0.05). C, Wound-healing of endothelial monolayers. HUVEC monolayers were scratched and conditioned medium from EPC cultures either pre-treated with TP siRNA (TP KD) (bottom images) or scrambled siRNA (CTRL KD) (top images) was added at a ratio of 1:2. The results presented are representative of 3 independent experiments. The width of the wound was measured (black bars) and plotted over time (supplemental Figure VI, A). Note that the effect was attenuated when experiments were repeated in the presence of 10 µg/mL anti- α v β 3 inhibitory antibody or 10 µmol/L RGD peptide (supplemental Figure VI, B and C). D, Angiogenesis in vivo. The neovascularization of Matrigel plugs containing PBS (Ctrl) (n =4), 250 µmol/L dRP (n =4), or 500 µmol/L 5Br-6Am-U (n =3) was measured (supplemental Figure VII). Arrows indicate vessels.

Sources of Funding

This work was funded by grants from the British Heart Foundation and Oak Foundation. M.M. was supported by a Senior Research Fellowship of the British Heart Foundation.

Disclosures

None.

References

- Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res*. 1999;85:221–228.
- Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*. 1997;275:964–967.
- Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, Oh BH, Lee MM, Park YB. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. *Arterioscler Thromb Vasc Biol*. 2004;24:288–293.
- Rehman J, Li J, Orschell CM, March KL. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. *Circulation*. 2003;107:1164–1169.

5. Rohde E, Malischnik C, Thaler D, Maierhofer T, Linkesch W, Lanzer G, Guell C, Strunk D. Blood monocytes mimic endothelial progenitor cells. *Stem Cells*. 2006;24:357–367.
6. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res*. 2001;89:e1–e7.
7. Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY, Kim TY, Cho HJ, Kang HJ, Chae IH, Yang HK, Oh BH, Park YB, Kim HS. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. *Circulation*. 2005;112:1618–1627.
8. Aicher A, Brenner W, Zuhayra M, Badorff C, Massoudi S, Assmus B, Eckey T, Henze E, Zeiher AM, Dimmeler S. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. *Circulation*. 2003;107:2134–2139.
9. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, Grunwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). *Circulation*. 2002;106:3009–3017.
10. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. *J Clin Invest*. 2001;108:391–397.
11. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A*. 2000;97:3422–3427.
12. Werner N, Kosiol S, Schiegel T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med*. 2005;353:999–1007.
13. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. *Circ Res*. 2004;95:343–353.
14. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. *Arterioscler Thromb Vasc Biol*. 2003;23:1185–1189.
15. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med*. 2003;348:593–600.
16. Gries DP, Ehsan A, Melo LG, Kong D, Zhang L, Mann MJ, Pratt RE, Mulligan RC, Dzau VJ. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. *Circulation*. 2003;108:2710–2715.
17. Goertler JR, Gustin SE, van Eekelen JA, Schmidt U, Hall MA, Jane SM, Green AR, Gottgens B, Izon DJ, Begley CG. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. *Blood*. 2004;104:1769–1777.
18. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Hertuala S, Alitalo K, Weissman IL, Salven P. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. *Proc Natl Acad Sci U S A*. 2008;105:6620–6625.
19. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. *J Mol Cell Cardiol*. 2005;39:733–742.
20. Mayr M, Madhu B, Xu Q. Proteomics and metabolomics combined in cardiovascular research. *Trends Cardiovasc Med*. 2007;17:43–48.
21. Mayr M, Zhang J, Greene AS, Guterman D, Perloff J, Ping P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. *Mol Cell Proteomics*. 2006;5:1853–1864.
22. Sidibe A, Yin X, Tarelli E, Xiao Q, Zampetaki A, Xu Q, Mayr M. Integrated membrane protein analysis of mature and embryonic stem cell-derived smooth muscle cells using a novel combination of CyDye/biotin labeling. *Mol Cell Proteomics*. 2007;6:1788–1797.
23. Mayr M, Zampetaki A, Sidibe A, Mayr U, Yin X, De Souza AI, Chung YL, Madhu B, Quax PH, Hu Y, Griffiths JR, Xu Q. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. *Circ Res*. 2008;102:1046–1056.
24. Mayr M, Siow R, Chung YL, Mayr U, Griffiths JR, Xu Q. Proteomic and metabolomic analysis of vascular smooth muscle cells: role of PKCdelta. *Circ Res*. 2004;94:e87–e96.
25. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Abolmaali ND, Chavakis E, Reinheckel T, Zeiher AM, Dimmeler S. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. *Nat Med*. 2005;11:206–213.
26. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W, Heldin CH. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature*. 1989;338:557–562.
27. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. *Cancer Res*. 2003;63:527–533.
28. Sengupta S, Sellers LA, Matheson HB, Fan TP. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. *Br J Pharmacol*. 2003;139:219–231.
29. Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. *Circulation*. 2003;108:3122–3127.
30. Mayr U, Zou Y, Zhang Z, Dietrich H, Hu Y, Xu Q. Accelerated arteriosclerosis of vein grafts in inducible NO synthase(-/-) mice is related to decreased endothelial progenitor cell repair. *Circ Res*. 2006;98:412–420.
31. Xu Q. The impact of progenitor cells in atherosclerosis. *Nat Clin Pract Cardiovasc Med*. 2006;3:94–101.
32. Assmus B, Honold J, Schachinger V, Britten MB, Fischer-Rasokat U, Lehmann R, Teupe C, Pistorius K, Martin H, Abolmaali ND, Tonn T, Dimmeler S, Zeiher AM. Transcoronary transplantation of progenitor cells after myocardial infarction. *N Engl J Med*. 2006;355:1222–1232.
33. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holzschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med*. 2006;355:1210–1221.
34. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. *Lancet*. 2002;360:427–435.
35. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Illebekk A, Mangschaau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjørnerheim R, Brekke M, Müller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. *N Engl J Med*. 2006;355:1199–1209.
36. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. *Nat Med*. 2003;9:702–712.
37. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. *Circulation*. 2004;109:2692–2697.
38. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. *Circulation*. 2004;109:2487–2491.
39. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. *Nat Med*. 2003;9:789–795.
40. Akiyama S, Furukawa T, Sumizawa T, Takebayashi Y, Nakajima Y, Shimaoka S, Haraguchi M. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. *Cancer Sci*. 2004;95:851–857.
41. Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, Akiba S, Miyadera K, Fukushima M, Yamada Y, Yoshida H, Kanzaki T, Akiyama S. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. *Cancer Res*. 1999;59:1911–1916.
42. Hockenberry DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell*. 1993;75:241–251.
43. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. *Cell*. 1993;74:609–619.
44. Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. *Proc Natl Acad Sci U S A*. 1995;92:998–1002.
45. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. *Blood*. 2007;109:1801–1809.

SUPPLEMENT MATERIAL

Proteomics Identifies Thymidine Phosphorylase as a Key Regulator of the Angiogenic Potential of Colony-forming Units and Endothelial Progenitor Cell Cultures

Giordano Pula*, Ursula Mayr*, Colin Evans, Marianna Prokopi, Dina S. Vara, Xiaoke Yin, Zoe Astroulakis, Qingzhong Xiao, Jonathan Hill, Qingbo Xu, Manuel Mayr

Cardiovascular Division, King's College London School of Medicine, King's College London, UK

* authors contributed equally

Correspondence to:

Dr. Manuel Mayr, Cardiovascular Division, King's College London School of Medicine, King's College London, 125 Coldharbour Lane, London SE5 9NU, UK

Phone: +44 (0) 20 7848 5238, Fax: +44 (0) 20 7848 5296

Email: manuel.mayr@kcl.ac.uk

Material and Methods

EPC culture and colony-forming units (CFUs). Human blood was drawn from healthy volunteers. Informed consent was obtained and the study was approved by the ethics review board of King's College London. For isolation of EPCs, peripheral blood mononuclear cells (PBMCs) were collected by separation onto Lymphoprep™ solution (LYS3772, Axis-Shield) at a ratio of 1 ml blood: 1 ml separation solution. Cells were centrifuged for 20 minutes at 2 krpm, 20°C. Buffy coat PBMCs were collected and washed 3 times with PBS containing 2% fetal bovine serum. EPCs were obtained according to two commonly used methods: First, PBMCs were suspended using endothelial basal medium (EBM, Clonetics cc-3121, Lonza) containing 20% fetal bovine serum, epidermal growth factor (10 µg/ml), bovine brain extract (3 µg/ml), gentamicine (50 µg/ml), amphotericin-B (50 µg/ml), hydrocortisone (1 µg/ml), and human VEGF (10 ng/ml), as described previously¹. Cells were seeded at 5×10^6 cells.well⁻¹ on human fibronectin-coated 6-well plates. Growth medium was changed every 3 days. EPC numbers were assessed by double positive staining for DiI-Ac-LDL and Lectin on day 5 of culture. Second, the colony forming unit (CFU) assay was performed as described previously². In brief, PBMCs were suspended in growth medium containing Medium 199 (22340, Gibco) with 20% fetal bovine serum and seeded at 5×10^6 cells.well⁻¹ on human fibronectin-coated (F0895, Sigma) 6-well plates. Wells were washed with growth medium after 48 hours and non-adherent cells were re-plated at 4×10^6 cells.well⁻¹ on human fibronectin-coated plates kept in the same growth medium, which was changed every 3 days. For both culture methods, cells were harvested for experimentation after 7 days of culture at 37°C with 5% CO₂-enriched atmosphere. For secretome analyses, cells were incubated with serum-free

culture medium for 24 hours at 37°C. The conditioned medium was cleared by centrifugation (30 min, 3,000g) to eliminate floating cells or cell debris and stored at -80°C.

Culture of Human Umbilical Vein Endothelial Cells (HUVECs). HUVECs were isolated from human umbilical cords as described previously^{3, 4} and were cultured in M199 medium supplemented with 1ng/ml Endothelial Cell Growth Factor (ECGF), 3µg/ml Endothelial Cell Growth Supplement (ECGS), 10U/ml Heparin, 2.5 µg/ml Thymidine and 5% FBS. The cells were cultured in collagen I-coated T75 flasks at 37°C with 5% CO₂-enriched atmosphere for up to 10 passages.

MALDI-Tof-Tof. Conditioned medium was thawed at 4°C. For CFUs and early EPCs, 500 µl of conditioned medium was placed in a Microcon Ultracel YM-10 (Millipore, 42406) and centrifuged for 45 minutes at 13.2 krpm. This procedure was repeated three times. A total volume of 1.5 ml conditioned medium was concentrated approximately 50-fold. Protein concentration was determined using the Bradford method as described above. Subsequently, proteins were reduced with DTT then alkylated and subject to an overnight tryptic digest. Tryptic peptides were separated by nano liquid chromatography (Ultimate 3000™, Dionex) on a C18 column (PepMap 100, 75 µm I.D., 15 cm length, Dionex) with a mobile phase (A) formed from HPLC grade water containing 5% acetonitril and 0.1% TFA and (B) HPLC grade acetonitrile containing 20% H₂O and 0.1% TFA according to the gradient 5% solvent B (0-5 min); 5-30% Solvent B (5-120 min); 60-95% Solvent B (120-150 min); and 95% Solvent B (151-160 min) at a flow rate of 200 nl/min. The HPLC was interfaced to a spotting robot (Dionex Probot). Several hundred fractions were collected per sample

(fraction size: 10 sec) on matrix-assisted laser desorption/ionisation (MALDI) target plates and mixed with matrix (CHCA, 2 mg/ml in 70% acetonitril in 0.1% TFA). Peptides were subsequently analyzed using a TOF/TOF analyser (4800 ToF/ToF, Applied Biosystems). Results were searched against a human / bovine database (Uniprot) in Mascot and filtered with ProteinPilot™ software (Applied Biosystems). All peptide sequence assignments were required to result from fully tryptic cleavages of the corresponding proteins. Assignments were accepted when the total score was > 2.0. The total score is a measure of the confidence of the protein identification (e.g. total score of 2.0 corresponds to a confidence of 99%) and was calculated by ProteinPilot software as $-\log(1\text{-percent confidence}/100)$. Results were further filtered for a minimum of ≥ 2 peptides per protein identification.

Cytokine measurements and confirmation of protein expression. Cytokine concentrations in the EPC secretomes were measured using a commercial assay (Bio-Plex, Biorad). The conditioned medium from several independent EPC cultures and CFU preparations was analyzed according to the manufacturers' instructions.

Difference in-gel electrophoresis (DIGE). For cellular proteomics, cell monolayers were rinsed thoroughly with cold PBS to remove any serum components. Protein extracts were prepared from CFUs and cultured EPCs using a lysis buffer (8M urea, 4% w/v CHAPS, 30mM Tris-Cl, pH 8.5) compatible with DIGE labelling (GE healthcare). After centrifugation at 13,000 g for 10 min, the supernatant containing soluble proteins was harvested and the protein concentration was determined using a modification of the method described by Bradford⁵. The fluorescence dye labelling reaction was carried out at a dye/protein ratio of 400pmol/100μg. After incubation on

ice for 30 min, the labelling reaction was stopped by scavenging non-bound dyes with 10mM lysine (L8662, Sigma) for 15 min. For two-dimensional gel electrophoresis, samples were mixed with 2x buffer (8M urea, 4% w/v CHAPS, 2% w/v DTT, 2% v/v Pharmalytes 3-10 for IEF), 50 μ g per sample were diluted in rehydration solution (8M urea, 0.5% w/v CHAPS, 0.2% w/v DTT, and 0.2% v/v Pharmalyte pH 3-10) and loaded on IPG strips (18cm, pH 3-10, nonlinear, GE healthcare). After rehydration overnight, strips were focused at 0.05 mA/IPG strip for 60 kVh at 20°C (Multiphor II, GE healthcare). Once IEF was complete the strips were equilibrated in 6M urea containing 30% v/v glycerol, 2% w/v SDS and 0.01% w/v Bromphenol blue, with addition of 1% w/v DTT for 15 min, followed by the same buffer without DTT, but with the addition of 4.8% w/v iodoacetamide for 15 min. SDS-PAGE was performed using 12% T (total acrylamide concentration), 2.6% C (degree of cross-linking) polyacrylamide gels without a stacking gel, using the Ettan DALT system (GE healthcare). The second dimension was terminated when the Bromophenol blue dye front had migrated off the lower end to the gels. After electrophoresis, fluorescence images were acquired using the Typhoon variable mode imager 9400 (GE healthcare). Finally, gels were fixed overnight in methanol: acetic acid: water solution (4:1:5 v/v/v). Protein profiles were visualised by silver staining using the Plus one silver staining kit (GE healthcare). For documentation, silver-stained gels were scanned in transmission scan mode using a calibrated scanner (GS-800, Bio-Rad). DIGE gels were analysed using SameSpot version 3.2 software (Nonlinear Dynamics). Spots exhibiting differential expression ($p<0.05$, one-way ANOVA) were excised for identification. A detailed methodology is available on our website <http://www.vascular-proteomics.com>.

Nano-LC MS/MS. Gel pieces containing selected protein spots were treated overnight with modified trypsin (Promega) according to a published protocol modified for use with an Investigator ProGest (Genomic Solutions, Huntington, UK) robotic digestion system. Following enzymatic degradation, peptides were separated by a nanoflow HPLC system (Ultimate 3000, Dionex) on a reverse-phase column and applied online to a LTQ XL ion-trap mass spectrometer. Spectra were collected from the ion-trap mass analyzer using full ion scan mode over the mass-to-charge (m/z) range 300-2000. MS-MS scans were performed on each ion using dynamic exclusion. Database search was performed using the TurboSEQUEST software (Thermo Finnigan). One missed cleavage per peptide was allowed and carbamidomethylation of cysteine as well as partial oxidation of methionine were assumed. The following filters were applied: Xcorr values of >2.0 (+1 charge), >2.5 (+2 charge) and >3.5 (+3 charge), deltaCN >0.1, a minimum of 2 peptides and a probability score < than e⁻⁰⁰³.

mRNA isolation and assessment of gene regulation by rtPCR. Total mRNA was extracted from CFUs or cultured EPCs with RNeasy mini kit (Qiagen), following manufacturer's instructions. Briefly, 2.5 µg of mRNA was converted to cDNA using Promega Reverse Transcription System (Promega). The cDNA products were amplified by PCR using gene-specific primers. The primers used were IL-8 forward: CTGCGCCAACACAGAAATTA; IL-8 reverse: GCTTGAAGTTCACT GGCATC; MMP-9 forward: GAGACCGGTGAGCTGGATAG; MMP-9 reverse: CACCAA ACTGGATGACGATG; ApoE forward: CCAATCACAGGCAGGA AGAT; ApoE reverse: CTCCTGCACCTGCTCAGAC; TP forward: CATGGATCTGGAGGA GACCT; TP reverse: TCTGGGCTCTGGATGACATT; CD133 forward: ACCCA TTGGCATTCTCTTG; PBEF forward: TATCCACCCAACACAAGCAA, PBEF

reverse: GCTCCTATGCCAGCAGTCTC; MCP-1 forward:
 TCTGTGCCTGCTGCTCATAG, MCP-1 reverse: GCAATTCCCCAAGTCTCTG;
 CD133 reverse: GGTGCATTCTCCACCACAT; vWF forward:
 GACCCTTGTCAGAAGGAA; VWF reverse: TCCCCAAGA TACACGGAGAG;
 CD14 forward: CTGCAACTTCTCCGAACCTC; CD14 reverse:
 TAGGTCTCGAGCGTCAGTT; KDR forward: GCTTG GCCCAATAATCAGA;
 KDR reverse: ACACGACTCCATGTTGGTCA; CD31 forward: TATTTCCA
 GCCCGAACTG; CD31 reverse: ATGACCTCAA ACTGGGCATC; GAPDH
 forward: CGGAGTCAACGGATTG GTCGTAT; and GAPDH reverse:
 AGCCTTCTCCATGGTGGTGAAGAC. PCR conditions were as follows: 94°C for 5
 min and then 30 cycles at 94°C for 30 s, 58°C for 1 min and 72°C for 1 min, followed
 by 72°C for 10 min. PCR products were separated by 1.5% agarose gel electrophoresis
 and visualized by ethidium bromide staining.

Immunoblot. Cells were lysed with an equal volume of radioimmuno-
 precipitation assay buffer (RIPA) (1% Triton X-100, 1% sodium deoxycholate, 0.1%
 SDS, 150 mM NaCl, 50 mM Tris, 5 mM EDTA) containing protease inhibitors
 (Complete mini, Roche). Proteins were quantified using the Bradford assay⁵ and
 resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
 using 8% to 10% polyacrylamide Tris-Glycine pre-cast gels (Invitrogen). Samples
 were then transferred to ProTran nitrocellulose transfer membrane (Whatman) and
 blocked with 10% w/v dry milk in TBS-T (25mM Tris, 150mM NaCl, 0.1% v/v
 Tween20, pH 7.2). Immunostaining for thymidine phosphorylase was performed with
 650 ng/ml anti-human PD-ECGF antibody (R&D Systems, AF1143) and 650 ng/ml
 anti-mouse IgG HRP-conjugated antibodies (Dako). Primary antibodies against actin

(Santa Cruz Biotechnology, sc-1616), Bcl-2 (Santa Cruz Biotechnology, sc-783), Bax (Santa Cruz Biotechnology, sc-6236), integrin $\beta 1$ (Santa Cruz Biotechnology, sc-8978), integrin αv (Santa Cruz Biotechnology, sc-6616), integrin $\beta 3$ (R&D Systems, AF2266), p38 MAPK (Cell Signaling Technology, #9212), phospho-p38 MAPK (Cell Signaling Technology, #9211), VASP (Alexis Biochemicals, ALX-210-898-R100), and vinculin (Chemicon International, CBL233), were used at different concentration depending on their efficiency and specificity in combination with species-specific HRP-conjugated anti-IgG secondary antibodies (Dako). Bound peroxidase activity was detected using enhanced chemiluminescence (ECL).

Immunofluorescence. EPCs normally were cultured as described until day 6, then transferred to 22mm coverslips coated with fibronectin ($20 \mu\text{g ml}^{-1}$) and cultured for a further 2 days. Alternatively, HUVECs were cultured for 24 hours on collagen I-coated coverslips ($20 \mu\text{g/ml}$). On the day of the experiment, cells were fixed with 3.7% formaldehyde in TBS (25mM Tris, 150 mM NaCl, pH 7.2) and permeabilised with TBS containing 0.05% Triton X-100. For EPCs, the immunostaining was performed with $1.5\mu\text{g/ml}$ anti-human PD-ECGF antibody (R&D Systems, AF1143), $1 \mu\text{g/ml}$ DAPI (Sigma), and $0.8 \mu\text{g/ml}$ fluorescein isothiocyanate (FITC)-labeled anti-mouse IgG antibody (Molecular Probes). For HUVECs, the staining was performed with $2 \mu\text{g/ml}$ anti-integrin $\beta 3$ antibody (R&D Systems, AF2266), $20 \mu\text{g/ml}$ FITC-conjugated anti-vinculin antibody (Sigma, F7053), $1 \mu\text{g/ml}$ DAPI and $0.8 \mu\text{g/ml}$ (TRITC)-labeled anti-goat IgG antibody (Molecular Probes). Coverslips were then mounted using Slow-Fade mounting medium and examined by microscopy on an upright Leica DMI 6000 CS inverted microscope connected to a Leica TCS SP5 confocal laser scanning system (objective: Leica HCX PL Apo 63x/1.40-0.60 oil).

Cell Death ELISA. EPCs were cultured until day 6, then different treatments were administrated by adding biological/pharmacological agents to the culture medium. On day 7, apoptosis was analysed with Cell Death Detection ELISA Plus (Roche), according to the manufacturer's instructions. Briefly, after cells lysis, cytoplasm and intact nuclei were fractionated by centrifugation. The cytoplasmic fraction was analysed for the presence of histone proteins released from the nucleus, by incubating 20 μ l of the medium with anti-histone biotin-conjugated antibody and anti-DNA peroxidase-conjugated antibody in a streptavidin-conjugated microplate for 2 hours at room temperature. Histone protein absorbed to the microplate was detected by a colorimetric reaction using a peroxidase substrate and absorbance measurement at 405nm using a Genios Pro microplate reader (Tecan).

Gene knock-down by siRNA. On day 6 of the normal culture procedure, EPCs were incubated with 80 pmols/well of TP siRNA (TP KD) in the presence of siRNA Transfection Reagent (Santa Cruz) in the absence of foetal bovine serum for 8 hours. Similarly, control cells were incubated with scrambled control siRNA (CTRL KD). Foetal bovine serum was subsequently added to the normal final concentration and cells were cultured overnight before experimentation.

Flow cytometry. EPCs used for apoptosis studies were cultured until day 6, when different compounds were added to the culture medium. On day 7, apoptosis was analysed by flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I (BD Pharmingen), according to manufacturer's instructions and as previously described⁶. Briefly, cells were detached by short trypsin treatment and quick blockade of the protease activity with foetal bovine serum. Cells were then washed in phosphate buffer saline (PBS: 4mM NaH₂PO₄, 16mM Na₂HPO₄, 150mM NaCl, pH 7.4) and

incubated with Annexin V and Propidium Iodide for 15 minutes at room temperature. The flow cytometric analysis was performed with a FACSCalibur flow cytometer (Becton Dickinson).

Cell transmigration analysis. The method was adapted from previous studies⁷. For HUVEC migration assays, 10^5 cells were added to the top inserts of 24 well-transmigration microplates (pore size 8 μm , Corning), coated with collagen-I (20 $\mu\text{g}/\text{ml}$, Sigma). The bottom chamber of the transmigration microplate was seeded with 2×10^5 EPCs (either TP KD or CTRL KD), following coating with fibronectin (20 $\mu\text{g}/\text{ml}$, Sigma). The gene knock-down procedure was performed on day 6 of the EPC culture, as described above, and 48 hours prior seeding onto the transmigration microplate. Transmigration was quantified 8 hours after assembly of the chemotaxis chamber by hematoxylin staining and phase-contrast microscopy (objective 4X/0.10, microscope Nikon Eclipse TS100, connected to a Nikon Digital Sight imaging system).

Wound-healing assay. HUVECs were cultured in 6 well-plates to confluence. The day of the experiment, the monolayer was injured manually, and following a brief wash with PBS, the conditioned medium from EPCs was added. The healing of the injury was followed at time 0, 2, 4, 6 and 16 hours by phase contrast microscopy (objective 4X/0.10, microscope Nikon Eclipse TS100, connected to a Nikon Digital Sight imaging system).

Matrigel plugs. 50 μl Matrigel was mixed with 250 μM dRP or 500 μM 5Br-6Am-U, and then injected subcutaneously into the back or flank of C57BL/6 mice. Three to four injections were performed for each group. The mice were killed on day 14, and the plugs were harvested and frozen immediately in liquid nitrogen, followed

by embedding with OCT, sectioning and hematoxylin-staining. The sections were visualized by phase contrast microscopy (objective 4X/0.10, microscope Nikon Eclipse TS100, connected to a Nikon Digital Sight imaging system).

Online Figures

Online Figure I. Cellular proteome of CFUs. A DIGE gel demonstrates the consistency of the proteomic profiles from CFUs of two different individuals, whose protein extracts were differentially labeled with Cy-dyes in green and red, respectively. Yellow color indicates proteins present in both samples.

Online Figure II. Flow cytometry. Apoptosis in EPC cultures following treatment with 5Br-6Am-U (100 μ M) was assessed by flow cytometric analysis of annexin V and propidium iodide staining (A). Apoptosis following knock-down of TP in EPC cultures by siRNA (TP KD) compared to scrambled control siRNA (CTRL KD) (B).

Online Figure III. TP gene silencing by siRNA. TP gene was knocked-down in cultured EPCs as described in the Methods section and protein extracts were obtained. The level of expression of TP was assessed by immunoblotting using a specific antibody (top panel). As a control, protein extracts were obtained from EPCs treated with a scrambled siRNA (A). Apoptosis induced in EPCs by TP knock-down with or without VEGF (10 ng/ml) was assessed by ELISA (B). Treatment with 5Br-6Am-U or dRP did not alter survival of HUVECs (C). The effect of 5Br-6Am-U or dRP or both (D), and TP knock-down by siRNA in the presence or absence of dRP (E) on cell numbers in EPC cultures (cells per optic field) is also presented. The data in the bar graphs are presented as mean \pm SEM from at least 3 independent experiments. Statistical significance was tested by one-way ANOVA with Bonferroni post-test (* = p<0.05).

Online Figure IV. Densitometry. dRP enhances Bcl-2 expression in EPCs under oxidative stress (Figure 5). Statistical significance was tested by one-way ANOVA with Bonferroni post-test (* = p<0.05).

Online Figure V. Quantification of focal adhesions. (A) HUVECs were cultured in the presence of conditioned medium from EPCs and the focal adhesions were visualized by immunofluorescence as described in the legend of Figure 6. The number of focal adhesions (FA) per cell is quantified in the bar graph (mean ± SEM, *white bars*). Where indicated dRP (50μM) was added. HUVECs without EPC conditioned medium served as a control (*black column*). The pictures utilized for quantification were from 3 independent experiments. Statistical significance was tested by one-way ANOVA with Bonferroni post-test (* = p<0.05; ** = p<0.01). (B) Densitometry. dRP stimulates integrin β3 expression in HUVECs (Figure 6B). Statistical significance was tested by one-way ANOVA with Bonferroni post-test (* = p<0.05).

Online Figure VI. Quantification of wound healing. The width of the wound was measured and plotted over time (A). Statistical significance was tested by two-way ANOVA, * denotes p<0.05. Note that the effect was attenuated when experiments were repeated in the presence of 10 μg/ml anti-αvβ3 inhibitory antibody (B) or 10 μM RGD peptide (C).

Online Figure VII. Neovascularization of matrigel plugs. Values are means ± SEM for Ctrl (n=4), 250μM dRP (n=4) or 500μM 5Br-6Am-U (n=3). Statistical significance was tested by one-way ANOVA with Bonferroni post-test (* = p<0.05).

Online Tables

Online Table I. Proteins identified in the conditioned medium.

Proteins in the conditioned medium of CFUs from 3 different individuals were identified by MALDI-TOF/TOF mass spectrometry. Proteins appearing in at least 2 samples are reported in the table and the results for the 3 biological replicates are highlighted in different colors (blue, red and black). The rank N is the position in the ranking of proteins in decreasing order of abundance. The total score is a measure of the confidence of the protein identification (e.g. total score of 2.0 corresponds to a confidence of 99%) and was calculated by ProteinPilot™ software as $-\log(1\text{-percent confidence}/100)$. Proteins also identified in cultured EPCs are highlighted in light grey.

Online Table II. Peptides identified in the conditioned medium.

Peptides in the conditioned medium of CFUs as identified by MALDI-TOF/TOF mass spectrometry. The 3 biological replicates are highlighted in different colors (blue, red and black).


Online Table III. Differentially expressed proteins in CFUs compared to EPC cultures.





CFUs and EPC cultures were compared by difference in-gel electrophoresis (DIGE). Results from 4 independent images were analyzed using SameSpot software (Nonlinear Dynamics). Spots exhibiting differential expression ($p<0.05$, one-way ANOVA) were excised for identification and reported in the table.






Online Table IV. Cytokine secretion. Cytokine concentrations in the conditioned medium were measured using the 27-plex cytokine assay from Biorad. The conditioned media from the 13 independent EPC cultures and 15 independent CFU preparations were analyzed according to the manufacturers' instructions. Depending on the cytokine, the intraplate variability of the assay measured as %CV (percent coefficient of variation) is between 2 and 13%, while the interplate %CV is between 4.3 and 21.5%. The limit of detection (LOD) ranges from 0.2 to 19.3 pg/ml.


References



1. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res.* 2001;89:E1-7.
2. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med.* 2003;348:593-600.
3. Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q, Wick G. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. *Circulation.* 1999;99:1560-1566.
4. Schett G, Xu Q, Amberger A, Van der Zee R, Recheis H, Willeit J, Wick G. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. *J Clin Invest.* 1995;96:2569-2577.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976;72:248-254.
6. van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. *Cytometry.* 1996;24:131-139.
7. Hotchkiss KA, Ashton AW, Klein RS, Lenzi ML, Zhu GH, Schwartz EL. Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. *Cancer Res.* 2003;63:527-533.





A**CTRL****5Br-6Am-U****B****CTRL KD****TP KD**











ONLINE TABLE I

HUMAN PROTEINS IDENTIFIED IN THE CONDITIONED MEDIUM OF CFUs (n=3)

Rank N.	Total Score	% Coverage	Accession	Protein name
108	8.2	20.7	Q00299 CLIC1_HUMAN	Chloride intracellular channel protein 1 (Nuclear chloride ion channel 27) (NCC27) (Chloride channel ABP) (Regulatory nuclear chloride ion channel protein) (hRNCC) - Homo sapiens (Human)
69	4.9	30.3	Q00299 CLIC1_HUMAN	Chloride intracellular channel protein 1 (Nuclear chloride ion channel 27) (NCC27) (Chloride channel ABP) (Regulatory nuclear chloride ion channel protein) (hRNCC) - Homo sapiens (Human)
123	9.5	31.1	Q00299 CLIC1_HUMAN	Chloride intracellular channel protein 1 (Nuclear chloride ion channel 27) (NCC27) (Chloride channel ABP) (Regulatory nuclear chloride ion channel protein) (hRNCC) - Homo sapiens (Human)
160	2.0	11.1	Q00391 QSCN6_HUMAN	Sulphydryl oxidase 1 precursor (EC 1.8.3.2) (Quiescin Q6) (hQSOX) - Homo sapiens (Human)
201	6.0	12.2	Q00391 QSCN6_HUMAN	Sulphydryl oxidase 1 precursor (EC 1.8.3.2) (Quiescin Q6) (hQSOX) - Homo sapiens (Human)
338	2.0	51.1	Q00479 HMGN4_HUMAN	High-mobility group nucleosome-binding domain-containing protein 4 (Nonhistone chromosomal protein HMG-17-like 3) (Non-histone chromosomal protein) - Homo sapiens (Human)
285	4.0	44.4	Q00479 HMGN4_HUMAN	High-mobility group nucleosome-binding domain-containing protein 4 (Nonhistone chromosomal protein HMG-17-like 3) (Non-histone chromosomal protein) - Homo sapiens (Human)
189	4.0	5.0	O14773 TPP1_HUMAN	Tripeptidyl-peptidase 1 precursor (EC 3.4.14.9) (Tripeptidyl-peptidase I) (TPP-1) (Tripeptidyl aminopeptidase) (Lysosomal peptidase insensitive protease) (LPIC) (Cell growth-inhibiting gene 1 protein) - Homo sapiens (Human)
138	2.1	14.9	O14773 TPP1_HUMAN	Tripeptidyl-peptidase 1 precursor (EC 3.4.14.9) (Tripeptidyl-peptidase I) (TPP-1) (TPP-1) (Tripeptidyl aminopeptidase) (Lysosomal peptidase insensitive protease) (LPIC) (Cell growth-inhibiting gene 1 protein) - Homo sapiens (Human)
490	2.0	4.6	O14773 TPP1_HUMAN	Tripeptidyl-peptidase 1 precursor (EC 3.4.14.9) (Tripeptidyl-peptidase I) (TPP-1) (TPP-1) (Tripeptidyl aminopeptidase) (Lysosomal peptidase insensitive protease) (LPIC) (Cell growth-inhibiting gene 1 protein) - Homo sapiens (Human)
202	3.7	11.7	O14818 PSA7_HUMAN	Proteasome subunit alpha type 7 (EC 3.4.25.1) (Proteasome subunit RC6-1) (Proteasome subunit XAPC7) - Homo sapiens (Human)
177	6.5	17.3	O14818 PSA7_HUMAN	Proteasome subunit alpha type 7 (EC 3.4.25.1) (Proteasome subunit RC6-1) (Proteasome subunit XAPC7) - Homo sapiens (Human)
278	2.1	19.5	O14979 HNRDL_HUMAN	Heterogeneous nuclear ribonucleoprotein D-like (hnRNP-like protein) (hnRNP-DL) (JKT41-binding protein) (AU-rich element RNA-binding factor) (Protein JaUF1) - Homo sapiens (Human)
87	4.0	18.8	O14979 HNRDL_HUMAN	Heterogeneous nuclear ribonucleoprotein D-like (hnRNP-like protein) (hnRNP-DL) (JKT41-binding protein) (AU-rich element RNA-binding factor) (Protein JaUF1) - Homo sapiens (Human)
452	6.0	9.8	O14979 HNRDL_HUMAN	Heterogeneous nuclear ribonucleoprotein D-like (hnRNP-like protein) (hnRNP-DL) (JKT41-binding protein) (AU-rich element RNA-binding factor) (Protein JaUF1) - Homo sapiens (Human)
85	8.9	22.3	O15143 ARCB1_HUMAN	Actin-related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41-ARC) - Homo sapiens (Human)
128	2.3	24.7	O15143 ARCB1_HUMAN	Actin-related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41-ARC) - Homo sapiens (Human)
152	8.0	17.7	O15143 ARCB1_HUMAN	Actin-related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41-ARC) - Homo sapiens (Human)
151	4.7	11.7	O15144 ARPC2_HUMAN	Actin-related protein 2/3 complex subunit 2 (ARP2/3 complex 34 kDa subunit) (p34-ARC) - Homo sapiens (Human)
196	1.7	21.0	O15144 ARPC2_HUMAN	Actin-related protein 2/3 complex subunit 2 (ARP2/3 complex 34 kDa subunit) (p34-ARC) - Homo sapiens (Human)
172	6.7	20.7	O15144 ARPC2_HUMAN	Actin-related protein 2/3 complex subunit 2 (ARP2/3 complex 34 kDa subunit) (p34-ARC) - Homo sapiens (Human)
247	2.3	15.2	O15145 ARPC3_HUMAN	Actin-related protein 2/3 complex subunit 3 (ARP2/3 complex 21 kDa subunit) (p21-ARC) - Homo sapiens (Human)
238	5.1	21.9	O15145 ARPC3_HUMAN	Actin-related protein 2/3 complex subunit 3 (ARP2/3 complex 21 kDa subunit) (p21-ARC) - Homo sapiens (Human)
216	3.2	8.5	O15204 ADEC1_HUMAN	ADAM DEC1 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain-like protein decysin 1) (ADAM-like protein decysin 1) - Homo sapiens (Human)
81	4.2	7.7	O15204 ADEC1_HUMAN	ADAM DEC1 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain-like protein decysin 1) (ADAM-like protein decysin 1) - Homo sapiens (Human)
264	4.3	10.4	O15204 ADEC1_HUMAN	ADAM DEC1 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain-like protein decysin 1) (ADAM-like protein decysin 1) - Homo sapiens (Human)
166	4.3	14.5	O43390 HNRPR_HUMAN	Heterogeneous nuclear ribonucleoprotein R (hnRNP R) - Homo sapiens (Human)
267	4.2	20.7	O43390 HNRPR_HUMAN	Heterogeneous nuclear ribonucleoprotein R (hnRNP R) - Homo sapiens (Human)
22	22.9	32.3	O43707 ACTN4_HUMAN	Alpha-actinin-4 (Non-muscle alpha-actinin 4) (F-actin cross-linking protein) - Homo sapiens (Human)
44	6.9	13.9	O43707 ACTN4_HUMAN	Alpha-actinin-4 (Non-muscle alpha-actinin 4) (F-actin cross-linking protein) - Homo sapiens (Human)
10	41.3	35.2	O43707 ACTN4_HUMAN	Alpha-actinin-4 (Non-muscle alpha-actinin 4) (F-actin cross-linking protein) - Homo sapiens (Human)
295	2.0	6.4	O43776 SYNC_HUMAN	Asparaginyl-tRNA synthetase, cytoplasmic (EC 6.1.1.22) (Asparagine--tRNA ligase) (AsnRS) - Homo sapiens (Human)
212	6.0	9.3	O43776 SYNC_HUMAN	Asparaginyl-tRNA synthetase, cytoplasmic (EC 6.1.1.22) (Asparagine--tRNA ligase) (AsnRS) - Homo sapiens (Human)
111	6.9	14.4	O75083 WDR1_HUMAN	WD repeat protein 1 (Actin-interacting protein 1) (AIP1) (NORI-1) - Homo sapiens (Human)
125	2.3	14.9	O75083 WDR1_HUMAN	WD repeat protein 1 (Actin-interacting protein 1) (AIP1) (NORI-1) - Homo sapiens (Human)
373	2.0	8.8	O75368 SH3L1_HUMAN	SH3 domain-binding glutamic acid-rich-like protein - Homo sapiens (Human)
320	4.0	24.6	O75368 SH3L1_HUMAN	SH3 domain-binding glutamic acid-rich-like protein - Homo sapiens (Human)
384	1.7	11.2	O75791 GRAP2_HUMAN	GRB2-related adapter protein 2 (GADS protein) (Growth factor receptor-binding protein) (GRBLG) (Grf40 adapter protein) (Grf-40) (GRB-2-like protein) (GRB2L) (GRBX) (P38) (Hematopoietic cell-associated adapter protein Grpl) (Adapter protein GRID) (SH3-SH2-SH3 adapter Mona) - Homo sapiens (Human)
553	2.0	3.3	O75791 GRAP2_HUMAN	GRB2-related adapter protein 2 (GADS protein) (Growth factor receptor-binding protein) (GRBLG) (Grf40 adapter protein) (Grf-40) (GRB-2-like protein) (GRB2L) (GRBX) (P38) (Hematopoietic cell-associated adapter protein Grpl) (Adapter protein GRID) (SH3-SH2-SH3 adapter Mona) - Homo sapiens (Human)
88	4.0	11.1	P00338 LDHA_HUMAN	L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A) (LDH muscle subunit) (LDH-M) (Proliferation-inducing gene 19 protein) (Renal carcinoma antigen NY-REN-59) - Homo sapiens (Human)
129	11.3	30.4	P00338 LDHA_HUMAN	L-lactate dehydrogenase A chain (EC 1.1.1.27) (LDH-A) (LDH muscle subunit) (LDH-M) (Proliferation-inducing gene 19 protein) (Renal carcinoma antigen NY-REN-59) - Homo sapiens (Human)
141	5.7	29.1	P00491 PNPH_HUMAN	Purine nucleoside phosphorylase (EC 2.4.2.1) (Inosine phosphorylase) (PNP) - Homo sapiens (Human)
166	7.0	32.9	P00491 PNPH_HUMAN	Purine nucleoside phosphorylase (EC 2.4.2.1) (Inosine phosphorylase) (PNP) - Homo sapiens (Human)
30	20.8	45.6	P00558 PGK1_HUMAN	Phosphoglycerate kinase 1 (EC 2.7.2.3) (Primer recognition protein 2) (PRP 2) (Cell migration-inducing gene 10 protein) - Homo sapiens (Human)
76	4.6	30.5	P00558 PGK1_HUMAN	Phosphoglycerate kinase 1 (EC 2.7.2.3) (Primer recognition protein 2) (PRP 2) (Cell migration-inducing gene 10 protein) - Homo sapiens (Human)
22	28.0	53.0	P00558 PGK1_HUMAN	Phosphoglycerate kinase 1 (EC 2.7.2.3) (Primer recognition protein 2) (PRP 2) (Cell migration-inducing gene 10 protein) - Homo sapiens (Human)
18	26.1	17.1	P01023 A2MG_HUMAN	Alpha-2-macroglobulin precursor (Alpha-2-M) - Homo sapiens (Human)
16	16.5	18.1	P01023 A2MG_HUMAN	Alpha-2-macroglobulin precursor (Alpha-2-M) - Homo sapiens (Human)
65	15.3	11.9	P01023 A2MG_HUMAN	Alpha-2-macroglobulin precursor (Alpha-2-M) - Homo sapiens (Human)
195	4.0	13.0	P01033 TIMP1_HUMAN	Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid-potentiating activity) (EPA) (Tissue inhibitor of metalloproteinases) (Fibroblast collagenase inhibitor) (Collagenase inhibitor) - Homo sapiens (Human)
169	2.0	22.2	P01033 TIMP1_HUMAN	Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid-potentiating activity) (EPA) (Tissue inhibitor of metalloproteinases) (Fibroblast collagenase inhibitor) (Collagenase inhibitor) - Homo sapiens (Human)
319	4.0	14.5	P01033 TIMP1_HUMAN	Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid-potentiating activity) (EPA) (Tissue inhibitor of metalloproteinases) (Fibroblast collagenase inhibitor) (Collagenase inhibitor) - Homo sapiens (Human)
355	2.0	13.7	P01034 CYTC_HUMAN	Cystatin C precursor (Cystatin-3) (Neuroendocrine basic polypeptide) (Gamma-trace) (Post-gamma-globulin) - Homo sapiens (Human)
104	3.4	26.0	P01034 CYTC_HUMAN	Cystatin C precursor (Cystatin-3) (Neuroendocrine basic polypeptide) (Gamma-trace) (Post-gamma-globulin) - Homo sapiens (Human)
302	4.0	25.3	P01034 CYTC_HUMAN	Cystatin C precursor (Cystatin-3) (Neuroendocrine basic polypeptide) (Gamma-trace) (Post-gamma-globulin) - Homo sapiens (Human)
188	4.0	31.1	P01834 KAC_HUMAN	Ig kappa chain C region - Homo sapiens (Human)
260	4.5	37.7	P01834 KAC_HUMAN	Ig kappa chain C region - Homo sapiens (Human)
203	3.7	28.6	P01842 LAC_HUMAN	Ig lambda chain C regions - Homo sapiens (Human)
64	5.3	19.0	P01842 LAC_HUMAN	Ig lambda chain C regions - Homo sapiens (Human)
332	3.67	39.0	P01842 LAC_HUMAN	Ig lambda chain C regions - Homo sapiens (Human)
106	7.6	17.2	P01871 MUC_HUMAN	Ig mu chain C region - Homo sapiens (Human)
195	1.7	7.0	P01871 MUC_HUMAN	Ig mu chain C region - Homo sapiens (Human)
570	1.7	1.8	P01871 MUC_HUMAN	Ig mu chain C region - Homo sapiens (Human)
337	2.0	14.3	P02746 C1QB_HUMAN	Complement C1q subcomponent subunit B precursor - Homo sapiens (Human)
95	4.0	13.5	P02746 C1QB_HUMAN	Complement C1q subcomponent subunit B precursor - Homo sapiens (Human)
354	2.0	10.2	P02747 C1QC_HUMAN	Complement C1q subcomponent subunit C precursor - Homo sapiens (Human)
190	2.0	3.7	P02747 C1QC_HUMAN	Complement C1q subcomponent subunit C precursor - Homo sapiens (Human)
386	2.4	14.7	P02747 C1QC_HUMAN	Complement C1q subcomponent subunit C precursor - Homo sapiens (Human)
27	21.3	16.4	P02751 FINC_HUMAN	Fibronectin precursor (FN) (Cold-insoluble globulin) (CIG) - Homo sapiens (Human)
22	13.3	13.7	P02751 FINC_HUMAN	Fibronectin precursor (FN) (Cold-insoluble globulin) (CIG) - Homo sapiens (Human)
584	1.4	1.1	P02751 FINC_HUMAN	Fibronectin precursor (FN) (Cold-insoluble globulin) (CIG) - Homo sapiens (Human)
370	2.0	8.6	P02792 FRIL_HUMAN	Ferritin light chain (Ferritin L subunit) - Homo sapiens (Human)
550	2.0	8.6	P02792 FRIL_HUMAN	Ferritin light chain (Ferritin L subunit) - Homo sapiens (Human)
114	6.7	62.3	P02795 MT2_HUMAN	Metallothionein-2 (MT-2) (Metallothionein-II) (MT-II) (Metallothionein-2A) - Homo sapiens (Human)
216	6.0	82.0	P02795 MT2_HUMAN	Metallothionein-2 (MT-2) (Metallothionein-II) (MT-II) (Metallothionein-2A) - Homo sapiens (Human)
159	4.5	13.6	P04004 VTNC_HUMAN	Vitronectin precursor (Serum-spreading factor) (S-protein) (V75) (Contains: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin B) - Homo sapiens (Human)
119	2.5	12.3	P04004 VTNC_HUMAN	Vitronectin precursor (Serum-spreading factor) (S-protein) (V75) (Contains: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin B) - Homo sapiens (Human)

482	2.0	6.1	P04004 VTNC_HUMAN	Vitronectin precursor (Serum-spreading factor) (S-protein) (V75) [Contains: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin B] - Homo sapiens (Human)
23	22.8	50.5	P04075 ALDOA_HUMAN	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Muscle-type aldolase) (Lung cancer antigen NY-LU-1) - Homo sapiens (Human)
52	6.2	29.4	P04075 ALDOA_HUMAN	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Muscle-type aldolase) (Lung cancer antigen NY-LU-1) - Homo sapiens (Human)
16	37.1	57.7	P04075 ALDOA_HUMAN	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Muscle-type aldolase) (Lung cancer antigen NY-LU-1) - Homo sapiens (Human)
277	2.1	30.6	P04080 CYTB_HUMAN	Cystatin-B (Stefin-B) (Liver thiol proteinase inhibitor) (CPI-B) - Homo sapiens (Human)
318	4.0	36.7	P04080 CYTB_HUMAN	Cystatin-B (Stefin-B) (Liver thiol proteinase inhibitor) (CPI-B) - Homo sapiens (Human)
34	19.3	40.3	P04406 G3P_HUMAN	Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) - Homo sapiens (Human)
74	4.7	25.4	P04406 G3P_HUMAN	Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) - Homo sapiens (Human)
30	24.2	49.6	P04406 G3P_HUMAN	Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) - Homo sapiens (Human)
161	4.4	25.8	P05109 S10AB_HUMAN	Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A) (Migration inhibitory factor-related protein 8) (MRP-8) (Cystic fibrosis antigen) (CFAG) (P8) (Leukocyte L1 complex light chain) (Calprotectin L1L subunit) (Urinary stone protein band A) - Homo sapiens (Human)
317	4.0	25.8	P05109 S10AB_HUMAN	Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A) (Migration inhibitory factor-related protein 8) (MRP-8) (Cystic fibrosis antigen) (CFAG) (P8) (Leukocyte L1 complex light chain) (Calprotectin L1L subunit) (Urinary stone protein band A) - Homo sapiens (Human)
17	26.4	37.3	P05120 PAI2_HUMAN	Plasminogen activator inhibitor 2 precursor (PAI-2) (Placental plasminogen activator inhibitor) (Monocyte Arg-serpin) (Urokinase inhibitor) - Homo sapiens (Human)
38	8.1	21.2	P05120 PAI2_HUMAN	Plasminogen activator inhibitor 2 precursor (PAI-2) (Placental plasminogen activator inhibitor) (Monocyte Arg-serpin) (Urokinase inhibitor) - Homo sapiens (Human)
114	10.0	13.5	P05120 PAI2_HUMAN	Plasminogen activator inhibitor 2 precursor (PAI-2) (Placental plasminogen activator inhibitor) (Monocyte Arg-serpin) (Urokinase inhibitor) - Homo sapiens (Human)
353	2.0	10.9	P05161 UCRP_HUMAN	Interferon-induced 17 kDa protein precursor [Contains: Ubiquitin cross-reactive protein (hUCRP) (Interferon-induced 15 kDa protein)] - Homo sapiens (Human)
502	2.0	12.7	P05161 UCRP_HUMAN	Interferon-induced 17 kDa protein precursor [Contains: Ubiquitin cross-reactive protein (hUCRP) (Interferon-induced 15 kDa protein)] - Homo sapiens (Human)
369	2.0	2.1	P05362 ICAM1_HUMAN	Intercellular adhesion molecule 1 precursor (ICAM-1) (Major group rhinovirus receptor) (CD54 antigen) - Homo sapiens (Human)
569	1.7	2.1	P05362 ICAM1_HUMAN	Intercellular adhesion molecule 1 precursor (ICAM-1) (Major group rhinovirus receptor) (CD54 antigen) - Homo sapiens (Human)
251	2.2	15.7	P06576 ATPB_HUMAN	ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) - Homo sapiens (Human)
316	4.0	6.6	P06576 ATPB_HUMAN	ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) - Homo sapiens (Human)
12	31.0	55.8	P06733 ENO4_HUMAN	Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) (Phosphopyruvate hydratase) (C-myc promoter-binding protein) (MBP-1) (MBP-1) (Plasminogen-binding protein) - Homo sapiens (Human)
19	14.1	35.3	P06733 ENO4_HUMAN	Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) (Phosphopyruvate hydratase) (C-myc promoter-binding protein) (MBP-1) (MBP-1) (Plasminogen-binding protein) - Homo sapiens (Human)
15	38.3	62.9	P06733 ENO4_HUMAN	Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural enolase) (NNE) (Enolase 1) (Phosphopyruvate hydratase) (C-myc promoter-binding protein) (MBP-1) (MBP-1) (Plasminogen-binding protein) - Homo sapiens (Human)
103	7.7	15.2	P06744 G6PI_HUMAN	Glucose-6-phosphate isomerase (EC 5.3.1.9) (GPI) (Phosphoglucosidase) (PGI) (Phosphohexose isomerase) (PHI) (Neuroleukin) (NLK) (Sperm antigen 36) (SA-36) - Homo sapiens (Human)
92	11.9	18.6	P06744 G6PI_HUMAN	Glucose-6-phosphate isomerase (EC 5.3.1.9) (GPI) (Phosphoglucosidase) (PGI) (Phosphohexose isomerase) (PHI) (Neuroleukin) (NLK) (Sperm antigen 36) (SA-36) - Homo sapiens (Human)
391	9.7	21.5	P06753 TPM3_HUMAN	Tropomyosin alpha-3 chain (Tropomyosin-3) (Tropomyosin gamma) (hTM5) - Homo sapiens (Human)
255	16.4	40.8	P06753 TPM3_HUMAN	Tropomyosin alpha-3 chain (Tropomyosin-3) (Tropomyosin gamma) (hTM5) - Homo sapiens (Human)
196	3.8	17.4	P07195 LDHB_HUMAN	L-lactate dehydrogenase B chain (EC 1.1.1.27) (LDH-B) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46) - Homo sapiens (Human)
207	4.0	20.1	P07195 LDHB_HUMAN	L-lactate dehydrogenase B chain (EC 1.1.1.27) (LDH-B) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46) - Homo sapiens (Human)
56	16.9	32.6	P07195 LDHB_HUMAN	L-lactate dehydrogenase B chain (EC 1.1.1.27) (LDH-B) (LDH heart subunit) (LDH-H) (Renal carcinoma antigen NY-REN-46) - Homo sapiens (Human)
298	2.0	6.7	P07237 PDIA1_HUMAN	Protein disulfide-isomerase precursor (EC 5.3.4.1) (PDI) (Prolyl 4-hydroxylase subunit beta) (Cellular thyroid hormone-binding protein) (p55) - Homo sapiens (Human)
481	2.0	6.5	P07237 PDIA1_HUMAN	Protein disulfide-isomerase precursor (EC 5.3.4.1) (PDI) (Prolyl 4-hydroxylase subunit beta) (Cellular thyroid hormone-binding protein) (p55) - Homo sapiens (Human)
149	4.9	16.0	P07339 CATD_HUMAN	Cathepsin D precursor (EC 3.4.23.5) [Contains: Cathepsin D light chain; Cathepsin D heavy chain] - Homo sapiens (Human)
70	4.9	20.9	P07339 CATD_HUMAN	Cathepsin D precursor (EC 3.4.23.5) [Contains: Cathepsin D light chain; Cathepsin D heavy chain] - Homo sapiens (Human)
199	6.0	18.2	P07339 CATD_HUMAN	Cathepsin D precursor (EC 3.4.23.5) [Contains: Cathepsin D light chain; Cathepsin D heavy chain] - Homo sapiens (Human)
47	15.8	30.0	P07437 TBBS_HUMAN	Tubulin beta chain (Tubulin beta-5 chain) - Homo sapiens (Human)
26	11.9	22.5	P07437 TBBS_HUMAN	Tubulin beta chain (Tubulin beta-5 chain) - Homo sapiens (Human)
21	28.5	47.3	P07437 TBBS5_HUMAN	Tubulin beta chain (Tubulin beta-5 chain) - Homo sapiens (Human)
89	8.3	11.8	P07602 SAP_HUMAN	Proactivator polypeptide precursor [Contains: Saposin A (Protein A); Saposin B-Val; Saposin B (Sphingolipid activator protein 1) (SAP-1) (Cerebroside sulfate activator) (CSAct) (Dispensir) (Sulfatide/GMT activator); Saposin C (Co-beta-glucosidase) (A1 activator) (Glucosylceramidase activator) (Sphingolipid activator protein 2) (SAP-2); Saposin D (Protein C) (Component C)] - Homo sapiens (Human)
92	4.0	5.7	P07602 SAP_HUMAN	Proactivator polypeptide precursor [Contains: Saposin A (Protein A); Saposin B-Val; Saposin B (Sphingolipid activator protein 1) (SAP-1) (Cerebroside sulfate activator) (CSAct) (Dispensir) (Sulfatide/GMT activator); Saposin C (Co-beta-glucosidase) (A1 activator) (Glucosylceramidase activator) (Sphingolipid activator protein 2) (SAP-2); Saposin D (Protein C) (Component C)] - Homo sapiens (Human)
204	6.0	9.7	P07602 SAP_HUMAN	Proactivator polypeptide precursor [Contains: Saposin A (Protein A); Saposin B-Val; Saposin B (Sphingolipid activator protein 1) (SAP-1) (Cerebroside sulfate activator) (CSAct) (Dispensir) (Sulfatide/GMT activator); Saposin C (Co-beta-glucosidase) (A1 activator) (Glucosylceramidase activator) (Sphingolipid activator protein 2) (SAP-2); Saposin D (Protein C) (Component C)] - Homo sapiens (Human)
225	2.9	22.2	P07711 CATL_HUMAN	Cathepsin L precursor (EC 3.4.22.15) (Major excreted protein) (MEP) [Contains: Cathepsin L heavy chain; Cathepsin L light chain] - Homo sapiens (Human)
210	1.4	5.1	P07711 CATL_HUMAN	Cathepsin L precursor (EC 3.4.22.15) (Major excreted protein) (MEP) [Contains: Cathepsin L heavy chain; Cathepsin L light chain] - Homo sapiens (Human)
438	2.0	7.8	P07711 CATL_HUMAN	Cathepsin L precursor (EC 3.4.22.15) (Major excreted protein) (MEP) [Contains: Cathepsin L heavy chain; Cathepsin L light chain] - Homo sapiens (Human)
29	20.9	61.4	P07737 PROF1_HUMAN	Profilin-1 (Profilin I) - Homo sapiens (Human)
21	13.4	61.4	P07737 PROF1_HUMAN	Profilin-1 (Profilin I) - Homo sapiens (Human)
36	22.5	82.1	P07737 PROF1_HUMAN	Profilin-1 (Profilin I) - Homo sapiens (Human)
48	15.7	34.2	P07858 CATB_HUMAN	Cathepsin B precursor (EC 3.4.22.11) (Cathepsin B1) (APP secretase) (APPS) [Contains: Cathepsin B light chain; Cathepsin B heavy chain] - Homo sapiens (Human)
71	4.9	28.0	P07858 CATB_HUMAN	Cathepsin B precursor (EC 3.4.22.11) (Cathepsin B1) (APP secretase) (APPS) [Contains: Cathepsin B light chain; Cathepsin B heavy chain] - Homo sapiens (Human)
51	17.4	38.3	P07858 CATB_HUMAN	Cathepsin B precursor (EC 3.4.22.11) (Cathepsin B1) (APP secretase) (APPS) [Contains: Cathepsin B light chain; Cathepsin B heavy chain] - Homo sapiens (Human)
117	16.0	29.9	P07900 HS90A_HUMAN	Heat shock protein HSP 90-alpha (HSP 86) (Renal carcinoma antigen NY-REN-38) - Homo sapiens (Human)
75	4.7	23.5	P07900 HS90A_HUMAN	Heat shock protein HSP 90-alpha (HSP 86) (Renal carcinoma antigen NY-REN-38) - Homo sapiens (Human)
20	29.4	29.9	P07900 HS90A_HUMAN	Heat shock protein HSP 90-alpha (HSP 86) (Renal carcinoma antigen NY-REN-38) - Homo sapiens (Human)
213	3.2	27.5	P07910 HNRPC_HUMAN	Heterogeneous nuclear ribonucleoprotein C1/C2 (hnRNP C1 / hnRNP C2) - Homo sapiens (Human)
241	5.0	8.8	P07910 HNRPC_HUMAN	Heterogeneous nuclear ribonucleoprotein C1/C2 (hnRNP C1 / hnRNP C2) - Homo sapiens (Human)
126	5.0	23.2	P08107 HSP71_HUMAN	Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2) - Homo sapiens (Human)
127	14.3	29.2	P08107 HSP71_HUMAN	Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2) - Homo sapiens (Human)
37	18.7	28.2	P08238 HS90B_HUMAN	Heat shock protein HSP 90-beta (HSP 84) (HSP 90) - Homo sapiens (Human)
197	3.6	24.4	P08238 HS90B_HUMAN	Heat shock protein HSP 90-beta (HSP 84) (HSP 90) - Homo sapiens (Human)
57	27.8	30.9	P08238 HS90B_HUMAN	Heat shock protein HSP 90-beta (HSP 84) (HSP 90) - Homo sapiens (Human)
182	4.0	18.1	P08571 CD14_HUMAN	Monocyte differentiation antigen CD14 precursor (Myeloid cell-specific leucine-rich glycoprotein) [Contains: Monocyte differentiation antigen CD14, urinary form; Monocyte differentiation antigen CD14, membrane-bound form] - Homo sapiens (Human)
145	2.1	16.3	P08571 CD14_HUMAN	Monocyte differentiation antigen CD14 precursor (Myeloid cell-specific leucine-rich glycoprotein) [Contains: Monocyte differentiation antigen CD14, urinary form; Monocyte differentiation antigen CD14, membrane-bound form] - Homo sapiens (Human)
548	2.0	4.8	P08571 CD14_HUMAN	Monocyte differentiation antigen CD14 precursor (Myeloid cell-specific leucine-rich glycoprotein) [Contains: Monocyte differentiation antigen CD14, urinary form; Monocyte differentiation antigen CD14, membrane-bound form] - Homo sapiens (Human)
323	2.0	6.7	P08575 CD45_HUMAN	Leukocyte common antigen precursor (EC 3.1.3.48) (L-Ca) (T200) (CD45 antigen) - Homo sapiens (Human)
250	4.7	3.7	P08575 CD45_HUMAN	Leukocyte common antigen precursor (EC 3.1.3.48) (L-Ca) (T200) (CD45 antigen) - Homo sapiens (Human)
8	44.3	62.2	P08670 VIME_HUMAN	Vimentin - Homo sapiens (Human)
8	22.8	70.6	P08670 VIME_HUMAN	Vimentin - Homo sapiens (Human)
3	63.4	70.0	P08670 VIME_HUMAN	Vimentin - Homo sapiens (Human)
99	8.0	18.6	P09211 GSTP1_HUMAN	Glutathione S-transferase P (EC 2.5.1.18) (GST class-pI) (GSTP1-1) - Homo sapiens (Human)
47	6.6	23.3	P09211 GSTP1_HUMAN	Glutathione S-transferase P (EC 2.5.1.18) (GST class-pI) (GSTP1-1) - Homo sapiens (Human)
96	11.7	37.6	P09211 GSTP1_HUMAN	Glutathione S-transferase P (EC 2.5.1.18) (GST class-pI) (GSTP1-1) - Homo sapiens (Human)
142	5.7	29.6	P09382 LEGI1_HUMAN	Galectin-1 (Lectin galactoside-binding soluble 1) (Beta-galactoside-binding lectin L-14-1) (Lactose-binding lectin 1) (S-Lac lectin 1) (Galaptin) (14 kDa lectin) (HBL) (Putative MAPK-activating protein MP12) - Homo sapiens (Human)
68	4.9	61.5	P09382 LEGI1_HUMAN	Galectin-1 (Lectin galactoside-binding soluble 1) (Beta-galactoside-binding lectin L-14-1) (Lactose-binding lectin 1) (S-Lac lectin 1) (Galaptin) (14 kDa lectin) (HBL) (Putative MAPK-activating protein MP12) - Homo sapiens (Human)
99	11.2	61.5	P09382 LEGI1_HUMAN	Galectin-1 (Lectin galactoside-binding soluble 1) (Beta-galactoside-binding lectin L-14-1) (Lactose-binding lectin 1) (S-Lac lectin 1) (Galaptin) (14 kDa lectin) (HBL) (Putative MAPK-activating protein MP12) - Homo sapiens (Human)
73	10.0	53.5	P09429 HMGB1_HUMAN	High mobility group protein B1 (High mobility group protein 1) (HMG-1) - Homo sapiens (Human)
40	7.5	33.5	P09429 HMGB1_HUMAN	High mobility group protein B1 (High mobility group protein 1) (HMG-1) - Homo sapiens (Human)
42	20.0	45.6	P09429 HMGB1_HUMAN	High mobility group protein B1 (High mobility group protein 1) (HMG-1) - Homo sapiens (Human)
203	1.5	11.3	P09496 CLCA_HUMAN	Clathrin light chain A (Lca) - Homo sapiens (Human)
315	4.0	12.9	P09496 CLCA_HUMAN	Clathrin light chain A (Lca) - Homo sapiens (Human)

65	13.9	51.1	P09651 ROA1_HUMAN	Heterogeneous nuclear ribonucleoprotein A1 (Helix-destabilizing protein) (Single-strand RNA-binding protein) (hnRNP core protein A1) - Homo sapiens (Human)
32	28.6	63.4	P09651 ROA1_HUMAN	Heterogeneous nuclear ribonucleoprotein A1 (Helix-destabilizing protein) (Single-strand RNA-binding protein) (hnRNP core protein A1) - Homo sapiens (Human)
224	2.9	3.9	P09874 PARP1_HUMAN	Poly (ADP-ribose) polymerase 1 (EC 2.4.2.30) (PARP-1) (ADPRT) (NAD(+) ADP-ribosyltransferase 1) (Poly[ADP-ribose] synthetase 1) - Homo sapiens (Human)
125	9.4	16.2	P09874 PARP1_HUMAN	Poly (ADP-ribose) polymerase 1 (EC 2.4.2.30) (PARP-1) (ADPRT) (NAD(+) ADP-ribosyltransferase 1) (Poly[ADP-ribose] synthetase 1) - Homo sapiens (Human)
342	2.0	5.1	P09960 LKHAA_HUMAN	Leukotriene A-4 hydrolase (EC 3.3.2.6) (LTA-4 hydrolase) (Leukotriene A(4) hydrolase) - Homo sapiens (Human)
115	9.9	14.1	P09960 LKHAA_HUMAN	Leukotriene A-4 hydrolase (EC 3.3.2.6) (LTA-4 hydrolase) (Leukotriene A(4) hydrolase) - Homo sapiens (Human)
82	9.0	39.2	P10124 PGSG_HUMAN	Secretory granule proteoglycan core protein precursor (Platelet proteoglycan core protein) (P.PG) (Hematopoietic proteoglycan core protein) (Serglycin) - Homo sapiens (Human)
48	6.5	39.2	P10124 PGSG_HUMAN	Secretory granule proteoglycan core protein precursor (Platelet proteoglycan core protein) (P.PG) (Hematopoietic proteoglycan core protein) (Serglycin) - Homo sapiens (Human)
179	6.4	39.2	P10124 PGSG_HUMAN	Secretory granule proteoglycan core protein precursor (Platelet proteoglycan core protein) (P.PG) (Hematopoietic proteoglycan core protein) (Serglycin) - Homo sapiens (Human)
105	7.7	56.6	P10145 IL8_HUMAN	Interleukin-8 precursor (IL-8) (CXCL8) (Monocyte-derived neutrophil chemotactic factor) (MDNCF) (T-cell chemotactic factor) (Neutrophil-activating protein 1) (NAP-1) (Protein 3-10C) (Granulocyte chemotactic protein 1) (GCP-1) (Monocyte-derived neutrophil-activating peptide) (MONAP) (Emotakin) [Contains: MDNCF-a (IL8/NAP1 form I) (GCP/IL-8 protein IV); Interleukin-8 (IL-8(1-77)) (MDNCF-b) (IL8/NAP1 form II) (GCP/IL-8 protein II) ((Ala-IL-8)77); IL-8(6-77) (Lymphocyte-derived neutrophil-activating factor) (LYNAP) (Neutrophil-activating factor) (NAF) (MDNCF-c) (IL8/NAP1 form III) (GCP/IL-8 protein I) ((Ser-IL-8)72); IL-8(7-77) (IL8/NAP1 form IV) (GCP/IL-8 protein V); IL-8(8-77) (IL8/NAP1 form V) (GCP/IL-8 protein VI); IL-8(9-77) (IL8/NAP1 form VI) (GCP/IL-8 protein VII)] - Homo sapiens (Human)
73	4.8	43.4	P10145 IL8_HUMAN	Interleukin-8 precursor (IL-8) (CXCL8) (Monocyte-derived neutrophil chemotactic factor) (MDNCF) (T-cell chemotactic factor) (Neutrophil-activating protein 1) (NAP-1) (Protein 3-10C) (Granulocyte chemotactic protein 1) (GCP-1) (Monocyte-derived neutrophil-activating peptide) (MONAP) (Emotakin) [Contains: MDNCF-a (IL8/NAP1 form I) (GCP/IL-8 protein IV); Interleukin-8 (IL-8(1-77)) (MDNCF-b) (IL8/NAP1 form II) (GCP/IL-8 protein II) ((Ala-IL-8)77); IL-8(6-77) (Lymphocyte-derived neutrophil-activating factor) (LYNAP) (Neutrophil-activating factor) (NAF) (MDNCF-c) (IL8/NAP1 form III) (GCP/IL-8 protein I) ((Ser-IL-8)72); IL-8(7-77) (IL8/NAP1 form IV) (GCP/IL-8 protein V); IL-8(8-77) (IL8/NAP1 form V) (GCP/IL-8 protein VI); IL-8(9-77) (IL8/NAP1 form VI) (GCP/IL-8 protein VII)] - Homo sapiens (Human)
133	8.4	49.5	P10145 IL8_HUMAN	Interleukin-8 precursor (IL-8) (CXCL8) (Monocyte-derived neutrophil chemotactic factor) (MDNCF) (T-cell chemotactic factor) (Neutrophil-activating protein 1) (NAP-1) (Protein 3-10C) (Granulocyte chemotactic protein 1) (GCP-1) (Monocyte-derived neutrophil-activating peptide) (MONAP) (Emotakin) [Contains: MDNCF-a (IL8/NAP1 form I) (GCP/IL-8 protein IV); Interleukin-8 (IL-8(1-77)) (MDNCF-b) (IL8/NAP1 form II) (GCP/IL-8 protein II) ((Ala-IL-8)77); IL-8(6-77) (Lymphocyte-derived neutrophil-activating factor) (LYNAP) (Neutrophil-activating factor) (NAF) (MDNCF-c) (IL8/NAP1 form III) (GCP/IL-8 protein I) ((Ser-IL-8)72); IL-8(7-77) (IL8/NAP1 form IV) (GCP/IL-8 protein V); IL-8(8-77) (IL8/NAP1 form V) (GCP/IL-8 protein VI); IL-8(9-77) (IL8/NAP1 form VI) (GCP/IL-8 protein VII)] - Homo sapiens (Human)
107	3.2	41.7	P10319 IB58_HUMAN	HLA class I histocompatibility antigen, B-58 alpha chain precursor (MHC class I antigen B*58) (Bw-58) - Homo sapiens (Human)
160	12.5	47.8	P10319 IB58_HUMAN	HLA class I histocompatibility antigen, B-58 alpha chain precursor (MHC class I antigen B*58) (Bw-58) - Homo sapiens (Human)
160	7.7	24.2	P10412 H14_HUMAN	Histone H1.4 (Histone H1b) - Homo sapiens (Human)
74	14.0	18.3	P10412 H14_HUMAN	Histone H1.4 (Histone H1b) - Homo sapiens (Human)
81	9.1	42.9	P10599 THIO_HUMAN	Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphhydryl protein) (SASP) - Homo sapiens (Human)
80	4.3	33.3	P10599 THIO_HUMAN	Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphhydryl protein) (SASP) - Homo sapiens (Human)
113	10.0	42.9	P10599 THIO_HUMAN	Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphhydryl protein) (SASP) - Homo sapiens (Human)
83	10.6	15.3	P11021 GRP78_HUMAN	78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 5) (Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum luminal Ca(2+)-binding protein grp78) - Homo sapiens (Human)
105	3.5	20.6	P11021 GRP78_HUMAN	78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 5) (Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum luminal Ca(2+)-binding protein grp78) - Homo sapiens (Human)
104	13.3	22.3	P11021 GRP78_HUMAN	78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 5) (Immunoglobulin heavy chain-binding protein) (BiP) (Endoplasmic reticulum luminal Ca(2+)-binding protein grp78) - Homo sapiens (Human)
26	21.5	28.9	P11142 HSP7C_HUMAN	Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) - Homo sapiens (Human)
15	16.6	32.5	P11142 HSP7C_HUMAN	Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) - Homo sapiens (Human)
9	43.1	46.0	P11142 HSP7C_HUMAN	Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) - Homo sapiens (Human)
101	7.7	22.9	P11413 G6PD_HUMAN	Glucose-6-phosphate 1-dehydrogenase (EC 1.1.1.49) (G6PD) - Homo sapiens (Human)
205	1.5	6.8	P11413 G6PD_HUMAN	Glucose-6-phosphate 1-dehydrogenase (EC 1.1.1.49) (G6PD) - Homo sapiens (Human)
100	11.1	20.8	P11413 G6PD_HUMAN	Glucose-6-phosphate 1-dehydrogenase (EC 1.1.1.49) (G6PD) - Homo sapiens (Human)
322	2.0	2.5	P11717 MPRI_HUMAN	Cation-independent mannose-6-phosphate receptor precursor (CI Man-6-P receptor) (CI-MPR) (M6PR) (Insulin-like growth factor 2 receptor) (Insulin-like growth factor II receptor) (IGF-II receptor) (M6P/IGF2 receptor) (M6P/IGF2R) (300 kDa manose 6-phosphate receptor) (MPR 300) (MPR300) (CD222 antigen) - Homo sapiens (Human)
201	1.5	6.2	P11717 MPRI_HUMAN	Cation-independent mannose-6-phosphate receptor precursor (CI Man-6-P receptor) (CI-MPR) (M6PR) (Insulin-like growth factor 2 receptor) (Insulin-like growth factor II receptor) (IGF-II receptor) (M6P/IGF2 receptor) (M6P/IGF2R) (300 kDa manose 6-phosphate receptor) (MPR 300) (MPR300) (CD222 antigen) - Homo sapiens (Human)
199	3.7	11.9	P11940 PABP1_HUMAN	Polyadenylate-binding protein 1 (Poly(A)-binding protein 1) (PABP 1) - Homo sapiens (Human)
117	2.6	18.4	P11940 PABP1_HUMAN	Polyadenylate-binding protein 1 (Poly(A)-binding protein 1) (PABP 1) - Homo sapiens (Human)
194	6.0	21.2	P11940 PABP1_HUMAN	Polyadenylate-binding protein 1 (Poly(A)-binding protein 1) (PABP 1) - Homo sapiens (Human)
367	2.0	2.0	P12955 PEPD_HUMAN	Xaa-Pro dipeptidase (EC 3.4.13.9) (X-Pro dipeptidase) (Proline dipeptidase) (Prolidase) (Imidodipeptidase) - Homo sapiens (Human)
572	1.5	3.4	P12955 PEPD_HUMAN	Xaa-Pro dipeptidase (EC 3.4.13.9) (X-Pro dipeptidase) (Proline dipeptidase) (Prolidase) (Imidodipeptidase) - Homo sapiens (Human)
227	2.9	11.8	P12956 KU70_HUMAN	ATP-dependent DNA helicase 2 subunit 1 (ATP-dependent DNA helicase II 70 kDa subunit) (Lupus Ku autoantigen protein p70) (Ku70) (70 kDa subunit of Ku antigen) (Thyroid-lipid autoantigen) (TLAA) (CTC box-binding factor 75 kDa subunit) (CTCBF) (CTC75) (DNA-repair protein XRC6 δ) - Homo sapiens (Human)
49	18.0	20.2	P12956 KU70_HUMAN	ATP-dependent DNA helicase 2 subunit 1 (ATP-dependent DNA helicase II 70 kDa subunit) (Lupus Ku autoantigen protein p70) (Ku70) (70 kDa subunit of Ku antigen) (Thyroid-lipid autoantigen) (TLAA) (CTC box-binding factor 75 kDa subunit) (CTCBF) (CTC75) (DNA-repair protein XRC6 δ) - Homo sapiens (Human)
366	2.0	4.2	P13284 GILT_HUMAN	Gamma-interferon-inducible lysosomal thiol reductase precursor (Gamma-interferon-inducible protein IP-30) - Homo sapiens (Human)
183	2.0	8.8	P13284 GILT_HUMAN	Gamma-interferon-inducible lysosomal thiol reductase precursor (Gamma-interferon-inducible protein IP-30) - Homo sapiens (Human)
545	2.0	4.2	P13284 GILT_HUMAN	Gamma-interferon-inducible lysosomal thiol reductase precursor (Gamma-interferon-inducible protein IP-30) - Homo sapiens (Human)
300	2.0	6.9	P13489 RINI_HUMAN	Ribonuclease inhibitor (Ribonuclease/angiogenin inhibitor 1) (RAI) (Placental ribonuclease inhibitor) (RNase inhibitor) (RI) - Homo sapiens (Human)
232	5.3	15.0	P13489 RINI_HUMAN	Ribonuclease inhibitor (Ribonuclease/angiogenin inhibitor 1) (RAI) (Placental ribonuclease inhibitor) (RNase inhibitor) (RI) - Homo sapiens (Human)
51	15.4	27.2	P13639 EF2_HUMAN	Elongation factor 2 (EF-2) - Homo sapiens (Human)
33	9.8	18.4	P13639 EF2_HUMAN	Elongation factor 2 (EF-2) - Homo sapiens (Human)
35	22.8	20.3	P13639 EF2_HUMAN	Elongation factor 2 (EF-2) - Homo sapiens (Human)
305	6.0	54.8	P13640 MT1G_HUMAN	Metallothionein-1G (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) - Homo sapiens (Human)
182	2.0	53.2	P13640 MT1G_HUMAN	Metallothionein-1G (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) - Homo sapiens (Human)
460	4.0	53.2	P13640 MT1G_HUMAN	Metallothionein-1G (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1G) (MT-1G) - Homo sapiens (Human)
299	2.0	6.5	P13686 PPA5_HUMAN	Tartrate-resistant acid phosphatase type 5 precursor (EC 3.1.3.2) (TR-AP) (Tartrate-resistant acid ATPase) (TrATPase) (Acid phosphatase 5, tartrate resistant) - Homo sapiens (Human)
144	2.1	15.7	P13686 PPA5_HUMAN	Tartrate-resistant acid phosphatase type 5 precursor (EC 3.1.3.2) (TR-AP) (Tartrate-resistant acid ATPase) (TrATPase) (Acid phosphatase 5, tartrate resistant) - Homo sapiens (Human)
247	4.9	12.3	P13686 PPA5_HUMAN	Tartrate-resistant acid phosphatase type 5 precursor (EC 3.1.3.2) (TR-AP) (Tartrate-resistant acid ATPase) (TrATPase) (Acid phosphatase 5, tartrate resistant) - Homo sapiens (Human)
24	22.6	37.5	P13796 PLSL_HUMAN	Plastin-2 (L-plastin) (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P) - Homo sapiens (Human)
18	14.2	31.4	P13796 PLSL_HUMAN	Plastin-2 (L-plastin) (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P) - Homo sapiens (Human)
25	26.0	32.2	P13796 PLSL_HUMAN	Plastin-2 (L-plastin) (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P) - Homo sapiens (Human)
194	4.0	17.4	P14174 MIF_HUMAN	Macrophage migration inhibitory factor (MIF) (Phenylpyruvate tautomerase) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) - Homo sapiens (Human)
94	4.0	17.4	P14174 MIF_HUMAN	Macrophage migration inhibitory factor (MIF) (Phenylpyruvate tautomerase) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) - Homo sapiens (Human)
193	6.0	22.6	P14174 MIF_HUMAN	Macrophage migration inhibitory factor (MIF) (Phenylpyruvate tautomerase) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) - Homo sapiens (Human)
153	4.6	17.9	P14317 HCLS1_HUMAN	Hematopoietic lineage cell-specific protein (Hematopoietic cell-specific LYN substrate 1) (LckBP1) (p75) - Homo sapiens (Human)
137	2.1	30.0	P14317 HCLS1_HUMAN	Hematopoietic lineage cell-specific protein (Hematopoietic cell-specific LYN substrate 1) (LckBP1) (p75) - Homo sapiens (Human)
130	8.7	13.8	P14317 HCLS1_HUMAN	Hematopoietic lineage cell-specific protein (Hematopoietic cell-specific LYN substrate 1) (LckBP1) (p75) - Homo sapiens (Human)
16	27.4	51.2	P14618 KPYH_HUMAN	Pyruvate kinase isozymes MT/M2 (EC 2.7.1.40) (Pyruvate kinase muscle isozyme) (Pyruvate kinase 2/3) (Cytosolic thyroid hormone-binding protein) (CTHBP) (THBP1) - Homo sapiens (Human)
49	6.4	37.1	P14618 KPYH_HUMAN	Pyruvate kinase isozymes MT/M2 (EC 2.7.1.40) (Pyruvate kinase muscle isozyme) (Pyruvate kinase 2/3) (Cytosolic thyroid hormone-binding protein) (CTHBP) (THBP1) - Homo sapiens (Human)
14	38.4	54.6	P14618 KPYH_HUMAN	Pyruvate kinase isozymes MT/M2 (EC 2.7.1.40) (Pyruvate kinase muscle isozyme) (Pyruvate kinase 2/3) (Cytosolic thyroid hormone-binding protein) (CTHBP) (THBP1) - Homo sapiens (Human)
316	2.0	8.8	P14625 ENPL_HUMAN	Endoplasmic precursor (Heat shock protein 90 kDa beta member 1) (94 kDa glucose-regulated protein) (GRP94) (gp96 homolog) (Tumor rejection antigen 1) - Homo sapiens (Human)
467	2.0	5.5	P14625 ENPL_HUMAN	Endoplasmic precursor (Heat shock protein 90 kDa beta member 1) (94 kDa glucose-regulated protein) (GRP94) (gp96 homolog) (Tumor rejection antigen 1) - Homo sapiens (Human)
6	46.9	48.9	P14780 MMP9_HUMAN	Matrix metalloproteinase-9 precursor (EC 3.4.24.35) (MMP-9) (92 kDa type IV collagenase) (92 kDa gelatinase) (Gelatinase B) (GELB) [Contains: 67 kDa matrix metalloproteinase-9; 82 kDa matrix metalloproteinase-9] - Homo sapiens (Human)
6	31.5	42.9	P14780 MMP9_HUMAN	Matrix metalloproteinase-9 precursor (EC 3.4.24.35) (MMP-9) (92 kDa type IV collagenase) (92 kDa gelatinase) (Gelatinase B) (GELB) [Contains: 67 kDa matrix metalloproteinase-9; 82 kDa matrix metalloproteinase-9] - Homo sapiens (Human)

8	44.0	50.2	P14780 MMP9_HUMAN	Matrix metalloproteinase-9 precursor (EC 3.4.24.35) (MMP-9) (92 kDa type IV collagenase) (92 kDa gelatinase) (Gelatinase B) (GELB) [Contains: 67 kDa matrix metalloproteinase-9; 82 kDa matrix metalloproteinase-9] - Homo sapiens (Human)
155	4.6	65.1	P14854 CX6B1_HUMAN	Cytochrome c oxidase subunit VIa isofrom 1 (EC 1.9.3.1) (COX VIb-1) - Homo sapiens (Human)
344	3.4	31.4	P14854 CX6B1_HUMAN	Cytochrome c oxidase subunit VIb isofrom 1 (EC 1.9.3.1) (COX VIb-1) - Homo sapiens (Human)
356	2.0	5.2	P15153 RAC2_HUMAN	Ras-related C3 botulinum toxin substrate 2 precursor (p21-Rac2) (Small G protein) (GX) - Homo sapiens (Human)
304	4.0	9.4	P15153 RAC2_HUMAN	Ras-related C3 botulinum toxin substrate 2 precursor (p21-Rac2) (Small G protein) (GX) - Homo sapiens (Human)
67	23.1	38.4	P15311 EZRI_HUMAN	Ezrin (p81) (Cytovillin) (Villin-2) - Homo sapiens (Human)
127	10.3	24.9	P15311 EZRI_HUMAN	Ezrin (p81) (Cytovillin) (Villin-2) - Homo sapiens (Human)
46	27.2	41.1	P15311 EZRI_HUMAN	Ezrin (p81) (Cytovillin) (Villin-2) - Homo sapiens (Human)
156	4.6	7.5	P16070 CD44_HUMAN	CD44 antigen precursor (Phagocytic glycoprotein I) (PGP-1) (HUTCH-I) (Extracellular matrix receptor-III) (ECMR-III) (GP90 lymphocyte homing/adhesion receptor) (Hermes antigen) (Hyaluronate receptor) (Heparan sulfate proteoglycan) (Epican) (CDw44) - Homo sapiens (Human)
109	3.2	6.9	P16070 CD44_HUMAN	CD44 antigen precursor (Phagocytic glycoprotein I) (PGP-1) (HUTCH-I) (Extracellular matrix receptor-III) (ECMR-III) (GP90 lymphocyte homing/adhesion receptor) (Hermes antigen) (Hyaluronate receptor) (Heparan sulfate proteoglycan) (Epican) (CDw44) - Homo sapiens (Human)
346	3.3	4.0	P16070 CD44_HUMAN	CD44 antigen precursor (Phagocytic glycoprotein I) (PGP-1) (HUTCH-I) (Extracellular matrix receptor-III) (ECMR-III) (GP90 lymphocyte homing/adhesion receptor) (Hermes antigen) (Hyaluronate receptor) (Heparan sulfate proteoglycan) (Epican) (CDw44) - Homo sapiens (Human)
193	4.0	13.4	P16152 CBR1_HUMAN	Carboxyl reductase [NADPH] 1 (EC 1.1.1.184) (NADPH-dependent carbonyl reductase 1) (Prostaglandin-E2 9-reductase) (EC 1.1.1.189) (Prostaglandin 9-ketoreductase) (15-hydroxyprostaglandin dehydrogenase [NADP+]) (EC 1.1.1.197) - Homo sapiens (Human)
329	3.7	13.4	P16152 CBR1_HUMAN	Carboxyl reductase [NADPH] 1 (EC 1.1.1.184) (NADPH-dependent carbonyl reductase 1) (Prostaglandin-E2 9-reductase) (EC 1.1.1.189) (Prostaglandin 9-ketoreductase) (15-hydroxyprostaglandin dehydrogenase [NADP+]) (EC 1.1.1.197) - Homo sapiens (Human)
246	2.3	22.6	P16401 H15_HUMAN	Histone H1.5 (Histone H1a) - Homo sapiens (Human)
235	6.0	23.5	P16401 H15_HUMAN	Histone H1.5 (Histone H1a) - Homo sapiens (Human)
309	3.7	30.3	P16402 H13_HUMAN	Histone H1.3 (Histone H1c) - Homo sapiens (Human)
451	6.0	23.5	P16402 H13_HUMAN	Histone H1.3 (Histone H1c) - Homo sapiens (Human)
102	7.7	23.5	P16403 H12_HUMAN	Histone H1.2 (Histone H1d) - Homo sapiens (Human)
227	11.4	22.1	P16403 H12_HUMAN	Histone H1.2 (Histone H1d) - Homo sapiens (Human)
297	2.0	21.5	P16949 STMN1_HUMAN	Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Protein Pr22) - Homo sapiens (Human)
149	2.0	12.8	P16949 STMN1_HUMAN	Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Protein Pr22) - Homo sapiens (Human)
243	4.9	27.5	P16949 STMN1_HUMAN	Stathmin (Phosphoprotein p19) (pp19) (Oncoprotein 18) (Op18) (Leukemia-associated phosphoprotein p18) (pp17) (Prosolin) (Metablastin) (Protein Pr22) - Homo sapiens (Human)
192	4.0	10.0	P17931 LEG3_HUMAN	Galectin-3 (Galactose-specific lectin 3) (Mac-2 antigen) (IgE-binding protein) (35 kDa lectin) (Carbohydrate-binding protein 35) (CBP 35) (Laminin-binding protein) (Lectin L-29) (L-31) (Galactoside-binding protein) (GALBP) - Homo sapiens (Human)
124	2.3	14.4	P17931 LEG3_HUMAN	Galectin-3 (Galactose-specific lectin 3) (Mac-2 antigen) (IgE-binding protein) (35 kDa lectin) (Carbohydrate-binding protein 35) (CBP 35) (Laminin-binding protein) (Lectin L-29) (L-31) (Galactoside-binding protein) (GALBP) - Homo sapiens (Human)
357	3.2	10.0	P17931 LEG3_HUMAN	Galectin-3 (Galactose-specific lectin 3) (Mac-2 antigen) (IgE-binding protein) (35 kDa lectin) (Carbohydrate-binding protein 35) (CBP 35) (Laminin-binding protein) (Lectin L-29) (L-31) (Galactoside-binding protein) (GALBP) - Homo sapiens (Human)
107	3.2	36.7	P18465 B1857_HUMAN	HLA class I histocompatibility antigen, B-57 alpha chain precursor (MHC class I antigen B*57) (Bw-57) - Homo sapiens (Human)
160	12.3	40.6	P18465 B1857_HUMAN	HLA class I histocompatibility antigen, B-57 alpha chain precursor (MHC class I antigen B*57) (Bw-57) - Homo sapiens (Human)
53	14.0	42.9	P18669 PGAM1_HUMAN	Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) (Phosphoglycerate mutase isozyme B) (PGAM-B) (BPG-dependent PGAM 1) - Homo sapiens (Human)
36	8.6	38.6	P18669 PGAM1_HUMAN	Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) (Phosphoglycerate mutase isozyme B) (PGAM-B) (BPG-dependent PGAM 1) - Homo sapiens (Human)
40	20.6	61.0	P18669 PGAM1_HUMAN	Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4) (EC 3.1.3.13) (Phosphoglycerate mutase isozyme B) (PGAM-B) (BPG-dependent PGAM 1) - Homo sapiens (Human)
128	6.0	33.9	P19105 MLRM_HUMAN	Myosin regulatory light chain 2, nonsarcomeric (Myosin RLC) - Homo sapiens (Human)
146	2.1	17.5	P19105 MLRM_HUMAN	Myosin regulatory light chain 2, nonsarcomeric (Myosin RLC) - Homo sapiens (Human)
151	8.0	29.2	P19105 MLRM_HUMAN	Myosin regulatory light chain 2, nonsarcomeric (Myosin RLC) - Homo sapiens (Human)
20	23.9	20.3	P19823 ITIH2_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin inhibitor complex component II) (Serum-derived hyaluronan-associated protein) (SHAP) - Homo sapiens (Human)
31	10.0	12.4	P19823 ITIH2_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin inhibitor complex component II) (Serum-derived hyaluronan-associated protein) (SHAP) - Homo sapiens (Human)
55	16.9	13.4	P19823 ITIH2_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H2 precursor (ITI heavy chain H2) (Inter-alpha-inhibitor heavy chain 2) (Inter-alpha-trypsin inhibitor complex component II) (Serum-derived hyaluronan-associated protein) (SHAP) - Homo sapiens (Human)
107	7.5	23.0	P19971 TYPH_HUMAN	Thymidine phosphorylase precursor (EC 2.4.2.4) (TdrPase) (TP) (Platelet-derived endothelial cell growth factor) (PD-ECGF) (Gliostatin) - Homo sapiens (Human)
416	2.1	8.9	P19971 TYPH_HUMAN	Thymidine phosphorylase precursor (EC 2.4.2.4) (TdrPase) (TP) (Platelet-derived endothelial cell growth factor) (PD-ECGF) (Gliostatin) - Homo sapiens (Human)
100	7.8	27.6	P20700 LMNB1_HUMAN	Lamin-B1 - Homo sapiens (Human)
97	11.5	26.1	P20700 LMNB1_HUMAN	Lamin-B1 - Homo sapiens (Human)
214	5.2	7.8	P20742 PPZ_HUMAN	Pregnancy zone protein precursor - Homo sapiens (Human)
358	7.7	8.4	P20742 PPZ_HUMAN	Pregnancy zone protein precursor - Homo sapiens (Human)
360	2.0	7.8	P21291 CSRP1_HUMAN	Cysteine and glycine-rich protein 1 (Cysteine-rich protein 1) (CRP1) (CRP) - Homo sapiens (Human)
527	2.0	7.8	P21291 CSRP1_HUMAN	Cysteine and glycine-rich protein 1 (Cysteine-rich protein 1) (CRP1) (CRP) - Homo sapiens (Human)
36	18.9	13.4	P21333 FLNA_HUMAN	Filamin-A (Alpha-filamin) (Filamin-1) (Endothelial actin-binding protein) (Actin-binding protein 280) (ABP-280) (Nonmuscle filamin) - Homo sapiens (Human)
29	10.2	7.9	P21333 FLNA_HUMAN	Filamin-A (Alpha-filamin) (Filamin-1) (Endothelial actin-binding protein) (Actin-binding protein 280) (ABP-280) (Nonmuscle filamin) - Homo sapiens (Human)
24	27.7	14.3	P21333 FLNA_HUMAN	Filamin-A (Alpha-filamin) (Filamin-1) (Endothelial actin-binding protein) (Actin-binding protein 280) (ABP-280) (Nonmuscle filamin) - Homo sapiens (Human)
261	2.2	9.4	P22314 UBE1_HUMAN	Ubiquitin-activating enzyme E1 (A1S9 protein) - Homo sapiens (Human)
226	5.4	5.3	P22314 UBE1_HUMAN	Ubiquitin-activating enzyme E1 (A1S9 protein) - Homo sapiens (Human)
131	6.0	44.7	P22392 NDKB_HUMAN	Nucleoside diphosphate kinase B (EC 2.7.4.6) (NDK B) (NDP kinase B) (nm23-H2) (C-myc purine-binding transcription factor PUF) - Homo sapiens (Human)
140	8.0	48.7	P22392 NDKB_HUMAN	Nucleoside diphosphate kinase B (EC 2.7.4.6) (NDK B) (NDP kinase B) (nm23-H2) (C-myc purine-binding transcription factor PUF) - Homo sapiens (Human)
134	6.0	25.2	P23246 SFPO_HUMAN	Splicing factor, proline- and glutamine-rich (Polypyrimidine tract-binding protein-associated-splicing factor) (PTB-associated-splicing factor) (PSF) (DNA-binding p52/p100 complex, 100 kDa subunit) (100 kDa DNA-binding protein) (hPOMp100) - Homo sapiens (Human)
212	1.3	16.4	P23246 SFPO_HUMAN	Splicing factor, proline- and glutamine-rich (Polypyrimidine tract-binding protein-associated-splicing factor) (PTB-associated-splicing factor) (PSF) (DNA-binding p52/p100 complex, 100 kDa subunit) (100 kDa DNA-pairing protein) (hPOMp100) - Homo sapiens (Human)
52	17.2	23.6	P23246 SFPO_HUMAN	Splicing factor, proline- and glutamine-rich (Polypyrimidine tract-binding protein-associated-splicing factor) (PTB-associated-splicing factor) (PSF) (DNA-binding p52/p100 complex, 100 kDa subunit) (100 kDa DNA-pairing protein) (hPOMp100) - Homo sapiens (Human)
248	2.3	10.1	P23284 PPIB_HUMAN	Peptidyl-prolyl cis-trans isomerase B precursor (EC 5.2.1.8) (PPase) (Rotamase) (Cyclophilin B) (S-cyclophilin) (SCYLP) (CYP-S1) - Homo sapiens (Human)
142	2.1	6.7	P23284 PPIB_HUMAN	Peptidyl-prolyl cis-trans isomerase B precursor (EC 5.2.1.8) (PPase) (Rotamase) (Cyclophilin B) (S-cyclophilin) (SCYLP) (CYP-S1) - Homo sapiens (Human)
38	18.5	32.7	P23381 SYWC_HUMAN	Tryptophanyl-tRNA synthetase, cytoplasmic (EC 6.1.1.2) (Tryptophanyl-tRNA ligase) (TrpRS) (IFP53) (hWRS) - Homo sapiens (Human)
110	3.1	24.8	P23381 SYWC_HUMAN	Tryptophanyl-tRNA synthetase, cytoplasmic (EC 6.1.1.2) (Tryptophanyl-tRNA ligase) (TrpRS) (IFP53) (hWRS) - Homo sapiens (Human)
43	19.9	32.9	P23381 SYWC_HUMAN	Tryptophanyl-tRNA synthetase, cytoplasmic (EC 6.1.1.2) (Tryptophanyl-tRNA ligase) (TrpRS) (IFP53) (hWRS) - Homo sapiens (Human)
54	13.7	60.2	P23528 COF1_HUMAN	Cofilin-1 (Cofilin, non-muscle isoform) (18 kDa phosphoprotein) (p18) - Homo sapiens (Human)
42	7.2	29.5	P23528 COF1_HUMAN	Cofilin-1 (Cofilin, non-muscle isoform) (18 kDa phosphoprotein) (p18) - Homo sapiens (Human)
37	22.3	51.8	P23528 COF1_HUMAN	Cofilin-1 (Cofilin, non-muscle isoform) (18 kDa phosphoprotein) (p18) - Homo sapiens (Human)
58	13.0	23.3	P25774 CATS_HUMAN	Cathepsin S precursor (EC 3.4.22.27) - Homo sapiens (Human)
39	8.0	30.2	P25774 CATS_HUMAN	Cathepsin S precursor (EC 3.4.22.27) - Homo sapiens (Human)
139	8.1	20.5	P25774 CATS_HUMAN	Cathepsin S precursor (EC 3.4.22.27) - Homo sapiens (Human)
144	5.3	26.2	P25786 PSA1_HUMAN	Proteasome subunit alpha type 1 (EC 3.4.25.1) (Proteasome component C2) (Macropain subunit C2) (Multicatalytic endopeptidase complex subunit C2) (Proteasome nu chain) (30 kDa prosomal protein) (PROS-30) - Homo sapiens (Human)
135	2.2	13.7	P25786 PSA1_HUMAN	Proteasome subunit alpha type 1 (EC 3.4.25.1) (Proteasome component C2) (Macropain subunit C2) (Multicatalytic endopeptidase complex subunit C2) (Proteasome nu chain) (30 kDa prosomal protein) (PROS-30) - Homo sapiens (Human)
118	9.7	26.2	P25786 PSA1_HUMAN	Proteasome subunit alpha type 1 (EC 3.4.25.1) (Proteasome component C2) (Macropain subunit C2) (Multicatalytic endopeptidase complex subunit C2) (Proteasome nu chain) (30 kDa prosomal protein) (PROS-30) - Homo sapiens (Human)
273	2.1	17.9	P25787 PSA2_HUMAN	Proteasome subunit alpha type 2 (EC 3.4.25.1) (Proteasome component C3) (Macropain subunit C3) (Multicatalytic endopeptidase complex subunit C3) - Homo sapiens (Human)
187	2.0	6.0	P25787 PSA2_HUMAN	Proteasome subunit alpha type 2 (EC 3.4.25.1) (Proteasome component C3) (Macropain subunit C3) (Multicatalytic endopeptidase complex subunit C3) - Homo sapiens (Human)
435	2.0	18.4	P25787 PSA2_HUMAN	Proteasome subunit alpha type 2 (EC 3.4.25.1) (Proteasome component C3) (Macropain subunit C3) (Multicatalytic endopeptidase complex subunit C3) - Homo sapiens (Human)
359	2.0	3.8	P25789 PSA4_HUMAN	Proteasome subunit alpha type 4 (EC 3.4.25.1) (Proteasome component C9) (Macropain subunit C9) (Multicatalytic endopeptidase complex subunit C9) (Proteasome subunit L) - Homo sapiens (Human)
147	2.0	12.6	P25789 PSA4_HUMAN	Proteasome subunit alpha type 4 (EC 3.4.25.1) (Proteasome component C9) (Macropain subunit C9) (Multicatalytic endopeptidase complex subunit C9) (Proteasome subunit L) - Homo sapiens (Human)
524	2.0	3.8	P25789 PSA4_HUMAN	Proteasome subunit alpha type 4 (EC 3.4.25.1) (Proteasome component C9) (Macropain subunit C9) (Multicatalytic endopeptidase complex subunit C9) (Proteasome subunit L) - Homo sapiens (Human)
7	44.9	56.7	P26038 MOES_HUMAN	Moesin (Membrane-organizing extension spike protein) - Homo sapiens (Human)
11	20.7	37.1	P26038 MOES_HUMAN	Moesin (Membrane-organizing extension spike protein) - Homo sapiens (Human)
5	53.4	55.3	P26038 MOES_HUMAN	Moesin (Membrane-organizing extension spike protein) - Homo sapiens (Human)

268	2.1	20.8	P26447 S10A4_HUMAN	Protein S100-A4 (S100 calcium-binding protein A4) (Metastasin) (Protein Mts1) (Placental calcium-binding protein) (Calvasculin) - Homo sapiens (Human)
181	2.0	19.8	P26447 S10A4_HUMAN	Protein S100-A4 (S100 calcium-binding protein A4) (Metastasin) (Protein Mts1) (Placental calcium-binding protein) (Calvasculin) - Homo sapiens (Human)
499	2.0	19.8	P26447 S10A4_HUMAN	Protein S100-A4 (S100 calcium-binding protein A4) (Metastasin) (Protein Mts1) (Placental calcium-binding protein) (Calvasculin) - Homo sapiens (Human)
264	8.2	39.7	P26583 HMGB2_HUMAN	High mobility group protein B2 (High mobility group protein 2) (HMG-2) - Homo sapiens (Human)
288	16.0	50.7	P26583 HMGB2_HUMAN	High mobility group protein B2 (High mobility group protein 2) (HMG-2) - Homo sapiens (Human)
159	2.0	28.9	P27695 APEX1_HUMAN	DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) (AP endonuclease 1) (APEX nuclelease) (APEN) (Protein REF-1) - Homo sapiens (Human)
158	7.6	24.8	P27695 APEX1_HUMAN	DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) (AP endonuclease 1) (APEX nuclelease) (APEN) (Protein REF-1) - Homo sapiens (Human)
123	6.0	13.9	P27797 CALR_HUMAN	Calreticulin precursor (CRP55) (Calregulin) (HACBP) (ERp60) (grp60) - Homo sapiens (Human)
86	12.2	25.4	P27797 CALR_HUMAN	Calreticulin precursor (CRP55) (Calregulin) (HACBP) (ERp60) (grp60) - Homo sapiens (Human)
131	2.2	13.0	P28062 PSBB_HUMAN	Proteasome subunit beta type 8 precursor (EC 3.4.25.1) (Proteasome component C13) (Macropain subunit C13) (Multicatalytic endopeptidase complex subunit C13) - Homo sapiens (Human)
149	8.0	21.7	P28062 PSBB_HUMAN	Proteasome subunit beta type 8 precursor (EC 3.4.25.1) (Proteasome component C13) (Macropain subunit C13) (Multicatalytic endopeptidase complex subunit C13) - Homo sapiens (Human)
190	4.0	14.1	P28066 PSA5_HUMAN	Proteasome subunit alpha type 5 (EC 3.4.25.1) (Proteasome zeta chain) (Macropain zeta chain) (Multicatalytic endopeptidase complex zeta chain) - Homo sapiens (Human)
169	6.7	26.6	P28066 PSA5_HUMAN	Proteasome subunit alpha type 5 (EC 3.4.25.1) (Proteasome zeta chain) (Macropain zeta chain) (Multicatalytic endopeptidase complex zeta chain) - Homo sapiens (Human)
136	2.2	22.3	P28070 PSB4_HUMAN	Proteasome subunit beta type 4 precursor (EC 3.4.25.1) (Proteasome beta chain) (Macropain beta chain) (Multicatalytic endopeptidase complex beta chain) (Proteasome chain 3) (HSN3) (HSproS26) - Homo sapiens (Human)
281	4.0	24.2	P28070 PSB4_HUMAN	Proteasome subunit beta type 4 precursor (EC 3.4.25.1) (Proteasome beta chain) (Macropain beta chain) (Multicatalytic endopeptidase complex beta chain) (Proteasome chain 3) (HSN3) (HSproS26) - Homo sapiens (Human)
175	4.0	11.9	P28482 MKO1_HUMAN	Mitogen-activated protein kinase 1 (EC 2.7.11.24) (Extracellular signal-regulated kinase 2) (ERK-2) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2) (p42-MAPK) (ERT1) - Homo sapiens (Human)
167	2.0	15.0	P28482 MKO1_HUMAN	Mitogen-activated protein kinase 1 (EC 2.7.11.24) (Extracellular signal-regulated kinase 2) (ERK-2) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2) (p42-MAPK) (ERT1) - Homo sapiens (Human)
229	2.8	13.2	P28799 GRN_HUMAN	Granulin precursor (Proepithelin) (PEPI) [Contains: Acrogranin; Paragranulin; Granulin-1 (Granulin G); Granulin-2 (Granulin F); Granulin-3 (Granulin B); Granulin-4 (Granulin A); Granulin-5 (Granulin C); Granulin-6 (Granulin D); Granulin-7 (Granulin E)] - Homo sapiens (Human)
368	2.9	10.1	P28799 GRN_HUMAN	Granulins precursor (Proepithelin) (PEPI) [Contains: Acrogranin; Paragranulin; Granulin-1 (Granulin G); Granulin-2 (Granulin F); Granulin-3 (Granulin B); Granulin-4 (Granulin A); Granulin-5 (Granulin C); Granulin-6 (Granulin D); Granulin-7 (Granulin E)] - Homo sapiens (Human)
32	20.0	37.2	P28838 AMPL_HUMAN	Cytosol aminopeptidase (EC 3.4.11.1) (Leucine aminopeptidase) (LAP) (Leucyl aminopeptidase) (Leucine aminopeptidase 3) (Proline aminopeptidase) (EC 3.4.11.5) (Prolyl aminopeptidase) (Peptidase S) - Homo sapiens (Human)
84	4.1	22.2	P28838 AMPL_HUMAN	Cytosol aminopeptidase (EC 3.4.11.1) (Leucine aminopeptidase) (LAP) (Leucyl aminopeptidase) (Leucine aminopeptidase 3) (Proline aminopeptidase) (EC 3.4.11.5) (Prolyl aminopeptidase) (Peptidase S) - Homo sapiens (Human)
44	19.5	30.1	P28838 AMPL_HUMAN	Cytosol aminopeptidase (EC 3.4.11.1) (Leucine aminopeptidase) (LAP) (Leucyl aminopeptidase) (Leucine aminopeptidase 3) (Proline aminopeptidase) (EC 3.4.11.5) (Prolyl aminopeptidase) (Peptidase S) - Homo sapiens (Human)
287	2.0	7.4	P29350 PTN6_HUMAN	Tyrosine-protein phosphatase non-receptor type 6 (EC 3.1.3.48) (Protein-tirosine phosphatase 1C) (PTP-1C) (Hematopoietic cell protein-tirosine phosphatase) (SH-PTP1) (Protein-tirosine phosphatase SHP-1) - Homo sapiens (Human)
128	9.2	25.0	P29350 PTN6_HUMAN	Tyrosine-protein phosphatase non-receptor type 6 (EC 3.1.3.48) (Protein-tirosine phosphatase 1C) (PTP-1C) (Hematopoietic cell protein-tirosine phosphatase) (SH-PTP1) (Protein-tirosine phosphatase SHP-1) - Homo sapiens (Human)
66	11.8	22.8	P29401 TKT_HUMAN	Transketolase (EC 2.2.1.1) (TK) - Homo sapiens (Human)
62	5.6	23.4	P29401 TKT_HUMAN	Transketolase (EC 2.2.1.1) (TK) - Homo sapiens (Human)
53	17.1	30.0	P29401 TKT_HUMAN	Transketolase (EC 2.2.1.1) (TK) - Homo sapiens (Human)
215	3.2	18.3	P30041 PRDX6_HUMAN	Peroxiredoxin-6 (EC 1.11.1.15) (Antioxidant protein 2) (1-Cys peroxiredoxin) (1-Cys PRX) (Acidic calcium-independent phospholipase A2) (EC 3.1.1.-) (alpL2) (Non-selenin glutathione peroxidase) (EC 1.11.1.7) (NSGPx) (24 kDa protein) (Liver 2D page spot 40) (Red blood cells page spot 12) - Homo sapiens (Human)
561	1.7	12.9	P30041 PRDX6_HUMAN	Peroxiredoxin-6 (EC 1.11.1.15) (Antioxidant protein 2) (1-Cys peroxiredoxin) (1-Cys PRX) (Acidic calcium-independent phospholipase A2) (EC 3.1.1.-) (alpL2) (Non-selenin glutathione peroxidase) (EC 1.11.1.7) (NSGPx) (24 kDa protein) (Liver 2D page spot 40) (Red blood cells page spot 12) - Homo sapiens (Human)
365	2.0	9.3	P30046 DOPD_HUMAN	D-dopachrome decarboxylase (EC 4.1.1.84) (D-dopachrome tautomerase) (Phenylpyruvate tautomerase II) - Homo sapiens (Human)
542	2.0	9.3	P30046 DOPD_HUMAN	D-dopachrome decarboxylase (EC 4.1.1.84) (D-dopachrome tautomerase) (Phenylpyruvate tautomerase II) - Homo sapiens (Human)
331	2.0	17.0	P30050 RL12_HUMAN	60S ribosomal protein L12 - Homo sapiens (Human)
411	2.2	19.4	P30050 RL12_HUMAN	60S ribosomal protein L12 - Homo sapiens (Human)
184	4.0	31.0	P30086 PEBP1_HUMAN	Phosphatidylethanolamine-binding protein 1 (PEBP-1) (Prostatic-binding protein) (HCNPpp) (Neuropolypeptide h3) (Raf kinase inhibitor protein) (RKIP) (Contains: Hippocampal cholinergic neurostimulating peptide (HCNP)) - Homo sapiens (Human)
102	10.6	55.1	P30086 PEBP1_HUMAN	Phosphatidylethanolamine-binding protein 1 (PEBP-1) (Prostatic-binding protein) (HCNPpp) (Neuropolypeptide h3) (Raf kinase inhibitor protein) (RKIP) (Contains: Hippocampal cholinergic neurostimulating peptide (HCNP)) - Homo sapiens (Human)
97	8.0	16.4	P30101 PDIA3_HUMAN	Protein disulfide-isomerase A3 precursor (EC 5.3.4.1) (Disulfide isomerase ER-60) (ERp60) (58 kDa microsomal protein) (p58) (ERp57) (58 kDa glucose-regulated protein) - Homo sapiens (Human)
61	5.8	17.8	P30101 PDIA3_HUMAN	Protein disulfide-isomerase A3 precursor (EC 5.3.4.1) (Disulfide isomerase ER-60) (ERp60) (58 kDa microsomal protein) (p58) (ERp57) (58 kDa glucose-regulated protein) - Homo sapiens (Human)
63	15.7	23.6	P30101 PDIA3_HUMAN	Protein disulfide-isomerase A3 precursor (EC 5.3.4.1) (Disulfide isomerase ER-60) (ERp60) (58 kDa microsomal protein) (p58) (ERp57) (58 kDa glucose-regulated protein) - Homo sapiens (Human)
270	7.4	30.9	P30508 1C12_HUMAN	HLA class I histocompatibility antigen, Cw-12 alpha chain precursor (MHC class I antigen Cw*12) - Homo sapiens (Human)
59	16.6	48.9	P30508 1C12_HUMAN	HLA class I histocompatibility antigen, Cw-12 alpha chain precursor (MHC class I antigen Cw*12) - Homo sapiens (Human)
272	2.1	11.3	P30740 ILEU_HUMAN	Leukocyte elastase inhibitor (LEI) (Serpin B1) (Monocyte/neutrophil elastase inhibitor) (M/NEI) (EI) - Homo sapiens (Human)
155	7.7	14.0	P30740 ILEU_HUMAN	Leukocyte elastase inhibitor (LEI) (Serpin B1) (Monocyte/neutrophil elastase inhibitor) (M/NEI) (EI) - Homo sapiens (Human)
25	21.5	32.8	P31146 COR1A_HUMAN	Coronin-1A (Coronin-like protein p57) (Coronin-like protein A1) (Clipin-A) (Tryptophan aspartate-containing coat protein) (TACO) - Homo sapiens (Human)
20	13.9	28.2	P31146 COR1A_HUMAN	Coronin-1A (Coronin-like protein p57) (Coronin-like protein A1) (Clipin-A) (Tryptophan aspartate-containing coat protein) (TACO) - Homo sapiens (Human)
26	25.9	41.2	P31146 COR1A_HUMAN	Coronin-1A (Coronin-like protein p57) (Coronin-like protein A1) (Clipin-A) (Tryptophan aspartate-containing coat protein) (TACO) - Homo sapiens (Human)
177	4.0	12.2	P31153 METK2_HUMAN	S-adenosylmethionine synthetase isomeric type-2 (EC 2.5.1.6) (Methionine adenosyltransferase 2) (AdoMet synthetase 2) (Methionine adenosyltransferase II) (MAT-II) - Homo sapiens (Human)
239	5.0	18.7	P31153 METK2_HUMAN	S-adenosylmethionine synthetase isomeric type-2 (EC 2.5.1.6) (Methionine adenosyltransferase 2) (AdoMet synthetase 2) (Methionine adenosyltransferase II) (MAT-II) - Homo sapiens (Human)
310	2.4	37.1	P31949 S10AB_HUMAN	Protein S100-A11 (S100 calcium-binding protein A11) (Protein S100C) (Calgizzarin) (MLN 70) - Homo sapiens (Human)
189	2.0	10.5	P31949 S10AB_HUMAN	Protein S100-A11 (S100 calcium-binding protein A11) (Protein S100C) (Calgizzarin) (MLN 70) - Homo sapiens (Human)
210	6.0	46.7	P31949 S10AB_HUMAN	Protein S100-A11 (S100 calcium-binding protein A11) (Protein S100C) (Calgizzarin) (MLN 70) - Homo sapiens (Human)
42	17.7	37.7	P32455 GBP1_HUMAN	Interferon-induced guanylate-binding protein 1 (GTP-binding protein 1) (Guanine nucleotide-binding protein 1) (GBP-1) (HuGBP-1) - Homo sapiens (Human)
54	17.0	27.2	P32455 GBP1_HUMAN	Interferon-induced guanylate-binding protein 1 (GTP-binding protein 1) (Guanine nucleotide-binding protein 1) (GBP-1) (HuGBP-1) - Homo sapiens (Human)
222	5.0	14.9	P32456 GBP2_HUMAN	Interferon-induced guanylate-binding protein 2 (GTP-binding protein 2) (Guanine nucleotide-binding protein 2) (GBP-2) (HuGBP-2) - Homo sapiens (Human)
234	7.3	9.6	P32456 GBP2_HUMAN	Interferon-induced guanylate-binding protein 2 (GTP-binding protein 2) (Guanine nucleotide-binding protein 2) (GBP-2) (HuGBP-2) - Homo sapiens (Human)
168	4.2	21.5	P33241 LSP1_HUMAN	Lymphocyte-specific protein 1 (Protein pp52) (52 kDa phosphoprotein) (Lymphocyte-specific antigen WP34) (47 kDa actin-binding protein) - Homo sapiens (Human)
84	12.3	35.7	P33241 LSP1_HUMAN	Lymphocyte-specific protein 1 (Protein pp52) (52 kDa phosphoprotein) (Lymphocyte-specific antigen WP34) (47 kDa actin-binding protein) - Homo sapiens (Human)
35	18.9	31.7	P35579 MYH9_HUMAN	Myosin-9 (Myosin heavy chain, nonmuscle IIa) (Nonmuscle myosin heavy chain IIa) (NMHC-IIa) - Homo sapiens (Human)
17	36.9	25.6	P35579 MYH9_HUMAN	Myosin-9 (Myosin heavy chain, nonmuscle IIa) (Nonmuscle myosin heavy chain IIa) (NMHC-IIa) - Homo sapiens (Human)
104	7.7	18.3	P36222 CH3L1_HUMAN	Chitinase-3-like protein 1 precursor (Cartilage glycoprotein 39) (GP-39) (39 kDa synovial protein) (HCgp-39) (YKL-40) - Homo sapiens (Human)
168	2.0	15.7	P36222 CH3L1_HUMAN	Chitinase-3-like protein 1 precursor (Cartilage glycoprotein 39) (GP-39) (39 kDa synovial protein) (HCgp-39) (YKL-40) - Homo sapiens (Human)
38	22.0	43.9	P36222 CH3L1_HUMAN	Chitinase-3-like protein 1 precursor (Cartilage glycoprotein 39) (GP-39) (39 kDa synovial protein) (HCgp-39) (YKL-40) - Homo sapiens (Human)
143	5.4	51.8	P37802 TAGL2_HUMAN	Transgelin-2 (SM22-alpha homolog) - Homo sapiens (Human)
97	3.8	32.7	P37802 TAGL2_HUMAN	Transgelin-2 (SM22-alpha homolog) - Homo sapiens (Human)
66	14.8	61.3	P37802 TAGL2_HUMAN	Transgelin-2 (SM22-alpha homolog) - Homo sapiens (Human)
220	3.1	18.4	P37837 TALDO_HUMAN	Transaldolase (EC 2.2.1.2) - Homo sapiens (Human)
209	1.4	6.8	P37837 TALDO_HUMAN	Transaldolase (EC 2.2.1.2) - Homo sapiens (Human)
219	5.9	11.9	P37837 TALDO_HUMAN	Transaldolase (EC 2.2.1.2) - Homo sapiens (Human)
294	2.0	39.4	P38159 HNRPG_HUMAN	Heterogeneous nuclear ribonucleoprotein G (hnRNP G) (RNA-binding motif protein, X chromosome) (Glycoprotein p43) - Homo sapiens (Human)
151	2.0	33.2	P38159 HNRPG_HUMAN	Heterogeneous nuclear ribonucleoprotein G (hnRNP G) (RNA-binding motif protein, X chromosome) (Glycoprotein p43) - Homo sapiens (Human)
107	10.1	32.5	P38159 HNRPG_HUMAN	Heterogeneous nuclear ribonucleoprotein G (hnRNP G) (RNA-binding motif protein, X chromosome) (Glycoprotein p43) - Homo sapiens (Human)

231	2.0	3.9	P38919 IF4A3_HUMAN	Eukaryotic initiation factor 4A-III (EC 3.6.1.-) (Eukaryotic translation initiation factor 4A isoform 3) (ATP-dependent RNA helicase eIF4A-3) (ATP-dependent RNA helicase DDX48) (DEAD box protein 48) (Eukaryotic initiation factor 4A-like NUK-34) (Nuclear matrix protein 265) (HNMP 265) - Homo sapiens (Human)
164	2.0	17.0	P38919 IF4A3_HUMAN	Eukaryotic initiation factor 4A-III (EC 3.6.1.-) (Eukaryotic translation initiation factor 4A isoform 3) (ATP-dependent RNA helicase eIF4A-3) (ATP-dependent RNA helicase DDX48) (DEAD box protein 48) (Eukaryotic initiation factor 4A-like NUK-34) (Nuclear matrix protein 265) (HNMP 265) - Homo sapiens (Human)
428	2.0	3.9	P38919 IF4A3_HUMAN	Eukaryotic initiation factor 4A-III (EC 3.6.1.-) (Eukaryotic translation initiation factor 4A isoform 3) (ATP-dependent RNA helicase eIF4A-3) (ATP-dependent RNA helicase DDX48) (DEAD box protein 48) (Eukaryotic initiation factor 4A-like NUK-34) (Nuclear matrix protein 265) (HNMP 265) - Homo sapiens (Human)
72	10.1	30.2	P40121 CAPG_HUMAN	Macrophage-capping protein (Actin-regulatory protein CAP-G) - Homo sapiens (Human)
30	10.0	23.0	P40121 CAPG_HUMAN	Macrophage-capping protein (Actin-regulatory protein CAP-G) - Homo sapiens (Human)
181	6.4	19.3	P40121 CAPG_HUMAN	Macrophage-capping protein (Actin-regulatory protein CAP-G) - Homo sapiens (Human)
63	12.0	26.3	P40925 MDHC_HUMAN	Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Cytosolic malate dehydrogenase) - Homo sapiens (Human)
58	6.0	12.9	P40925 MDHC_HUMAN	Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Cytosolic malate dehydrogenase) - Homo sapiens (Human)
90	12.0	31.4	P40925 MDHC_HUMAN	Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Cytosolic malate dehydrogenase) - Homo sapiens (Human)
280	2.1	17.2	P40926 MDHM_HUMAN	Malate dehydrogenase, mitochondrial precursor (EC 1.1.1.37) - Homo sapiens (Human)
71	14.1	42.6	P40926 MDHM_HUMAN	Malate dehydrogenase, mitochondrial precursor (EC 1.1.1.37) - Homo sapiens (Human)
60	12.8	19.9	P42224 STAT1_HUMAN	Signal transducer and activator of transcription 1-alpha/beta (Transcription factor ISGF-3 components p91/p84) - Homo sapiens (Human)
83	4.1	11.2	P42224 STAT1_HUMAN	Signal transducer and activator of transcription 1-alpha/beta (Transcription factor ISGF-3 components p91/p84) - Homo sapiens (Human)
58	16.7	19.1	P42224 STAT1_HUMAN	Signal transducer and activator of transcription 1-alpha/beta (Transcription factor ISGF-3 components p91/p84) - Homo sapiens (Human)
55	13.4	20.2	P43490 NAMP_T_HUMAN	Nicotinamide phosphoribosyltransferase (EC 2.4.2.12) (NAMPRTase) (Nampt) (Pre-B cell-enhancing factor) (Pre-B cell-colony-enhancing factor 1) (Visfatin) - Homo sapiens (Human)
341	3.4	6.3	P43490 NAMP_T_HUMAN	Nicotinamide phosphoribosyltransferase (EC 2.4.2.12) (NAMPRTase) (Nampt) (Pre-B cell-enhancing factor) (Pre-B cell-colony-enhancing factor 1) (Visfatin) - Homo sapiens (Human)
244	2.3	24.9	P46777 RLS_HUMAN	60S ribosomal protein L5 - Homo sapiens (Human)
79	13.3	35.0	P46777 RLS_HUMAN	60S ribosomal protein L5 - Homo sapiens (Human)
210	3.3	47.9	P46781 RS9_HUMAN	40S ribosomal protein S9 - Homo sapiens (Human)
220	5.8	28.4	P46781 RS9_HUMAN	40S ribosomal protein S9 - Homo sapiens (Human)
162	4.4	11.2	P46940 IOGA1_HUMAN	Ras GTP-activating-like protein IOGA1 (p195) - Homo sapiens (Human)
180	6.4	6.8	P46940 IOGA1_HUMAN	Ras GTP-activating-like protein IOGA1 (p195) - Homo sapiens (Human)
329	2.0	10.3	P48739 PIPNB_HUMAN	Phosphatidylinositol transfer protein beta isoform (Ptldns transfer protein beta) (PtldnsTP) (PI-TP-beta) - Homo sapiens (Human)
473	2.0	14.4	P48739 PIPNB_HUMAN	Phosphatidylinositol transfer protein beta isoform (Ptldns transfer protein beta) (PtldnsTP) (PI-TP-beta) - Homo sapiens (Human)
285	2.0	14.7	P49368 TCPG_HUMAN	T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (hTRiCS) - Homo sapiens (Human)
87	12.2	23.9	P49368 TCPG_HUMAN	T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (hTRiCS) - Homo sapiens (Human)
91	8.1	20.4	P50395 GDIB_HUMAN	Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate dissociation inhibitor 2) (GDI-2) - Homo sapiens (Human)
54	6.1	16.0	P50395 GDIB_HUMAN	Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate dissociation inhibitor 2) (GDI-2) - Homo sapiens (Human)
75	13.8	25.4	P50395 GDIB_HUMAN	Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate dissociation inhibitor 2) (GDI-2) - Homo sapiens (Human)
379	1.7	12.2	P50453 SPB9_HUMAN	Serpin B9 (Cytoplasmic antiproteinase 3) (CAP-3) (CAP3) (Protease inhibitor 9) - Homo sapiens (Human)
209	6.0	14.9	P50453 SPB9_HUMAN	Serpin B9 (Cytoplasmic antiproteinase 3) (CAP-3) (CAP3) (Protease inhibitor 9) - Homo sapiens (Human)
138	5.8	21.1	P50552 VASP_HUMAN	Vasodilator-stimulated phosphoprotein (VASP) - Homo sapiens (Human)
83	12.7	31.8	P50552 VASP_HUMAN	Vasodilator-stimulated phosphoprotein (VASP) - Homo sapiens (Human)
113	2.9	7.3	P50990 TCPQ_HUMAN	T-complex protein 1 subunit theta (TCP-1-theta) (Renal carcinoma antigen NY-REN-15) - Homo sapiens (Human)
208	6.0	6.4	P50990 TCPQ_HUMAN	T-complex protein 1 subunit theta (TCP-1-theta) (CCT-theta) (Renal carcinoma antigen NY-REN-15) - Homo sapiens (Human)
209	3.4	11.6	P51149 RAB7A_HUMAN	Ras-related protein Rab-7a - Homo sapiens (Human)
362	3.0	20.3	P51149 RAB7A_HUMAN	Ras-related protein Rab-7a - Homo sapiens (Human)
208	3.7	29.6	P51991 ROA3_HUMAN	Heterogeneous nuclear ribonucleoprotein A3 (hnRNP A3) - Homo sapiens (Human)
162	7.4	39.7	P51991 ROA3_HUMAN	Heterogeneous nuclear ribonucleoprotein A3 (hnRNP A3) - Homo sapiens (Human)
50	15.5	26.3	P52209 6PGD_HUMAN	6-phosphogluconate dehydrogenase, decarboxylating (EC 1.1.1.44) - Homo sapiens (Human)
121	2.4	10.8	P52209 6PGD_HUMAN	6-phosphogluconate dehydrogenase, decarboxylating (EC 1.1.1.44) - Homo sapiens (Human)
414	2.2	13.5	P52209 6PGD_HUMAN	6-phosphogluconate dehydrogenase, decarboxylating (EC 1.1.1.44) - Homo sapiens (Human)
86	8.8	51.0	P52565 GDIR_HUMAN	Rho GDP-dissociation inhibitor 1 (Rho GDI 1) (Rho-GDI alpha) - Homo sapiens (Human)
82	4.1	26.0	P52565 GDIR_HUMAN	Rho GDP-dissociation inhibitor 1 (Rho GDI 1) (Rho-GDI alpha) - Homo sapiens (Human)
28	24.6	49.0	P52565 GDIR_HUMAN	Rho GDP-dissociation inhibitor 1 (Rho GDI 1) (Rho-GDI alpha) - Homo sapiens (Human)
269	2.1	49.3	P52566 GDIS_HUMAN	Rho GDP-dissociation inhibitor 2 (Rho GDI 2) (Rho-GDI beta) (Ly-GDI) - Homo sapiens (Human)
101	12.0	49.8	P52566 GDIS_HUMAN	Rho GDP-dissociation inhibitor 2 (Rho GDI 2) (Rho-GDI beta) (Ly-GDI) - Homo sapiens (Human)
230	2.7	12.3	P52597 HNRPF_HUMAN	Heterogeneous nuclear ribonucleoprotein F (hnRNP F) (Nucleolin-like protein mcs94-1) - Homo sapiens (Human)
334	6.0	20.7	P52597 HNRPF_HUMAN	Heterogeneous nuclear ribonucleoprotein F (hnRNP F) (Nucleolin-like protein mcs94-1) - Homo sapiens (Human)
282	2.1	15.4	P52907 CAZ1_HUMAN	F-actin capping protein subunit alpha-1 (Cap2 alpha-1) - Homo sapiens (Human)
166	2.0	19.2	P52907 CAZ1_HUMAN	F-actin capping protein subunit alpha-1 (Cap2 alpha-1) - Homo sapiens (Human)
233	5.3	19.9	P52907 CAZ1_HUMAN	F-actin capping protein subunit alpha-1 (Cap2 alpha-1) - Homo sapiens (Human)
311	2.0	3.7	P53634 CATC_HUMAN	Dipeptidyl-peptidase 1 precursor (EC 3.4.14.1) (Dipeptidyl-peptidase I) (DPP-I) (DPPI) (Cathepsin C) (Cathepsin J) (Dipeptidyl transferase) [Contains: Dipeptidyl-peptidase 1 exclusion domain chain (Dipeptidyl-peptidase I exclusion domain chain); Dipeptidyl-peptidase 1 heavy chain (Dipeptidyl-peptidase I heavy chain); Dipeptidyl-peptidase 1 light chain (Dipeptidyl-peptidase I light chain)] - Homo sapiens (Human)
101	3.5	11.9	P53634 CATC_HUMAN	Dipeptidyl-peptidase 1 precursor (EC 3.4.14.1) (Dipeptidyl-peptidase I) (DPP-I) (DPPI) (Cathepsin C) (Cathepsin J) (Dipeptidyl transferase) [Contains: Dipeptidyl-peptidase 1 exclusion domain chain (Dipeptidyl-peptidase I exclusion domain chain); Dipeptidyl-peptidase 1 heavy chain (Dipeptidyl-peptidase I heavy chain); Dipeptidyl-peptidase 1 light chain (Dipeptidyl-peptidase I light chain)] - Homo sapiens (Human)
126	6.0	28.9	P54819 KAD2_HUMAN	Adenylate kinase isoenzyme 2, mitochondrial (EC 2.7.4.3) (ATP-AMP transphosphorylase) - Homo sapiens (Human)
118	2.6	30.5	P54819 KAD2_HUMAN	Adenylate kinase isoenzyme 2, mitochondrial (EC 2.7.4.3) (ATP-AMP transphosphorylase) - Homo sapiens (Human)
189	6.1	34.7	P54819 KAD2_HUMAN	Adenylate kinase isoenzyme 2, mitochondrial (EC 2.7.4.3) (ATP-AMP transphosphorylase) - Homo sapiens (Human)
61	12.8	18.7	P55072 TERA_HUMAN	Transitional endoplasmic reticulum ATPase (TER ATPase) (155 Mg(2+)-ATPase p97 subunit) (Valosin-containing protein) (VCP) - Homo sapiens (Human)
45	19.1	25.3	P55072 TERA_HUMAN	Transitional endoplasmic reticulum ATPase (TER ATPase) (155 Mg(2+)-ATPase p97 subunit) (Valosin-containing protein) (VCP) - Homo sapiens (Human)
187	4.0	10.0	P55209 NP1L1_HUMAN	Nucleosome assembly protein 1-like 1 (NAP-1-related protein) (hNRP) - Homo sapiens (Human)
98	3.8	10.2	P55209 NP1L1_HUMAN	Nucleosome assembly protein 1-like 1 (NAP-1-related protein) (hNRP) - Homo sapiens (Human)
198	6.0	10.5	P55209 NP1L1_HUMAN	Nucleosome assembly protein 1-like 1 (NAP-1-related protein) (hNRP) - Homo sapiens (Human)
181	4.0	6.7	P55786 PSA_HUMAN	Puromycin-sensitive aminopeptidase (EC 3.4.11.-) (PSA) - Homo sapiens (Human)
152	2.0	7.5	P55786 PSA_HUMAN	Puromycin-sensitive aminopeptidase (EC 3.4.11.-) (PSA) - Homo sapiens (Human)
407	2.3	3.8	P55786 PSA_HUMAN	Puromycin-sensitive aminopeptidase (EC 3.4.11.-) (PSA) - Homo sapiens (Human)
327	2.0	19.0	P59998 ARPC4_HUMAN	Actin-related protein 2/3 complex subunit 4 (ARP2/3 complex 20 kDa subunit) (p20-ARC) - Homo sapiens (Human)
123	2.3	23.8	P59998 ARPC4_HUMAN	Actin-related protein 2/3 complex subunit 4 (ARP2/3 complex 20 kDa subunit) (p20-ARC) - Homo sapiens (Human)
197	6.0	29.8	P59998 ARPC4_HUMAN	Actin-related protein 2/3 complex subunit 4 (ARP2/3 complex 20 kDa subunit) (p20-ARC) - Homo sapiens (Human)
40	18.1	57.0	P60174 TPIS_HUMAN	Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-phosphate isomerase) - Homo sapiens (Human)
13	18.3	66.7	P60174 TPIS_HUMAN	Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-phosphate isomerase) - Homo sapiens (Human)
23	28.0	61.0	P60174 TPIS_HUMAN	Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-phosphate isomerase) - Homo sapiens (Human)
122	6.1	50.3	P60660 MYL6_HUMAN	Myosin light polypeptide 6 (Smooth muscle and nonmuscle myosin light chain alkali 6) (Myosin light chain alkali 3) (Myosin light chain 3) (MLC-3) (LC17) - Homo sapiens (Human)
65	5.2	31.1	P60660 MYL6_HUMAN	Myosin light polypeptide 6 (Smooth muscle and nonmuscle myosin light chain alkali 6) (Myosin light chain alkali 3) (Myosin light chain 3) (MLC-3) (LC17) - Homo sapiens (Human)
112	10.0	50.3	P60660 MYL6_HUMAN	Myosin light polypeptide 6 (Smooth muscle and nonmuscle myosin light chain alkali 6) (Myosin light chain alkali 3) (Myosin light chain 3) (MLC-3) (LC17) - Homo sapiens (Human)
5	31.5	66.4	P60709 ACTB_HUMAN	Actin, cytoplasmic 1 (Beta-actin) - Homo sapiens (Human)
449	54.1	69.9	P60709 ACTB_HUMAN	Actin, cytoplasmic 1 (Beta-actin) - Homo sapiens (Human)
356	2.0	5.2	P15153 RAC2_HUMAN	Ras-related G30 kDa protein toxin substrate 2 precursor (p21-Rac2) (Small G protein) (GX) - Homo sapiens (Human)
304	2.0	9.4	P15153 RAC2_HUMAN	Ras-related G30 kDa protein toxin substrate 2 precursor (p21-Rac2) (Small G protein) (GX) - Homo sapiens (Human)
231	2.7	12.3	P60842 IF4A1_HUMAN	Eukaryotic initiation factor 4A-I (EC 3.6.1.-) (ATP-dependent RNA helicase eIF4A-1) (eIF4A-I) (eIF-4A-I) - Homo sapiens (Human)
428	2.1	10.8	P60842 IF4A1_HUMAN	Eukaryotic initiation factor 4A-I (EC 3.6.1.-) (ATP-dependent RNA helicase eIF4A-1) (eIF4A-I) (eIF-4A-I) - Homo sapiens (Human)
165	4.4	21.8	P60866 RS20_HUMAN	40S ribosomal protein S20 - Homo sapiens (Human)
354	3.2	29.4	P60866 RS20_HUMAN	40S ribosomal protein S20 - Homo sapiens (Human)
94	8.1	24.8	P60900 PSA6_HUMAN	Proteasome subunit alpha type 6 (EC 3.4.25.1) (Proteasome iota chain) (Macropain iota chain) (Multicatalytic endopeptidase complex iota chain) (27 kDa prosomal protein) (PROS-27) (p27K) - Homo sapiens (Human)
180	2.0	8.5	P60900 PSA6_HUMAN	Proteasome subunit alpha type 6 (EC 3.4.25.1) (Proteasome iota chain) (Macropain iota chain) (Multicatalytic endopeptidase complex iota chain) (27 kDa prosomal protein) (PROS-27) (p27K) - Homo sapiens (Human)
69	14.4	40.2	P60900 PSA6_HUMAN	Proteasome subunit alpha type 6 (EC 3.4.25.1) (Proteasome iota chain) (Macropain iota chain) (Multicatalytic endopeptidase complex iota chain) (27 kDa prosomal protein) (PROS-27) (p27K) - Homo sapiens (Human)
79	9.5	18.2	P61158 ARP3_HUMAN	Actin-like protein 3 (Actin-related protein 3) - Homo sapiens (Human)
111	10.0	14.4	P61158 ARP3_HUMAN	Actin-like protein 3 (Actin-related protein 3) - Homo sapiens (Human)
112	2.9	15.5	P61160 ARP2_HUMAN	Actin-like protein 2 (Actin-related protein 2) - Homo sapiens (Human)
141	8.0	24.6	P61160 ARP2_HUMAN	Actin-like protein 2 (Actin-related protein 2) - Homo sapiens (Human)
136	5.8	18.2	P61247 RS3A_HUMAN	40S ribosomal protein S3a - Homo sapiens (Human)

63	5.5	16.3	P61247 RS3A_HUMAN	40S ribosomal protein S3a - Homo sapiens (Human)
73	14.0	30.7	P61247 RS3A_HUMAN	40S ribosomal protein S3a - Homo sapiens (Human)
271	2.1	29.7	P61254 RL26_HUMAN	60S ribosomal protein L26 - Homo sapiens (Human)
445	2.0	15.2	P61254 RL26_HUMAN	60S ribosomal protein L26 - Homo sapiens (Human)
374	1.9	26.5	P61604 CH10_HUMAN	10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) (Early-pregnancy factor) (EPF) - Homo sapiens (Human)
	5.7	26.5	P61604 CH10_HUMAN	10 kDa heat shock protein, mitochondrial (Hsp10) (10 kDa chaperonin) (CPN10) (Early-pregnancy factor) (EPF) - Homo sapiens (Human)
45	16.3	68.2	P61626 LYSC_HUMAN	Lysozyme C precursor (EC 3.2.1.17) (1,4-beta-N-acetylmuramidase C) - Homo sapiens (Human)
23	12.6	81.1	P61626 LYSC_HUMAN	Lysozyme C precursor (EC 3.2.1.17) (1,4-beta-N-acetylmuramidase C) - Homo sapiens (Human)
41	20.4	81.8	P61626 LYSC_HUMAN	Lysozyme C precursor (EC 3.2.1.17) (1,4-beta-N-acetylmuramidase C) - Homo sapiens (Human)
69	10.4	37.8	P61769 B2MG_HUMAN	Beta-2-microglobulin precursor [Contains: Beta-2-microglobulin variant pf 5.3] - Homo sapiens (Human)
53	6.1	26.1	P61769 B2MG_HUMAN	Beta-2-microglobulin precursor [Contains: Beta-2-microglobulin variant pf 5.3] - Homo sapiens (Human)
94	11.7	49.6	P61769 B2MG_HUMAN	Beta-2-microglobulin precursor [Contains: Beta-2-microglobulin variant pf 5.3] - Homo sapiens (Human)
386	1.7	10.6	P61916 NPC2_HUMAN	Epididymal secretory protein E1 precursor (Niemann-Pick disease type C2 protein) (HE1) - Homo sapiens (Human)
536	2.0	10.6	P61916 NPC2_HUMAN	Epididymal secretory protein E1 precursor (Niemann-Pick disease type C2 protein) (HE1) - Homo sapiens (Human)
254	2.2	19.5	P62158 CALM_HUMAN	Calmodulin (CaM) - Homo sapiens (Human)
237	5.2	36.9	P62158 CALM_HUMAN	Calmodulin (CaM) - Homo sapiens (Human)
169	4.1	52.9	P62241 RS8_HUMAN	40S ribosomal protein S8 - Homo sapiens (Human)
106	10.1	52.4	P62241 RS8_HUMAN	40S ribosomal protein S8 - Homo sapiens (Human)
387	1.7	16.9	P62244 RS15A_HUMAN	40S ribosomal protein S15a - Homo sapiens (Human)
296	4.0	21.5	P62244 RS15A_HUMAN	40S ribosomal protein S15a - Homo sapiens (Human)
68	10.9	52.1	P62249 RS16_HUMAN	40S ribosomal protein S16 - Homo sapiens (Human)
106	3.3	35.6	P62249 RS16_HUMAN	40S ribosomal protein S16 - Homo sapiens (Human)
159	7.4	47.3	P62249 RS16_HUMAN	40S ribosomal protein S16 - Homo sapiens (Human)
256	3.5	18.8	P62258 1433E_HUMAN	14-3-3 protein epsilon (14-3-SE) - Homo sapiens (Human)
109	12.0	37.3	P62258 1433E_HUMAN	14-3-3 protein epsilon (14-3-SE) - Homo sapiens (Human)
135	5.9	37.5	P62269 RS18_HUMAN	40S ribosomal protein S18 (K ϵ -3) (K ϵ 3) - Homo sapiens (Human)
164	7.2	34.9	P62269 RS18_HUMAN	40S ribosomal protein S18 (K ϵ -3) (K ϵ 3) - Homo sapiens (Human)
240	2.4	33.9	P62273 RS29_HUMAN	40S ribosomal protein S29 - Homo sapiens (Human)
379	2.6	33.9	P62273 RS29_HUMAN	40S ribosomal protein S29 - Homo sapiens (Human)
116	6.6	34.2	P62280 RS11_HUMAN	40S ribosomal protein S11 - Homo sapiens (Human)
72	4.9	25.3	P62280 RS11_HUMAN	40S ribosomal protein S11 - Homo sapiens (Human)
82	12.8	39.2	P62280 RS11_HUMAN	40S ribosomal protein S11 - Homo sapiens (Human)
361	2.0	7.8	P62310 LSM3_HUMAN	UnsnRNA-associated Sm-like protein LSM3 - Homo sapiens (Human)
311	4.0	28.4	P62310 LSM3_HUMAN	UnsnRNA-associated Sm-like protein LSM3 - Homo sapiens (Human)
333	2.0	19.8	P62318 SMD3_HUMAN	Small nuclear ribonucleoprotein Sm D3 (snRNP core protein D3) (Sm-D3) - Homo sapiens (Human)
207	6.0	38.9	P62318 SMD3_HUMAN	Small nuclear ribonucleoprotein Sm D3 (snRNP core protein D3) (Sm-D3) - Homo sapiens (Human)
28	21.1	97.7	P62328 TYBA_HUMAN	Thymosin beta-4 (T beta 4) (Fx) [Contains: Hematopoietic system regulatory peptide (Seraspenide)] - Homo sapiens (Human)
29	24.5	97.7	P62328 TYBA_HUMAN	Thymosin beta-4 (T beta 4) (Fx) [Contains: Hematopoietic system regulatory peptide (Seraspenide)] - Homo sapiens (Human)
179	2.0	15.8	P62633 CNBP_HUMAN	Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) - Homo sapiens (Human)
353	3.2	41.8	P62633 CNBP_HUMAN	Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) - Homo sapiens (Human)
93	8.1	28.1	P62701 RS4X_HUMAN	40S ribosomal protein S4, X isoform (Single copy abundant mRNA protein) (SCR10) - Homo sapiens (Human)
195	6.0	21.7	P62701 RS4X_HUMAN	40S ribosomal protein S4, X isoform (Single copy abundant mRNA protein) (SCR10) - Homo sapiens (Human)
291	2.0	24.9	P62753 RS6_HUMAN	40S ribosomal protein S6 (Phosphoprotein NP33) - Homo sapiens (Human)
140	2.1	37.8	P62753 RS6_HUMAN	40S ribosomal protein S6 (Phosphoprotein NP33) - Homo sapiens (Human)
192	6.0	27.3	P62753 RS6_HUMAN	40S ribosomal protein S6 (Phosphoprotein NP33) - Homo sapiens (Human)
31	20.7	88.3	P62805 H4_HUMAN	Histone H4 - Homo sapiens (Human)
46	6.6	70.9	P62805 H4_HUMAN	Histone H4 - Homo sapiens (Human)
64	15.6	82.5	P62805 H4_HUMAN	Histone H4 - Homo sapiens (Human)
147	5.0	20.4	P62826 RAN_HUMAN	GTP-binding nuclear protein Ran (GTPase Ran) (Ras-like protein TC4) (Androgen receptor-associated protein 24) - Homo sapiens (Human)
90	4.0	22.2	P62826 RAN_HUMAN	GTP-binding nuclear protein Ran (GTPase Ran) (Ras-like protein TC4) (Androgen receptor-associated protein 24) - Homo sapiens (Human)
397	2.3	28.7	P62826 RAN_HUMAN	GTP-binding nuclear protein Ran (GTPase Ran) (Ras-like protein TC4) (Androgen receptor-associated protein 24) - Homo sapiens (Human)
292	2.0	30.4	P62854 RS26_HUMAN	40S ribosomal protein S26 - Homo sapiens (Human)
178	2.0	29.6	P62854 RS26_HUMAN	40S ribosomal protein S26 - Homo sapiens (Human)
222	5.7	51.3	P62854 RS26_HUMAN	40S ribosomal protein S26 - Homo sapiens (Human)
363	2.0	3.8	P62873 GBB1_HUMAN	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1 (Transducin beta chain 1) - Homo sapiens (Human)
534	2.0	3.8	P62873 GBB1_HUMAN	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1 (Transducin beta chain 1) - Homo sapiens (Human)
87	8.7	45.5	P62937 PIPA_HUMAN	Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) (Cyclophilin A) (Cyclosporin A-binding protein) - Homo sapiens (Human)
17	16.0	57.0	P62937 PIPA_HUMAN	Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) (Cyclophilin A) (Cyclosporin A-binding protein) - Homo sapiens (Human)
27	24.9	81.8	P62937 PIPA_HUMAN	Peptidyl-prolyl cis-trans isomerase A (EC 5.2.1.8) (PPIase A) (Rotamase A) (Cyclophilin A) (Cyclosporin A-binding protein) - Homo sapiens (Human)
191	4.0	25.0	P62942 FKB1A_HUMAN	FK506-binding protein 1A (EC 5.2.1.8) (Peptidyl-prolyl cis-trans Isomerase) (PPIase) (Rotamase) (12 kDa FKBP) (FKBP12) (Immunophilin FKBP12) - Homo sapiens (Human)
174	2.0	40.7	P62942 FKB1A_HUMAN	FK506-binding protein 1A (EC 5.2.1.8) (Peptidyl-prolyl cis-trans Isomerase) (PPIase) (Rotamase) (12 kDa FKBP) (FKBP12) (Immunophilin FKBP12) - Homo sapiens (Human)
215	6.0	29.6	P62942 FKB1A_HUMAN	FK506-binding protein 1A (EC 5.2.1.8) (Peptidyl-prolyl cis-trans Isomerase) (PPIase) (Rotamase) (12 kDa FKBP) (FKBP12) (Immunophilin FKBP12) - Homo sapiens (Human)
157	4.6	55.0	P62979 RS27A_HUMAN	40S ribosomal protein S27A - Homo sapiens (Human)
372	2.8	55.0	P62979 RS27A_HUMAN	40S ribosomal protein S27A - Homo sapiens (Human)
56	13.3	51.4	P63104 1433Z_HUMAN	14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) - Homo sapiens (Human)
67	5.1	35.1	P63104 1433Z_HUMAN	14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) - Homo sapiens (Human)
34	22.8	65.7	P63104 1433Z_HUMAN	14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) - Homo sapiens (Human)
382	1.7	8.5	P63244 GBLP_HUMAN	Guanine nucleotide-binding protein subunit beta 2-like 1 (Guanine nucleotide-binding protein subunit beta 2-like protein 12.3) (Receptor of activated protein kinase C 1) (RACK1) (Receptor for activated C kinase) - Homo sapiens (Human)
533	2.0	4.1	P63244 GBLP_HUMAN	Guanine nucleotide-binding protein subunit beta 2-like 1 (Guanine nucleotide-binding protein subunit beta 2-like protein 12.3) (Receptor of activated protein kinase C 1) (RACK1) (Receptor for activated C kinase) - Homo sapiens (Human)
5	50.7	69.1	P63261 ACTG_HUMAN	Actin, cytoplasmic 2 (Gamma-actin) - Homo sapiens (Human)
154	31.4	66.4	P63261 ACTG_HUMAN	Actin, cytoplasmic 2 (Gamma-actin) - Homo sapiens (Human)
4	54.2	69.9	P63261 ACTG_HUMAN	Actin, cytoplasmic 2 (Gamma-actin) - Homo sapiens (Human)
173	2.0	15.8	P63279 UBC9_HUMAN	SUMO-conjugating enzyme UBC9 (EC 6.3.2.) (SUMO-protein ligase) (Ubiquitin-conjugating enzyme E2 I) (Ubiquitin-protein ligase I) (Ubiquitin carrier protein I) (Ubiquitin carrier protein 9) (p18) - Homo sapiens (Human)
497	2.0	7.0	P63279 UBC9_HUMAN	SUMO-conjugating enzyme UBC9 (EC 6.3.2.) (SUMO-protein ligase) (Ubiquitin-conjugating enzyme E2 I) (Ubiquitin-protein ligase I) (Ubiquitin carrier protein I) (Ubiquitin carrier protein 9) (p18) - Homo sapiens (Human)
57	13.2	49.6	P67936 TPM4_HUMAN	Tropomyosin alpha-4 chain (Tropomyosin-4) (TM30p1) - Homo sapiens (Human)
78	4.5	44.4	P67936 TPM4_HUMAN	Tropomyosin alpha-4 chain (Tropomyosin-4) (TM30p1) - Homo sapiens (Human)
39	21.0	45.6	P67936 TPM4_HUMAN	Tropomyosin alpha-4 chain (Tropomyosin-4) (TM30p1) - Homo sapiens (Human)
90	8.2	22.1	P68104 EF1A1_HUMAN	Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) (Elongation factor Tu) (EF-Tu) (Leukocyte receptor cluster member 7) - Homo sapiens (Human)
129	2.3	10.2	P68104 EF1A1_HUMAN	Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) (Elongation factor Tu) (EF-Tu) (Leukocyte receptor cluster member 7) - Homo sapiens (Human)
91	12.0	21.4	P68104 EF1A1_HUMAN	Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) (Elongation factor Tu) (EF-Tu) (Leukocyte receptor cluster member 7) - Homo sapiens (Human)
49	15.5	29.9	P68363 TBKA_HUMAN	Tubulin alpha-ubiquitous chain (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1) - Homo sapiens (Human)
33	23.4	38.6	P68363 TBKA_HUMAN	Tubulin alpha-ubiquitous chain (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1) - Homo sapiens (Human)
112	6.9	37.5	P68431 H31_HUMAN	Histone H3.1 (H3 α) (H3 β) (H3 γ) (H3 δ) (H3 ϵ) (H3 ζ) (H3 η) (H3 ι) - Homo sapiens (Human)
139	2.1	19.1	P68431 H31_HUMAN	Histone H3.1 (H3 α) (H3 β) (H3 γ) (H3 δ) (H3 ϵ) (H3 ζ) (H3 η) (H3 ι) - Homo sapiens (Human)
154	7.9	41.2	P68431 H31_HUMAN	Histone H3.1 (H3 α) (H3 β) (H3 γ) (H3 δ) (H3 ϵ) (H3 ζ) (H3 η) (H3 ι) - Homo sapiens (Human)
146	5.1	28.6	P78417 GSTO1_HUMAN	Glutathione transferase omega-1 (EC 2.5.1.18) (GSTO 1-1) - Homo sapiens (Human)
188	2.0	3.3	P78417 GSTO1_HUMAN	Glutathione transferase omega-1 (EC 2.5.1.18) (GSTO 1-1) - Homo sapiens (Human)
369	2.9	14.5	P78417 GSTO1_HUMAN	Glutathione transferase omega-1 (EC 2.5.1.18) (GSTO 1-1) - Homo sapiens (Human)
304	6.0	54.1	P80295 MT11_HUMAN	Metallothionein-11 (MT-11) (Metallothionein-11) - Homo sapiens (Human)
182	2.0	19.7	P80295 MT11_HUMAN	Metallothionein-11 (MT-11) (Metallothionein-11) - Homo sapiens (Human)
459	4.0	52.5	P80295 MT11_HUMAN	Metallothionein-11 (MT-11) (Metallothionein-11) - Homo sapiens (Human)
313	2.0	46.3	P84103 SFRS3_HUMAN	Splicing factor, arginine/serine-rich 3 (Pre-mRNA-splicing factor SRP20) - Homo sapiens (Human)
279	4.0	37.8	P84103 SFRS3_HUMAN	Splicing factor, arginine/serine-rich 3 (Pre-mRNA-splicing factor SRP20) - Homo sapiens (Human)
234	2.5	3.5	Q00610 CLH1_HUMAN	Clathrin heavy chain 1 (CLH-1) - Homo sapiens (Human)
408	2.3	3.6	Q00610 CLH1_HUMAN	Clathrin heavy chain 1 (CLH-1) - Homo sapiens (Human)
140	5.7	20.6	Q00839 HNRP_U_HUMAN	Heterogeneous nuclear ribonucleoprotein U (hnRNP U) (Scaffold attachment factor A) (SAF-A) (p120) (pp120) - Homo sapiens (Human)
93	11.9	23.1	Q00839 HNRP_U_HUMAN	Heterogeneous nuclear ribonucleoprotein U (hnRNP U) (Scaffold attachment factor A) (SAF-A) (p120) (pp120) - Homo sapiens (Human)

255	2.2	7.9	Q01082 SPTB2_HUMAN	Spectrin beta chain, brain 1 (Spectrin, non-erythroid beta chain 1) (Beta-II spectrin) (Fodrin beta chain) - Homo sapiens (Human)
119	9.6	8.6	Q01082 SPTB2_HUMAN	Spectrin beta chain, brain 1 (Spectrin, non-erythroid beta chain 1) (Beta-II spectrin) (Fodrin beta chain) - Homo sapiens (Human)
127	6.0	22.8	Q01105 SET_HUMAN	Protein SET (Phosphatase 2A inhibitor 12PP2A) (I-2PP2A) (Template-activating factor 1) (TAF-1) (HLA-DR-associated protein II) (PHAPII) (Inhibitor of granzyme A-activated DNase) (IGAAD) - Homo sapiens (Human)
61	16.1	15.2	Q01105 SET_HUMAN	Protein SET (Phosphatase 2A inhibitor 12PP2A) (I-2PP2A) (Template-activating factor 1) (TAF-1) (HLA-DR-associated protein II) (PHAPII) (Inhibitor of granzyme A-activated DNase) (IGAAD) - Homo sapiens (Human)
226	2.9	31.9	Q01469 FABPE_HUMAN	Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP) - Homo sapiens (Human)
176	6.5	57.8	Q01469 FABPE_HUMAN	Fatty acid-binding protein, epidermal (E-FABP) (Psoriasis-associated fatty acid-binding protein homolog) (PA-FABP) - Homo sapiens (Human)
110	7.1	21.1	Q01518 CAP1_HUMAN	Adenyl cyclase-associated protein 1 (CAP 1) - Homo sapiens (Human)
56	6.0	14.5	Q01518 CAP1_HUMAN	Adenyl cyclase-associated protein 1 (CAP 1) - Homo sapiens (Human)
121	9.6	16.2	Q01518 CAP1_HUMAN	Adenyl cyclase-associated protein 1 (CAP 1) - Homo sapiens (Human)
312	2.0	16.8	Q01844 EWS_HUMAN	RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein) - Homo sapiens (Human)
115	2.8	23.6	Q01844 EWS_HUMAN	RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein) - Homo sapiens (Human)
268	4.1	25.8	Q01844 EWS_HUMAN	RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein) - Homo sapiens (Human)
150	4.7	23.4	Q02818 NUCB1_HUMAN	Nucleobindin-1 precursor (CALNUC) - Homo sapiens (Human)
271	4.1	18.2	Q02818 NUCB1_HUMAN	Nucleobindin-1 precursor (CALNUC) - Homo sapiens (Human)
332	2.0	12.8	Q02878 RLE6_HUMAN	60S ribosomal protein L6 (TAX-responsive enhancer element-binding protein 107) (TAXREB107) (Neoplasm-related protein C140) - Homo sapiens (Human)
355	3.2	21.2	Q02878 RLE6_HUMAN	60S ribosomal protein L6 (TAX-responsive enhancer element-binding protein 107) (TAXREB107) (Neoplasm-related protein C140) - Homo sapiens (Human)
92	8.1	13.8	Q06033 ITIH3_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H3 precursor (ITI heavy chain H3) (Inter-alpha-inhibitor heavy chain 3) (Serum-derived hyaluronan-associated protein) (SHAP) - Homo sapiens (Human)
100	3.5	8.6	Q06033 ITIH3_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H3 precursor (ITI heavy chain H3) (Inter-alpha-inhibitor heavy chain 3) (Serum-derived hyaluronan-associated protein) (SHAP) - Homo sapiens (Human)
116	9.7	7.3	Q06033 ITIH3_HUMAN	Inter-alpha-trypsin inhibitor heavy chain H3 precursor (ITI heavy chain H3) (Inter-alpha-inhibitor heavy chain 3) (Serum-derived hyaluronan-associated protein) (SHAP) - Homo sapiens (Human)
59	12.9	34.1	Q06323 PSME1_HUMAN	Proteasome activator complex subunit 1 (Proteasome activator 28-alpha subunit) (PA28alpha) (PA28a) (Activator of multicatalytic protease subunit 1) (11S regulator complex subunit alpha) (REG-alpha) (Interferon gamma up-regulated I-5111 protein) (IGUP I-5111) - Homo sapiens (Human)
50	6.3	26.9	Q06323 PSME1_HUMAN	Proteasome activator complex subunit 1 (Proteasome activator 28-alpha subunit) (PA28alpha) (PA28a) (Activator of multicatalytic protease subunit 1) (11S regulator complex subunit alpha) (REG-alpha) (Interferon gamma up-regulated I-5111 protein) (IGUP I-5111) - Homo sapiens (Human)
68	14.7	38.2	Q06323 PSME1_HUMAN	Proteasome activator complex subunit 1 (Proteasome activator 28-alpha subunit) (PA28alpha) (PA28a) (Activator of multicatalytic protease subunit 1) (11S regulator complex subunit alpha) (REG-alpha) (Interferon gamma up-regulated I-5111 protein) (IGUP I-5111) - Homo sapiens (Human)
41	18.0	49.7	Q06830 PRDX1_HUMAN	Pereroxidoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin-dependent peroxide reductase 2) (Proliferation-associated gene protein) (PAG) (Natural killer cell-enhancing factor A) (NKEF-A) - Homo sapiens (Human)
25	12.3	52.8	Q06830 PRDX1_HUMAN	Pereroxidoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin-dependent peroxide reductase 2) (Proliferation-associated gene protein) (PAG) (Natural killer cell-enhancing factor A) (NKEF-A) - Homo sapiens (Human)
48	18.3	55.3	Q06830 PRDX1_HUMAN	Pereroxidoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin-dependent peroxide reductase 2) (Proliferation-associated gene protein) (PAG) (Natural killer cell-enhancing factor A) (NKEF-A) - Homo sapiens (Human)
276	2.1	7.5	Q08380 LG3BP_HUMAN	Galectin-3-binding protein precursor (Lectin galactoside-binding soluble 3-binding protein) (Mac-2-binding protein) (Mac-2 BP) (MAC2BP) (Tumor-associated antigen 90K) - Homo sapiens (Human)
161	2.0	6.3	Q08380 LG3BP_HUMAN	Galectin-3-binding protein precursor (Lectin galactoside-binding soluble 3-binding protein) (Mac-2-binding protein) (Mac-2 BP) (MAC2BP) (Tumor-associated antigen 90K) - Homo sapiens (Human)
436	2.0	9.1	Q08380 LG3BP_HUMAN	Galectin-3-binding protein precursor (Lectin galactoside-binding soluble 3-binding protein) (Mac-2-binding protein) (Mac-2 BP) (MAC2BP) (Tumor-associated antigen 90K) - Homo sapiens (Human)
249	2.2	8.2	Q12906 ILF3_HUMAN	Interleukin enhancer-binding factor 3 (Nuclear factor of activated T-cells 90 kDa) (NF-AT-90) (Double-stranded RNA-binding protein 76) (DRBP76) (Translational control protein 80) (TCP80) (Nuclear factor associated with dsDNA) (NFAR) (M-phase phosphoprotein 4) (MPP4) - Homo sapiens (Human)
60	16.5	21.9	Q12906 ILF3_HUMAN	Interleukin enhancer-binding factor 3 (Nuclear factor of activated T-cells 90 kDa) (NF-AT-90) (Double-stranded RNA-binding protein 76) (DRBP76) (Translational control protein 80) (TCP80) (Nuclear factor associated with dsDNA) (NFAR) (M-phase phosphoprotein 4) (MPP4) - Homo sapiens (Human)
172	2.0	10.0	Q13093 PAFA_HUMAN	Platelet-activating factor acetylhydrolase precursor (EC 3.1.1.47) (PAF acetylhydrolase) (PAF 2-acetylhydrolase) (LDL-associated phospholipase A2) (LDL-PLA(2)) (2-acetyl-1-alkylglycerophosphocholine esterase) (1-alkyl-2-acetylglycerophosphocholine esterase) - Homo sapiens (Human)
529	2.0	3.6	Q13093 PAFA_HUMAN	Platelet-activating factor acetylhydrolase precursor (EC 3.1.1.47) (PAF acetylhydrolase) (PAF 2-acetylhydrolase) (LDL-associated phospholipase A2) (LDL-PLA(2)) (2-acetyl-1-alkylglycerophosphocholine esterase) (1-alkyl-2-acetylglycerophosphocholine esterase) - Homo sapiens (Human)
346	2.0	8.2	Q13151 ROAO_HUMAN	Heterogeneous nuclear ribonucleoprotein AO (hnRNP AO) - Homo sapiens (Human)
591	1.4	24.3	Q13151 ROAO_HUMAN	Heterogeneous nuclear ribonucleoprotein AO (hnRNP AO) - Homo sapiens (Human)
212	3.2	37.3	Q14019 COTL1_HUMAN	Coactosin-like protein - Homo sapiens (Human)
126	9.3	50.7	Q14019 COTL1_HUMAN	Coactosin-like protein - Homo sapiens (Human)
157	4.0	11.0	Q14103 HNRPD_HUMAN	Heterogeneous nuclear ribonucleoprotein D0 (hnRNP D0) (AU-rich element RNA-binding protein 1) - Homo sapiens (Human)
85	12.2	35.2	Q14103 HNRPD_HUMAN	Heterogeneous nuclear ribonucleoprotein D0 (hnRNP D0) (AU-rich element RNA-binding protein 1) - Homo sapiens (Human)
404	1.3	16.4	Q14152 IF3A_HUMAN	Eukaryotic translation initiation factor 3 subunit 10 (eIF-3 theta) (eIF3 p167) (eIF3 p180) (eIF3 p185) (eIF3a) - Homo sapiens (Human)
137	8.2	16.1	Q14152 IF3A_HUMAN	Eukaryotic translation initiation factor 3 subunit 10 (eIF-3 theta) (eIF3 p167) (eIF3 p180) (eIF3 p185) (eIF3a) - Homo sapiens (Human)
145	5.1	15.8	Q14764 MVP_HUMAN	Major vault protein (MVP) (Lung resistance-related protein) - Homo sapiens (Human)
122	9.5	13.9	Q14764 MVP_HUMAN	Major vault protein (MVP) (Lung resistance-related protein) - Homo sapiens (Human)
124	6.0	33.7	Q14847 LASP1_HUMAN	LIM and SH3 domain protein 1 (LASP-1) (MLN 50) - Homo sapiens (Human)
72	14.1	37.9	Q14847 LASP1_HUMAN	LIM and SH3 domain protein 1 (LASP-1) (MLN 50) - Homo sapiens (Human)
232	2.6	21.4	Q15233 NONO_HUMAN	Non-POU domain-containing octamer-binding protein (Nono protein) (54 kDa nuclear RNA- and DNA-binding protein) (p54(nrb)) (p54(nrb)) (55 kDa nuclear protein) (NMT55) (DNA-binding p52/p100 complex, 52 kDa subunit) - Homo sapiens (Human)
78	15.9	33.3	Q15233 NONO_HUMAN	Non-POU domain-containing octamer-binding protein (Nono protein) (54 kDa nuclear RNA- and DNA-binding protein) (p54(nrb)) (p54(nrb)) (55 kDa nuclear protein) (NMT55) (DNA-binding p52/p100 complex, 52 kDa subunit) - Homo sapiens (Human)
206	3.5	10.3	Q16181 SEPT7_HUMAN	Septin-7 (CDC10 protein homolog) - Homo sapiens (Human)
406	2.3	9.8	Q16181 SEPT7_HUMAN	Septin-7 (CDC10 protein homolog) - Homo sapiens (Human)
286	2.0	9.8	Q16555 DPYL2_HUMAN	Dihydropyrimidinase-related protein 2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3) - Homo sapiens (Human)
336	3.5	5.9	Q16555 DPYL2_HUMAN	Dihydropyrimidinase-related protein 2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3) - Homo sapiens (Human)
344	2.0	4.7	Q16658 FSCN1_HUMAN	Fascin (Singed-like protein) (55 kDa actin-binding protein) (p55) - Homo sapiens (Human)
383	2.5	11.2	Q16658 FSCN1_HUMAN	Fascin (Singed-like protein) (55 kDa actin-binding protein) (p55) - Homo sapiens (Human)
343	2.0	4.6	Q16881 TRXR1_HUMAN	Thioredoxin reductase 1, cytoplasmic precursor (EC 1.8.1.9) (TR1) - Homo sapiens (Human)
392	2.4	9.2	Q16881 TRXR1_HUMAN	Thioredoxin reductase 1, cytoplasmic precursor (EC 1.8.1.9) (TR1) - Homo sapiens (Human)
129	4.0	39.2	Q16F113 H2A2A_HUMAN	Histone H2A type 2-A (H2A.2) - Homo sapiens (Human)
111	3.1	52.3	Q16F113 H2A2A_HUMAN	Histone H2A type 2-A (H2A.2) - Homo sapiens (Human)
112	6.9	37.5	Q17D13 H2A2_HUMAN	Histone H3.2 (H3/m) (H3/o) - Homo sapiens (Human)
139	2.1	19.1	Q17D13 H2A2_HUMAN	Histone H3.2 (H3/m) (H3/o) - Homo sapiens (Human)
154	7.9	41.2	Q17D13 H2A2_HUMAN	Histone H3.2 (H3/m) (H3/o) - Homo sapiens (Human)
319	2.0	9.9	Q86UX7 URP2_HUMAN	Unc-112-related protein 2 (Kindlin-3) (MIG2-like) - Homo sapiens (Human)
409	2.2	12.7	Q86UX7 URP2_HUMAN	Unc-112-related protein 2 (Kindlin-3) (MIG2-like) - Homo sapiens (Human)
260	2.2	16.7	Q8NHJ6 LRB4_HUMAN	Leukocyte immunoglobulin-like receptor subfamily B member 4 precursor (Leukocyte immunoglobulin-like receptor 5) (LIR-5) (Immunoglobulin-like transcript 3) (ILT-3) (Monocyte inhibitory receptor HM18) (CD85k antigen) - Homo sapiens (Human)
191	1.9	5.1	Q8NHJ6 LRB4_HUMAN	Leukocyte immunoglobulin-like receptor subfamily B member 4 precursor (Leukocyte immunoglobulin-like receptor 5) (LIR-5) (Immunoglobulin-like transcript 3) (ILT-3) (Monocyte inhibitory receptor HM18) (CD85k antigen) - Homo sapiens (Human)
327	3.7	7.1	Q8NHJ6 LRB4_HUMAN	Leukocyte immunoglobulin-like receptor subfamily B member 4 precursor (Leukocyte immunoglobulin-like receptor 5) (LIR-5) (Immunoglobulin-like transcript 3) (ILT-3) (Monocyte inhibitory receptor HM18) (CD85k antigen) - Homo sapiens (Human)
315	2.0	9.6	Q92598 HS105_HUMAN	Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY-CO-25) - Homo sapiens (Human)
194	1.7	10.7	Q92598 HS105_HUMAN	Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY-CO-25) - Homo sapiens (Human)
290	4.0	6.9	Q92598 HS105_HUMAN	Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY-CO-25) - Homo sapiens (Human)
274	2.1	14.0	Q96C23 GALM_HUMAN	Aldose 1-epimerase (EC 5.1.3.3) (Galactose mutarotase) - Homo sapiens (Human)
148	8.0	19.3	Q96C23 GALM_HUMAN	Aldose 1-epimerase (EC 5.1.3.3) (Galactose mutarotase) - Homo sapiens (Human)
139	5.7	25.5	Q96CX2 KCD12_HUMAN	BTB/POZ domain-containing protein KCTD12 (Ptfetin) (Predominantly fetal expressed T1 domain) - Homo sapiens (Human)
474	2.0	7.4	Q96CX2 KCD12_HUMAN	BTB/POZ domain-containing protein KCTD12 (Ptfetin) (Predominantly fetal expressed T1 domain) - Homo sapiens (Human)
395	1.5	7.6	Q96EP5 DAZP1_HUMAN	DAZ-associated protein 1 (Deleted in azoospermia-associated protein 1) - Homo sapiens (Human)
283	4.0	11.3	Q96EP5 DAZP1_HUMAN	DAZ-associated protein 1 (Deleted in azoospermia-associated protein 1) - Homo sapiens (Human)
236	2.5	11.4	Q96IU4 ABHEB_HUMAN	Abhydrolase domain-containing protein 14B (EC 3.3.-.-) (CCG1-interacting factor B) - Homo sapiens (Human)
308	4.0	11.4	Q96IU4 ABHEB_HUMAN	Abhydrolase domain-containing protein 14B (EC 3.3.-.-) (CCG1-interacting factor B) - Homo sapiens (Human)
253	2.2	7.4	Q96KP4 CNDP2_HUMAN	Cytosolic nonspecific dipeptidase (CNDP dipeptidase 2) (Glutamate carboxypeptidase-like protein 1) - Homo sapiens (Human)
347	3.3	8.4	Q96KP4 CNDP2_HUMAN	Cytosolic nonspecific dipeptidase (CNDP dipeptidase 2) (Glutamate carboxypeptidase-like protein 1) - Homo sapiens (Human)
266	2.1	20.1	Q99497 PARK7_HUMAN	Protein DJ-1 (Oncogene DJ1) (Parkinson disease protein 7) - Homo sapiens (Human)
177	2.0	14.8	Q99497 PARK7_HUMAN	Protein DJ-1 (Oncogene DJ1) (Parkinson disease protein 7) - Homo sapiens (Human)
120	9.6	28.6	Q99497 PARK7_HUMAN	Protein DJ-1 (Oncogene DJ1) (Parkinson disease protein 7) - Homo sapiens (Human)
358	2.0	11.4	Q9BRA2 TXNL5_HUMAN	Thioredoxin-like protein 5 (14 kDa thioredoxin-related protein) (TRP14) (Protein 42-9-9) - Homo sapiens (Human)
307	4.0	19.5	Q9BRA2 TXNL5_HUMAN	Thioredoxin-like protein 5 (14 kDa thioredoxin-related protein) (TRP14) (Protein 42-9-9) - Homo sapiens (Human)

340	2.0	49.5	Q9H299 SH3L3_HUMAN	SH3 domain-binding glutamic acid-rich-like protein 3 (SH3 domain-binding protein 1) (SH3BP-1) - Homo sapiens (Human)
176	2.0	20.4	Q9H299 SH3L3_HUMAN	SH3 domain-binding glutamic acid-rich-like protein 3 (SH3 domain-binding protein 1) (SH3BP-1) - Homo sapiens (Human)
213	6.0	31.2	Q9H299 SH3L3_HUMAN	SH3 domain-binding glutamic acid-rich-like protein 3 (SH3 domain-binding protein 1) (SH3BP-1) - Homo sapiens (Human)
118	6.4	26.1	Q9NUV9 GIMA4_HUMAN	GTPase IMAP family member 4 (Immunity-associated protein 4) (Immunity-associated nucleotide 1 protein) (hIAN1) - Homo sapiens (Human)
213	1.3	23.1	Q9NUV9 GIMA4_HUMAN	GTPase IMAP family member 4 (Immunity-associated protein 4) (Immunity-associated nucleotide 1 protein) (hIAN1) - Homo sapiens (Human)
105	10.4	24.9	Q9NUV9 GIMA4_HUMAN	GTPase IMAP family member 4 (Immunity-associated protein 4) (Immunity-associated nucleotide 1 protein) (hIAN1) - Homo sapiens (Human)
171	4.0	11.9	Q9NY33 DPP3_HUMAN	Dipeptidyl-peptidase 3 (EC 3.4.14.4) (Dipeptidyl-peptidase III) (DPP III) (Dipeptidyl aminopeptidase III) (Dipeptidyl arylamidase III) - Homo sapiens (Human)
170	2.0	6.1	Q9NY33 DPP3_HUMAN	Dipeptidyl-peptidase 3 (EC 3.4.14.4) (Dipeptidyl-peptidase III) (DPP III) (Dipeptidyl aminopeptidase III) (Dipeptidyl arylamidase III) - Homo sapiens (Human)
185	6.2	15.7	Q9NY33 DPP3_HUMAN	Dipeptidyl-peptidase 3 (EC 3.4.14.4) (Dipeptidyl-peptidase III) (DPP III) (Dipeptidyl aminopeptidase III) (Dipeptidyl arylamidase III) - Homo sapiens (Human)
330	2.0	11.6	Q9NYL9 TMOD3_HUMAN	Tropomodulin-3 (Ubiquitous tropomodulin) (U-Tmod) - Homo sapiens (Human)
305	4.0	7.1	Q9NYL9 TMOD3_HUMAN	Tropomodulin-3 (Ubiquitous tropomodulin) (U-Tmod) - Homo sapiens (Human)
211	3.2	10.5	Q9P258 RCC2_HUMAN	Protein RCC2 (Telophase disk protein of 60 kDa) (RCC1-like protein TD-60) - Homo sapiens (Human)
273	4.1	8.2	Q9P258 RCC2_HUMAN	Protein RCC2 (Telophase disk protein of 60 kDa) (RCC1-like protein TD-60) - Homo sapiens (Human)
113	6.8	38.9	Q9UBR2 CATZ_HUMAN	Cathepsin Z precursor (EC 3.4.22.-) (Cathepsin X) (Cathepsin P) - Homo sapiens (Human)
99	3.7	11.6	Q9UBR2 CATZ_HUMAN	Cathepsin Z precursor (EC 3.4.22.-) (Cathepsin X) (Cathepsin P) - Homo sapiens (Human)
145	8.0	24.8	Q9UBR2 CATZ_HUMAN	Cathepsin Z precursor (EC 3.4.22.-) (Cathepsin X) (Cathepsin P) - Homo sapiens (Human)
223	3.0	17.0	Q9UJU6 DBNL_HUMAN	Drebrin-like protein (SH3 domain-containing protein 7) (Drebrin-F) (Cervical SH3P7) (HPK1-interacting protein of 55 kDa) (HIP-55) (Cervical mucin-associated protein) - Homo sapiens (Human)
248	4.7	22.6	Q9UJU6 DBNL_HUMAN	Drebrin-like protein (SH3 domain-containing protein 7) (Drebrin-F) (Cervical SH3P7) (HPK1-interacting protein of 55 kDa) (HIP-55) (Cervical mucin-associated protein) - Homo sapiens (Human)
95	8.1	26.4	Q9UL46 PSME2_HUMAN	Proteasome activator complex subunit 2 (Proteasome activator 28-subunit beta) (PA28beta) (PA28b) (Activator of multicatalytic protease subunit 2) (11S regulator complex subunit beta) (REG-beta) - Homo sapiens (Human)
163	2.0	16.3	Q9UL46 PSME2_HUMAN	Proteasome activator complex subunit 2 (Proteasome activator 28-subunit beta) (PA28beta) (PA28b) (Activator of multicatalytic protease subunit 2) (11S regulator complex subunit beta) (REG-beta) - Homo sapiens (Human)
182	6.2	26.4	Q9UL46 PSME2_HUMAN	Proteasome activator complex subunit 2 (Proteasome activator 28-subunit beta) (PA28beta) (PA28b) (Activator of multicatalytic protease subunit 2) (11S regulator complex subunit beta) (REG-beta) - Homo sapiens (Human)
198	4.0	14.6	Q9ULV4 COR1C_HUMAN	Coronin-1C (Coronin-3) (hCRNN4) - Homo sapiens (Human)
200	1.8	17.3	Q9ULV4 COR1C_HUMAN	Coronin-1C (Coronin-3) (hCRNN4) - Homo sapiens (Human)
223	6.0	18.1	Q9ULV4 COR1C_HUMAN	Coronin-1C (Coronin-3) (hCRNN4) - Homo sapiens (Human)
288	2.0	6.3	Q9UO80 PA2G4_HUMAN	Proliferation-associated protein 2G4 (Cell cycle protein p38-2G4 homolog) (hG4-1) (ErbB3-binding protein 1) - Homo sapiens (Human)
174	6.5	18.8	Q9UQ80 PA2G4_HUMAN	Proliferation-associated protein 2G4 (Cell cycle protein p38-2G4 homolog) (hG4-1) (ErbB3-binding protein 1) - Homo sapiens (Human)
75	9.8	7.6	Q9Y490 TLN1_HUMAN	Talin-1 - Homo sapiens (Human)
67	14.8	8.8	Q9Y490 TLN1_HUMAN	Talin-1 - Homo sapiens (Human)
328	2	27.0	Q9Y5S9 RBM8A_HUMAN	RNA-binding protein 8A (RNA-binding motif protein 8A) (Ribonucleoprotein RBM8A) (RNA-binding protein Y14) (Binder of OVCA1-1) (BOV-1) - Homo sapiens (Human)
485	2	18.4	Q9Y5S9 RBM8A_HUMAN	RNA-binding protein 8A (RNA-binding motif protein 8A) (Ribonucleoprotein RBM8A) (RNA-binding protein Y14) (Binder of OVCA1-1) (BOV-1) - Homo sapiens (Human)

ONLINE TABLE II

PEPTIDES IDENTIFIED IN THE CONDITIONED MEDIUM OF CFUs (n=3)

N	Unused	Total	% Cov	Contrib	Conf	Sequence	Prec MW	Prec m/z	Theor MW	Theor m/z
O00299 CLIC1_HUMAN						Chloride intracellular channel protein 1 (Nuclear chloride ion channel 27) (NCC27) (Chloride channel ABP) (Regulatory nuclear chloride ion channe				
123.0	9.5	9.5	31.1	2.0	99.0	AEEQPOVELFK	1457.7	1458.8	1457.7	1458.7
123.0	9.5	9.5	31.1	2.0	99.0	EFAFASTCPDDEELAYEQQAK	2572.1	2573.1	2572.1	2573.1
123.0	9.5	9.5	31.1	2.0	99.0	LAALNPESNTAGLDIFAK	1844.0	1845.0	1844.0	1845.0
123.0	9.5	9.5	31.1	1.4	96.0	GFTIPEAFR	1036.5	1037.5	1036.5	1037.5
123.0	9.5	9.5	31.1	1.2	94.0	YLSNAYAR	956.5	957.5	956.5	957.5
123.0	9.5	9.5	31.1	0.9	86.0	YRGFTIPEAFR	1355.7	1356.7	1355.7	1356.7
69.0	4.9	4.9	30.3	2.0	99.0	LAALNPESNTAGLDIFAK	1844.0	1845.0	1844.0	1845.0
69.0	4.9	4.9	30.3	1.7	98.0	YRGFTIPEAFR	1355.7	1356.7	1355.7	1356.7
69.0	4.9	4.9	30.3	1.2	93.0	GFTIPEAFR	1036.5	1037.5	1036.5	1037.5
108.0	7.3	8.2	20.7	2.0	99.0	EEQPOVELFK	1328.7	1329.7	1328.7	1329.7
108.0	7.3	8.2	20.7	2.0	99.0	GFTIPEAFR	1036.5	1037.5	1036.5	1037.5
108.0	7.3	8.2	20.7	1.7	98.0	YRGFTIPEAFR	1355.7	1356.7	1355.7	1356.7
108.0	7.3	8.2	20.7	1.2	93.0	IGNCPFSQR	1077.5	1078.5	1077.5	1078.5
108.0	7.3	8.2	20.7	0.5	65.0	YLSNAYAR	956.5	957.5	956.5	957.5
108.0	7.3	8.2	20.7	0.0	86.0	FSAYIK	727.4	728.4	727.4	728.4
O00391 QSCN6_HUMAN						Sulfhydryl oxidase 1 precursor (EC 1.8.3.2) (Quiescin Q6) (hQSOX) - Homo sapiens (Human)				
201.0	6.0	6.0	12.2	2.0	99.0	LAGAPSEDPDFPK	1355.7	1356.7	1355.7	1356.7
201.0	6.0	6.0	12.2	2.0	99.0	NNEEYLALIYEK	1481.8	1482.8	1481.7	1482.7
201.0	6.0	6.0	12.2	2.0	99.0	SFTYTAYLQR	1147.6	1148.6	1147.6	1148.6
160.0	2.0	2.0	11.1	2.0	99.0	NNEEYLALIYEK	1481.8	1482.8	1481.7	1482.7
O00479 MNGM4_HUMAN						High-mobility group nucleosome-binding domain-containing protein 4 (Nonhistone chromosomal protein HMG-17-like 3) (Non-histone chromosom				
285.0	4.0	4.0	44.4	2.0	99.0	LSAKPAPPKPEPR	1386.8	1387.8	1386.8	1387.8
285.0	4.0	4.0	44.4	2.0	99.0	LSAKPAPPKPEPRPK	1611.9	1613.0	1611.9	1613.0
338.0	2.0	2.0	51.1	2.0	99.0	LSAKPAPPKPEPRPK	1611.9	1613.0	1611.9	1613.0
O14773 TPP1_HUMAN						Tripeptidyl-peptidase 1 precursor (EC 3.4.14.9) (Tripeptidyl-peptidase I) (TPP-1) (Tripeptidyl aminopeptidase) (Lysosomal pepstatin insen				
490.0	2.0	2.0	4.6	2.0	99.0	LYQHQHAGLFDTVR	1603.8	1604.8	1603.8	1604.8
138.0	2.1	2.1	14.9	2.0	99.0	LGFGNFHAQASVAR	1473.7	1474.7	1473.7	1474.8
138.0	2.1	2.1	14.9	0.1	26.0	LYQHQHAGLFDTVR	1603.8	1604.8	1603.8	1604.8
189.0	4.0	4.0	5.0	2.0	99.0	LGFGNFHAQASVAR	1473.7	1474.8	1473.7	1474.8
189.0	4.0	4.0	5.0	2.0	99.0	LYQHQHAGLFDTVR	1603.8	1604.8	1603.8	1604.8
O14818 PSA7_HUMAN						Proteasome subunit alpha type 7 (EC 3.4.2.15) (Proteasome subunit RC6-1) (Proteasome subunit XAPC7) - Homo sapiens (Human)				
177.0	6.5	6.5	17.3	2.0	99.0	KIOTDPGTYHAWK	2311.1	2312.1	2311.1	2312.1
177.0	6.5	6.5	17.3	2.0	99.0	YIASLKR	1665.8	1666.8	1665.8	1666.8
177.0	6.5	6.5	17.3	2.0	99.0	ICALDDNVCMAGFLTADAR	977.6	978.6	977.6	978.6
202.0	3.7	3.7	11.7	2.0	99.0	KICALDDNVCMAGFLTADAR	2183.0	2184.0	2183.0	2184.0
202.0	3.7	3.7	11.7	1.7	98.0	YIASLKR	977.6	978.6	977.6	978.6
O14979 HNRDL_HUMAN						Heterogeneous nuclear ribonucleoprotein D-like (hnRPD-like protein) (hnHNRP-DL) (JKT41-binding protein) (AU-rich element RNA-binding factor)				
452.0	2.0	6.0	9.8	2.0	99.0	RGFCTITYDEEPVKK	1989.0	1990.0	1989.0	1990.0
452.0	2.0	6.0	9.8	0.0	99.0	GFGFVLFK	913.5	914.5	913.5	914.5
452.0	2.0	6.0	9.8	0.0	99.0	SRGGFVLFK	1156.6	1157.6	1156.6	1157.6
87.0	4.0	4.0	18.8	2.0	99.0	GFGFVLFK	913.5	914.5	913.5	914.5
87.0	4.0	4.0	18.8	2.0	99.0	PSAPATLASR	1044.6	1045.6	1044.5	1045.5
278.0	2.1	2.1	19.5	2.0	99.0	GFGFVLFK	913.5	914.5	913.5	914.5
O15143 ARC1B_HUMAN						Actin-related protein 2/3 complex subunit 1B (ARP2/3 complex 41 kDa subunit) (p41-ARC) - Homo sapiens (Human)				
152.0	8.0	8.0	17.7	2.0	99.0	CSQFCTTGMDGGMISWVK	2164.9	2165.9	2164.9	2165.9
152.0	8.0	8.0	17.7	2.0	99.0	TWKPTLVIR	1225.8	1226.8	1225.8	1226.8
152.0	8.0	8.0	17.7	2.0	99.0	VHELKEHNGQVTGIDWAPESNR	2516.2	2517.2	2516.2	2517.2
152.0	8.0	8.0	17.7	2.0	99.0	WAPNENKFAVGSSR	1618.8	1619.8	1618.8	1619.8
152.0	8.0	8.0	17.7	0.0	99.0	CSQFCTTGMDGGMISWVK	2178.9	2179.9	2178.9	2179.9
128.0	2.3	2.3	24.7	2.0	99.0	CSQFCTTGMDGGMISWVK	2161.9	2162.9	2161.9	2162.9
128.0	2.3	2.3	24.7	0.3	48.0	TWKPTLVIR	1225.8	1226.8	1225.8	1226.8
128.0	2.3	2.3	24.7	0.0	99.0	CSQFCTTGMDGGMISWVK	2178.9	2179.9	2178.9	2179.9
85.0	8.9	8.9	22.3	2.0	99.0	AYHSFLVEPI SCHAWNKDR	2371.1	2372.1	2371.1	2372.1
85.0	8.9	8.9	22.3	2.0	99.0	CSQFCTTGMDGGMISWVK	2161.9	2162.9	2161.9	2162.9
85.0	8.9	8.9	22.3	2.0	99.0	EVEERPAWPWGSK	1581.8	1582.8	1581.8	1582.8
85.0	8.9	8.9	22.3	2.0	99.0	WAPNENKFAVGSSR	1618.8	1619.8	1618.8	1619.8
85.0	8.9	8.9	22.3	0.9	86.0	FSAYIK	727.4	728.4	727.4	728.4
O15144 ARPC2_HUMAN						Actin-related protein 2/3 complex subunit 2 (ARP2/3 complex 34 kDa subunit) (p34-ARC) - Bos taurus (Bovine) : Actin-related protein 2/3 comple				
172.0	6.7	6.7	20.7	2.0	99.0	DNTINLIHTFR	1342.7	1343.7	1342.7	1343.7
172.0	6.7	6.7	20.7	2.0	99.0	VFMQEKFEGR	1269.6	1270.6	1269.6	1270.6
172.0	6.7	6.7	20.7	2.0	99.0	YFOFOEEKGEGENR	1759.8	1760.8	1759.8	1760.8
196.0	1.7	1.7	21.0	1.2	93.0	DNTINLIHTFR	1100.6	1101.6	1100.6	1101.6
196.0	1.7	1.7	21.0	0.5	71.0	YFOFOEEKGEGENR	1342.7	1343.7	1342.7	1343.7
151.0	4.7	4.7	11.7	2.0	99.0	DSIVHQAGMLKR	1353.7	1354.7	1353.7	1354.7
151.0	4.7	4.7	11.7	2.0	99.0	VFMQEKFEGR	1269.6	1270.6	1269.6	1270.6
151.0	4.7	4.7	11.7	0.7	79.0	VFMQEKF	927.5	928.5	927.5	928.5
O15145 ARPC3_HUMAN						Actin-related protein 2/3 complex subunit 3 (ARP2/3 complex 21 kDa subunit) (p21-ARC) - Bos taurus (Bovine) : Actin-related protein 2/3 comple				
238.0	5.1	5.1	21.9	2.0	99.0	LIGNMALLPIR	1209.7	1210.7	1209.7	1210.7
238.0	5.1	5.1	21.9	1.7	98.0	AQYQLQR	890.5	891.5	890.5	891.5
238.0	5.1	5.1	21.9	1.4	96.0	SOFKGAPPR	986.5	987.5	986.5	987.5
247.0	2.3	2.3	15.2	2.0	99.0	LIGNMALLPIR	1209.7	1210.7	1209.7	1210.7
247.0	2.3	2.3	15.2	0.3	47.0	AQYQLQR	890.5	891.5	890.5	891.5
247.0	2.3	2.3	15.2	0.0	31.0	AQYQLQR	890.5	891.5	890.5	891.5
O15204 ADEC1_HUMAN						ADAM DEC1 precursor (EC 3.4.24.-) (A disintegrin and metalloproteinase domain-like protein decysin 1) (ADAM-like protein decysin 1) - Homo sap				
264.0	4.3	4.3	10.4	2.0	99.0	LHPDPTYETLYSPR	1760.9	1761.9	1760.9	1761.9
264.0	4.3	4.3	10.4	2.0	99.0	LKPGTDCGGDAPNHTTE	1768.8	1769.8	1768.8	1769.8
264.0	4.3	4.3	10.4	0.3	44.0	GYFTHHOR	1181.5	1182.5	1181.5	1182.6
81.0	4.2	4.2	7.7	2.0	99.0	ECTLCCEALTC	1657.7	1658.7	1657.7	1658.7
81.0	4.2	4.2	7.7	2.0	99.0	HLLGPDTETYLYSPR	1760.9	1761.9	1760.9	1761.9
81.0	4.2	4.2	7.7	0.2	39.0	YLSQLPK	975.6	976.6	975.6	976.6
216.0	3.2	3.2	8.5	2.0	99.0	LKGPGTDCGGDAPNHTTE	1768.8	1769.8	1768.8	1769.8
216.0	3.2	3.2	8.5	1.2	99.0	GYFTHHOR	1181.6	1182.6	1181.5	1182.6
O43390 HNRPR_HUMAN						Heterogeneous nuclear ribonucleoprotein (hRNP R) - Homo sapiens (Human)				
267.0	4.2	4.2	20.7	2.0	99.0	DLYEDELVPFLEK	1608.8	1609.8	1608.8	1609.8
267.0	4.2	4.2	20.7	2.0	99.0	LDQALNHLIR	1538.8	1539.8	1538.8	1539.8
267.0	4.2	4.2	20.7	0.1	26.0	STAYEDYYHPPPR	1757.8	1758.8	1757.8	1758.8
166.0	4.3	4.3	14.5	2.0	99.0	LDQYAFVHFEDR	1538.8	1539.8	1538.8	1539.8
166.0	4.3	4.3	14.5	1.5	97.0	RGRAGYSQR	1130.5	1131.5	1130.5	1131.5
166.0	4.3	4.3	14.5	0.8	84.0	DLYEDELVPFLEK	1608.8	1609.8	1608.8	1609.8
O43707 ACTN4_HUMAN						Alpha-actinin-4 (Non-muscle alpha-actinin 4) (F-actin cross-linking protein) - Homo sapiens (Human)				
10.0	41.3	41.3	35.2	2.0	99.0	ASFNHDKDQHGGALGPEEFK	2199.0	2200.0	2202.0	2203.0
10.0	41.3	41.3	35.2	2.0	99.0	COLEINFNTLTK	1590.8	1591.8	1590.8	1591.8
10.0	41.3	41.3	35.2	2.0	99.0	DGLAFNLHILR	1225.6	1226.6	1225.7	1226.7
10.0	41.3	41.3	35.2	2.0	99.0	EGILLWQCR	1173.6	1174.6	1173.6	1174.6
10.0	41.3	41.3	35.2	2.0	99.0	GIQEOMOEOF	1351.6	1352.6	1351.6	1352.6
10.0	41.3	41.3	35.2	2.0	99.0	ICDOWDALGSLTHSR	1757.8	1758.8	1757.8	1758.8
10.0	41.3	41.3	35.2	2.0	99.0	KTFTAWCNSHLR	1519			

10.0	41.3	41.3	35.2	1.0	89.0	HTNYTMEHIR	1300.6	1301.6	1300.6	1301.6
10.0	41.3	41.3	35.2	0.2	30.0	DAKGISQOEQMOEQR	1665.8	1666.8	1665.8	1666.8
10.0	41.3	41.3	35.2	0.0	99.0	LEDFRDYRR	1268.6	1269.6	1268.6	1269.6
44.0	6.9	6.9	13.9	2.0	99.0	ELPPDDAECYCIAR	1560.7	1561.7	1560.7	1561.7
44.0	6.9	6.9	13.9	2.0	99.0	VGWEQLLTTIAR	1385.7	1386.8	1385.8	1386.8
44.0	6.9	6.9	13.9	1.7	98.0	LEDFRDYR	1112.5	1113.5	1112.5	1113.5
44.0	6.9	6.9	13.9	0.9	88.0	LSNRPAPMPSGEK	1432.7	1433.7	1432.7	1433.7
44.0	6.9	6.9	13.9	0.3	44.0	LEDFRDYRR	1268.6	1269.6	1268.6	1269.6
44.0	6.9	6.9	13.9	0.0	84.0	ELPPDDAECYCIAR	1557.7	1558.7	1560.7	1561.7
44.0	6.9	6.9	13.9	0.0	95.0	LEDFRDYR	1112.5	1113.6	1112.5	1113.5
22.0	22.9	22.9	32.3	2.0	99.0	ASFNHFDDKDHGGALGPPEEFK	2202.0	2203.0	2202.0	2203.0
22.0	22.9	22.9	32.3	2.0	99.0	EGLLILWCQR	1173.6	1174.6	1173.6	1174.6
22.0	22.9	22.9	32.3	2.0	99.0	ELPPDDAECYCIAR	1560.7	1561.7	1560.7	1561.7
22.0	22.9	22.9	32.3	2.0	99.0	GISOEQMEOEFR	1351.6	1352.6	1351.6	1352.6
22.0	22.9	22.9	32.3	2.0	99.0	HTNYTMEHIR	1300.6	1301.6	1300.6	1301.6
22.0	22.9	22.9	32.3	2.0	99.0	KTTFTAWCNSHLR	1519.7	1520.7	1519.7	1520.7
22.0	22.9	22.9	32.3	2.0	99.0	LEDFRDYR	1112.5	1113.5	1112.5	1113.5
22.0	22.9	22.9	32.3	2.0	99.0	LSNRPAPMPSGEK	1432.7	1433.7	1432.7	1433.7
22.0	22.9	22.9	32.3	2.0	99.0	TINEVENQILTR	1426.8	1428.8	1426.8	1428.8
22.0	22.9	22.9	32.3	2.0	99.0	VLAGDKNITAEELRR	1831.0	1832.0	1831.0	1832.0
22.0	22.9	22.9	32.3	1.7	98.0	LEDFRDYRR	1268.6	1269.6	1268.6	1269.6
22.0	22.9	22.9	32.3	0.8	85.0	KHEAFESDLAAHQDR	1752.8	1753.8	1752.8	1753.8
22.0	22.9	22.9	32.3	0.4	56.0	EALIAHHEKAQR	1377.8	1378.8	1377.8	1378.8
22.0	22.9	22.9	32.3	0.0	99.0	ASFNHFDDKDHGGALGPPEEFK	2203.0	2204.0	2203.0	2204.0
22.0	22.9	22.9	32.3	0.0	20.0	ASFNHFDDKDHGGALGPPEEFK	2199.0	2200.0	2202.0	2203.0
22.0	22.9	22.9	32.3	0.0	97.0	LEDFRDYRR	1268.6	1269.6	1268.6	1269.6
O43776 SYNC_HUMAN Asparaginyl-tRNA synthetase, cytoplasmic (EC 6.1.1.22) (Asparagine--tRNA ligase) (AsnRS) - Homo sapiens (Human)										
212.0	6.0	6.0	9.3	2.0	99.0	EGIDPTPYWYTDTOR	1902.8	1903.9	1902.8	1903.8
212.0	6.0	6.0	9.3	2.0	99.0	IDFSEELILAYGKR	1539.8	1540.8	1539.8	1540.8
212.0	6.0	6.0	9.3	2.0	99.0	NLMFLVRL	1004.6	1005.6	1004.6	1005.6
295.0	2.0	2.0	6.4	2.0	99.0	NLMFLVRL	1004.6	1005.6	1004.6	1005.6
O75083 WDR1_HUMAN WD repeat protein 1 (Actin-interacting protein 1) (AIP1) (NORI-1) - Homo sapiens (Human)										
108.0	10.0	10.0	16.5	2.0	99.0	IKDIAWTEDSKR	1460.8	1461.8	1460.8	1461.8
108.0	10.0	10.0	16.5	2.0	99.0	MTVDESQLISCSMDTDVR	2142.9	2144.0	2142.9	2143.9
108.0	10.0	10.0	16.5	2.0	99.0	VFASLPOVER	1114.6	1145.6	1144.6	1145.6
108.0	10.0	10.0	16.5	2.0	99.0	YAPSGFYIASGDSVGKLR	1887.0	1888.0	1887.0	1888.0
108.0	10.0	10.0	16.5	2.0	99.0	YEYOPFAQK	1101.5	1102.5	1101.5	1102.5
111.0	6.9	6.9	14.4	2.0	99.0	IKDIAWTEDSKR	1460.8	1461.8	1460.8	1461.8
111.0	6.9	6.9	14.4	2.0	99.0	YEYQPFPK	1101.5	1102.5	1101.5	1102.5
111.0	6.9	6.9	14.4	1.3	95.0	VFASLPOVER	1114.6	1145.6	1144.6	1145.6
111.0	6.9	6.9	14.4	0.9	88.0	FTIGDHSK	931.5	932.5	931.5	932.5
111.0	6.9	6.9	14.4	0.5	65.0	LATGSDNDNAFFEGPPFKFK	2318.1	2319.1	2318.1	2319.1
111.0	6.9	6.9	14.4	0.2	33.0	YAPSGFYIASGDSVGKLR	1887.0	1888.0	1887.0	1888.0
O75368 SH3L1_HUMAN SH3 domain-binding glutamic acid-rich-like protein - Homo sapiens (Human)										
320.0	4.0	4.0	24.6	2.0	99.0	ENAVYAFGLTAPPGSK	1847.9	1849.0	1847.9	1848.9
320.0	4.0	4.0	24.6	2.0	99.0	GDYDAFFEAR	1189.5	1190.6	1189.5	1190.5
373.0	2.0	2.0	8.8	2.0	99.0	GDYDAFFEAR	1189.5	1190.5	1189.5	1190.5
O75791 GRAP2_HUMAN GRB2-related adapter protein 2 (GADS protein) (Growth factor receptor-binding protein) (GRBLG) (Grf40 adapter protein) (Grf-40) (GRB-2-like pr										
553.0	2.0	2.0	3.3	2.0	99.0	YLQHHHHQER	1530.7	1531.7	1530.7	1531.7
384.0	1.7	1.7	11.2	1.7	98.0	YLQHHHHQER	1530.7	1531.7	1530.7	1531.7
P00338 LDHA_HUMAN L-lactate dehydrogenase A chain (EC 1.11.1.27) (LDH-A) (LDH muscle subunit) (LDH) (Proliferation-inducing gene 19 protein) (Renal carcinoma)										
129.0	9.1	11.3	30.4	2.0	99.0	GEMMDLOHGSFLR	1632.8	1633.8	1632.8	1633.8
129.0	9.1	11.3	30.4	2.0	99.0	KSDTLWGIQKELOF	1762.9	1763.9	1762.9	1763.9
129.0	9.1	11.3	30.4	2.0	99.0	SADTLWGIQKELOF	1634.8	1635.8	1634.8	1635.8
129.0	9.1	11.3	30.4	1.5	99.0	SADTLWGIQK	1117.6	1118.6	1117.6	1118.6
129.0	9.1	11.3	30.4	1.2	99.0	DLADELALVDIEDK	1656.8	1657.8	1656.8	1657.9
129.0	9.1	11.3	30.4	0.2	43.0	RHPVSTMIK	1166.7	1167.7	1166.7	1167.7
129.0	9.1	11.3	30.4	0.1	25.0	FRYLMGER	1070.5	1071.5	1070.5	1071.5
129.0	9.1	11.3	30.4	0.0	26.0	QQEGERSLNLVOR	1555.8	1556.8	1555.8	1556.8
129.0	9.1	11.3	30.4	0.0	83.0	VIGSGCNLDSAR	1247.6	1248.6	1247.6	1248.6
156.0	2.0	4.0	11.1	2.0	99.0	SADTLWGIQKELOF	1634.8	1635.9	1634.8	1635.8
156.0	2.0	4.0	11.1	0.0	99.0	SADTLWGIQK	1117.6	1118.6	1117.6	1118.6
P00491 PNPH_HUMAN Purine nucleoside phosphorylase (EC 2.4.2.1) (Inosine phosphorylase) (PNP) - Homo sapiens (Human)										
166.0	7.0	7.0	32.9	2.0	99.0	FGDRFPAMSDAYDR	1646.7	1647.7	1646.7	1647.7
166.0	7.0	7.0	32.9	2.0	99.0	FHMEGYPLWK	1469.7	1470.7	1469.7	1470.7
166.0	7.0	7.0	32.9	2.0	99.0	LGDAVGMSVTPREVIVAR	1784.0	1785.0	1784.0	1785.0
141.0	5.7	5.7	29.1	2.0	99.0	FEVGDMILR	1191.6	1192.6	1191.6	1192.6
141.0	5.7	5.7	29.1	2.0	99.0	FHMEGYPLWK	1469.7	1470.7	1469.7	1470.7
141.0	5.7	5.7	29.1	1.7	98.0	FGDRFPAMSDAYDR	1646.7	1647.7	1646.7	1647.7
P00558 PGK1_HUMAN Phosphoglycerate kinase 1 (EC 2.7.2.3) (Primer recognition protein 2) (PRP 2) (Cell migration-inducing gene 10 protein) - Homo sapiens (Human)										
22.0	28.0	28.0	53.0	2.0	99.0	ACANPAAGSVILLENR	1767.9	1768.9	1767.9	1768.9
22.0	28.0	28.0	53.0	2.0	99.0	AEPAKIEAFR	1130.6	1131.6	1130.6	1131.6
22.0	28.0	28.0	53.0	2.0	99.0	AHSSMVGVLNPQK	1366.7	1367.7	1366.7	1367.7
22.0	28.0	28.0	53.0	2.0	99.0	SADTLWGIQKELOF	1634.8	1635.8	1634.8	1635.8
22.0	28.0	28.0	53.0	2.0	99.0	FHVEEEGKGDASGNVK	1958.0	1959.0	1958.0	1959.0
22.0	28.0	28.0	53.0	2.0	99.0	GCITIIGGDTATCCKA	1753.8	1754.8	1753.8	1754.8
22.0	28.0	28.0	53.0	2.0	99.0	ITLPVDFVTAQFDENAK	2022.0	2023.0	2022.0	2023.0
22.0	28.0	28.0	53.0	2.0	99.0	LGDVYVNDAFGTAHR	1633.8	1634.8	1633.8	1634.8
22.0	28.0	28.0	53.0	0.0	99.0	AEPAKIEAFR	1130.6	1131.6	1130.6	1131.6
22.0	28.0	28.0	53.0	0.0	99.0	AHSSMVGVLNPQK	1366.7	1367.7	1366.7	1367.7
76.0	4.6	4.6	30.5	2.0	99.0	ITLPVDFVTAQFDENAK	2022.0	2023.0	2022.0	2023.0
76.0	4.6	4.6	30.5	2.0	99.0	LGDVYVNDAFGTAHR	1633.8	1634.8	1633.8	1634.8
76.0	4.6	4.6	30.5	0.3	53.0	VDFNPMKNNQITNNQR	2031.0	2032.0	2031.0	2032.0
76.0	4.6	4.6	30.5	0.2	39.0	VLNMMIEGTSLFDEEGAK	1965.9	1967.0	1965.9	1966.9
30.0	20.8	20.8	45.6	2.0	99.0	ACANPAAGSVILLENR	1919.9	1920.9	1919.9	1920.9
30.0	20.8	20.8	45.6	2.0	99.0	AEPAKIEAFR	1130.6	1131.6	1130.6	1131.6
30.0	20.8	20.8	45.6	2.0	99.0	AHSSMVGVLNPQK	1366.7	1367.7	1366.7	1367.7
30.0	20.8	20.8	45.6	2.0	99.0	ALESPERPFLAILGGAK	1768.0	1769.0	1768.0	1769.0
30.0	20.8	20.8	45.6	2.0	99.0	FHVEEEGKGDASGNVK	1958.0	1959.0	1958.0	1959.0
30.0	20.8	20.8	45.6	2.0	99.0	GCITIIGGDTATCCKA	1753.8	1754.8	1753.8	1754.8
30.0	20.8	20.8	45.6	2.0	99.0	ITLPVDFVTAQFDENAK	2022.0	2023.0	2022.0	2023.0
30.0	20.8	20.8	45.6	2.0	99.0	LGDVYVNDAFGTAHR	1633.8	1634.8	1633.8	1634.8
30.0	20.8	20.8	45.6	0.7	78.0	ELNYFAK	883.5	884.5	883.4	884.5
30.0	20.8	20.8	45.6	0.0	93.0	ACANPAAGSVILLENR	1761.9	1762.9	1761.9	1762.9

16.0	16.5	16.5	18.1	0.6	73.0	YGAATFTR	1013.5	1014.5	1013.5	1014.5
16.0	16.5	16.5	18.1	0.4	60.0	ALLAYAFALAGNODK	1606.8	1607.9	1606.9	1607.9
16.0	16.5	16.5	18.1	0.2	30.0	NCGNTWLTAFLVK	1635.7	1636.7	1635.7	1636.7
16.0	16.5	16.5	18.1	0.0	30.0	NALFCLESAWK	1475.6	1476.6	1475.6	1476.6
16.0	16.5	16.5	18.1	0.0	25.0	OTVSWAVTPK	1115.6	1116.6	1115.6	1116.6
18.0	26.1	26.1	17.1	2.0	99.0	AIGYLNTGYQR	1310.7	1311.7	1310.7	1311.7
18.0	26.1	26.1	17.1	2.0	99.0	DMSFLLEDMGLK	1446.6	1447.6	1446.7	1447.7
18.0	26.1	26.1	17.1	2.0	99.0	GRNQGNVTWLAFVVK	1635.8	1636.8	1635.8	1636.8
18.0	26.1	26.1	17.1	2.0	99.0	HYDGSYSTFGERY	1538.7	1539.7	1538.7	1539.7
18.0	26.1	26.1	17.1	2.0	99.0	LPPNVVEESAR	1209.6	1210.6	1209.6	1210.6
18.0	26.1	26.1	17.1	2.0	99.0	NALFCLESAWK	1324.6	1325.6	1324.6	1325.6
18.0	26.1	26.1	17.1	2.0	99.0	OTVSWAVTPK	1098.5	1099.5	1098.6	1099.6
18.0	26.1	26.1	17.1	2.0	99.0	SGGRTEHPIFTVEEFVLPK	2001.0	2002.0	2001.0	2002.0
18.0	26.1	26.1	17.1	2.0	99.0	SKAIGYLNTGYQR	1525.8	1526.8	1525.8	1526.8
18.0	26.1	26.1	17.1	2.0	99.0	VTAAPOSVCALR	1301.7	1302.7	1301.7	1302.7
18.0	26.1	26.1	17.1	2.0	99.0	VVDYIETDEFIAEYNAPCSK	2506.0	2507.1	2506.1	2507.1
18.0	26.1	26.1	17.1	2.0	99.0	YGAATFTRG	1043.5	1044.5	1043.5	1044.5
18.0	26.1	26.1	17.1	1.4	96.0	ALLAYAFALAGNODK	1606.8	1607.9	1606.9	1607.9
18.0	26.1	26.1	17.1	0.5	70.0	KSGGRTEHPIFTVEEFVLPK	2554.4	2555.4	2554.4	2555.4
18.0	26.1	26.1	17.1	0.2	33.0	FSGQLNSHCFYQQVTK	2057.9	2058.9	2057.9	2058.9
18.0	26.1	26.1	17.1	0.0	99.0	NALFCLESAWK	1323.6	1324.6	1323.6	1324.6
18.0	26.1	26.1	17.1	0.0	99.0	NALFCLESAWK	1475.6	1476.6	1475.6	1476.6
PO1033 TIMP1_HUMAN	Metalloproteinase inhibitor 1 precursor (TIMP-1) (Erythroid-potentiating activity) (EPA) (Tissue inhibitor of metalloproteinases) (Fibroblast collagenase inhibitor)									
319.0	4.0	4.0	14.5	2.0	99.0	EPLGLCTWQSLSR	1345.6	1346.7	1345.6	1346.7
319.0	4.0	4.0	14.5	2.0	99.0	LSGTHCLWTDLQOLGSEK	2200.0	2201.1	2200.1	2201.1
169.0	2.0	2.0	22.2	2.0	99.0	GFOALGDAADIR	1232.6	1233.6	1232.6	1233.6
195.0	4.0	4.0	13.0	2.0	99.0	EPLGLCTWQSLSR	1345.6	1346.7	1345.6	1346.7
195.0	4.0	4.0	13.0	2.0	99.0	FVTPAMESVCGVYFHR	1962.9	1963.9	1962.9	1963.9
PO1034 CYTC_HUMAN	Cystatin-C precursor (Cystatin-3) (Neuroendocrine basic polypeptide) (Gamma-trace) (Post-gamma-globulin) - Homo sapiens (Human)									
302.0	4.0	4.0	25.3	2.0	99.0	ALDAVGEYNK	1225.6	1226.6	1225.6	1226.6
302.0	4.0	4.0	25.3	2.0	99.0	LVGGPMDSVVEEGVRR	1799.9	1800.9	1799.9	1800.9
104.0	3.4	3.4	26.0	2.0	99.0	ALDAVGEYNK	1225.6	1226.6	1225.6	1226.6
104.0	3.4	3.4	26.0	1.4	96.0	TOPNIIDCPFHDPHILK	2060.0	2061.0	2060.0	2061.0
355.0	2.0	2.0	13.7	2.0	99.0	ALDAVGEYNK	1225.6	1226.6	1225.6	1226.6
PO1834 KAC_HUMAN	Ig kappa chain C region - Homo sapiens (Human)									
260.0	4.5	4.5	37.7	2.0	99.0	ADYEKHKVVAECEVHQLSSPVTK	2746.3	2747.3	2746.3	2747.3
260.0	4.5	4.5	37.7	2.0	99.0	VVACEVTHGLSSPVTK	1874.9	1875.9	1874.9	1875.9
260.0	4.5	4.5	37.7	0.4	64.0	SGTASVCLLNNFYPR	1797.9	1798.9	1797.9	1798.9
188.0	4.0	4.0	31.1	2.0	99.0	SGTASVCLLNNFYPR	1797.9	1798.9	1797.9	1798.9
188.0	4.0	4.0	31.1	2.0	99.0	VVACEVTHGLSSPVTK	1874.9	1875.9	1874.9	1875.9
PO1842 LAC_HUMAN	Ig lambda chain C regions - Homo sapiens (Human)									
332.0	3.7	3.7	39.0	2.0	99.0	YAASSYSLTPEQW	1677.8	1678.8	1677.7	1678.7
332.0	3.7	3.7	39.0	1.5	97.0	SYSQCVTHGSTVEK	1710.8	1711.8	1710.8	1711.8
332.0	3.7	3.7	39.0	0.1	29.1	OPKAAPSVTLF	1256.7	1257.7	1256.7	1257.7
64.0	5.3	5.3	19.0	2.0	99.0	YAASSYSLTPEQW	1677.8	1678.8	1677.7	1678.7
64.0	5.3	5.3	19.0	2.0	99.0	YAASSYSLTPEQW	1742.9	1743.9	1742.9	1743.9
64.0	5.3	5.3	19.0	1.3	95.0	OSNNKYAAASSYSLTPEQW	2314.1	2315.1	2314.1	2315.1
203.0	3.7	3.7	28.6	2.0	99.0	SYSQKVTHGSTVEK	1710.8	1711.8	1710.8	1711.8
203.0	3.7	3.7	28.6	1.7	98.0	YAASSYSLTPEQW	1742.9	1743.9	1742.9	1743.9
PO1871 MUC_HUMAN	Ig mu chain C region - Homo sapiens (Human)									
570.0	1.7	1.7	1.8	1.7	98.0	OIQVSWLR	1011.5	1012.6	1011.6	1012.6
195.0	1.7	1.7	7.0	1.7	98.0	OIQVSWLR	1028.6	1029.6	1028.6	1029.6
106.0	7.6	7.6	17.2	2.0	99.0	ESDWLSSMFTCR	1645.7	1646.7	1645.7	1646.7
106.0	7.6	7.6	17.2	2.0	99.0	GFPSPVL	774.4	775.4	774.4	775.4
106.0	7.6	7.6	17.2	2.0	99.0	GOPSPEKVTSAPEMPQAPGR	2436.2	2437.2	2436.2	2437.2
106.0	7.6	7.6	17.2	1.5	97.0	OIQVSWLR	1011.5	1012.5	1011.6	1012.6
106.0	7.6	7.6	17.2	0.0	96.0	OIQVSWLR	1028.6	1029.6	1028.6	1029.6
PO2746 C1QB_HUMAN	Complement C1q subcomponent subunit B precursor - Homo sapiens (Human)									
95.0	4.0	4.0	13.5	2.0	99.0	FDHVITNMNNNYEPR	1862.8	1863.8	1862.8	1863.8
95.0	4.0	4.0	13.5	2.0	99.0	VPGLYFTYHASSR	1659.8	1660.8	1659.8	1660.8
337.0	2.0	2.0	14.3	2.0	99.0	VPGLYFTYHASSR	1659.8	1660.8	1659.8	1660.8
PO2747 C1QC_HUMAN	Complement C1q subcomponent subunit C precursor - Homo sapiens (Human)									
386.0	2.4	2.4	14.7	1.7	98.0	OTHOPPAPNSLIR	1457.8	1458.8	1457.8	1458.8
386.0	2.4	2.4	14.7	0.7	81.0	FOSFVTVR	1083.6	1084.6	1083.6	1084.6
190.0	2.0	2.0	3.7	2.0	99.0	FOSFVTVR	1083.6	1084.6	1083.6	1084.6
354.0	2.0	2.0	10.2	2.0	99.0	OTHOPPAPNSLIR	1457.8	1458.8	1457.8	1458.8
PO2751 FINC_HUMAN	Fibronectin precursor (FN) (Cold-insoluble globulin) (CI G) - Homo sapiens (Human)									
584.0	1.4	1.4	1.1	1.4	96.0	YOCYCYGR	1168.4	1169.5	1168.4	1169.5
22.0	13.3	13.3	13.7	2.0	99.0	GEWTCAIYSLQR	1482.7	1483.7	1482.7	1483.7
22.0	13.3	13.3	13.7	2.0	99.0	IGDOWDKOHDMGHMMR	1983.9	1984.9	1983.9	1984.9
22.0	13.3	13.3	13.7	2.0	99.0	LLCOCLGFGSGHFR	1650.8	1651.8	1650.8	1651.8
22.0	13.3	13.3	13.7	2.0	99.0	YOCYCYGR	1168.4	1169.5	1168.4	1169.5
22.0	13.3	13.3	13.7	1.7	98.0	IYLYTLNDNR	1354.7	1355.7	1354.7	1355.7
22.0	13.3	13.3	13.7	1.5	97.0	QDGHLCSTTSNYEQODK	2195.9	2196.9	2195.9	2196.9
22.0	13.3	13.3	13.7	1.4	96.0	EVLGAIICSTCFGGQR	1877.8	1878.8	1877.8	1878.8
22.0	13.3	13.3	13.7	0.6	72.0	GATYNIIVEALKDOQR	1817.9	1819.0	1818.0	1819.0
27.0	21.3	21.3	16.4	2.0	99.0	WLPSSPVGTYR	1348.7	1349.7	1348.7	1349.7
27.0	21.3	21.3	16.4	2.0	99.0	WSRPQAPITGR	1430.7	1431.8	1430.7	1431.7
27.0	21.3	21.3	16.4	1.2	93.0	IGDOWDKOHDMGHMMR	1998.8	2000.9	1998.8	2000.9
27.0	21.3	21.3	16.4	0.0	99.0	YOCYCYGR	1171.5	1172.5	1168.4	1169.5
PO2792 FRIL_HUMAN	Ferritin light chain (Ferritin L subunit) - Homo sapiens (Human)									
550.0	2.0	2.0	8.6	2.0	99.0	LGFLPEALGEYLER	1606.8	1607.8	1606.8	1607.8
370.0	2.0	2.0	8.6	2.0	99.0	LGFLPEALGEYLER	1606.8	1607.8	1606.8	1607.8
PO2795 MT2_HUMAN	Metallothionein-2 (MT-2) (Metallothionein-1) (MT-1) (Metallothionein-2A) - Homo sapiens (Human)									
216.0	6.0	6.0	82.0	2.0	99.0	CAQGICKGASDKSCCA	2074.7	2075.7	2074.8	2075.8
216.0	6.0	6.0	82.0	2.0	99.0	MDPNCSAACGDSCTAGSCK	2249.8	2250.8	2249.8	2250.8
216.0	6.0	6.0	82.0	2.0	99.0	SCSCCPVGCAK	1444.5	1445.5	1444.5	1445.5
216.0	6.0	6.0	82.0	0.0	99.0	MDPNCSAACGDSCTAGSCK	2252.8	2253.8	2252.8	2253.8
216.0	6.0	6.0	82.0	0.0	99.0	MDPNCSAACGDSCTAGSCK	2192.7	2193.7	2192.7	2193.7
216.0	6.0	6.0	82.0	0.0	47.0	MDPNCSAACGDSCTAGSCK	2253.8	2254.8	2253.7	2254.7
216.0	6.0	6.0	82.0	0.0	99.0	SCSCCPVGCAK	1447.5	1448.5	1444.5	1445.5
114.0	6.7	6.7	62.3	2.0	99.0	KSCSCCPVGCAK	1573.6	1574.6	1572.6	1573.6
114.0	6.7	6.7	62.3	2.0	99.0	MDPNCSAACGDSCTAGSCK	2249.8	2250.8	2249.8	2250.8
114.0	6.7	6.7	62.3	2.0	99.0	SCSCCPVGCAK	1444.5	1445.5	1444.5	1445.5
114.0	6.7	6.7	62.3	0.7	81.0	MDPNCSAACGDSCTAGSCKCECK	2955.0	2956.0</td		

16.0	37.1	37.1	57.7	2.0	99.0	DGADFAKWR	1064.5	1065.5	1064.5	1065.5
16.0	37.1	37.1	57.7	2.0	99.0	IGEHTPSALIMENANVLAR	2106.1	2107.1	2106.1	2107.1
16.0	37.1	37.1	57.7	2.0	99.0	IVAPKGGLADESTGSIKR	2053.1	2054.2	2053.2	2054.2
16.0	37.1	37.1	57.7	2.0	99.0	KELSDIAHR	1067.6	1068.6	1067.6	1068.6
16.0	37.1	37.1	57.7	2.0	99.0	LOSGITENTEEENR	1645.8	1646.8	1645.8	1646.8
16.0	37.1	37.1	57.7	2.0	99.0	PYQYPALTEPEOKK	1433.7	1434.7	1433.7	1434.7
16.0	37.1	37.1	57.7	2.0	99.0	PYQYPALTEPEOKKESLDIAHR	1561.8	1562.8	1561.8	1562.8
16.0	37.1	37.1	57.7	2.0	99.0	RLOGSIGTENTEEENR	2483.3	2484.3	2483.3	2484.3
16.0	37.1	37.1	57.7	2.0	99.0	YTPSGOAGAASESLSFVSNHAY	1801.9	1802.9	1801.9	1802.9
16.0	37.1	37.1	57.7	1.7	98.0	YQYPALTEPEOKKESLDIAHR	2227.0	2228.0	2227.0	2228.0
16.0	37.1	37.1	57.7	1.4	96.0	KENLKAQAEYVKR	2479.2	2480.2	2479.2	2480.2
16.0	37.1	37.1	57.7	0.7	82.0	ENLKAQAEYVKR	1704.9	1705.9	1704.9	1705.9
16.0	37.1	37.1	57.7	0.5	70.0	VDKGVPLAGTNGETTQGLDSLER	2614.3	2615.3	2614.3	2615.3
16.0	37.1	37.1	57.7	0.5	65.0	GVPVLAGTNGETTQGLDSLER	2272.1	2273.1	2272.1	2273.1
16.0	37.1	37.1	57.7	0.3	51.0	MPYQYPALTEPEOKKESLDIAHR	2495.3	2496.3	2495.3	2496.3
16.0	37.1	37.1	57.7	0.0	58.0	LOSGITENTEEENR	1648.8	1649.8	1645.8	1646.8
52.0	6.2	6.2	29.4	2.0	99.0	IGEHTPSALIMENANVLAR	2106.1	2107.1	2106.1	2107.1
52.0	6.2	6.2	29.4	2.0	99.0	PYQYPALTEPEOKK	1561.8	1562.8	1561.8	1562.8
52.0	6.2	6.2	29.4	1.5	97.0	LOSGITENTEEENR	1645.8	1646.8	1645.8	1646.8
52.0	6.2	6.2	29.4	0.6	75.0	YTPSGOAGAASESLSFVSNHAY	2227.0	2228.0	2227.0	2228.0
52.0	6.2	6.2	29.4	0.1	15.0	FSHEIJAMATVTLARKR	1830.9	1832.0	1830.9	1831.9
23.0	22.8	22.8	50.5	2.0	99.0	ADDGRPPPOVIK	1341.7	1342.7	1341.7	1342.7
23.0	22.8	22.8	50.5	2.0	99.0	ALANSLACQKG	1131.6	1132.6	1131.6	1132.6
23.0	22.8	22.8	50.5	2.0	99.0	AWGGKCKENLKAQAEYVKR	2204.2	2205.2	2204.2	2205.2
23.0	22.8	22.8	50.5	2.0	99.0	CAQYKKDGDAFK	1483.7	1484.7	1483.7	1484.7
23.0	22.8	22.8	50.5	2.0	99.0	IGEHTPSALIMENANVLAR	2106.1	2107.1	2106.1	2107.1
23.0	22.8	22.8	50.5	2.0	99.0	KENLKAQAEYVKR	1704.9	1705.9	1704.9	1705.9
23.0	22.8	22.8	50.5	2.0	99.0	LQSIGTENTEEENR	1645.8	1646.8	1645.8	1646.8
23.0	22.8	22.8	50.5	2.0	99.0	PYQYPALTEPEOKK	1433.7	1434.7	1433.7	1434.7
23.0	22.8	22.8	50.5	2.0	99.0	PYQYPALTEPEOKK	1561.8	1562.8	1561.8	1562.8
23.0	22.8	22.8	50.5	2.0	99.0	PYQYPALTEPEOKKESLDIAHR	2483.3	2484.3	2483.3	2484.3
23.0	22.8	22.8	50.5	2.0	99.0	YTPSGOAGAASESLSFVSNHAY	2227.0	2228.0	2227.0	2228.0
23.0	22.8	22.8	50.5	1.7	98.0	YQYPALTEPEOKKESLDIAHR	2479.2	2480.2	2479.2	2480.2
23.0	22.8	22.8	50.5	1.4	96.0	KENLKAQAEYVKR	1704.9	1705.9	1704.9	1705.9
23.0	22.8	22.8	50.5	0.7	82.0	ENLKAQAEYVKR	1576.8	1577.8	1576.8	1577.8
23.0	22.8	22.8	50.5	0.5	70.0	VDKGVPLAGTNGETTQGLDSLER	2614.3	2615.3	2614.3	2615.3
23.0	22.8	22.8	50.5	0.5	65.0	GVPVLAGTNGETTQGLDSLER	2272.1	2273.1	2272.1	2273.1
23.0	22.8	22.8	50.5	0.3	51.0	MPYQYPALTEPEOKKESLDIAHR	2495.3	2496.3	2495.3	2496.3
23.0	22.8	22.8	50.5	0.0	58.0	LOSGITENTEEENR	1648.8	1649.8	1645.8	1646.8
52.0	6.2	6.2	29.4	2.0	99.0	IGEHTPSALIMENANVLAR	2106.1	2107.1	2106.1	2107.1
52.0	6.2	6.2	29.4	2.0	99.0	PYQYPALTEPEOKK	1561.8	1562.8	1561.8	1562.8
52.0	6.2	6.2	29.4	1.5	97.0	LOSGITENTEEENR	1645.8	1646.8	1645.8	1646.8
52.0	6.2	6.2	29.4	0.6	75.0	YTPSGOAGAASESLSFVSNHAY	2227.0	2228.0	2227.0	2228.0
52.0	6.2	6.2	29.4	0.1	15.0	FSHEIJAMATVTLARKR	1830.9	1832.0	1830.9	1831.9
23.0	22.8	22.8	50.5	0.0	98.0	YQYPALTEPEOKKESLDIAHR	2484.3	2485.3	2484.3	2484.3
PO4080 CYTB_HUMAN										
Cystatin-B (Stefin-B) (Liver thiol proteinase inhibitor) (CPI-1B) - Homo sapiens (Human)										
318.0	4.0	4.0	36.7	2.0	99.0	MMCGAPSATQPATATEHOIADQR	2612.2	2613.2	2612.2	2613.2
318.0	4.0	4.0	36.7	2.0	99.0	VHVGDEFVHLR	1421.7	1422.7	1421.7	1422.7
277.0	2.1	2.1	30.6	2.0	99.0	VHVGDEFVHLR	1421.7	1422.7	1421.7	1422.7
PO4406 G3P_HUMAN										
Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) - Homo sapiens (Human)										
30.0	24.2	24.2	49.6	2.0	99.0	DGRGANOLNIPASTGAAK	1738.9	1739.9	1738.9	1739.9
30.0	24.2	24.2	49.6	2.0	99.0	GVKVGVNGFGR	1217.7	1218.7	1217.7	1218.7
30.0	24.2	24.2	49.6	2.0	99.0	IISNASCTNCLAPLAK	1832.9	1833.9	1832.9	1833.9
30.0	24.2	24.2	49.6	2.0	99.0	IKWGDAGAEYVESTGVFTTMEK	2517.2	2518.2	2517.2	2518.2
30.0	24.2	24.2	49.6	2.0	99.0	LEPKAKYDDIK	1446.8	1447.8	1446.8	1447.8
30.0	24.2	24.2	49.6	2.0	99.0	LISWYDNEFGYSNR	1762.8	1763.8	1762.8	1763.8
30.0	24.2	24.2	49.6	2.0	99.0	VGVNFGFR	805.4	806.4	805.4	806.4
30.0	24.2	24.2	49.6	2.0	99.0	VIIAPSADAPMFMVGVNHEK	2212.1	2213.1	2212.1	2213.1
30.0	24.2	24.2	49.6	2.0	99.0	VIIAPSADAPMFVMVGVNHEKDSL	2932.4	2933.5	2932.4	2933.5
30.0	24.2	24.2	49.6	2.0	99.0	VPTANVSVDLTCR	1529.8	1530.8	1529.8	1530.8
30.0	24.2	24.2	49.6	2.0	99.0	WDGAGAEYVESTGVFTTMEK	2276.1	2277.1	2276.0	2277.0
30.0	24.2	24.2	49.6	1.3	95.0	VIELPNLKGLTGMAFR	1645.9	1646.9	1645.9	1646.9
30.0	24.2	24.2	49.6	0.5	67.0	LTGMAFR	794.4	795.4	794.4	795.4
30.0	24.2	24.2	49.6	0.4	60.0	LTGMFRVPTANVSVDLTCR	2306.2	2307.2	2306.2	2307.2
30.0	24.2	24.2	49.6	0.0	97.0	GVKVGVNGFGR	1217.7	1218.7	1217.7	1218.7
30.0	24.2	24.2	49.6	0.0	80.0	GVKVGVNGFGR	1217.7	1218.7	1217.7	1218.7
30.0	24.2	24.2	49.6	0.0	99.0	LISWYDNEFGYSNR	1764.8	1765.8	1762.8	1763.8
30.0	24.2	24.2	49.6	0.0	99.0	LISWYDNEFGYSNR	1778.8	1779.8	1778.8	1779.8
30.0	24.2	24.2	49.6	0.0	80.0	LISWYDNEFGYSNR	1763.8	1764.8	1763.8	1764.8
74.0	4.7	4.7	25.4	2.0	99.0	LISWYDNEFGYSNR	1762.8	1763.8	1762.8	1763.8
74.0	4.7	4.7	25.4	2.0	99.0	VPTANVSVDLTCR	1529.8	1530.8	1529.8	1530.8
74.0	4.7	4.7	25.4	0.5	65.0	VIIAPSADAPMFVMVGVNHEK	2212.1	2213.1	2212.1	2213.1
74.0	4.7	4.7	25.4	0.3	44.0	PELNGLKLTGMAFR	1465.8	1466.8	1465.7	1466.7
74.0	4.7	4.7	25.4	0.0	60.0	LISWYDNEFGYSNR	1778.8	1779.8	1778.8	1779.8
74.0	4.7	4.7	25.4	0.0	43.0	LISWYDNEFGYSNR	1754.7	1755.8	1762.8	1763.8
34.0	19.3	19.3	40.3	2.0	99.0	GALONIPASTGAAK	1410.8	1411.8	1410.8	1411.8
34.0	19.3	19.3	40.3	2.0	99.0	IISNASCTNCLAPLAK	1832.9	1833.9	1832.9	1833.9
34.0	19.3	19.3	40.3	2.0	99.0	IKWGDAGAEYVESTGVFTTMEK	2517.2	2518.2	2517.2	2518.2
34.0	19.3	19.3	40.3	2.0	99.0	LEPKAKYDDIK	1446.8	1447.8	1446.8	1447.8
34.0	19.3	19.3	40.3	2.0	99.0	LISWYDNEFGYSNR	1762.8	1763.8	1762.8	1763.8
34.0	19.3	19.3	40.3	2.0	99.0	VGVNFGFR	805.4	806.4	805.4	806.4
34.0	19.3	19.3	40.3	2.0	99.0	VIIAPSADAPMFVMVGVNHEK	2212.1	2213.1	2212.1	2213.1
34.0	19.3	19.3	40.3	2.0	99.0	VPTANVSVDLTCR	1529.8	1530.8	1529.8	1530.8
34.0	19.3	19.3	40.3	2.0	99.0	VVDLMMASMAKE	1329.6	1330.7	1329.6	1330.6
34.0	19.3	19.3	40.3	2.0	99.0	WGDAGAEYVESTGVFTTMEK	2276.0	2277.0	2276.0	2277.0
34.0	19.3	19.3	40.3	1.2	94.0	LEPKAKYDDIK	1318.7	1319.7	1318.7	1319.7
34.0	19.3	19.3	40.3	0.7	80.0	LTGMAFR	794.4	795.4	794.4	795.4
34.0	19.3	19.3	40.3	0.0	99.0	LISWYDNEFGYSNR	1763.8	1764.8	1763.8	1764.8
34.0	19.3	19.3	40.3	0.0	99.0	LISWYDNEFGYSNR	1778.8	1779.8	1778.8	1779.8
34.0	19.3	19.3	40.3	0.0	98.0	LISWYDNEFGYSNR	1794.8	1795.8	1794.8	1795.8
PO5109 S10A8_HUMAN										
Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A) (Migration inhibitory factor-related protein 8) (MRP-8) (Cystic fibrosis antigen)										
317.0	4.0	4.0	25.8	2.0	99.0	GNFH				

P06576 ATPB_HUMAN	ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) - Homo sapiens (Human)													
251.0	2.2	2.2	15.7	2.0	99.0	AHGGYSVAGVGER	1405.7	1406.7	1405.7	1406.7				
251.0	2.2	2.2	15.7	0.2	38.0	IMDPNVGSEHYDVAR	1814.9	1815.9	1814.9	1815.9				
316.0	4.0	4.0	6.6	2.0	99.0	AIAELGIYPAVDPLDTSR	1987.0	1988.0	1987.0	1988.0				
316.0	4.0	4.0	6.6	2.0	99.0	IMDPNVGSEHYDVAR	1814.9	1815.9	1814.9	1815.9				
P06733 ENOAHUMAN	Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neuronal enolase) (NNE) (Enolase 1) (Phosphopyruvate hydratase) (C-myc)													
15.0	38.3	38.3	62.9	2.0	99.0	AAVPAGSTGIVYEALERL	1803.9	1804.9	1803.9	1804.9				
15.0	38.3	38.3	62.9	2.0	99.0	AGAVEKGVPYR	1258.7	1259.7	1258.7	1259.7				
15.0	38.3	38.3	62.9	2.0	99.0	EIFDSRGNPTEVDFLTSK	2153.1	2154.1	2153.1	2154.1				
15.0	38.3	38.3	62.9	2.0	99.0	FTASAGIQVGVDDLTVPNKR	2188.1	2189.1	2188.1	2189.2				
15.0	38.3	38.3	62.9	2.0	99.0	IGAEVHNLK	1142.6	1143.6	1142.6	1143.6				
15.0	38.3	38.3	62.9	2.0	99.0	LAKYNOLLR	1117.6	1118.6	1117.7	1118.7				
15.0	38.3	38.3	62.9	2.0	99.0	LAMQEFMILPVGAANFR	1907.0	1908.0	1907.0	1908.0				
15.0	38.3	38.3	62.9	2.0	99.0	LAQANGWGVMSH	1525.7	1526.7	1525.7	1526.8				
15.0	38.3	38.3	62.9	2.0	99.0	NFRNPLAK	958.5	959.5	958.5	959.5				
15.0	38.3	38.3	62.9	2.0	99.0	SCNCLLK	1006.5	1007.5	1006.5	1007.5				
15.0	38.3	38.3	62.9	2.0	99.0	SGKYLDLFKSPDDPSR	1825.8	1826.9	1825.8	1826.9				
15.0	38.3	38.3	62.9	2.0	99.0	VNOIGSVTESLOACK	1632.8	1633.8	1632.8	1633.8				
15.0	38.3	38.3	62.9	2.0	99.0	VNOIGSVTESLOACKL	1784.8	1785.8	1784.8	1785.8				
15.0	38.3	38.3	62.9	2.0	99.0	VGIMDVAASEFF	1539.8	1540.8	1539.8	1540.8				
15.0	38.3	38.3	62.9	2.0	99.0	YGKDATNVGDEGGFAPNILENK	2308.1	2309.1	2308.1	2309.1				
15.0	38.3	38.3	62.9	2.0	99.0	YGKDATNVGDEGGFAPNILENKEGLELLK	3090.6	3091.6	3090.6	3091.6				
15.0	38.3	38.3	62.9	2.0	99.0	YISPDOLADLYK	1424.7	1425.7	1424.7	1425.7				
15.0	38.3	38.3	62.9	1.3	95.0	AGYTDKVIGMDVAASEFFR	2175.1	2176.1	2175.1	2176.1				
15.0	38.3	38.3	62.9	1.3	95.0	EIFDSR	765.4	766.4	765.4	766.4				
15.0	38.3	38.3	62.9	1.1	92.0	AAVPAGSTGIVYEALERLNDKTR	2533.3	2534.3	2533.2	2534.2				
15.0	38.3	38.3	62.9	0.6	75.0	GVPYR	703.4	704.4	703.4	704.4				
15.0	38.3	38.3	62.9	0.0	45.0	AGAVEKGVPYR	1260.7	1261.7	1258.7	1259.7				
15.0	38.3	38.3	62.9	0.0	99.0	LAKYNOLLR	1117.7	1118.7	1117.7	1118.7				
15.0	38.3	38.3	62.9	0.0	99.0	LAMQEFMILPVGAANFR	1910.0	1911.0	1907.0	1908.0				
15.0	38.3	38.3	62.9	0.0	53.0	LAQANGWGVMSH	1541.7	1542.8	1541.7	1542.7				
15.0	38.3	38.3	62.9	0.0	99.0	NFRNPLAK	958.5	959.5	958.5	959.5				
15.0	38.3	38.3	62.9	0.0	99.0	YISPDOLADLYK	1420.7	1421.7	1424.7	1425.7				
15.0	38.3	38.3	62.9	0.0	57.0	YISPDOLADLYK	1423.7	1424.7	1424.7	1425.7				
19.0	14.1	14.1	35.3	2.0	99.0	GNPITVEVDFLTSK	1405.7	1406.7	1405.7	1406.7				
19.0	14.1	14.1	35.3	2.0	99.0	IGAEVHNLK	1142.6	1143.6	1142.6	1143.6				
19.0	14.1	14.1	35.3	2.0	99.0	LAMQEFMILPVGAANFR	1907.0	1908.0	1907.0	1908.0				
19.0	14.1	14.1	35.3	2.0	99.0	LAQANGWGVMSH	1525.7	1526.8	1525.7	1526.8				
19.0	14.1	14.1	35.3	2.0	99.0	NFRNPLAK	958.5	959.5	958.5	959.5				
19.0	14.1	14.1	35.3	1.4	96.0	AAVPAGSTGIVYEALELR	1803.9	1804.9	1803.9	1804.9				
19.0	14.1	14.1	35.3	0.8	83.0	VNOIGSVTESLOACK	1632.8	1633.8	1632.8	1633.8				
19.0	14.1	14.1	35.3	0.7	81.0	LAKYNOLLR	1117.6	1118.6	1117.7	1118.7				
19.0	14.1	14.1	35.3	0.5	70.0	SGKYLDLFKSPDDPSR	1825.8	1826.9	1825.8	1826.9				
19.0	14.1	14.1	35.3	0.4	57.0	NFRNPLAK	958.5	959.5	958.5	959.5				
19.0	14.1	14.1	35.3	0.3	50.0	YNOQLLR	805.5	806.5	805.4	806.5				
19.0	14.1	14.1	35.3	0.0	99.0	YISPDOLADLYK	1423.7	1424.7	1424.7	1425.7				
12.0	31.0	31.0	55.8	2.0	99.0	AAVPAGSTGIVYEALELR	1803.9	1804.9	1803.9	1804.9				
12.0	31.0	31.0	55.8	2.0	99.0	AGYTDKVIGMDVAASEFFR	2175.0	2176.0	2175.1	2176.1				
12.0	31.0	31.0	55.8	2.0	99.0	DATNVGDEGGFAPNILENKEGLELLK	2742.4	2743.4	2742.3	2743.3				
12.0	31.0	31.0	55.8	2.0	99.0	EIFDSRGNPTEVDFLTSK	2153.1	2154.1	2153.1	2154.1				
12.0	31.0	31.0	55.8	2.0	99.0	GNPITVEVDFLTSK	1405.7	1406.7	1405.7	1406.7				
12.0	31.0	31.0	55.8	2.0	99.0	IGAEVHNLK	1142.6	1143.6	1142.6	1143.6				
12.0	31.0	31.0	55.8	2.0	99.0	LAQANGWGVMSH	1525.7	1526.8	1525.7	1526.8				
12.0	31.0	31.0	55.8	2.0	99.0	NFRNPLAK	958.5	959.5	958.5	959.5				
12.0	31.0	31.0	55.8	2.0	99.0	SGKYLDLFKSPDDPSR	1825.8	1826.9	1825.8	1826.9				
12.0	31.0	31.0	55.8	2.0	99.0	VNOIGSVTESLOACK	1632.8	1633.8	1632.8	1633.8				
12.0	31.0	31.0	55.8	2.0	99.0	VGIMDVAASEFFR	1539.8	1540.8	1539.8	1540.8				
12.0	31.0	31.0	55.8	2.0	99.0	YISPDOLADLYK	1424.7	1425.7	1424.7	1425.7				
12.0	31.0	31.0	55.8	1.5	97.0	VNQIQGSVTESLOACKL	1784.8	1785.8	1784.8	1785.8				
12.0	31.0	31.0	55.8	1.5	97.0	YNOQLLR	805.5	806.5	805.4	806.5				
12.0	31.0	31.0	55.8	1.3	95.0	SGETEDTFIADLVGLCTGQIK	2352.2	2353.2	2352.1	2353.1				
12.0	31.0	31.0	55.8	1.0	91.0	AAVPAGSTGIVYEALERLNDKTR	2533.3	2534.3	2533.3	2534.3				
12.0	31.0	31.0	55.8	0.7	82.0	SCNCLLK	1006.5	1007.5	1006.5	1007.5				
12.0	31.0	31.0	55.8	0.3	49.0	GVPYR	703.4	704.4	703.4	704.4				
12.0	31.0	31.0	55.8	0.2	42.0	LAMQEFMILPVGAANFR	1907.9	1909.0	1907.0	1908.0				
12.0	31.0	31.0	55.8	0.2	32.0	LAKYNOLLR	1117.6	1118.6	1117.7	1118.7				
12.0	31.0	31.0	55.8	0.1	25.0	AVNEKSCNCLLK	1562.8	1563.8	1562.8	1563.8				
12.0	31.0	31.0	55.8	0.0	48.0	GVPYR	703.4	704.4	703.4	704.4				
12.0	31.0	31.0	55.8	0.0	99.0	NFRNPLAK	958.5	959.5	958.5	959.5				
12.0	31.0	31.0	55.8	0.0	99.0	YISPDOLADLYK	1420.7	1421.7	1424.7	1425.7				
103.0	7.7	7.7	15.2	2.0	99.0	AALTRDPQFK	1315.7	1316.7	1315.7	1316.7				
103.0	7.7	7.7	15.2	2.0	99.0	LQQWYR	892.5	893.5	892.5	893.5				
103.0	7.7	7.7	15.2	2.0	99.0	MIPCDFLPQTQHPIRK	2192.2	2193.2	2192.2	2193.2				
103.0	7.7	7.7	15.2	1.7	98.0	FAAYFQQGDMESNGKYITK	2198.0	2199.0	2198.0	2199.0				
103.0	7.7	7.7	15.2	0.0	98.0	LQQWYR	892.5	893.5	892.5	893.5				
P06753 TPMP3_HUMAN	Tropomyosin alpha-3 chain (Tropomyosin-3) (Tropomyosin gamma) (hTM5) - Homo sapiens (Human)													
255.0	4.6	16.4	40.8	2.0	99.0	ALKDEEKMELQEIQLEK	2273.1	2274.1	2272.2	2273.2				
255.0	4.6	16.4	40.8	1.4	96.0	KLVIEGLDERTEER	1799.0	1800.0	1799.0	1800.0				
255.0	4.6	16.4	40.8	1.2	99.0	KLVIEGLDER	1283.7	1284.8	1283.7	1284.8				
255.0	4.6	16.4	40.8	0.0	99.0	HIAEADRKYEEVAR	1826.9	1827.9	1826.9	1827.9				
255.0	4.6	16.4	40.8	0.0	99.0	IQLVEELDRAQER	1726.9	1727.9	1726.9	1727.9				
255.0	4.6	16.4	40.8	0.0	99.0	LATALOKLEEAKAADESER	2201.1	2202.1	2201.1	2202.1				
255.0	4.6	16.4	40.8	0.0	89.0	LEEAKEAADESER	1475.7	1476.7	1475.7	1476.7				
255.0	4.6	16.4	40.8	0.0	99.0	RIOLVEEELDR	1398.7	1399.8	139					

P07339 CATD_HUMAN	Cathepsin D precursor (EC 3.4.23.5) [Contains: Cathepsin D light chain; Cathepsin D heavy chain] - Homo sapiens (Human)									
199.0	6.0	6.0	18.2	2.0	99.0	FDGILGMAYPR	1238.6	1239.6	1238.6	1239.6
199.0	6.0	6.0	18.2	2.0	99.0	QVFGEATKOPGIFTIAAK	1905.0	1906.0	1905.0	1906.0
199.0	6.0	6.0	18.2	2.0	99.0	RISVNNNLPVFDNLMOQK	2211.1	2212.1	2211.1	2212.1
70.0	4.9	4.9	20.9	2.0	99.0	AIGAVPLIQEYMPICEK	1988.0	1989.0	1988.0	1989.0
70.0	4.9	4.9	20.9	2.0	99.0	FDGILGMAYPR	1238.6	1239.6	1238.6	1239.6
70.0	4.9	4.9	20.9	0.9	86.0	YTVTFDRDNR	1462.7	1463.7	1462.6	1463.7
70.0	4.9	4.9	20.9	0.0	81.0	YTVTFDRDNR	1461.7	1462.7	1461.7	1462.7
149.0	4.9	4.9	16.0	2.0	99.0	AIGAVPLIQEYMPICEK	1988.0	1989.0	1988.0	1989.0
149.0	4.9	4.9	16.0	2.0	99.0	FDGILGMAYPR	1238.6	1239.6	1238.6	1239.6
149.0	4.9	4.9	16.0	0.7	82.0	YTVTFDRDNR	1461.7	1462.7	1461.7	1462.7
149.0	4.9	4.9	16.0	0.1	20.0	QVFGEATKOPGIFTIAAK	1905.0	1906.0	1905.0	1906.0
P07437 TBB5_HUMAN	Tubulin beta chain (Tubulin beta-5 chain) - Homo sapiens (Human)									
21.0	28.5	28.5	47.3	2.0	99.0	ALTVPELTOQVFDAK	1658.9	1659.9	1658.9	1659.9
21.0	28.5	28.5	47.3	2.0	99.0	EINHQAOCGNCQIAGK	1821.9	1822.9	1821.9	1822.9
21.0	28.5	28.5	47.3	2.0	99.0	FWEVISDEHGIDPTGTYHGDSDLQLDR	3101.4	3102.4	3101.4	3102.4
21.0	28.5	28.5	47.3	2.0	99.0	GHYTEGAELVSDVLDVVR	1957.9	1958.9	1958.0	1959.0
21.0	28.5	28.5	47.3	2.0	99.0	ISEQFTAMFR	1228.6	1229.6	1228.6	1229.6
21.0	28.5	28.5	47.3	2.0	99.0	ISVYNEATGGK	1300.6	1301.6	1300.6	1301.6
21.0	28.5	28.5	47.3	2.0	99.0	ISVYNEATGGKVYPR	1815.9	1816.9	1815.9	1816.9
21.0	28.5	28.5	47.3	2.0	99.0	LAVNMMVPPR	1142.6	1143.6	1142.6	1143.6
21.0	28.5	28.5	47.3	2.0	99.0	MSMKEVDQEMLNVNQK	1922.9	1923.9	1922.9	1923.9
21.0	28.5	28.5	47.3	2.0	99.0	NSSYFVEWIPVNPK	1695.8	1696.8	1695.8	1696.8
21.0	28.5	28.5	47.3	2.0	99.0	YLTVAAFR	1038.6	1039.6	1038.6	1039.6
21.0	28.5	28.5	47.3	1.7	98.0	IMNTFSVPSPK	1318.7	1319.7	1318.7	1319.7
21.0	28.5	28.5	47.3	1.5	97.0	LHFFMPGFAPLTSR	1619.8	1620.8	1619.8	1620.8
21.0	28.5	28.5	47.3	1.3	95.0	IREEYDPRMNTFSVSPPK	2377.2	2378.2	2377.2	2378.2
21.0	28.5	28.5	47.3	0.9	87.0	RISEQFTAMFR	1384.7	1385.7	1384.7	1385.7
21.0	28.5	28.5	47.3	0.5	69.0	IREEYDP	1076.5	1077.5	1076.5	1077.5
21.0	28.5	28.5	47.3	0.5	66.0	AILVLEPGTMDSVR	1614.8	1615.8	1614.8	1615.8
21.0	28.5	28.5	47.3	0.1	24.9	GOLNADLR	887.5	888.5	887.4	888.4
26.0	11.9	11.9	22.5	2.0	99.0	ISVYNEATGGKVYPR	1815.9	1816.9	1815.9	1816.9
26.0	11.9	11.9	22.5	2.0	99.0	KLAVNMVPPR	1270.7	1271.7	1270.7	1271.7
26.0	11.9	11.9	22.5	2.0	99.0	LAVNMMVPPR	1142.6	1143.6	1142.6	1143.6
26.0	11.9	11.9	22.5	2.0	99.0	NSSYFVEWIPVNPK	1695.8	1696.8	1695.8	1696.8
26.0	11.9	11.9	22.5	2.0	99.0	YLTVAAFR	1038.6	1039.6	1038.6	1039.6
26.0	11.9	11.9	22.5	1.7	98.0	ISEQFTAMFR	1228.6	1229.6	1228.6	1229.6
26.0	11.9	11.9	22.5	0.1	26.0	ALTVPELTOOVFADK	1658.9	1659.9	1658.9	1659.9
47.0	15.8	15.8	30.0	2.0	99.0	ALTVPELTOQVFDAK	1658.9	1659.9	1658.9	1659.9
47.0	15.8	15.8	30.0	2.0	99.0	ISEQFTAMFR	1228.6	1229.6	1228.6	1229.6
47.0	15.8	15.8	30.0	2.0	99.0	ISVYNEATGGK	1300.6	1301.6	1300.6	1301.6
47.0	15.8	15.8	30.0	2.0	99.0	KLAVNMVPPR	1815.9	1816.9	1815.9	1816.9
47.0	15.8	15.8	30.0	2.0	99.0	LAVNMMVPPR	1270.7	1271.7	1270.7	1271.7
47.0	15.8	15.8	30.0	2.0	99.0	NSSYFVEWIPVNPK	1695.8	1696.8	1695.8	1696.8
47.0	15.8	15.8	30.0	1.4	96.0	YLTVAAFR	1038.4	1039.5	1038.5	1039.6
47.0	15.8	15.8	30.0	0.3	45.0	RISEQFTAMFR	1384.7	1385.7	1384.7	1385.7
47.0	15.8	15.8	30.0	0.0	99.0	ISVYNEATGGKVYPR	1813.9	1814.9	1815.9	1816.9
47.0	15.8	15.8	30.0	0.0	99.0	YLTVAAFR	1038.6	1039.6	1038.6	1039.6
P07602 SAP_HUMAN	Proactivator polypeptide precursor [Contains: Saposin A (Protein A); Saposin B-Val; Saposin B (Sphingolipid activator protein 1) (SAP-1) (Cerebro)									
204.0	6.0	6.0	9.7	2.0	99.0	NGDVCDCIQMVTDIQTA	2420.1	2421.1	2420.0	2421.0
204.0	6.0	6.0	9.7	2.0	99.0	GDVCDQDCIQMVTDIQTA	2208.0	2209.0	2208.0	2209.0
204.0	6.0	6.0	9.7	2.0	99.0	SDVVCDCIQMVTDIQTA	1646.7	1647.7	1646.7	1647.7
92.0	4.0	4.0	5.7	2.0	99.0	DYVCEVCEFLVK	1559.7	1560.7	1559.7	1560.7
92.0	4.0	4.0	5.7	2.0	99.0	SDVVCDCIQMVTDIQTA	1646.7	1647.7	1646.7	1647.7
89.0	8.3	8.3	11.8	2.0	99.0	NGDVCDCIQMVTDIQTA	2438.1	2439.1	2438.1	2439.1
89.0	8.3	8.3	11.8	2.0	99.0	GDVCDQDCIQMVTDIQTA	2208.0	2209.0	2208.0	2209.0
89.0	8.3	8.3	11.8	2.0	99.0	SDVVCDCIQMVTDIQTA	2323.0	2324.0	2323.0	2324.0
89.0	8.3	8.3	11.8	2.0	99.0	SDVVCDCIQMVTDIQTA	1646.7	1647.7	1646.7	1647.7
89.0	8.3	8.3	11.8	0.1	27.0	LGPMADICK	1060.5	1061.5	1060.5	1061.5
89.0	8.3	8.3	11.8	0.1	24.0	SDVVCDCIQMVTDIQTA	2103.9	2104.0	2103.0	2105.0
P07711 CATL_HUMAN	Cathepsin L precursor (EC 3.4.22.15) (Major excreted protein) (MEP) [Contains: Cathepsin L heavy chain; Cathepsin L light chain] - Homo sapiens									
438.0	2.0	2.0	7.8	2.0	99.0	NSWGEEWGMGGYVK	1598.7	1599.7	1598.7	1599.7
438.0	2.0	2.0	7.8	0.0	99.0	NSWGEEWGMGGYVK	1614.7	1615.7	1614.7	1615.7
210.0	1.4	1.4	5.1	1.4	96.0	NSWGEEWGMGGYVK	1598.7	1599.7	1598.7	1599.7
210.0	1.4	1.4	5.1	0.0	94.0	NSWGEEWGMGGYVK	1614.7	1615.7	1614.7	1615.7
225.0	2.9	2.9	22.2	2.0	99.0	NSWGEEWGMGGYVK	1598.7	1599.7	1598.7	1599.7
225.0	2.9	2.9	22.2	0.9	86.0	VQEPLFYEAR	1494.7	1495.8	1494.8	1495.8
225.0	2.9	2.9	22.2	0.0	99.0	NSWGEEWGMGGYVK	1614.7	1615.7	1614.7	1615.7
P07737 PROF1_HUMAN	Profilin-1 (Profilin 1) - Homo sapiens (Human)									
36.0	22.5	22.5	82.1	2.0	99.0	CSVIRDSLQDGFSMDLR	2223.0	2224.0	2223.0	2224.0
36.0	22.5	22.5	82.1	2.0	99.0	CYEMASHLR	1148.5	1149.5	1148.5	1149.5
36.0	22.5	22.5	82.1	2.0	99.0	DSSLQDGFSMDLR	1624.7	1625.7	1624.7	1625.7
36.0	22.5	22.5	82.1	2.0	99.0	EGVHGLLINKK	1150.6	1151.7	1150.6	1151.7
36.0	22.5	22.5	82.1	2.0	99.0	KCYEMASHLR	1293.6	1294.6	1293.6	1294.6
36.0	22.5	22.5	82.1	2.0	99.0	SSFYVNGLTLGGOK	1470.7	1471.7	1470.7	1471.7
36.0	22.5	22.5	82.1	2.0	99.0	STGGAPTFLVTKTDK	1378.7	1379.7	1378.7	1379.7
36.0	22.5	22.5	82.1	2.0	99.0	TFVNITPAEVGVLVGK	1642.9	1643.9	1642.9	1643.9
36.0	22.5	22.5	82.1	2.0	99.0	TKSTGGAPTFLVTKT	1914.1	1915.1	1914.1	1915.1
36.0	22.5	22.5	82.1	2.0	99.0	TKSTGGAPTFLVTKT	1607.9	1608.9	1607.9	1608.9
36.0	22.5	22.5	82.1	0.3	55.0	CYEMASHLR	1304.6	1305.6	1304.6	1305.6
36.0	22.5	22.5	82.1	0.2	31.0	KCYEMASHLR	1449.7	1450.7	1449.7	1450.7
36.0	22.5	22.5	82.1	0.0	99.0	CSVIRDSLQDGFSMDLR	2240.0	2241.1	2240.1	2241.1
36.0	22.5	22.5	82.1	0.0	99.0	CYEMASHLR	1165.5	1166.5	1165.5	1166.5
36.0	22.5	22.5	82.1	0.0	41.0	CYEMASHLR	1321.6	1322.6	1321.6	1322.6
36.0	22.5	22.5	82.1	0.0	99.0	SSFYVNGLTLGGOK	1470.7	1471.7	1470.7	1471.7
36.0	22.5	22.5	82.1	0.0	99.0	TKSTGGAPTFLVTKT	1607.9	1608.9	1607.9	1608.9
21.0	13.4	13.4	61.4	2.0	99.0	CYEMASHLR	1165.5	1166.5	1165.5	1166.5
21.0	13.4	13.4	61.4	2.0	99.0	SDLLQDGFSMDLR	1321.6	1322.6	1321.6	1322.6
21.0	13.4	13.4	61.4	2.0	99.0	DSSLQDGFSMDLR	1624.7	1625.7	1624.7	1625.7
21.0	13.4	13.4	61.4	2.0	99.0	SSFYVNGLTLGGOK	1469.8	1470.8	1469.8	1470.8
21.0	13.4	13.4	61.4	2.0	99.0	TFVNITPAEVGVLVGKDR	1914.0	1915.1	1914.1	1915.1
21.0	13.4	13.4	61.4	1.0	89.0	KCYEMASHLR	1293.6	1294.6	1293.6	1294.6
21.0	13.4	13.4	61.4	0.5	67.0	CSVIRDSLQDGFSMDLR	2240.1	2241.1	2240.1	2241.1
21.0	13.4	13.4	61.4	0.0	46.0	CSVIRDSLQDGFSMDLR	2223.0	2224.1	2223.0	2224.0
21.0	13.4	13.4	61.4	0.0	96.0	CYEMASHLR	1148.5	1149.5	1148.5	1149.5
21.0	13.4	13.4	61.4	0.0	39.0	KCYEMASHLR	1304.6	1305.6	1304.6	1305.6
21.0	13.4	13.4	61.4	0.0	99.0	SSFYVNGLTLGGOK	1470.7	1471.7	1470.7	1471.7
21.0	13.4	13.4	61.4	0.0	99.0	TFVNITPAEVGVLVGKDR	1642.9	1643.9	1642.9	1643.9
29.0	20.9	20.9	61.4	2.0	99.0	EGVHGLLINKK	1914.1	1915.1	1914.1	1915.1
2										

51.0	17.4	17.4	38.3	2.0	99.0	LCGTFLLGGPKPPQR	1526.8	1527.8	1526.8	1527.8
51.0	17.4	17.4	38.3	2.0	99.0	LPASFNDAR	875.5	876.5	875.5	876.5
51.0	17.4	17.4	38.3	2.0	99.0	VMTFEDLKLPAFSNDAR	1928.9	1929.9	1928.9	1929.9
51.0	17.4	17.4	38.3	1.5	97.0	EWPOCPTIK	1838.9	1839.9	1838.9	1839.9
51.0	17.4	17.4	38.3	1.2	94.0	ILRGQDHCGIESEVAVAGIPR	2205.1	2206.1	2205.1	2206.1
51.0	17.4	17.4	38.3	0.5	67.0	DQGSCGSCWAFGAVEAISDR	2171.9	2172.9	2171.9	2172.9
51.0	17.4	17.4	38.3	0.1	26.0	RLCGTFLLGGPKPPQR	1682.9	1683.9	1682.9	1683.9
71.0	4.9	4.9	28.0	2.0	99.0	EWPOCPTIKIEIR	1683.8	1684.8	1683.8	1684.8
71.0	4.9	4.9	28.0	2.0	99.0	SGVYQHVTGEMMGGHAIR	1928.9	1929.9	1928.9	1929.9
71.0	4.9	4.9	28.0	0.9	86.0	EWPOCPTIK	1285.6	1286.6	1285.6	1286.6
48.0	15.7	15.7	34.2	2.0	99.0	DQGSCGSCWAFGAVEAISDR	2171.9	2172.9	2171.9	2172.9
48.0	15.7	15.7	34.2	2.0	99.0	EWPOCPTIKIEIR	1683.8	1684.8	1683.8	1684.8
48.0	15.7	15.7	34.2	2.0	99.0	ICEPGYSPTYKQDK	1684.8	1685.8	1684.8	1685.8
48.0	15.7	15.7	34.2	2.0	99.0	ILRGQDHCGIESEVAVAGIPR	2205.1	2206.1	2205.1	2206.1
48.0	15.7	15.7	34.2	2.0	99.0	LPASFNDAR	875.5	876.5	875.5	876.5
48.0	15.7	15.7	34.2	2.0	99.0	SGVYQHVTGEMMGGHAIR	1928.9	1929.9	1928.9	1929.9
48.0	15.7	15.7	34.2	2.0	99.0	VMTFEDLKLPAFSNDAR	1838.9	1839.9	1838.9	1839.9
48.0	15.7	15.7	34.2	1.7	98.0	EWPOCPTIK	1285.6	1286.6	1285.6	1286.6
P07900 HS90A_HUMAN Heat shock protein HSP 90-alpha (HSP 86) (Renal carcinoma antigen NY-REN-38) - Homo sapiens (Human)										
75.0	4.7	4.7	23.5	2.0	99.0	HYIYTGETK	1223.6	1224.6	1223.6	1224.6
75.0	4.7	4.7	23.5	2.0	99.0	SLTNWDWEHLAVK	1526.7	1527.7	1526.7	1527.7
75.0	4.7	4.7	23.5	0.6	73.0	RAPFDLFENR	1263.6	1264.7	1263.6	1264.6
75.0	4.7	4.7	23.5	0.1	23.0	KHLEINPDHSIETLR	1914.0	1915.0	1914.0	1915.0
20.0	29.4	29.4	29.9	2.0	99.0	ALLFVPR	814.5	815.5	814.5	815.5
20.0	29.4	29.4	29.9	2.0	99.0	AQALRDNSTMGYMAAK	1726.8	1727.8	1726.8	1727.8
20.0	29.4	29.4	29.9	2.0	99.0	FEYEFPSK	947.4	948.4	947.4	948.4
20.0	29.4	29.4	29.9	2.0	99.0	HFSVEGOLFR	1347.7	1348.7	1347.7	1348.7
20.0	29.4	29.4	29.9	2.0	99.0	HYIYTGETK	1223.6	1224.6	1223.6	1224.6
20.0	29.4	29.4	29.9	2.0	99.0	HYIYTGETKDQVANSAFVER	2440.2	2441.2	2440.2	2441.2
20.0	29.4	29.4	29.9	2.0	99.0	KHLEINPDHSIETLR	1914.0	1915.0	1914.0	1915.0
20.0	29.4	29.4	29.9	2.0	99.0	LVTSPCCIVTSTYVGWANMER	2445.1	2446.1	2445.1	2446.1
20.0	29.4	29.4	29.9	2.0	99.0	NPDDITNEFYEGEYFK	1832.8	1833.8	1832.8	1833.8
20.0	29.4	29.4	29.9	2.0	99.0	RAPFDLFENR	1263.6	1264.6	1263.6	1264.6
20.0	29.4	29.4	29.9	2.0	99.0	VLHLKEDOTEYLEER	2014.0	2015.0	2014.0	2015.0
20.0	29.4	29.4	29.9	2.0	99.0	YIDOEELNPK	1150.6	1151.6	1150.6	1151.6
20.0	29.4	29.4	29.9	2.0	99.0	YIDOEELNKTPIWTR	2033.1	2034.1	2033.1	2034.1
20.0	29.4	29.4	29.9	2.0	99.0	YTSASGDEMVSLLKDVCYTR	2245.0	2246.0	2245.0	2246.0
20.0	29.4	29.4	29.9	1.4	96.0	AQALRDNSTMGYMAAK	1854.9	1855.9	1854.9	1855.9
20.0	29.4	29.4	29.9	0.0	99.0	HYIYTGETK	1235.6	1236.6	1235.6	1236.6
20.0	29.4	29.4	29.9	0.0	99.0	YIDOEELNPK	1152.5	1153.5	1150.6	1151.6
P07910 HNRPC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 (hnRNP C1 / hnRNP C2) - Homo sapiens (Human)										
241.0	5.0	5.0	8.8	2.0	99.0	GFAFVQYVNER	1328.6	1329.7	1328.7	1329.7
241.0	5.0	5.0	8.8	2.0	99.0	SYPARVPPPPPPIAR	1516.8	1517.9	1516.9	1517.9
241.0	5.0	5.0	8.8	0.6	72.0	MYSYPARVPPPPPPIAR	1811.0	1812.0	1811.0	1812.0
241.0	5.0	5.0	8.8	0.4	63.0	VPPPPPPIAR	942.6	943.6	942.6	943.6
213.0	3.2	3.2	27.5	2.0	99.0	GFAFVQYVNER	1328.6	1329.6	1328.7	1329.7
213.0	3.2	3.2	27.5	1.2	93.0	VPPPPPPIAR	942.6	943.6	942.6	943.6
P08107 HSP71_HUMAN Heat shock 70 kDa protein 1 (HSP70.1) (HSP70.1/HSP70-2) - Homo sapiens (Human)										
127.0	9.2	14.3	29.2	2.0	99.0	FEELCSDLR	1314.6	1315.6	1314.6	1315.6
127.0	9.2	14.3	29.2	2.0	99.0	LLQDFFNGRDLNKE	1579.8	1580.8	1579.8	1580.8
127.0	9.2	14.3	29.2	2.0	99.0	MVOEAEKYKADEVORER	2237.1	2238.1	2237.1	2238.1
127.0	9.2	14.3	29.2	1.7	98.0	ARFEELCSDLR	1541.5	1542.7	1541.7	1542.7
127.0	9.2	14.3	29.2	1.2	99.0	ATAGDTHLGGEDFDNR	1674.7	1675.7	1674.7	1675.7
127.0	9.2	14.3	29.2	0.3	46.0	DAGVIAGLNLVR	1196.7	1197.7	1196.7	1197.7
127.0	9.2	14.3	29.2	0.0	45.0	LDKAOIHDVLVVGSGTR	1837.0	1838.0	1837.0	1838.0
127.0	9.2	14.3	29.2	0.0	99.0	TTPSVYAFDTDER	1486.7	1487.7	1486.7	1487.7
127.0	9.2	14.3	29.2	0.0	99.0	VEIIANDGCR	1227.6	1228.6	1227.6	1228.6
126.0	2.3	5.0	23.2	1.5	97.0	AFYPEEISSMVLTK	1613.8	1614.8	1613.8	1614.8
126.0	2.3	5.0	23.2	0.5	80.0	IINEPTAAIAAYGLDR	1686.9	1687.9	1686.9	1687.9
126.0	2.3	5.0	23.2	0.2	43.0	FEELCSDLR	1314.6	1315.6	1314.6	1315.6
126.0	2.3	5.0	23.2	0.0	47.0	ATAGDTHLGGEDFDNR	1690.7	1691.7	1690.7	1691.7
126.0	2.3	5.0	23.2	0.0	39.0	NALESYAFNMK	1302.6	1303.6	1302.6	1303.6
126.0	2.3	5.0	23.2	0.0	99.0	TTPSVYAFDTDER	1486.7	1487.7	1486.7	1487.7
P08571 CD14_HUMAN Monocyte differentiation antigen CD14 precursor (Myeloid cell-specific leucine-rich glycoprotein) [Contains: Monocyte differentiation antigen CD1]										
548.0	2.0	2.0	4.8	2.0	99.0	VLSIAOAHPSAFCEQVR	1999.0	2000.0	1999.0	2000.0
145.0	2.1	2.1	16.3	2.0	99.0	VLSIAOAHPSAFCEQVR	1999.0	2000.0	1999.0	2000.0
182.0	4.0	4.0	18.1	2.0	99.0	AFPALTSQSLDSNPGLGER	1972.0	1973.0	1972.0	1973.0
182.0	4.0	4.0	18.1	2.0	99.0	VLSIAQAHPSAFCEQVR	1999.0	2000.0	1999.0	2000.0
P08575 CD45_HUMAN Leukocyte common antigen precursor (EC 3.1.3.48) (L-CA) (T200) (CD45 antigen) - Homo sapiens (Human)										
250.0	4.7	4.7	3.7	2.0	99.0	FQLDHTCTQVEK	1403.7	1404.7	1403.7	1404.7
250.0	4.7	4.7	3.7	0.7	80.0	LFLAEFOSPIR	1319.7	1320.7	1319.7	1320.7
250.0	4.7	4.7	3.7	0.7	80.0	TDFGSPGEPQIFCR	1722.8	1723.8	1722.8	1723.8
323.0	2.0	2.0	6.7	2.0	99.0	LFLAEFOSPIR	1319.7	1320.7	1319.7	1320.7
P08670 VIME_HUMAN Vimentin - Homo sapiens (Human)										
3.0	63.4	63.4	70.0	2.0	99.0	EEAENTLQSRQDVNDASLR	2392.1	2393.1	2392.1	2393.1
3.0	63.4	63.4	70.0	2.0	99.0	EKLOEMLREOREAENTLQSF	2607.2	2608.3	2607.3	2608.3
3.0	63.4	63.4	70.0	2.0	99.0	EMEEFNAAVEANYDTIGR	2186.0	2187.0	2186.0	2187.0
3.0	63.4	63.4	70.0	2.0	99.0	FADLSEAANRNNDAL	1775.9	1776.9	1775.9	1776.9
3.0	63.4	63.4	70.0	2.0	99.0	FANFYDVK	1124.6	1125.6	1124.6	1125.6
3.0	63.4	63.4	70.0	2.0	99.0	FSLADAINTEFK	1354.7	1355.7	1354.7	1355.7
3.0	63.4	63.4	70.0	2.0	99.0	FSLADAINTEKFKNTR	1725.9	1726.9	1725.9	1726.9
3.0	63.4	63.4	70.0	2.0	99.0	HREYDNLNVK	1526.8	1527.8	1526.8	1527.8
3.0	63.4	63.4	70.0	2.0	99.0	KLHEEIQELOAQIQEHOVQID	2684.3	2685.3	2684.3	2685.3
3.0	63.4	63.4	70.0	2.0	99.0	KVESLOOEIAFLK	1532.8	1533.8	1532.8	1533.8
3.0	63.4	63.4	70.0	2.0	99.0	KLGEYEEEMR	1253.6	1254.6	1253.6	1254.6
3.0	63.4	63.4	70.0	2.0	99.0	LGDLYEEMR	1651.8	1652.8	1651.8	1652.8
3.0	63.4	63.4	70.0	2.0	99.0	LGDLYEEMMRREL	1807.9	1808.9	1807.9	1808.9
3.0	63.4	63.4	70.0	2.0	99.0	LHEEEIQELOAQIQEHOVQID	2556.2	2557.2	2556.2	2557.3
3.0	63.4	63.4	70.0	2.0	99.0	LODEIIONMKKEAMIR	1733.8	1734.8	1733.8	1734.8
3.0	63.4	63.4	70.0	2.0	99.0	LOEEMLOREEAENTLQSF	2350.1	2351.1	2350.1	2351.1
3.0	63.4	63.4	70.0	2.0	99.0	MFGGGTASRPVSSR	1493.7	1494.7	1493.7	1494.7
3.0	63.4	63.4	70.0	0.0	99.0	EMEENFAVEAANYDTIGR	2191.0	2192.0	2186.0	2187.0
3.0	63.4	63.4	70.0	0.0	99.0	OVSQLTCEVDALKGTNESLR	2376.1	2377.2	2376.2	2377.2
3.0	63.4	63.4	70.0	0.0	95.0	VEVERDNLNAEIDMR	1687.8	1688.8	1687.8	1688.8
3.0	63.4	63.4	70.0	1.5	97.0	YDQDLNNVK				

8.0	22.8	22.8	70.6	0.1	28.0	HLREYQDLLNVK	1526.8	1527.8	1526.8	1527.8
8.0	22.8	22.8	70.6	0.1	18.0	FANYIDKVR	1124.6	1125.6	1124.6	1125.6
8.0	22.8	22.8	70.6	0.0	95.0	QVOSLTCVEDALKGTNESLER	2376.2	2377.2	2376.2	2377.2
8.0	22.8	22.8	70.6	0.0	56.0	TNEKVELOELNDR	1586.8	1587.8	1586.8	1587.8
8.0	44.3	44.3	62.2	2.0	99.0	DGQVINETSQHHDDLE	1835.8	1836.8	1835.8	1836.8
8.0	44.3	44.3	62.2	2.0	99.0	EEAENTLQSFRQVDNALSAR	2392.1	2393.1	2392.1	2393.1
8.0	44.3	44.3	62.2	2.0	99.0	EKLOEEMLOR	1302.7	1303.7	1302.7	1303.7
8.0	44.3	44.3	62.2	2.0	99.0	EKLOEEMLOREEAENTLQSFR	2607.3	2608.3	2607.3	2608.3
8.0	44.3	44.3	62.2	2.0	99.0	EMEENFAVEAAANYDTIGR	2185.9	2186.9	2186.0	2187.0
8.0	44.3	44.3	62.2	2.0	99.0	FADLSSEAANRNNDALR	1775.9	1776.9	1775.9	1776.9
8.0	44.3	44.3	62.2	2.0	99.0	FANYIDKVR	1124.6	1125.6	1124.6	1125.6
8.0	44.3	44.3	62.2	2.0	99.0	FSLADAINTEFK	1354.7	1355.7	1354.7	1355.7
8.0	44.3	44.3	62.2	2.0	99.0	FSLADAINTEFKNTR	1725.9	1726.9	1725.9	1726.9
8.0	44.3	44.3	62.2	2.0	99.0	HLDREYQDLLNVK	1526.8	1527.8	1526.8	1527.8
8.0	44.3	44.3	62.2	2.0	99.0	LGDLYEEMMRLRR	1253.6	1254.6	1253.6	1254.6
8.0	44.3	44.3	62.2	2.0	99.0	LGDLYEEMMKEEMAR	1807.9	1808.9	1807.9	1808.9
8.0	44.3	44.3	62.2	2.0	99.0	LODEIONMKEMAR	1733.8	1734.8	1733.8	1734.9
8.0	44.3	44.3	62.2	2.0	99.0	LOQEMLQR	1045.5	1046.5	1045.5	1046.5
8.0	44.3	44.3	62.2	2.0	99.0	NLQEAEEWYK	1306.6	1305.6	1306.6	1305.6
8.0	44.3	44.3	62.2	2.0	99.0	QVOSLTCVEDALKGTNESLER	2359.1	2360.2	2359.1	2360.1
8.0	44.3	44.3	62.2	2.0	99.0	ROVDQLTNDKAR	1442.8	1443.8	1442.8	1443.8
8.0	44.3	44.3	62.2	2.0	99.0	TNEKVELOELNDR	1586.8	1587.8	1586.8	1587.8
8.0	44.3	44.3	62.2	2.0	99.0	TVETRDGVINETSQHHDDLE	2423.1	2424.1	2423.1	2424.1
8.0	44.3	44.3	62.2	2.0	99.0	VEVERDNLAEIDMR	1687.8	1688.8	1687.8	1688.8
8.0	44.3	44.3	62.2	1.7	98.0	YEQDQLLNVK	1120.6	1121.6	1120.6	1121.6
8.0	44.3	44.3	62.2	1.2	93.0	VELOELNDR	1114.6	1115.6	1114.6	1115.6
8.0	44.3	44.3	62.2	0.9	87.0	KVSELOOEIAFLK	1532.8	1533.8	1532.8	1533.9
8.0	44.3	44.3	62.2	0.3	46.0	EEAENTLQSFR	1322.6	1323.6	1322.6	1323.6
8.0	44.3	44.3	62.2	0.2	42.0	QVDQLTNDKAR	1286.7	1287.7	1286.7	1287.7
8.0	44.3	44.3	62.2	0.0	99.0	FADLSSEAANRNNDALR	1777.9	1778.9	1775.9	1776.9
8.0	44.3	44.3	62.2	0.0	42.0	FSLADAINTEFK	1350.6	1351.6	1354.7	1355.7
8.0	44.3	44.3	62.2	0.0	32.0	QVDQLTNDKAR	1270.6	1271.7	1270.6	1271.6
8.0	44.3	44.3	62.2	0.0	99.0	QVOSLTCVEDALKGTNESLER	2376.1	2377.2	2376.2	2377.2
8.0	44.3	44.3	62.2	0.0	94.0	TNEKVELOELNDR	1586.8	1587.8	1586.8	1587.8
8.0	44.3	44.3	62.2	0.0	22.0	TVETRDGOVINETSQHHDDLE	2422.1	2423.1	2422.1	2423.1
P09211 GSTP1_HUMAN	Glutathione S-transferase P (EC 2.5.1.18) (GST class-1) (GSTP1-1) - Homo sapiens (Human)									
96.0	11.7	11.7	37.6	2.0	99.0	AFLASPEVNLPINGKGO	2033.0	2034.0	2033.0	2034.0
96.0	11.7	11.7	37.6	2.0	99.0	ALPGQKLPFETLLSQNOQGGK	2125.2	2126.2	2125.2	2126.2
96.0	11.7	11.7	37.6	2.0	99.0	FQDGLTLTYSNTL	1882.9	1883.9	1882.9	1883.9
96.0	11.7	11.7	37.6	2.0	99.0	MLNGOGOSWK	1275.7	1276.7	1275.6	1276.6
96.0	11.7	11.7	37.6	2.0	99.0	PPTYVVYFPV	1336.7	1337.7	1336.7	1337.7
96.0	11.7	11.7	37.6	1.7	98.0	PPTYVVYFPVGR	1549.8	1550.8	1549.8	1550.8
96.0	11.7	11.7	37.6	0.0	47.0	PPTYVVYFPVGR	1552.8	1553.8	1549.8	1550.8
47.0	6.6	6.6	23.3	2.0	99.0	ALPGQLKPETLLSQNOQGGK	2125.2	2126.2	2125.2	2126.2
47.0	6.6	6.6	23.3	2.0	99.0	PPTYVVYFPV	1336.7	1337.7	1336.7	1337.7
47.0	6.6	6.6	23.3	2.0	99.0	PPTYVVYFPVGR	1549.8	1550.8	1549.8	1550.8
47.0	6.6	6.6	23.3	0.6	72.0	FQDGLTLTYSNTL	1882.9	1883.9	1882.9	1883.9
99.0	8.0	8.0	18.6	2.0	99.0	ACSLYQLPKL	1135.6	1136.6	1135.6	1136.6
99.0	8.0	8.0	18.6	2.0	99.0	FQDGLTLTYSNTL	1882.9	1883.9	1882.9	1883.9
99.0	8.0	8.0	18.6	2.0	99.0	PPTYVVYFPV	1336.7	1337.7	1336.7	1337.7
99.0	8.0	8.0	18.6	2.0	99.0	PPTYVVYFPVGR	1549.8	1550.8	1549.8	1550.8
P09382 LEG1_HUMAN	Galectin-1 (Lectin galactoside-binding soluble 1) (Beta-galactoside-binding lectin L-14-I) (Lactose-binding lectin 1) (S-Lac lectin 1) (Galaptin) (14									
99.0	11.2	11.2	61.5	2.0	99.0	ACGLVASNLNLKPGCELR	2013.0	2014.0	2013.0	2014.0
99.0	11.2	11.2	61.5	2.0	99.0	DSNNLCLHNPNR	1485.7	1486.7	1485.7	1486.7
99.0	11.2	11.2	61.5	2.0	99.0	FNHAHDGANTIVCNK	1646.8	1647.8	1646.7	1647.8
99.0	11.2	11.2	61.5	2.0	99.0	LNLEAINYMAADKOPYEK	1783.8	1784.9	1783.8	1784.9
99.0	11.2	11.2	61.5	1.2	94.0	DGGAWCTEOR	1075.5	1076.5	1075.5	1076.5
99.0	11.2	11.2	61.5	0.0	71.0	LPDGYEFKPNR	1480.7	1481.7	1481.7	1482.7
68.0	4.9	4.9	61.5	2.0	99.0	ACGLVASNLNLKPGCELR	2013.0	2014.0	2013.0	2014.0
68.0	4.9	4.9	61.5	2.0	99.0	DSNNLCLHNPNR	1485.7	1486.7	1485.7	1486.7
68.0	4.9	4.9	61.5	0.7	81.0	FNHAHDGANTIVCNK	1646.8	1647.8	1646.7	1647.8
68.0	4.9	4.9	61.5	0.2	38.0	LPDGYEFKPNR	1481.7	1482.7	1481.7	1482.7
142.0	5.7	5.7	29.6	2.0	99.0	ACGLVASNLNLKPGCELR	2013.0	2014.0	2013.0	2014.0
142.0	5.7	5.7	29.6	2.0	99.0	LPDGYEFKPNR	1481.7	1482.7	1481.7	1482.7
142.0	5.7	5.7	29.6	1.7	98.0	DGGAWCTEOR	1075.5	1076.5	1075.5	1076.5
P09429 HMGB1_HUMAN	High mobility group protein B1 (High mobility group protein 1) (HMGB-1) - Homo sapiens (Human)									
42.0	20.0	20.0	45.6	2.0	99.0	GKMSYYAFFVOTCR	1680.8	1681.8	1680.8	1681.8
42.0	20.0	20.0	45.6	2.0	99.0	GKMSYYAFFVOTCREEHKK	2332.1	2333.1	2332.1	2333.1
42.0	20.0	20.0	45.6	2.0	99.0	KHPDASVNFSEFGSK	1719.9	1720.9	1719.9	1720.9
42.0	20.0	20.0	45.6	2.0	99.0	KLGEWMWNNTAACDDKOPYEK	2237.0	2238.0	2237.0	2238.0
42.0	20.0	20.0	45.6	2.0	99.0	LGEWMWNNTAACDDKOPYEK	2109.0	2110.0	2108.9	2110.0
42.0	20.0	20.0	45.6	2.0	99.0	LGEMWNNTAACDDKOPYEK	2237.0	2238.0	2237.0	2238.0
42.0	20.0	20.0	45.6	2.0	99.0	LKEKYEKDIAAYR	1625.9	1626.9	1625.9	1626.9
42.0	20.0	20.0	45.6	2.0	99.0	MSSYAFFVOTCR	1495.7	1496.7	1495.7	1496.7
42.0	20.0	20.0	45.6	2.0	99.0	MSSYAFFVOTCREEHKK	2147.0	2148.0	2147.0	2148.0
42.0	20.0	20.0	45.6	2.0	99.0	YKLEAVYR	1495.7	1496.7	1495.7	1496.7
42.0	20.0	20.0	45.6	2.0	99.0	YKLEAVYR	1217.6	1218.6	1217.6	1218.6
73.0	10.0	10.0	53.5	2.0	99.0	GKMSYYAFFVOTCR	1680.8	1681.8	1680.8	1681.8
73.0	10.0	10.0	53.5	2.0	99.0	IKGEHPGLSIGDVAK	1519.8	1520.8	1519.8	1520.8
73.0	10.0	10.0	53.5	2.0	99.0	LPDGYEFKPNR	1626.9	1627.8	1626.9	1627.8
73.0	10.0	10.0	53.5	2.0	99.0	RPPSAFFLFCSEYRPK	2001.0	2002.0	2001.0	2002.0
73.0	10.0	10.0	53.5	2.0	99.0	YKLEAVYR	1127.6	1128.6	1127.6	1128.6
73.0	10.0	10.0	53.5	0.0	35.0	LKEKYEKDIAAYR	1622.8	1623.8	1622.8	1623.8
P09496 CLCA_HUMAN	Clathrin light chain A (Lca) - Homo sapiens (Human)									
315.0	4.0	4.0	12.9	2.0	99.0	AEEAFVNVIDDESSPGTEWER	2351.0	2352.0	2351.0	2352.0
315.0	4.0	4.0	12.9	2.0	99.0	AIKELEEWYR	1406.7	1407.7	1406.7	1407.7
203.0	1.5	1.5	11.3	1.5	97.0	AIKELEEWYR	1406.7	1407.7	1406.7	1407.7
P09651 ROA1_HUMAN	Heterogeneous nuclear ribonucleoprotein A1 (Hdxl destabilizing protein) (Single-strand RNA-binding protein) (hnRNP core protein A1) - Homo sae									
32.0	23.7	28.6	63.4	2.0	99.0	AKLSQEMEASSSORGR	1820.9	1821.9	1820.9	1821.9
32.0	23.7	28.6	63.4	2.0	99.0	AVSREDSDRGPAGHLTVK	1978.1	1979.1	1978.1	1979.1
32.0	23.7	28.6	63.4	2.0	99.0	EDSRGPAGHLTVK	1436.7	1437.8	1436.7	1437.7
32.0	23.7	28.6	63.4	2.0	99.0	GFATVFTDDHSDVKV1QK	2280.1	2281.2	2280.1	2281.1
32.0	23.7	28.6	63.4	2.0	99.0	KALSKOEMEASSSORGR	1949.0	1950.0	1949.0	1950.0
32.0	23.7	28.6	63.4	2.0	99.0	NCGGYGSSSSYSGSGR	1693.7	1694.7	1693.7	1694.7
32.0	23.7	28.6	63.4	2.0	99.0	RAVSREDSDRGPAGHLTVK	2134.2	2		

65.0	11.9	13.9	51.1	0.0	99.0	IFVGGIKEDEEEHHLR	1878.9	1880.0	1879.0	1880.0
65.0	11.9	13.9	51.1	0.0	99.0	IFVGGIKEDEEEHHLR	1879.0	1880.0	1879.0	1880.0
P09874 PARP1_HUMAN Poly [ADP-ribose] polymerase 1 (EC 2.4.2.30) (PARP-1) (ADPRT) (NAD(+) ADP-ribosyltransferase 1) (Poly[ADP-ribose] synthetase 1) - Homo sapiens (Human)										
125.0	9.4	9.4	16.2	2.0	99.0	NREELGFRPEYASOLK	2023.0	2024.0	2023.0	2024.0
125.0	9.4	9.4	16.2	2.0	99.0	SDAYCTGTDVTAWTK	1736.8	1737.8	1736.7	1737.7
125.0	9.4	9.4	16.2	2.0	99.0	VGHISRHPDVEVDGFSCLR	2148.2	2149.2	2148.1	2149.1
125.0	9.4	9.4	16.2	2.0	99.0	WYHPGCFVK	1192.5	1193.6	1192.5	1193.6
125.0	9.4	9.4	16.2	0.7	79.0	MVDPEPKPQLGMIDR	1627.8	1628.8	1627.8	1628.8
125.0	9.4	9.4	16.2	0.6	77.0	LLWHSR	867.5	868.5	867.5	868.5
224.0	2.9	2.9	3.9	1.5	97.0	WYHPGCFVK	1192.5	1193.6	1192.5	1193.6
224.0	2.9	2.9	3.9	1.4	96.0	MAESSKKLYR	1214.6	1215.6	1214.6	1215.6
P09960 LKHA4_HUMAN Leukotriene A-4 hydrolase (EC 3.3.2.6) (LTA-4 hydrolase) (Leukotriene A(4) hydrolase) - Homo sapiens (Human)										
342.0	2.0	2.0	5.1	2.0	99.0	MOEVYNFNAINNEIR	1940.9	1941.9	1940.9	1941.9
115.0	9.9	9.9	14.1	2.0	99.0	HFNALGGWGELONSVK	1755.9	1756.9	1755.9	1756.9
115.0	9.9	9.9	14.1	2.0	99.0	MOEVYNFNAINNEIR	1940.9	1941.9	1940.9	1941.9
115.0	9.9	9.9	14.1	2.0	99.0	PEIVDTCSLASPASVCR	1860.9	1861.9	1860.9	1861.9
115.0	9.9	9.9	14.1	2.0	99.0	TLTGAAITLVOSQEDNLR	1917.0	1918.0	1917.0	1918.0
115.0	9.9	9.9	14.1	1.7	98.0	APLPLGHIKR	1100.7	1101.7	1100.7	1101.7
115.0	9.9	9.9	14.1	0.2	34.0	MFKTRPLFK	1166.7	1167.7	1166.7	1167.7
P10124 PGSG_HUMAN Secretory granule proteoglycan core protein precursor (Platelet proteoglycan core protein) (P.PG) (Hematopoietic proteoglycan core protein) (Ser)										
179.0	6.4	6.4	39.2	2.0	99.0	GPMFELLPGESNKPRL	1783.9	1784.9	1783.9	1784.9
179.0	6.4	6.4	39.2	2.0	99.0	NLPSDSQDLGQHGLEDFML	2244.0	2245.0	2244.0	2245.0
179.0	6.4	6.4	39.2	2.0	99.0	YOLVDESDAFHDNLR	1820.8	1821.8	1820.8	1821.8
179.0	6.4	6.4	39.2	0.4	61.0	ARYQWR	977.5	978.5	977.5	978.5
179.0	6.4	6.4	39.2	0.0	99.0	YOLVDESDAFHDNLR	1820.8	1821.8	1820.8	1821.8
48.0	6.5	6.5	39.2	2.0	99.0	GPMFELLPGESNKPRL	1783.9	1784.9	1783.9	1784.9
48.0	6.5	6.5	39.2	2.0	99.0	NLPSDSQDLGQHGLEDFML	2244.0	2245.0	2244.0	2245.0
48.0	6.5	6.5	39.2	1.5	97.0	YOLVDESDAFHDNLR	1820.8	1821.8	1820.8	1821.8
48.0	6.5	6.5	39.2	0.9	86.0	ARYQWR	977.5	978.5	977.5	978.5
48.0	6.5	6.5	39.2	0.1	23.0	YQWR	750.4	751.4	750.4	751.4
82.0	9.0	9.0	39.2	2.0	99.0	GPMFELLPGESNKPRL	1783.9	1784.9	1783.9	1784.9
82.0	9.0	9.0	39.2	2.0	99.0	NLPSDSQDLGQHGLEDFML	2244.0	2245.0	2244.0	2245.0
82.0	9.0	9.0	39.2	2.0	99.0	SLDRNLPSDLGQHGLEDFML	2715.3	2716.3	2715.3	2716.3
82.0	9.0	9.0	39.2	0.5	69.0	YQWR	750.4	751.4	750.4	751.4
82.0	9.0	9.0	39.2	0.5	65.0	ARYQWR	977.5	978.5	977.5	978.5
82.0	9.0	9.0	39.2	0.0	99.0	YOLVDESDAFHDNLR	1820.8	1821.8	1820.8	1821.8
P10145 IL8_HUMAN Interleukin-8 precursor (IL-8) (CXCL8) (Monocyte-derived neutrophil chemotactic factor) (MDNCF) (T-cell chemotactic factor) (Neutrophil-activat										
133.0	8.4	8.4	49.5	2.0	99.0	ELCLDPKENWVR	1685.8	1686.8	1685.8	1686.8
133.0	8.4	8.4	49.5	2.0	99.0	LSDGRELCLDPKENWVR	2214.1	2215.1	2214.1	2215.1
133.0	8.4	8.4	49.5	2.0	99.0	TYSKPFPHK	1103.6	1104.6	1103.6	1104.6
133.0	8.4	8.4	49.5	0.2	40.0	ENWVR	830.4	831.4	830.4	831.4
133.0	8.4	8.4	49.5	0.1	27.0	FIKLR	804.5	805.5	804.5	805.5
133.0	8.4	8.4	49.5	0.0	99.0	VIESGPHCANTEIIVK	1765.9	1766.9	1765.9	1766.9
133.0	8.4	8.4	49.5	0.0	99.0	VIESGPHCANTEIIVK	1917.9	1918.9	1917.8	1918.9
133.0	8.4	8.4	49.5	0.0	99.0	VIESGPHCANTEIIVK	1767.9	1768.9	1765.9	1766.9
73.0	4.8	4.8	43.4	2.0	99.0	LSDGRELCLDPKENWVR	2214.1	2215.1	2214.1	2215.1
73.0	4.8	4.8	43.4	2.0	99.0	VIESGPHCANTEIIVK	1765.9	1766.9	1765.9	1766.9
73.0	4.8	4.8	43.4	0.6	74.0	ELCLDPKENWVR	1685.8	1686.8	1685.8	1686.8
73.0	4.8	4.8	43.4	0.2	36.0	TYSKPFPHK	1103.6	1104.6	1103.6	1104.6
73.0	4.8	4.8	43.4	0.0	24.0	VIESGPHCANTEIIVK	1765.9	1766.9	1765.9	1766.9
105.0	7.7	7.7	56.6	2.0	99.0	ELCLDPKENWVR	1685.8	1686.8	1685.8	1686.8
105.0	7.7	7.7	56.6	2.0	99.0	LSDGRELCLDPKENWVR	2214.1	2215.1	2214.1	2215.1
105.0	7.7	7.7	56.6	2.0	99.0	VIESGPHCANTEIIVK	1765.9	1766.9	1765.9	1766.9
105.0	7.7	7.7	56.6	1.4	96.0	TYSKPFPHK	1103.6	1104.6	1103.6	1104.6
105.0	7.7	7.7	56.6	0.3	47.0	FIKLR	804.5	805.5	804.5	805.5
105.0	7.7	7.7	56.6	0.0	99.0	VIESGPHCANTEIIVK	1765.9	1766.9	1765.9	1766.9
P10319 B1B58_HUMAN HLA class I histocompatibility antigen, B-58 alpha chain precursor (MHC class I antigen B*58) (Bw-58) - Homo sapiens (Human)										
107.0	3.2	3.2	41.7	2.0	99.0	WAAVVVPSPGEOR	1426.7	1427.7	1426.7	1427.7
107.0	3.2	3.2	41.7	0.7	79.0	ALEGLCVEWLR	1507.8	1508.8	1507.7	1508.8
107.0	3.2	3.2	41.7	0.3	55.0	APWIEQEPGEYWMDGETR	2061.9	2062.9	2061.9	2062.9
107.0	3.2	3.2	41.7	0.1	22.0	YFTYAMSPRGRGPR	1786.8	1787.9	1786.9	1787.9
160.0	7.4	12.3	40.6	2.0	99.0	APWIEQEPGEYWMDGETR	2061.9	2062.9	2061.9	2062.9
160.0	7.4	12.3	40.6	2.0	99.0	DGEDOTDTDELTPRAGDRTFOK	2735.3	2736.3	2735.3	2736.3
160.0	7.4	12.3	40.6	2.0	99.0	YTCHVIOHEGLPKPLT	1778.9	1779.9	1778.9	1779.9
160.0	7.4	12.3	40.6	1.2	99.0	MYGGCDVGPDGR	1225.5	1226.5	1225.5	1226.5
160.0	7.4	12.3	40.6	0.2	38.0	AYLEGLCWEVLR	1507.8	1508.8	1507.7	1508.8
160.0	7.4	12.3	40.6	0.0	99.0	FIAVGYVDDTOFVR	1628.8	1629.8	1628.8	1629.8
160.0	7.4	12.3	40.6	0.0	99.0	WAAVVVPSPGEOR	1426.7	1427.7	1426.7	1427.7
P10412 H14_HUMAN Histone H1.4 (Histone H1b) - Homo sapiens (Human)										
74.0	14.0	14.0	18.3	2.0	99.0	ALAAGYDVKEKNNSR	1577.8	1578.8	1577.8	1578.8
74.0	14.0	14.0	18.3	2.0	99.0	KALAAAGYDVKEKNNSR	1705.9	1706.9	1705.9	1706.9
74.0	14.0	14.0	18.3	2.0	99.0	SETAAPAAPAAPA	1519.8	1520.8	1519.8	1520.8
74.0	14.0	14.0	18.3	2.0	99.0	SETAAPAAPAAPAETPKV	1945.0	1946.0	1945.0	1946.0
74.0	14.0	14.0	18.3	2.0	99.0	SETAAPAAPAAPAETPKVKK	2073.1	2074.1	2073.1	2074.1
74.0	14.0	14.0	18.3	2.0	99.0	SETAAPAAPAAPAETPKVKKAR	2428.4	2429.4	2428.3	2429.4
74.0	14.0	14.0	18.3	0.0	99.0	ALAAGYDVKEKNNSR	1578.8	1579.8	1578.8	1579.8
74.0	14.0	14.0	18.3	0.0	20.0	ALAAGYDVKEKNNSR	1578.8	1579.8	1578.8	1579.8
160.0	4.4	7.7	24.2	2.0	99.0	SETAAPAAPAAPAETPKV	2073.1	2074.1	2073.1	2074.1
160.0	4.4	7.7	24.2	1.2	99.0	SETAAPAAPAAPAETPKV	1945.0	1946.0	1945.0	1946.0
160.0	4.4	7.7	24.2	1.2	99.0	SETAAPAAPAAPAETPKVKK	2201.2	2202.2	2201.2	2202.2
160.0	4.4	7.7	24.2	0.0	98.0	ALAAGYDVKEKNNSR	1578.8	1579.8	1578.8	1579.8
160.0	4.4	7.7	24.2	0.0	98.0	MIKPFFHSLSEK	1577.8	1578.8	1577.8	1578.8
80.0	4.3	4.3	33.3	2.0	99.0	MIKPFFHSLSEK	1462.8	1463.8	1462.8	1463.8
80.0	4.3	4.3	33.3	0.3	51.0	CMPTFOFFK	1315.6	1316.6	1315.6	1316.6
80.0	4.3	4.3	33.3	0.0	99.0	CMPTFOFFK	1204.5	1205.5	1204.5	1205.5
80.0	4.3	4.3	33.3	0.0	99.0	CMPTFOFFK	1187.5	1188.5	1187.5	1188.6
80.0	4.3	4.3	33.3	0.0	79.0	CMPTFOFFK	1205.5	1206.5	1203.5	1204.5
80.0	4.3	4.3	33.3	0.0	41.0	CMPTFOFFK	1220.5	1221.5	1220.5	1221.5
81.0	9.1	9.1	42.9	2.0	99.0	CMPTFOFFK	1187.5	1188.5	1187.5	1188.6
81.0	9.1	9.1	42.9	2.0	99.0	CMPTFOFFK	1628.8	1629.8	1628.8	1629.8
81.0	9.1	9.1	42.9	2.0	99.0	MIKPFFHSLSEK	1478.8	1479.8	1478.8	1479.8
81.0	9.1	9.1	42.9	1.1	92.0	CMPTFOFFK	1247.1	1248.1	1247.1	1248.1
81.0	9.1	9.1	42.9	0.0	99.0	CMPTFOFFK	1315.6	1316.6	1315.6	1316.6
81.0	9.1	9.1	42.9	0.0	99.0	CMPTFOFFK	1189.5	1190.5	1189.5	1190.6
81.0	9.1	9.1	42.9	0.0	99.0	MIKPFFHSLSEK				

83.0	9.0	10.6	15.3	1.0	92.0	FEELNMDLFR	1312.6	1313.6	1312.6	1313.6
83.0	9.0	10.6	15.3	0.0	36.0	FEELNMDLFR	1252.6	1253.6	1252.6	1253.6
P11142 HSP7C_HUMAN Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) - Homo sapiens (Human)										
9.0	43.1	43.1	46.0	2.0	99.0	ARFEELNADLFR	1479.7	1480.8	1479.7	1480.8
9.0	43.1	43.1	46.0	2.0	99.0	ATVEDEKLQGKINDEDKOK	2229.1	2230.2	2229.1	2230.2
9.0	43.1	43.1	46.0	2.0	99.0	FEELNADLFR	1252.6	1253.6	1252.6	1253.6
9.0	43.1	43.1	46.0	2.0	99.0	HWPFMVVNDAGRKP	1652.8	1653.8	1652.8	1653.8
9.0	43.1	43.1	46.0	2.0	99.0	LDKSQIHDIVLVVGSTR	1837.0	1838.0	1837.0	1838.0
9.0	43.1	43.1	46.0	2.0	99.0	LLQDFNGKELNK	1565.8	1566.8	1565.8	1566.8
9.0	43.1	43.1	46.0	2.0	99.0	MVNHFIAEFK	1234.6	1235.6	1234.6	1235.6
9.0	43.1	43.1	46.0	2.0	99.0	MVNHFIAEFKR	1390.7	1391.7	1390.7	1391.7
9.0	43.1	43.1	46.0	2.0	99.0	MVOEAEKYKAEDEKQR	1980.0	1981.0	1981.0	1982.0
9.0	43.1	43.1	46.0	2.0	99.0	MVOEAEKYKAEDEKQRDKVSSK	2625.3	2626.3	2625.3	2626.3
9.0	43.1	43.1	46.0	2.0	99.0	NOVAMNPNTVTDK	1648.8	1649.8	1648.8	1649.8
9.0	43.1	43.1	46.0	2.0	99.0	NOVAMNPNTVFDK	1805.0	1806.0	1804.9	1805.9
9.0	43.1	43.1	46.0	2.0	99.0	NOVAMNPNTVFDK	1302.6	1303.6	1302.6	1303.6
9.0	43.1	43.1	46.0	2.0	99.0	NSLESYAFNMK	1179.6	1180.6	1179.6	1180.6
9.0	43.1	43.1	46.0	1.7	98.0	RFDDAVQSDMK	1409.7	1410.7	1409.7	1410.7
9.0	43.1	43.1	46.0	1.3	95.0	MVQEAEKYKAEDEKQRD	2224.1	2225.1	2224.1	2225.1
9.0	43.1	43.1	46.0	0.0	79.0	MVQEAEKYKAEDEKQR	1981.0	1982.0	1981.0	1982.0
9.0	43.1	43.1	46.0	0.0	99.0	STAGDTHLGGEDFDNR	1693.8	1694.8	1690.7	1691.7
15.0	16.6	16.6	32.5	2.0	99.0	INEPPTAAIAYGLDKK	1787.0	1788.0	1787.0	1788.0
15.0	16.6	16.6	32.5	2.0	99.0	MVNHFIAEFK	1234.6	1235.6	1234.6	1235.6
15.0	16.6	16.6	32.5	2.0	99.0	MVNHFIAEFKR	1390.7	1391.7	1390.7	1391.7
15.0	16.6	16.6	32.5	2.0	99.0	SFYPEEVSSMLVK	1615.7	1616.7	1615.8	1616.8
15.0	16.6	16.6	32.5	2.0	99.0	STAGDTHLGGEDFDNR	1690.7	1691.7	1690.7	1691.7
15.0	16.6	16.6	32.5	2.0	99.0	TTPSYYAFTTDER	1486.7	1487.7	1486.7	1487.7
15.0	16.6	16.6	32.5	1.4	96.0	TVTNAVTVPAYFNDSQR	1981.0	1982.0	1981.0	1982.0
15.0	16.6	16.6	32.5	1.2	93.0	NOVAMNPNTVFDK	1804.9	1805.9	1804.9	1805.9
15.0	16.6	16.6	32.5	1.0	91.0	MVOEAEKYKAEDEKOR	1981.0	1982.0	1981.0	1982.0
15.0	16.6	16.6	32.5	0.7	82.0	NSLESYAFNMK	1302.6	1303.6	1302.6	1303.6
15.0	16.6	16.6	32.5	0.2	34.0	DAGTIAGLNLVR	1198.7	1199.7	1198.7	1199.7
26.0	21.5	21.5	28.8	2.0	99.0	DAGTIAGLNLVR	1198.7	1198.7	1198.7	1199.7
26.0	21.5	21.5	28.8	2.0	99.0	LDKSQIHDIVLVGSTR	1837.0	1838.0	1837.0	1838.0
26.0	21.5	21.5	28.8	2.0	99.0	MVNHFIAEFK	1234.6	1235.6	1234.6	1235.6
26.0	21.5	21.5	28.8	2.0	99.0	NOVAMNPNTVFDK	1804.8	1805.8	1804.9	1805.9
26.0	21.5	21.5	28.8	2.0	99.0	OATKDAGTIAGLNLVR	1609.9	1610.9	1609.9	1610.9
26.0	21.5	21.5	28.8	2.0	99.0	SFYPEEVSSMLVK	1615.8	1616.8	1615.8	1616.8
26.0	21.5	21.5	28.8	2.0	99.0	STAGDTHLGGEDFDNR	1690.7	1691.7	1690.7	1691.7
26.0	21.5	21.5	28.8	2.0	99.0	TTPSYYAFTTDER	1486.7	1487.7	1486.7	1487.7
26.0	21.5	21.5	28.8	1.4	96.0	VEIIANDDGNR	1227.6	1228.6	1227.6	1228.6
26.0	21.5	21.5	28.8	1.1	92.0	FEELNADLFR	1252.6	1253.6	1252.6	1253.6
26.0	21.5	21.5	28.8	0.9	88.0	MVNHFIAEFK	1390.7	1391.7	1390.7	1391.7
26.0	21.5	21.5	28.8	0.0	99.0	STAGDTHLGGEDFDNR	1694.8	1695.8	1690.7	1691.7
26.0	21.5	21.5	28.8	0.0	99.0	STAGDTHLGGEDFDNR	1693.8	1694.8	1690.7	1691.7
26.0	21.5	21.5	28.8	0.0	99.0	STAGDTHLGGEDFDNR	1688.7	1689.7	1690.7	1691.7
P11413 G6PD_HUMAN Glucose-6-phosphate 1-dehydrogenase (EC 1.1.1.49) (G6PD) - Homo sapiens (Human)										
100.0	11.1	11.1	20.8	2.0	99.0	DGLLPENTFIVGYAR	1663.9	1664.9	1663.9	1664.9
100.0	11.1	11.1	20.8	2.0	99.0	LKLEDFFAR	1137.6	1138.6	1137.6	1138.6
100.0	11.1	11.1	20.8	2.0	99.0	LNSHMNALHLSQANR	1761.9	1762.9	1761.9	1762.9
100.0	11.1	11.1	20.8	2.0	99.0	NIHESCMQSIGWNR	1730.8	1731.8	1730.8	1731.8
100.0	11.1	11.1	20.8	2.0	99.0	NSYVAGOYDQAASYQR	1806.8	1807.8	1806.8	1807.8
100.0	11.1	11.1	20.8	0.6	74.0	WDGVFPLR	1101.6	1102.6	1101.6	1102.6
100.0	11.1	11.1	20.8	0.5	69.0	LOFHIVAGDIFHQCKR	2098.0	2099.0	2098.0	2099.0
205.0	1.5	1.5	6.8	1.0	89.0	LKLEDFFAR	1137.6	1138.6	1137.6	1138.6
205.0	1.5	1.5	6.8	0.5	70.0	LOFHIVAGDIFHQCKR	2098.0	2099.0	2098.0	2099.0
101.0	7.7	7.7	22.9	2.0	99.0	LKLEDFFAR	1137.6	1138.6	1137.6	1138.6
101.0	7.7	7.7	22.9	2.0	99.0	LQFHDVAGDIFHQCK	1941.9	1942.9	1941.9	1942.9
101.0	7.7	7.7	22.9	2.0	99.0	NSYVAGOYDQAASYQR	1806.8	1807.8	1806.8	1807.8
101.0	7.7	7.7	22.9	1.7	98.0	DGLLPENTFIVGYAR	1663.9	1664.9	1663.9	1664.9
101.0	7.7	7.7	22.9	0.0	99.0	NSYVAGOYDQAASYQR	1807.8	1808.8	1807.8	1808.8
P11717 MPRI_HUMAN Cation-independent mannose-6-phosphate receptor precursor (CI Man-6-P receptor) (CI-MPR) (M6PR) (Insulin-like growth factor 2 receptor) (In										
201.0	1.5	1.5	6.2	1.5	97.0	GHOAQFDVGQPR	1210.6	1211.6	1210.6	1211.6
322.0	2.0	2.0	2.5	2.0	99.0	GHOAQFDVGQPR	1210.6	1211.6	1210.6	1211.6
P11940 PABP1_HUMAN Polyadenylate-binding protein 1 (Poly(A)-binding protein 1) (PABP 1) - Homo sapiens (Human)										
194.0	6.0	6.0	21.2	2.0	99.0	GFFGVFSER	1044.5	1045.5	1044.5	1045.5
194.0	6.0	6.0	21.2	2.0	99.0	QAHLTNYMOR	1371.6	1372.6	1371.6	1372.6
194.0	6.0	6.0	21.2	2.0	99.0	SLGYAVNFQOCPADAER	1927.9	1928.9	1927.9	1928.9
194.0	6.0	6.0	21.2	0.0	99.0	QAHLTNYMOR	1388.7	1389.7	1388.7	1389.7
117.0	2.6	2.6	18.4	1.4	96.0	SLGYAVNFQOCPADAER	1927.9	1928.9	1927.9	1928.9
117.0	2.6	2.6	18.4	1.2	94.0	GFCGVFSER	1044.5	1045.5	1044.5	1045.5
199.0	3.7	3.7	11.9	2.0	99.0	GFCGVFSER	1044.5	1045.5	1044.5	1045.5
199.0	3.7	3.7	11.9	1.7	98.0	GYFVFHFETQEAAER	1739.8	1740.8	1738.8	1740.8
P12955 PEPD_HUMAN Xaa-Pro dipeptidase (EC 3.4.13.9) (X-Pro dipeptidase) (Proline dipeptidase) (Prolidase) (l (imidodipeptidase) - Homo sapiens (Human)										
572.0	1.5	1.5	3.4	1.5	97.0	AFTPFGPK	950.5	951.5	950.5	951.5
367.0	2.0	2.0	2.0	2.0	99.0	VPLALFALNR	1112.7	1113.7	1112.7	1113.7
P12956 KU70_HUMAN ATP-dependent DNA helicase 2 subunit 2 (ATP-dependent DNA helicase II 70 kDa subunit) (Lupus Ku autoantigen protein p70) (Ku70) (70 kDa su										
49.0	18.0	18.0	20.2	2.0	99.0	DTGIFLDLMLHK	1401.7	1402.7	1401.7	1402.7
49.0	18.0	18.0	20.2	2.0	99.0	GFGDISLYR	1173.6	1174.6	1173.6	1174.6
49.0	18.0	18.0	20.2	2.0	99.0	IILEDQFKGQOGQR	1787.0	1788.0	1787.0	1788.0
49.0	18.0	18.0	20.2	2.0	99.0	IMATPEQVKG	1072.6	1073.6	1072.6	1073.6
49.0	18.0	18.0	20.2	2.0	99.0	IMLFTEQDNPHGDSAK	1901.9	1902.9	1901.9	1902.9
49.0	18.0	18.0	20.2	2.0	99.0	NIYVQELDNPQAK	1728.9	1729.9	1728.9	1729.9
49.0	18.0	18.0	20.2	2.0	99.0	SDSFENPVLOQHFR	1702.8	1703.8	1702.8	1703.8
49.0	18.0	18.0	20.2	2.0	99.0	SGWESYYK	1060.5	1061.5	1060.5	1061.5
49.0	18.0	18.0	20.2	2.0	99.0	VHFEQSSKLEDLLR	1705.8	1706.8	1702.8	1703.8
227.0	2.9	2.9	11.8	2.0	99.0	GGFDFISLYR	1173.6	1174.6	1173.6	1174.6
227.0	2.9	2.9	11.8	0.9	87.0	KPGGFDFISLYR	1398.7	1399.7	1398.7	1399.7
P13241 GILT_HUMAN Gamma-interferon-inducible lysosomal thiol reductase precursor (Gamma-interferon-inducible protein 1P-30) - Homo sapiens (Human)										
545.0	2.0	2.0	4.2	2.0	99.0	GMOLMHANAQR	1256.6	1256.6	1256.6	1256.6
545.0	2.0	2.0	4.2	0.0	99.0	GMOLMHANAQR	1256.6	1257.6	1256.6	1257.6
183.0	2.0	2.0	8.8	2.0	99.0	GMOLMHANAQR	1255.6	1256.6	1255.6	1256.6
366.0	2.0	2.0	4.2	2.0	99.0	GMOLMHANAQR	1271.6	1272.6	1271.6	1272.6
366.0	2.0	2.0	4.2	0.0	99.0	GMOLMHANAQR	1256.6	1257.6	1256.	

33.0	9.8	9.8	18.4	2.0	99.0	CLYASVLTQPR	1377.7	1378.7	1377.7	1378.7
33.0	9.8	9.8	18.4	2.0	99.0	GHVFEESQAVGTPMFVVK	1961.0	1962.0	1961.0	1962.0
33.0	9.8	9.8	18.4	2.0	99.0	YLAEKYEWDVVAEAR	1741.8	1742.8	1741.8	1742.8
33.0	9.8	9.8	18.4	1.3	95.0	YEWDVVAEAR	1137.5	1138.5	1137.5	1138.5
33.0	9.8	9.8	18.4	0.2	42.0	FSVVPVR	889.5	890.5	889.5	890.5
33.0	9.8	9.8	18.4	0.2	37.0	CELLYEPPDDEAMGIK	1989.9	1990.9	1989.9	1990.9
51.0	15.4	15.4	27.2	2.0	99.0	CLAYASVLTQPR	1360.7	1361.7	1360.7	1361.7
51.0	15.4	15.4	27.2	2.0	99.0	GHVFEESQAVGTPMFVVK	1961.0	1962.0	1961.0	1962.0
51.0	15.4	15.4	27.2	2.0	99.0	IMGPNTPTGKKEDLYLKPQR	2460.3	2461.3	2460.3	2461.3
51.0	15.4	15.4	27.2	2.0	99.0	VNFTVDQIR	1090.6	1091.6	1090.6	1091.6
51.0	15.4	15.4	27.2	2.0	99.0	YLAEKYEWDVVAEAR	1137.5	1138.5	1137.5	1138.5
51.0	15.4	15.4	27.2	2.0	99.0	YLAEKYEWDVVAEAR	1741.8	1742.8	1741.8	1742.8
51.0	15.4	15.4	27.2	1.7	98.0	AYLPVNESFGFTADLR	1798.9	1799.9	1798.9	1799.9
51.0	15.4	15.4	27.2	1.1	92.0	FYAFAGR	759.4	760.4	759.4	760.4
51.0	15.4	15.4	27.2	0.3	49.0	ANIRNMSVIAHVDHGK	1763.8	1764.8	1763.9	1764.9
51.0	15.4	15.4	27.2	0.2	30.0	FAAKGEQGLGPAER	1429.7	1430.7	1429.7	1430.7
51.0	15.4	15.4	27.2	0.1	22.0	GGCQIITPARR	1124.6	1125.7	1124.6	1125.6
P13640 MT1G_HUMAN	Metallothionein-1G (MT-1G) (Metallothionein-1G) (MT-1G) (Metallothionein-1K) (MT-1K) - Homo sapiens (Human)									
460.0	2.0	4.0	53.2	2.0	99.0	MDPNCSAAAGVSTCASSCK	2334.8	2335.8	2334.8	2335.9
460.0	2.0	4.0	53.2	0.0	99.0	SCS CCPVGC AK	1444.5	1445.5	1444.5	1445.5
460.0	2.0	4.0	53.2	0.0	99.0	SCS CCPVGC AK	1447.5	1448.5	1444.5	1445.5
460.0	2.0	4.0	53.2	0.0	99.0	SCS CCPVGC AK	1447.5	1448.5	1444.5	1445.5
182.0	2.0	53.2	2.0	99.0	SCS CCPVGC AK	1444.5	1445.5	1444.5	1445.5	
305.0	2.0	6.0	54.8	2.0	99.0	MDPNCSAAAGVSTCASSCK	2334.8	2335.9	2334.8	2335.9
305.0	2.0	6.0	54.8	0.0	99.0	KSCS CCPVGC AK	1573.6	1574.6	1572.6	1573.6
305.0	2.0	6.0	54.8	0.0	99.0	SCS CCPVGC AK	1444.5	1445.5	1444.5	1445.5
305.0	2.0	6.0	54.8	0.0	99.0	SCS CCPVGC AK	1446.5	1447.5	1444.5	1445.5
305.0	2.0	6.0	54.8	0.0	99.0	SCS CCPVGC AK	1446.5	1447.5	1444.5	1445.5
P13686 PPA5_HUMAN	Tartarate-resistant acid phosphatase type 5 precursor (EC 3.1.3.2) (TR-AP) (Tartarate-resistant acid ATPase) (TrATPase) (Acid phosphatase 5, tartrate-resistant acid phosphatase)									
247.0	4.9	4.9	12.3	2.0	99.0	FOETFEDVFSDR	1518.7	1519.7	1518.7	1519.7
247.0	4.9	4.9	12.3	2.0	99.0	FVAVGDWGVGPNAFPHTAR	1997.0	1998.0	1997.0	1998.0
247.0	4.9	4.9	12.3	0.9	86.0	WNFPSPEYR	1212.6	1213.6	1212.6	1213.6
144.0	2.1	2.1	15.7	2.0	99.0	FVAVGDWGVGPNAFPHTAR	1997.0	1998.0	1997.0	1998.0
299.0	2.0	6.5	2.0	99.0	FOETFEDVFSDR	1518.7	1519.7	1518.7	1519.7	
P13796 PLSL_HUMAN	Plastin-2 (L-plastin) (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P) - Homo sapiens (Human)									
25.0	26.0	32.2	2.0	99.0	AECMLQQAER	1234.5	1235.6	1234.5	1235.6	
25.0	26.0	32.2	2.0	99.0	FSLVGIGGQDLNEGNR	1674.8	1675.8	1674.8	1675.8	
25.0	26.0	32.2	2.0	99.0	GDEEGPVAVIDMSGLR	1742.9	1743.9	1742.9	1743.9	
25.0	26.0	32.2	2.0	99.0	IKVPVDWNR	1125.6	1126.6	1125.6	1126.6	
25.0	26.0	32.2	2.0	99.0	KLEN CNYAVELG KNOAK	1978.0	1979.0	1978.0	1979.0	
25.0	26.0	32.2	2.0	99.0	LENC NYAVELG KNOAK	1849.9	1850.9	1849.9	1850.9	
25.0	26.0	32.2	2.0	99.0	MINLSVPDTIDER	1501.7	1502.8	1501.7	1502.8	
25.0	26.0	32.2	2.0	99.0	OFTV ATDVR	1134.6	1135.6	1134.6	1135.6	
25.0	26.0	32.2	2.0	99.0	VNDII VNVVNETL R	1798.9	1799.9	1798.9	1799.9	
25.0	26.0	32.2	2.0	99.0	VVAL PEDLVEVNPK	1584.8	1585.8	1584.8	1585.8	
25.0	26.0	32.2	2.0	99.0	YAFVN WINK	1153.6	1154.6	1153.6	1154.6	
25.0	26.0	32.2	2.0	99.0	YT LNILEE IGG QK	1533.8	1534.8	1533.8	1534.8	
25.0	26.0	32.2	1.4	96.0	VNPKYPK	941.5	942.5	941.5	942.5	
25.0	26.0	32.2	0.6	75.0	TFRN WMNSLG VNPR	1690.8	1691.8	1690.8	1691.8	
25.0	26.0	32.2	0.0	99.0	KLEN CNYAVELG KNOAK	1978.0	1979.0	1978.0	1979.0	
25.0	26.0	32.2	0.0	97.0	YAFVN WINK	1155.6	1156.6	1153.6	1154.6	
18.0	14.2	31.4	2.0	99.0	FSLVGIGGQDLNEGNR	1674.8	1675.8	1674.8	1675.8	
18.0	14.2	31.4	2.0	99.0	GDEEGPVAVIDMSGLR	1742.9	1743.9	1742.9	1743.9	
18.0	14.2	31.4	2.0	99.0	IKVPVDWNR	1125.6	1126.6	1125.6	1126.6	
18.0	14.2	31.4	2.0	99.0	KLEN CNYAVELG KNOAK	1978.0	1979.0	1977.9	1979.0	
18.0	14.2	31.4	2.0	99.0	NVM NSLG VNPR	1286.6	1287.6	1286.6	1287.6	
18.0	14.2	31.4	2.0	99.0	VVAL PEDLVEVNPK	1584.8	1585.8	1584.8	1585.8	
18.0	14.2	31.4	1.0	91.0	OFTV ATDVR	1134.6	1135.6	1134.6	1135.6	
18.0	14.2	31.4	0.6	72.0	VNDII VNVVNETL R	1798.9	1799.9	1798.9	1799.9	
18.0	14.2	31.4	0.3	45.0	YAFVN WINK	1153.6	1154.6	1153.6	1154.6	
18.0	14.2	31.4	0.1	27.0	MINLSVPDTIDER	1501.7	1502.8	1501.7	1502.8	
18.0	14.2	31.4	0.1	23.0	OFTV ATDVR GPNPK	1530.8	1531.8	1530.8	1531.8	
18.0	14.2	31.4	0.1	21.2	DLLTEN LNL DEK	1562.7	1563.8	1562.7	1563.7	
18.0	14.2	31.4	0.0	83.0	KLEN CNYAVELG KNOAK	1978.0	1979.0	1978.0	1979.0	
18.0	14.2	31.4	0.0	83.0	OFTV ATDVR	1130.6	1131.6	1134.6	1135.6	
P14174 MIF_F_HUMAN	Macrophage migration inhibitory factor (MIF) (Phenylpyruvate tautomerase) (EC 5.3.2.1) (Glycosylation-inhibiting factor) (GIF) - Homo sapiens (Human)									
193.0	6.0	6.0	22.6	2.0	99.0	LLCG LL AER	1043.6	1044.6	1043.6	1044.6
193.0	6.0	6.0	22.6	2.0	99.0	PMFIV NTN VR	1286.7	1287.7	1286.7	1287.7
193.0	6.0	6.0	22.6	2.0	99.0	SYSKLL CGLL AER	1508.8	1509.8	1508.8	1509.8
193.0	6.0	6.0	22.6	0.0	99.0	PMFIV NTN VR	1298.7	1299.7	1298.7	1299.7
193.0	6.0	6.0	22.6	0.0	92.0	PMFIV NTN VR	1289.7	1290.7	1286.7	1287.7
193.0	6.0	6.0	22.6	0.0	90.0	PMFIV NTN VR	1314.7	1315.7	1314.7	1315.7
94.0	4.0	4.0	17.4	2.0	99.0	LLCG LL AER	1043.6	1044.6	1043.6	1044.6
94.0	4.0	4.0	17.4	2.0	99.0	PMFIV NTN VR	1286.7	1287.7	1286.7	1287.7
94.0	4.0	4.0	17.4	0.0	99.0	PMFIV NTN VR	1298.7	1299.7	1298.7	1299.7
94.0	4.0	4.0	17.4	0.0	98.0	PMFIV NTN VR	1287.7	1288.7	1287.7	1288.7
94.0	4.0	4.0	17.4	0.0	75.0	PMFIV NTN VR	1289.7	1290.7	1286.7	1287.7
194.0	4.0	4.0	17.4	2.0	99.0	LLCG LL AER	1043.6	1044.6	1043.6	1044.6
194.0	4.0	4.0	17.4	2.0	99.0	PMFIV NTN VR	1286.7	1287.7	1286.7	1287.7
194.0	4.0	4.0	17.4	0.0	99.0	PMFIV NTN VR	1298.7	1299.7	1298.7	1299.7
P14317 HCLS1_HUMAN	Hematopoietic lineage cell-specific protein (Hematopoietic cell-specific LYN substrate 1) (LckBP1) (p75) - Homo sapiens (Human)									
130.0	8.7	8.7	13.8	2.0	99.0	EHPV PLL PIR	1169.7	1170.7	1169.7	1170.7
130.0	8.7	8.7	13.8	2.0	99.0	GFGG OYGIOK	1053.5	1054.5	1053.5	1054.5
130.0	8.7	8.7	13.8	2.0	99.0	RSP EAPV IAMEEP AVAPL PK	2423.3	2424.3	2423.3	2424.3
130.0	8.7	8.7	13.8	2.0	99.0	TEHIN HQLR	1259.7	1260.7	1259.7	1260.7
130.0	8.7	8.7	13.8	0.5	71.0	TIECG SRTE HIN HQLR	1960.0	1961.0	1960.0	1961.0
130.0	8.7	8.7	13.8	0.2	36.0	GFGG QYGIOK DR	1324.7	1325.7	1324.7	1325.7
130.0	8.7	8.7	13.8	0.0	99.0	TEHIN HQLR	1259.7	1260.7	1259.7	1260.7
137.0	2.1	2.1	30.0	2.0	99.0	GFGG OYGIOK	1053.5	1054.5	1053.5	1054.5
153.0	4.6	4.6	17.9	2.0	99.0	EHPV PLL PIR	1169.7	1170.7	1169.7	1170.7
153.0	4.6	4.6	17.9	2.0	99.0	TEHIN HQLR	1259.7	1260.7	1259.7	1260.7
153.0	4.6	4.6	17.9	0.5	68.0	ASHG YGR FVER	1391.7	1392.7	1391.7	1392.7
153.0	4.6	4.6	17.9	0.1	29.0	GFGG QYGIOK DR	1666.8	1667.9	1666.8	1667.8
P14618 PYKM_HUMAN	Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Pyruvate kinase muscle Isozyme) (Pyruvate kinase 2/3) (Cytosolic thyroid hormone-binding protein)									
14.0	38.4	38.4	54.6	2.0	99.0	APIA VART POTAR	1506.9	1507.9	1506.9	1507.9
14.0	38.4	38.4	54.6	2.0	99.0	CDEN ILW LDY	1450.6	1451.6	1450.6	1451.6
14.0	38.4	38.4	54.6	2.0	99.0	CDEN ILW LDY KNIC	1983.0	1984.0	1982.9	1983.9

45.0	16.3	16.3	68.2	0.0	52.0	RLGMDGYR	982.5	983.5	982.5	983.5
45.0	16.3	16.3	68.2	0.0	99.0	STDYGFQINSR	1400.7	1401.7	1400.7	1401.7
45.0	16.3	16.3	68.2	0.0	95.0	WESGYNTR	1011.4	1012.5	1011.4	1012.4
45.0	16.3	16.3	68.2	0.0	65.0	WESGYNTR	1021.4	1022.4	1021.4	1022.4
45.0	16.3	16.3	68.2	0.0	23.0	WESGYNTR	1027.4	1028.5	1027.4	1028.4
P61769 B2MG_HUMAN	Beta-2-microglobulin precursor [Contains: Beta-2-microglobulin variant pl 5.3] - Homo sapiens (Human)									
94.0	11.7	11.7	49.6	2.0	99.0	IEKVEHSDLSFSK	1517.8	1518.8	1517.8	1518.8
94.0	11.7	11.7	49.6	2.0	99.0	IQVYSRHPAENGK	1497.8	1498.8	1497.8	1498.8
94.0	11.7	11.7	49.6	2.0	99.0	IVKVDRDM	1061.5	1062.5	1061.5	1062.5
94.0	11.7	11.7	49.6	2.0	99.0	VNHVTLSQPK	1121.6	1122.6	1121.6	1122.6
94.0	11.7	11.7	49.6	2.0	99.0	YTFEPTPEKDEYACR	1908.8	1909.8	1908.8	1909.8
94.0	11.7	11.7	49.6	1.2	94.0	IQVYSR	764.4	765.4	764.4	765.4
94.0	11.7	11.7	49.6	0.4	58.0	IVKVDR	815.5	816.5	815.5	816.5
94.0	11.7	11.7	49.6	0.0	99.0	IQVYSRHPAENGK	1498.8	1499.8	1498.8	1499.8
94.0	11.7	11.7	49.6	0.0	99.0	VNHVTLSQPK	1104.6	1105.6	1104.6	1105.6
53.0	6.1	6.1	26.1	2.0	99.0	IQVYSRHPAENGK	1498.8	1499.8	1498.8	1499.8
53.0	6.1	6.1	26.1	2.0	99.0	IVKVDRDM	1061.5	1062.5	1061.5	1062.5
53.0	6.1	6.1	26.1	0.1	27.0	IVKVDR	815.5	816.5	815.5	816.5
53.0	6.1	6.1	26.1	0.0	89.0	IQVYSRHPAENGK	1497.8	1498.8	1497.8	1498.8
69.0	10.4	10.4	37.8	2.0	99.0	IEKVEHSDLSFSK	1517.8	1518.8	1517.8	1518.8
69.0	10.4	10.4	37.8	2.0	99.0	IQVYSR	764.4	765.4	764.4	765.4
69.0	10.4	10.4	37.8	2.0	99.0	IQVYSRHPAENGK	1498.8	1499.8	1498.8	1499.8
69.0	10.4	10.4	37.8	2.0	99.0	IVKVDRDM	1061.5	1062.5	1061.5	1062.5
69.0	10.4	10.4	37.8	2.0	99.0	VNHVTLSQPK	1121.6	1122.6	1121.6	1122.6
69.0	10.4	10.4	37.8	0.4	60.0	IVKVDR	815.5	816.5	815.5	816.5
69.0	10.4	10.4	37.8	0.0	97.0	IQVYSRHPAENGK	1497.8	1498.8	1497.8	1498.8
69.0	10.4	10.4	37.8	0.0	99.0	VNHVTLSQPK	1122.6	1123.6	1121.6	1122.6
69.0	10.4	10.4	37.8	0.0	99.0	VNHVTLSQPK	1104.6	1105.6	1104.6	1105.6
P61916 NPCC2_HUMAN	Epilidymal secretory protein E1 precursor (Niemann-Pick disease type C2 protein) (hE1) - Homo sapiens (Human)									
536.0	2.0	2.0	10.6	2.0	99.0	EVNVSPCPTOPCQLSK	1842.9	1843.9	1842.9	1843.9
386.0	1.7	1.7	6.1	1.7	98.0	EVNVSPCPTOPCQLSK	1842.9	1843.9	1842.9	1843.9
P62158 CALM_HUMAN	Calmodulin (CaM) - Homo sapiens (Human)									
237.0	5.2	5.2	36.9	2.0	99.0	ADQLTEEQIAEFK	1562.7	1563.7	1562.7	1563.8
237.0	5.2	5.2	36.9	2.0	99.0	EADIDGDDGVNYEEFVOMMTAK	2489.1	2490.1	2489.1	2490.1
237.0	5.2	5.2	36.9	1.2	94.0	HVMTNLGEKLTDVEEMIR	2400.2	2401.2	2400.2	2401.2
254.0	2.2	2.2	19.5	2.0	99.0	ADQLTEEQIAEFK	1562.7	1563.8	1562.7	1563.8
254.0	2.2	2.2	19.5	0.2	38.0	VFDKGNGYISAAELR	1754.9	1755.9	1754.8	1755.9
P62241 RS8_HUMAN	40S ribosomal protein S8 - Homo sapiens (Human)									
106.0	10.1	10.1	52.4	2.0	99.0	ADGYVLEGKELEFYL	1901.0	1902.0	1901.0	1902.0
106.0	10.1	10.1	52.4	2.0	99.0	ELFYLYR	968.5	969.5	968.5	969.5
106.0	10.1	10.1	52.4	2.0	99.0	IDDVYVNASNNELVR	1717.9	1718.9	1717.9	1718.9
106.0	10.1	10.1	52.4	2.0	99.0	ISSLLEOFOOGK	1505.8	1506.8	1505.8	1506.8
106.0	10.1	10.1	52.4	2.0	99.0	OQWYESHYALPLGR	1601.8	1602.8	1601.8	1602.8
106.0	10.1	10.1	52.4	0.1	26.0	LLACIASRPGOCGR	1557.8	1558.8	1557.8	1558.8
106.0	10.1	10.1	52.4	0.0	78.0	OQWYESHYALPLGR	1618.8	1619.8	1618.8	1619.8
169.0	4.1	4.1	52.9	2.0	99.0	ADGYVLEGKELEFYL	1900.9	1902.0	1901.0	1902.0
169.0	4.1	4.1	52.9	2.0	99.0	OQWYESHYALPLGR	1601.8	1602.8	1601.8	1602.8
169.0	4.1	4.1	52.9	0.0	99.0	OQWYESHYALPLGR	1618.8	1619.8	1618.8	1619.8
P62244 RS15A_HUMAN	40S ribosomal protein S15a - Homo sapiens (Human)									
296.0	4.0	4.0	21.5	2.0	99.0	HGYIIGFEIIIDDH	1699.8	1700.8	1699.8	1700.8
296.0	4.0	4.0	21.5	2.0	99.0	IVVNLTGR	870.5	871.5	870.5	871.5
387.0	1.7	1.7	16.9	0.9	87.0	HGYIIGFEIIIDDH	1699.8	1700.8	1699.8	1700.8
387.0	1.7	1.7	16.9	0.8	84.0	IVVNLTGR	870.5	871.5	870.5	871.5
P62249 RS16_HUMAN	40S ribosomal protein S16 - Homo sapiens (Human)									
159.0	7.4	7.4	47.3	2.0	99.0	GGCHVAQIYAIR	1240.7	1241.7	1240.7	1241.7
159.0	7.4	7.4	47.3	2.0	99.0	LLEPVLLKG	1093.7	1094.7	1093.7	1094.7
159.0	7.4	7.4	47.3	2.0	99.0	PSKGPLSVOVFGR	1498.8	1499.8	1498.8	1499.8
159.0	7.4	7.4	47.3	0.8	85.0	EIKDILIOYDR	1404.8	1405.8	1404.8	1405.8
159.0	7.4	7.4	47.3	0.6	75.0	VKGHHVAQIYAIR	1467.8	1468.8	1467.8	1468.8
106.0	3.3	3.3	35.6	2.0	99.0	PSKGPLSVOVFGR	1498.8	1499.8	1498.8	1499.8
106.0	3.3	3.3	35.6	1.2	94.0	EIKDILIOYDR	1404.8	1405.8	1404.8	1405.8
68.0	10.9	10.9	52.1	2.0	99.0	EIKDILIOYDR	1404.8	1405.8	1404.8	1405.8
68.0	10.9	10.9	52.1	2.0	99.0	GGGHVAQIYAIR	1240.7	1241.7	1240.7	1241.7
68.0	10.9	10.9	52.1	2.0	99.0	PSKGPLQSQVFGR	1498.8	1499.8	1498.8	1499.8
68.0	10.9	10.9	52.1	2.0	99.0	VKGHHVAQIYAIR	1467.8	1468.8	1467.8	1468.8
68.0	10.9	10.9	52.1	1.5	97.0	FAGVDIR	776.4	777.4	776.4	777.4
68.0	10.9	10.9	52.1	1.3	94.0	ALAVYYQQ	954.5	955.5	954.5	955.5
P62258 1433E_HUMAN	14-3-3 protein epsilon (14-3-3E) - Homo sapiens (Human)									
109.0	10.0	12.0	37.3	2.0	99.0	IISIEQKEENGGEDIKLK	2144.1	2145.1	2144.1	2145.1
109.0	10.0	12.0	37.3	2.0	99.0	LAEAQERYDEMVKKK	2056.0	2057.0	2056.0	2057.0
109.0	10.0	12.0	37.3	2.0	99.0	MDDREDLVYQAK	1523.7	1524.7	1523.7	1524.7
109.0	10.0	12.0	37.3	2.0	99.0	YLAEFATGNDRK	1383.7	1384.7	1383.7	1384.7
109.0	10.0	12.0	37.3	0.0	99.0	DSTLIMOLLR	1188.7	1189.7	1188.7	1189.7
256.0	2.2	3.5	18.8	2.0	99.0	MDDREDLVYQAK	1523.7	1524.7	1523.7	1524.7
256.0	2.2	3.5	18.8	0.2	36.0	YLAEFATGNDRK	1383.7	1384.7	1383.7	1384.7
256.0	2.2	3.5	18.8	0.0	94.0	DSTLIMOLLR	1188.7	1189.7	1188.7	1189.7
P62269 RS18_HUMAN	40S ribosomal protein S18 (Ke-3) (Ke-3) - Homo sapiens (Human)									
164.0	7.2	7.2	34.9	2.0	99.0	IPDWFLNR	1059.5	1060.5	1059.6	1060.6
164.0	7.2	7.2	34.9	2.0	99.0	SLIPIKEFOHLIR	1620.9	1621.9	1620.9	1621.9
164.0	7.2	7.2	34.9	0.5	71.0	YAHVLRK	984.6	985.6	984.6	985.6
164.0	7.2	7.2	34.9	0.4	59.0	YAHVLR	856.5	857.5	856.5	857.5
164.0	7.2	7.2	34.9	0.0	70.0	VITIMONPR	1070.6	1071.6	1070.6	1071.6
135.0	5.9	5.9	37.5	2.0	99.0	VITIMONPR	1059.5	1060.5	1059.6	1060.6
135.0	5.9	5.9	37.5	2.0	99.0	VITIMQNPR	1070.6	1071.6	1070.6	1071.6
135.0	5.9	5.9	37.5	1.4	96.0	NMSVHSLPCFR	1620.9	1621.9	1620.9	1621.9
135.0	5.9	5.9	37.5	0.3	50.0	HFWGLR	814.4	815.4	814.4	815.4
135.0	5.9	5.9	37.5	0.2	37.0	YAHVLR	856.5	857.5	856.5	857.5
P62273 RS29_HUMAN	40S ribosomal protein S29 - Homo sapiens (Human)									
379.0	2.6	2.6	33.9	2.0	99.0	GHOOLYWSHPR	1407.7	1408.7	1407.7	1408.7
379.0	2.6	2.6	33.9	0.6	73.0	YGLNMR	912.4	913.4	912.4	913.4
379.0	2.6	2.6	33.9	0.0	99.0	GHOOLYWSHPR	1407.7	1408.7	1407.7	1408.7
240.0	2.4	2.4	33.9	2.0	99.0	GHOOLYWSHPR	1407.7	1408.7	1407.7	1408.7
240.0	2.4	2.4	33.9	0.3	49.0	YGLNMR	912.4	913.4	912.4	913.4
240.0	2.4	2.4	33.9	0.0	99.0	GHOOLYWSHPR	1407.7	1408.7	1407.7	1408.7
P62280 RS11_HUMAN	40S ribosomal protein S11 - Bos taurus (Bovine) - 40S ribosomal protein S11 - Rattus norvegicus (Rat) - 40S ribosomal protein S11 - Mus musculus									
82.0	12.8	12.8	39.2	2.0	99.0	AYOKOPTIFONKK	1464.8	1465.8	1464.8	1465.8

87.0	8.7	8.7	45.5	0.7	79.0	VNPTVFFDIAVDGEPLGR	1987.0	1988.0	1987.0	1988.0
87.0	8.7	8.7	45.5	0.0	99.0	GFGYKGSCFHR	1314.6	1315.6	1314.6	1315.6
87.0	8.7	8.7	45.5	0.0	91.0	GFGYKGSCFHR	1315.6	1316.7	1314.6	1315.6
87.0	8.7	8.7	45.5	0.0	99.0	SIYGEKFEDENFILK	1834.9	1835.9	1830.9	1831.9
87.0	8.7	8.7	45.5	0.0	99.0	VKEGMNIVNEAMER	1504.7	1505.7	1504.7	1505.7
P62942 FKB1A_HUMAN	FK506-binding protein 1A (EC 5.2.1.8) (Peptidyl-prolyl cis-trans isomerase) (PPIase) (Rotamase) (12 kDa FKBP) (FKBP-12) (Immunophilin FKBP1)									
174.0	2.0	2.0	40.7	2.0	99.0	GWEEGVAQMSVGOR	1532.7	1533.7	1532.7	1533.7
215.0	6.0	6.0	29.6	2.0	99.0	GVOVETISPQGDGR	1313.7	1314.7	1313.7	1314.7
215.0	6.0	6.0	29.6	2.0	99.0	GWEEGVAQMSVGOR	1532.7	1533.7	1532.7	1533.7
215.0	6.0	6.0	29.6	2.0	99.0	OEVIRGWEEGVAQMSVQR	2158.1	2159.1	2158.1	2159.1
191.0	4.0	4.0	25.0	2.0	99.0	GVQVETISPQGDGR	1313.7	1314.7	1313.7	1314.7
191.0	4.0	4.0	25.0	2.0	99.0	GWEEGVAQMSVGOR	1532.7	1533.7	1532.7	1533.7
P62979 RS27A_HUMAN	40S ribosomal protein S27a - Homo sapiens (Human)									
372.0	2.8	2.8	55.0	1.7	98.0	CCLTCFCNPKPEDK	1716.7	1717.7	1716.7	1717.7
372.0	2.8	2.8	55.0	0.6	77.0	YYKVDENKGISR	1471.8	1472.8	1471.7	1472.7
372.0	2.8	2.8	55.0	0.5	67.0	ECPSDECAGACVFMASHFDR	2170.9	2171.9	2170.9	2171.9
157.0	4.6	4.6	55.0	2.0	99.0	CCLTCFCNPKPEDK	1716.7	1717.7	1716.7	1717.8
157.0	4.6	4.6	55.0	2.0	99.0	ECPSDECAGACVFMASHFDR	2170.8	2171.9	2170.9	2171.9
157.0	4.6	4.6	55.0	0.6	74.0	YYKVDENKGISR	1471.7	1472.7	1471.7	1472.7
P63104 1433Z_HUMAN	14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) (KCIP-1) - Homo sapiens (Human)									
34.0	22.8	22.8	65.7	2.0	99.0	AKLAEAQERYDDMACMK	2099.5	2100.9	2099.9	2101.0
34.0	22.8	22.8	65.7	2.0	99.0	DICNDVLSLEK	1417.7	1418.7	1417.7	1418.7
34.0	22.8	22.8	65.7	2.0	99.0	DSTLIMQLLR	1188.7	1189.7	1188.7	1189.7
34.0	22.8	22.8	65.7	2.0	99.0	FLIPNASQAEVKFYLK	1954.1	1955.1	1954.1	1955.1
34.0	22.8	22.8	65.7	2.0	99.0	GIVDQSQAYQEAFEISKK	2168.1	2169.1	2168.1	2169.1
34.0	22.8	22.8	65.7	2.0	99.0	KEMOPTPHPIR	1235.6	1236.7	1235.6	1236.7
34.0	22.8	22.8	65.7	2.0	99.0	MDKNELVQK	1145.6	1146.6	1145.6	1146.6
34.0	22.8	22.8	65.7	2.0	99.0	NLLSVAYKNVVGAR	1502.9	1503.9	1502.9	1503.9
34.0	22.8	22.8	65.7	2.0	99.0	SVTEQGAELSNEER	1547.7	1548.7	1547.7	1548.7
34.0	22.8	22.8	65.7	2.0	99.0	YDDMAACMI	1103.4	1104.4	1103.4	1104.4
34.0	22.8	22.8	65.7	2.0	99.0	YLAEVAAQDDKK	1278.6	1279.7	1278.6	1279.7
34.0	22.8	22.8	65.7	0.6	72.0	VSSIEQKTEGAKKQOMAR	2246.2	2247.2	2246.2	2247.2
34.0	22.8	22.8	65.7	0.1	25.0	MKGDYR	931.4	932.4	931.4	932.4
67.0	5.1	5.1	35.1	2.0	99.0	GIVDQSOQAYQEAFEISKK	2168.1	2169.1	2168.1	2169.1
67.0	5.1	5.1	35.1	2.0	99.0	NLLSVAYKNVVGAR	1502.9	1503.9	1502.9	1503.9
67.0	5.1	5.1	35.1	1.0	91.0	DSTLIMQLLR	1188.7	1189.7	1188.7	1189.7
P63244 BLBP_HUMAN	Guanine nucleotide-binding protein subunit beta-2 like 1 (Guanine nucleotide-binding protein subunit beta-like protein 12.3) (Receptor of activate									
533.0	2.0	2.0	4.1	2.0	99.0	LTDRETNYGIPQR	1561.7	1562.8	1561.8	1562.8
382.0	1.7	1.7	8.5	1.7	98.0	LTDRETNYGIPQR	1561.8	1562.8	1561.8	1562.8
P63261 ACTG_HUMAN	Actin, cytoplasmic 2 (Gamma-actin) - Homo sapiens (Human)									
4.0	54.2	54.2	69.9	2.0	99.0	AGFAFDAPR	975.4	976.4	975.4	976.4
4.0	54.2	54.2	69.9	2.0	99.0	AVFPSIVGPR	1041.6	1042.6	1041.6	1042.6
4.0	54.2	54.2	69.9	2.0	99.0	AVFPSIVGPR	1197.7	1198.7	1197.7	1198.7
4.0	54.2	54.2	69.9	2.0	99.0	CVALDFQEMATAASSSSLEK	2549.0	2550.0	2549.0	2550.0
4.0	54.2	54.2	69.9	2.0	99.0	DLYANTVLSGGTTMYPGIADR	2214.0	2215.1	2214.1	2215.1
4.0	54.2	54.2	69.9	2.0	99.0	EEELAALVIDNGSGMCK	1876.9	1877.9	1876.9	1877.9
4.0	54.2	54.2	69.9	2.0	99.0	ETTALAPSTMK	1160.6	1161.6	1160.6	1161.6
4.0	54.2	54.2	69.9	2.0	99.0	GYSFTTAER	1131.5	1132.5	1131.5	1132.5
4.0	54.2	54.2	69.9	2.0	99.0	GYSFTTAERIVDRDIK	1985.1	1986.1	1985.0	1986.0
4.0	54.2	54.2	69.9	2.0	99.0	HQGMVVMGQGKDSYVGDEAQSK	1170.6	1171.6	1170.6	1171.6
4.0	54.2	54.2	69.9	0.7	81.0	MDKNELVQK	1145.6	1146.6	1145.6	1146.6
4.0	54.2	54.2	69.9	0.5	68.0	TAFDEAIEALDTLSEESYK	2131.0	2132.0	2131.0	2132.0
4.0	54.2	54.2	69.9	0.1	21.0	TDICNDVLSLEK	1417.7	1418.7	1417.7	1418.7
4.0	54.2	54.2	69.9	2.0	99.0	YIWHHTFYNE	1514.7	1515.7	1514.7	1515.7
4.0	54.2	54.2	69.9	2.0	99.0	KDLYANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.1	2343.1
4.0	54.2	54.2	69.9	2.0	99.0	MOKETIALAPSTMK	1547.8	1548.8	1547.8	1548.8
4.0	54.2	54.2	69.9	2.0	99.0	OEYDESGPSIVH	1515.7	1516.7	1515.7	1516.7
4.0	54.2	54.2	69.9	2.0	99.0	OEYDESGPSIVH	1643.8	1644.8	1643.8	1644.8
4.0	54.2	54.2	69.9	2.0	99.0	SELPDPGVITIGNER	1789.9	1790.9	1789.9	1790.9
4.0	54.2	54.2	69.9	2.0	99.0	VAPEEHPVLLTEAPLNPKANRE	1953.0	1954.0	1953.1	1954.1
4.0	54.2	54.2	69.9	2.0	99.0	VIKIAPPER	1035.6	1036.7	1035.6	1036.7
4.0	54.2	54.2	69.9	2.0	99.0	YIWHHTFYNE	1514.7	1515.7	1514.7	1515.7
4.0	54.2	54.2	69.9	2.0	99.0	KDLYANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.1	2343.1
4.0	54.2	54.2	69.9	2.0	99.0	MOKETIALAPSTMK	1547.8	1548.8	1547.8	1548.8
4.0	54.2	54.2	69.9	2.0	99.0	OEYDESGPSIVH	1515.7	1516.7	1515.7	1516.7
4.0	54.2	54.2	69.9	2.0	99.0	OEYDESGPSIVH	1643.8	1644.8	1643.8	1644.8
4.0	54.2	54.2	69.9	2.0	99.0	SELPDPGVITIGNER	1789.9	1790.9	1789.9	1790.9
4.0	54.2	54.2	69.9	2.0	99.0	VAPEEHPVLLTEAPLNPKANRE	1953.0	1954.0	1953.1	1954.1
4.0	54.2	54.2	69.9	1.7	98.0	VIKIAPPER	1035.6	1036.7	1035.6	1036.7
4.0	54.2	54.2	69.9	1.7	98.0	YIWHHTFYNE	1514.7	1515.7	1514.7	1515.7
4.0	54.2	54.2	69.9	1.7	98.0	KDLYANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.1	2343.1
4.0	54.2	54.2	69.9	1.7	98.0	MOKETIALAPSTMK	1547.8	1548.8	1547.8	1548.8
4.0	54.2	54.2	69.9	1.7	98.0	OEYDESGPSIVH	1515.7	1516.7	1515.7	1516.7
4.0	54.2	54.2	69.9	1.7	98.0	OEYDESGPSIVH	1643.8	1644.8	1643.8	1644.8
4.0	54.2	54.2	69.9	1.7	98.0	SELPDPGVITIGNER	1789.9	1790.9	1789.9	1790.9
4.0	54.2	54.2	69.9	1.7	98.0	VAPEEHPVLLTEAPLNPKANRE	1953.0	1954.0	1953.1	1954.1
4.0	54.2	54.2	69.9	0.9	83.0	VIKIAPPER	1163.7	1164.8	1163.7	1164.7
4.0	54.2	54.2	69.9	0.9	83.0	YIWHHTFYNE	1514.7	1515.7	1514.7	1515.7
4.0	54.2	54.2	69.9	0.9	83.0	KDLYANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.1	2343.1
4.0	54.2	54.2	69.9	0.9	83.0	MOKETIALAPSTMK	1547.8	1548.8	1547.8	1548.8
4.0	54.2	54.2	69.9	0.9	83.0	OEYDESGPSIVH	1515.7	1516.7	1515.7	1516.7
4.0	54.2	54.2	69.9	0.9	83.0	OEYDESGPSIVH	1643.8	1644.8	1643.8	1644.8
4.0	54.2	54.2	69.9	0.9	83.0	SELPDPGVITIGNER	1789.9	1790.9	1789.9	1790.9
4.0	54.2	54.2	69.9	0.9	83.0	VAPEEHPVLLTEAPLNPKANRE	1953.0	1954.0	1953.1	1954.1
4.0	54.2	54.2	69.9	0.9	83.0	VIKIAPPER	1035.6	1036.7	1035.6	1036.7
4.0	54.2	54.2	69.9	0.9	83.0	YIWHHTFYNE	1514.7	1515.7	1514.7	1515.7
4.0	54.2	54.2	69.9	0.9	83.0	KDLYANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.1	2343.1
4.0	54.2	54.2	69.9	0.9	83.0	MOKETIALAPSTMK	1547.8	1548.8	1547.8	1548.8
4.0	54.2	54.2	69.9	0.9	83.0	OEYDESGPSIVH	1515.7	1516.7	1515.7	1516.7
4.0	54.2	54.2	69.9	0.9	83.0	OEYDESGPSIVH	1643.8	1644.8	1643.8	1644.8
4.0	54.2	54.2	69.9	0.9	83.0	SELPDPGVITIGNER	1789.9	1790.9	1789.9	1790.9
4.0	54.2	54.2	69.9	0.9	83.0	VAPEEHPVLLTEAPLNPKANRE	1953.0	1954.0	1953.1	1954.1
4.0	54.2	54.2	69.9	0.9	83.0	VIKIAPPER	1035.6	1036.7	1035.6	1036.7
4.0	54.2	54.2	69.9	0.9	83.0	YIWHHTFYNE	1514.7	1515.7	1514.7	1515.7
4.0	54.2	54.2	69.9	0.9	83.0	KDLYANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.1	2343.1
4.0	54.2	5								

154.0	2.0	31.4	66.4	0.0	98.0	GYSFTTTAEREIVR	1628.8	1629.8	1628.8	1629.8
154.0	2.0	31.4	66.4	0.0	99.0	HOGVMVGMGQK	1170.6	1171.6	1170.6	1171.6
154.0	2.0	31.4	66.4	0.0	94.0	HOGVMVGMGQK	1171.6	1172.6	1170.6	1171.6
154.0	2.0	31.4	66.4	0.0	22.0	HOGVMVGMGQK	1186.6	1187.6	1186.6	1187.6
154.0	2.0	31.4	66.4	0.0	99.0	HOGVMVGMGQKDSYVGDEAQSK	2350.1	2351.1	2350.1	2351.1
154.0	2.0	31.4	66.4	0.0	99.0	HOGVMVGMGQKDSYVGDEAQSKR	2506.2	2507.2	2506.1	2507.1
154.0	2.0	31.4	66.4	0.0	96.0	HOGVMVGMGQKDSYVGDEAQSKR	2506.2	2507.2	2506.2	2507.2
154.0	2.0	31.4	66.4	0.0	89.0	IKIAPPER	1035.7	1036.7	1035.6	1036.7
154.0	2.0	31.4	66.4	0.0	99.0	IWHHTFYNELR	1514.7	1515.7	1514.7	1515.7
154.0	2.0	31.4	66.4	0.0	99.0	IWHHTFYNELR	1515.8	1516.8	1515.7	1516.7
154.0	2.0	31.4	66.4	0.0	98.0	IWHHTFYNELR	1546.7	1547.7	1546.7	1547.7
154.0	2.0	31.4	66.4	0.0	99.0	LCYVALDFEQEMATASSSLEK	2549.0	2550.0	2549.1	2550.1
154.0	2.0	31.4	66.4	0.0	36.0	QEYDESCPSIVH	1496.7	1497.7	1496.7	1497.7
154.0	2.0	31.4	66.4	0.0	99.0	QEYDESCPSIVH	1643.8	1644.8	1643.8	1644.8
154.0	2.0	31.4	66.4	0.0	74.0	QEYDESCPSIVH	1626.8	1627.8	1626.8	1627.8
154.0	2.0	31.4	66.4	0.0	99.0	SYELPDGQVITIGNER	1789.9	1790.9	1789.9	1790.9
154.0	2.0	31.4	66.4	0.0	99.0	VAPEEHPVLLTEAPLNPK	1953.1	1954.1	1953.1	1954.1
154.0	2.0	31.4	66.4	0.0	64.0	VAPEEHPVLLTEAPLNPKANRE	2294.2	2295.3	2294.2	2295.2
154.0	2.0	31.4	66.4	0.0	99.0	VAPEEHPVLLTEAPLNPKANRE	2551.4	2552.4	2551.4	2552.4
154.0	2.0	31.4	66.4	0.0	99.0	YPIEHGIVTNWDDMEK	1959.9	1960.9	1959.9	1960.9
5.0	50.7	50.7	69.1	2.0	99.0	AGFAGDAPP	975.4	976.5	975.4	976.4
5.0	50.7	50.7	69.1	2.0	99.0	AVFPSIVGRPR	1197.7	1198.7	1197.7	1198.7
5.0	50.7	50.7	69.1	2.0	99.0	CYVALDFEQEMATASSSLEK	2549.0	2550.0	2549.0	2550.0
5.0	50.7	50.7	69.1	2.0	99.0	DLYANTVLSGGTTMYPGIADR	2214.1	2215.1	2214.1	2215.1
5.0	50.7	50.7	69.1	2.0	99.0	EEEAALVLDNGSMCK	1877.8	1878.8	1877.8	1878.8
5.0	50.7	50.7	69.1	2.0	99.0	GILTCKYPIEHGIVTNWDDMEK	2585.3	2586.3	2585.3	2586.3
5.0	50.7	50.7	69.1	2.0	99.0	GYSTTAAER	1131.5	1132.5	1131.5	1132.5
5.0	50.7	50.7	69.1	2.0	99.0	GYSTTAAER	1628.8	1629.8	1628.8	1629.8
5.0	50.7	50.7	69.1	2.0	99.0	GYSTTAAERIVRDIKEK	2242.2	2243.2	2242.2	2243.2
5.0	50.7	50.7	69.1	2.0	99.0	HOGVMVGMGQK	1170.6	1171.6	1170.6	1171.6
5.0	50.7	50.7	69.1	2.0	99.0	HOGVMVGMGQKDSYVGDEAQSK	2350.1	2351.1	2350.1	2351.1
5.0	50.7	50.7	69.1	2.0	99.0	HOGVMVGMGQKDSYVGDEAQSKR	2506.2	2507.2	2506.2	2507.2
5.0	50.7	50.7	69.1	2.0	99.0	IKIAPPER	1035.7	1036.7	1035.6	1036.7
5.0	50.7	50.7	69.1	2.0	99.0	IKIAPPER	1163.7	1164.8	1163.7	1164.7
5.0	50.7	50.7	69.1	2.0	99.0	IWHHTFYNELR	1515.7	1516.7	1515.7	1516.7
5.0	50.7	50.7	69.1	2.0	99.0	KDLANTVLSGGTTMYPGIADR	2342.2	2343.2	2342.2	2343.2
5.0	50.7	50.7	69.1	2.0	99.0	MKEITALAPSTMK	1547.8	1548.8	1547.8	1548.8
5.0	50.7	50.7	69.1	2.0	99.0	QEYDESCPSIVH	1515.7	1516.7	1515.7	1516.7
5.0	50.7	50.7	69.1	2.0	99.0	QEYDESCPSIVH	1626.8	1627.8	1626.8	1627.8
5.0	50.7	50.7	69.1	2.0	99.0	SYELPDGQVITIGNER	1789.5	1789.9	1789.9	1790.9
5.0	50.7	50.7	69.1	2.0	99.0	VAPEEHPVLLTEAPLNPK	1953.0	1954.1	1953.1	1954.1
5.0	50.7	50.7	69.1	2.0	99.0	VAPEEHPVLLTEAPLNPKANRE	2294.2	2295.2	2294.2	2295.2
5.0	50.7	50.7	69.1	2.0	99.0	YPIEHGIVTNWDDMEK	1975.9	1976.9	1975.9	1976.9
5.0	50.7	50.7	69.1	1.5	97.0	DLAGRDLTDLMLK	1622.8	1623.8	1622.8	1623.8
5.0	50.7	50.7	69.1	1.3	95.0	IAPPER	922.6	923.6	922.6	923.6
5.0	50.7	50.7	69.1	0.7	81.0	RGILTLK	799.5	800.5	799.5	800.5
5.0	50.7	50.7	69.1	0.6	72.0	VAPEEHPVLLTEAPLNPKANRE	2551.4	2552.4	2551.4	2552.4
5.0	50.7	50.7	69.1	0.5	65.0	FRCPEALFQPS	1350.6	1351.7	1350.6	1351.6
5.0	50.7	50.7	69.1	0.2	30.0	DSYYGDEAQSKR	1353.6	1354.6	1353.6	1354.6
5.0	50.7	50.7	69.1	0.0	99.0	EEEAALVLDNGSMCK	1876.9	1877.9	1876.9	1877.9
5.0	50.7	50.7	69.1	0.0	94.0	EEEAALVLDNGSMCK	1875.8	1876.8	1875.8	1876.8
5.0	50.7	50.7	69.1	0.0	27.0	EEEAALVLDNGSMCK	1893.9	1895.0	1893.8	1894.8
5.0	50.7	50.7	69.1	0.0	99.0	HOGVMVGMGQK	1173.6	1174.6	1170.6	1171.6
5.0	50.7	50.7	69.1	0.0	99.0	HOGVMVGMGQKDSYVGDEAQSK	1186.6	1187.6	1186.6	1187.6
5.0	50.7	50.7	69.1	0.0	99.0	HOGVMVGMGQKDSYVGDEAQSKR	1262.2	1263.2	1262.2	1263.2
5.0	50.7	50.7	69.1	0.0	99.0	HOGVMVGMGQKDSYVGDEAQSKR	2518.2	2519.2	2518.2	2519.2
5.0	50.7	50.7	69.1	0.0	96.0	HOGVMVGMGQKDSYVGDEAQSKR	2522.2	2523.2	2522.2	2523.2
5.0	50.7	50.7	69.1	0.0	99.0	IKIAPPER	1035.7	1036.7	1035.6	1036.7
5.0	50.7	50.7	69.1	0.0	95.0	IKIAPPER	1163.7	1164.8	1163.7	1164.7
5.0	50.7	50.7	69.1	0.0	99.0	IWHHTFYNELR	1516.7	1517.7	1514.7	1515.7
5.0	50.7	50.7	69.1	0.0	99.0	IWHHTFYNELR	1546.7	1547.7	1546.7	1547.7
5.0	50.7	50.7	69.1	0.0	99.0	IWHHTYNELR	1530.7	1531.7	1530.7	1531.7
5.0	50.7	50.7	69.1	0.0	99.0	IWHHTYNELR	1514.7	1515.7	1514.7	1515.7
5.0	50.7	50.7	69.1	0.0	97.0	IWHHTYNELR	1512.8	1513.8	1514.7	1515.7
5.0	50.7	50.7	69.1	0.0	99.0	QEYDESCPSIVH	1498.7	1499.7	1498.7	1499.7
5.0	50.7	50.7	69.1	0.0	97.0	QEYDESCPSIVH	1498.7	1499.7	1498.7	1499.7
5.0	50.7	50.7	69.1	0.0	99.0	QEYDESCPSIVH	1643.8	1644.8	1643.8	1644.8
5.0	50.7	50.7	69.1	0.0	99.0	QEYDESCPSIVH	1642.8	1643.8	1643.8	1644.8
5.0	50.7	50.7	69.1	0.0	94.0	QEYDESCPSIVH	1642.8	1643.8	1642.8	1643.8
5.0	50.7	50.7	69.1	0.0	67.0	QEYDESCPSIVH	1644.8	1645.8	1644.8	1645.8
5.0	50.7	50.7	69.1	0.0	99.0	SYELPDGQVITIGNER	1789.9	1790.9	1789.9	1790.9
5.0	50.7	50.7	69.1	0.0	99.0	SYELPDGQVITIGNER	1789.9	1790.9	1789.9	1790.9
5.0	50.7	50.7	69.1	0.0	99.0	SYELPDGQVITIGNER	1802.9	1803.9	1802.9	1803.9
5.0	50.7	50.7	69.1	0.0	99.0	SYELPDGQVITIGNER	1790.9	1791.9	1790.9	1791.9
5.0	50.7	50.7	69.1	0.0	99.0	YPIEHGIVTNWDDMEK	1959.9	1960.9	1959.9	1960.9
P63279 UBC9_HUMAN SUMO-conjugating enzyme UBC9 (EC 6.3.2.-) (SUMO-protein ligase) (Ubiquitin-conjugating enzyme E2 1) (Ubiquitin-protein ligase I) (Ubiquitin carboxyl-terminal hydrolase)										
497.0	2.0	7.0	2.0	99.0	GTPWEGGLF	1090.5	1091.6	1090.5	1091.6	
173.0	2.0	15.8	2.0	99.0	GTPWEGGLF	1090.5	1091.6	1090.5	1091.6	
P67936 TPM4_HUMAN Tropomyosin alpha-4 chain (Tropomyosin-4) (TM30p1) - Homo sapiens (Human)										
39.0	21.0	21.0	45.6	2.0	99.0	AMKDEEKM1QEMQLK	1979.9	1980.9	1979.9	1980.9
39.0	21.0	21.0	45.6	2.0	99.0	HIAEADRKYEEVAR	1814.9	1815.9	1814.9	1815.9
39.0	21.0	21.0	45.6	2.0	99.0	IQAQQADAEAD	1613.8	1614.8	1613.8	1614.8
39.0	21.0	21.0	45.6	2.0	99.0	IQAQQADAEADRAQGLR	2267.1	2268.1	2267.1	2268.1
39.0	21.0	21.0	45.6	2.0	99.0	IQLVEELDRAQER	1726.9	1727.9	1726.9	1727.9
39.0	21.0	21.0	45.6	2.0	99.0	KIAOLOQQADEAD	1741.9	1742.9	1741.9	1742.9
39.0	21.0	21.0	45.6	2.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	2.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1726.9	1727.9	1726.9	1727.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1726.9	1727.9	1726.9	1727.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1726.9	1727.9	1726.9	1727.9
39.0	21.0	21.0	45.6	0.0	99.0	KIAOLOQQADEAD	1769.9	1770.9	1769.9	1770.9
39.0	21.0	21.0	45.6	0.0</td						

90.0	8.2	8.2	22.1	2.0	99.0	YYVTIIDAPGHDRFIK	1907.0	1908.0	1907.0	1908.0
90.0	8.2	8.2	22.1	0.2	42.0	STTTGGHLIYK	1119.6	1120.6	1119.6	1120.6
90.0	8.2	8.2	22.1	0.0	97.0	QTAVGVVIK	896.5	897.5	896.5	897.5
P68433 TBAK_HUMAN Tubulin alpha-ubiquitous chain (Alpha-tubulin ubiquitous) (Tubulin K-alpha-1) - Homo sapiens (Human)										
33.0	23.4	23.4	38.6	2.0	99.0	AVCMLSNTTAAEAWAR	1863.9	1864.9	1863.9	1864.9
33.0	23.4	23.4	38.6	2.0	99.0	AVFDLEPTVIDEV	1700.9	1701.9	1700.9	1701.9
33.0	23.4	23.4	38.6	2.0	99.0	LDHKFDLMLYAKR	1535.8	1536.8	1535.8	1536.8
33.0	23.4	23.4	38.6	2.0	99.0	OLFHPEQLITGKEDANNYR	1392.7	1393.8	1392.7	1393.7
33.0	23.4	23.4	38.6	2.0	99.0	TIGGGDDSFNTFSETGAGK	2414.2	2415.2	2414.2	2415.2
33.0	23.4	23.4	38.6	2.0	99.0	TIGGGDDSFNTFSETGAGK	2006.9	2007.9	2006.9	2007.9
33.0	23.4	23.4	38.6	2.0	99.0	TIGGGDDSFNTFSETGAGK	2496.2	2497.2	2496.1	2497.1
33.0	23.4	23.4	38.6	2.0	99.0	VGINYOPPTVPGDGLAK	1824.0	1825.0	1824.0	1825.0
33.0	23.4	23.4	38.6	2.0	99.0	YMACCLLYR	1248.5	1249.6	1248.5	1249.6
33.0	23.4	23.4	38.6	2.0	99.0	YMACCLLYRGDVPVK	1843.9	1844.9	1843.9	1844.9
33.0	23.4	23.4	38.6	1.4	96.0	RSIOFWDWPCTGFK	1739.9	1740.9	1739.8	1740.9
33.0	23.4	23.4	38.6	1.3	95.0	AFHVHWYVGEGMEEGEFSEAR	2329.0	2330.0	2329.0	2330.0
33.0	23.4	23.4	38.6	0.7	78.0	EIDLVLDR	1084.6	1085.6	1084.6	1085.6
33.0	23.4	23.4	38.6	0.0	98.0	OLFHPEQLITGK	1409.8	1410.8	1409.8	1410.8
33.0	23.4	23.4	38.6	0.0	94.0	OLFHPEQLITGKEDAANNYR	2397.2	2398.2	2397.2	2398.2
49.0	15.5	15.5	29.9	2.0	99.0	AFHVHWYVGEGMEEGEFSEAR	2329.0	2330.0	2329.0	2330.0
49.0	15.5	15.5	29.9	2.0	99.0	AVCMLSNTTAAEAWAR	1863.9	1864.9	1863.9	1864.9
49.0	15.5	15.5	29.9	2.0	99.0	AVFDLEPTVIDEV	1700.9	1701.9	1700.9	1701.9
49.0	15.5	15.5	29.9	2.0	99.0	LDHKFDLMLYAKR	1535.8	1536.8	1535.8	1536.8
49.0	15.5	15.5	29.9	2.0	99.0	OLFHPEQLITGKEDAANNYR	1392.7	1393.7	1392.7	1393.7
49.0	15.5	15.5	29.9	1.5	97.0	YMACCLLYR	2397.2	2398.2	2397.2	2398.2
49.0	15.5	15.5	29.9	1.5	97.0	YMACCLLYRGDVPVK	1843.9	1844.9	1843.9	1844.9
49.0	15.5	15.5	29.9	0.0	99.0	OLFHPEQLITGKEDAANNYR	2414.2	2415.2	2414.2	2415.2
P68431 H31_HUMAN Histone H3.1 (H3/a) (H3/b) (H3/c) (H3/d) (H3/f) (H3/h) (H3/i) (H3/k) (H3/l) (H3/m) - Homo sapiens (Human)										
154.0	7.9	7.9	41.2	2.0	99.0	EIAQDFKTDLR	1334.6	1335.6	1334.7	1335.7
154.0	7.9	7.9	41.2	2.0	99.0	KSAPATGGVKKPHR	1488.9	1489.9	1488.9	1489.9
154.0	7.9	7.9	41.2	1.5	97.0	STERLIR	830.5	831.5	830.5	831.5
154.0	7.9	7.9	41.2	0.3	54.0	KOLATAKAR	1031.6	1032.6	1031.6	1032.6
154.0	7.9	7.9	41.2	0.0	99.0	EIAQDFKTDLR	1027.6	1028.6	1027.7	1028.7
154.0	7.9	7.9	41.2	0.0	99.0	KSAPATGGVKKPHR	1348.7	1349.7	1348.7	1349.7
112.0	6.9	6.9	37.5	2.0	99.0	EIAQDFKTDLR	1334.7	1335.7	1334.7	1335.7
112.0	6.9	6.9	37.5	2.0	99.0	KSAPATGGVKKPHR	1488.9	1489.9	1488.9	1489.9
112.0	6.9	6.9	37.5	0.7	80.0	KLPFQR	1031.6	1032.6	1031.6	1032.6
112.0	6.9	6.9	37.5	0.1	23.0	STERLIR	787.5	788.5	787.5	788.5
112.0	6.9	6.9	37.5	0.0	99.0	EIAQDFKTDLR	830.5	831.5	830.5	831.5
112.0	6.9	6.9	37.5	0.0	53.0	EIAQDFKTDLR	1348.7	1349.7	1348.7	1349.7
112.0	6.9	6.9	37.5	0.0	41.0	KLPFQR	1362.7	1363.7	1362.7	1363.7
139.0	2.1	2.1	19.1	2.0	99.0	EIAQDFKTDLR	1334.6	1335.6	1334.7	1335.7
139.0	2.1	2.1	19.1	0.1	24.0	STERLIR	830.5	831.5	830.5	831.5
P78417 GSTO1_HUMAN Glutathione transferase omega-1 (EC 2.5.1.18) (GSTO 1-1) - Homo sapiens (Human)										
369.0	2.9	2.9	14.5	2.0	99.0	VPSLVGSFIR	1073.6	1074.6	1073.6	1074.6
369.0	2.9	2.9	14.5	0.6	75.0	SLKGSAAPPVGPEGSR	1704.9	1705.9	1704.9	1705.9
369.0	2.9	2.9	14.5	0.3	46.0	GSAAPPGVPEGSR	1319.7	1320.7	1319.7	1320.7
188.0	2.0	2.0	3.3	2.0	99.0	NKPEWFKF	1094.6	1095.6	1094.6	1095.6
146.0	5.1	5.1	28.6	2.0	99.0	SLKGSAAPPVGPEGSR	1704.9	1705.9	1704.9	1705.9
146.0	5.1	5.1	28.6	2.0	99.0	VPSLVGSFIR	1073.6	1074.6	1073.6	1074.6
146.0	5.1	5.1	28.6	0.7	78.0	NKPEWFKF	1094.6	1095.6	1094.6	1095.6
146.0	5.1	5.1	28.6	0.3	46.0	GIRHEVINILNK	1404.8	1405.8	1404.8	1405.8
146.0	5.1	5.1	28.6	0.1	23.0	GSAAPPGVPEGSR	1319.7	1320.7	1319.7	1320.7
P80295 MT11_HUMAN Metallothionein-11 (MT-11) - Homo sapiens (Human)										
459.0	2.0	4.0	52.5	2.0	99.0	MDPNCSCAAGVSCTAGSCK	2263.8	2264.8	2263.8	2264.8
459.0	2.0	4.0	52.5	0.0	99.0	MDPNCSCAAGVSCTAGSCK	2233.8	2234.8	2233.8	2234.8
459.0	2.0	4.0	52.5	0.0	99.0	SCSCCPVCGCAK	1444.5	1445.5	1444.5	1445.5
459.0	2.0	4.0	52.5	0.0	99.0	SCSCCPVCGCAK	1447.5	1448.5	1444.5	1445.5
304.0	2.0	6.0	54.1	2.0	99.0	SCDPNCSCAAGVSCTAGSCK	2263.8	2264.8	2263.8	2264.8
304.0	2.0	6.0	54.1	0.0	99.0	KSCSCCPVCGCAK	1573.6	1574.6	1572.6	1573.6
304.0	2.0	6.0	54.1	0.0	99.0	SCSCCPVCGCAK	1444.5	1445.5	1444.5	1445.5
304.0	2.0	6.0	54.1	0.0	99.0	SCSCCPVCGCAK	1446.5	1447.5	1444.5	1445.5
182.0	2.0	2.0	53.2	2.0	99.0	SCSCCPVCGCAK	1444.5	1445.5	1444.5	1445.5
P84103 SFRS3_HUMAN Splicing factor, arginine/serine-rich 3 (Bos taurus (Bovine) : Splicing factor, arginine/serine-rich 3 (Pre-mRNA-splicing factor SRP20) - Homo sapiens (Human))										
279.0	4.0	4.0	37.8	2.0	99.0	AFGYPYDSR	1042.5	1043.5	1042.5	1043.5
279.0	4.0	4.0	37.8	2.0	99.0	NPPGFAFVEFEDPRDAADAVR	2319.1	2320.1	2319.1	2320.1
313.0	2.0	2.0	46.3	2.0	99.0	AFGYGPLR	1042.5	1043.5	1042.5	1043.5
Q00610 CLH1_HUMAN Clathrin heavy chain 1 (CLH1) - Homo sapiens (Human)										
408.0	2.3	2.3	3.6	2.0	99.0	FIRENPYDSR	1458.7	1459.7	1458.7	1459.7
408.0	2.3	2.3	3.6	0.2	43.0	LLLPWLEAR	1109.7	1110.7	1109.7	1110.7
234.0	2.5	2.5	3.5	2.0	99.0	IHEGCEEPATHNALAK	1775.8	1776.8	1775.8	1776.8
234.0	2.5	2.5	3.5	0.5	68.0	NNRSEPGLOTR	1384.6	1385.7	1384.7	1385.7
Q00839 HNRP_U_HUMAN Heterogeneous nuclear ribonucleoprotein U (hnRNPU) (Scaffold attachment factor A) (SAF-A) (p120) (pp120) - Homo sapiens (Human)										
93.0	11.9	11.9	23.1	2.0	99.0	GHGEOPPOPPATQQQQQQQR	2395.1	2396.1	2395.1	2396.1
93.0	11.9	11.9	23.1	2.0	99.0	GYFEYIEENKYSR	1696.8	1697.8	1696.8	1697.8
93.0	11.9	11.9	23.1	2.0	99.0	KMCFLAGFOR	1256.6	1257.6	1256.6	1257.6
93.0	11.9	11.9	23.1	2.0	99.0	MCLFAGFOR	1128.5	1129.5	1128.5	1129.5
93.0	11.9	11.9	23.1	2.0	99.0	SSGPTSLFAVTAPPGR	1713.9	1714.9	1713.9	1714.9
93.0	11.9	11.9	23.1	1.7	98.0	FIEIAAR	818.5	819.5	818.5	819.5
93.0	11.9	11.9	23.1	0.2	31.0	RGNMPORGGGGGGGGYYPYPR	2303.1	2304.1	2303.1	2304.1
93.0	11.9	11.9	23.1	0.0	99.0	SSGPTSLFAVTAPPGR	1711.9	1712.9	1713.9	1714.9
140.0	5.7	5.7	20.6	2.0	99.0	FIEIAAR	818.5	819.5	818.5	819.5
140.0	5.7	5.7	20.6	2.0	99.0	MCLFAGFOR	1128.5	1129.5	1128.5	1129.5
140.0	5.7	5.7	20.6	1.7	98.0	AFGYGPLR	1696.8	1697.8	1696.8	1697.8
Q01082 SPTB2_HUMAN Spectrin beta chain, brain 1 (Spectrin, non-erythroid beta chain 1) (Beta-II spectrin) (Fodrin beta chain) - Homo sapiens (Human)										
119.0	9.6	9.6	8.6	2.0	99.0	DLDLFSQWSLR	1380.6	1381.6	1380.6	1381.6
119.0	9.6	9.6	8.6	2.0	99.0	EVDDELEQWIAER	1501.7	1502.7	1501.7	1502.7
119.0	9.6	9.6	8.6	2.0	99.0	FMLEPLENIR	1389.7	1390.7	1389.7	1390.7
119.0	9.6	9.6	8.6	1.7	98.0	FYHDKEIFGR	1381.7	1382.7	1381.7	1382.7
119.0	9.6	9.6	8.6	1.2	94.0	DASVAEWLLQQEPYLLSR	2091.0	2092.0	2091.0	2092.0
119.0	9.6	9.6	8.6	0.5	70.0	WVNLSHAR	981.5	982.5	981.5	982.5
119.0	9.6	9.6	8.6	0.1	27.0	LOAAAGDKADDQK	1761.9	1762.9	1761.9	1762.9
119.0	9.6	9.6	8.6	0.0	37.0	FYHDKEIFGR	1381.7	1382.7	1381.7	1382.7
255.0	2.2	2.2	7.9	2.0	99.0	DASVAEWLLQQEPYLLSR	2091.0	2092.1	2091.0	2092.0
255.0	2									

121.0	9.6	9.6	16.2	2.0	99.0	SGPKPFSAPKPQTSPSPK	1993.1	1994.1	1993.1	1994.1
121.0	9.6	9.6	16.2	1.5	97.0	LEAVSHTSDMR	1381.6	1382.7	1381.6	1382.6
56.0	6.0	6.0	14.5	2.0	99.0	ADMQNLLVER	1116.5	1117.5	1116.5	1117.5
56.0	6.0	6.0	14.5	2.0	99.0	SGPKPFSAPKPQTSPSPK	1837.0	1838.0	1837.0	1838.0
56.0	6.0	6.0	14.5	2.0	99.0	SSLFAQINQGESEITHALK	1927.0	1928.0	1927.0	1928.0
110.0	7.1	7.1	21.1	2.0	99.0	ADMQNLLVER	1116.5	1117.5	1116.5	1117.5
110.0	7.1	7.1	21.1	2.0	99.0	LEAVSHTSDMR	1381.6	1382.7	1381.6	1382.6
110.0	7.1	7.1	21.1	2.0	99.0	SGPKPFSAPKPQTSPSPK	1837.0	1838.0	1837.0	1838.0
110.0	7.1	7.1	21.1	1.0	91.0	THKNPALKAQSGPVR	1602.9	1603.9	1602.9	1603.9
Q01844 EWS_HUMAN		RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein) - Homo sapiens (Human)								
268.0	4.1	4.1	25.8	2.0	99.0	AAVEWFQDGKDFQGSK	1683.8	1684.8	1683.8	1684.8
268.0	4.1	4.1	25.8	2.0	99.0	AGDWCPNPQCGNQNFQWR	2233.9	2234.9	2233.9	2234.9
268.0	4.1	4.1	25.8	0.1	25.0	GRRGGDRGFRGRRGMRDGGFGGRR	2582.2	2583.2	2582.2	2583.2
115.0	2.8	2.8	23.6	2.0	99.0	AAVEWFQDGKDFQGSK	1683.8	1684.8	1683.8	1684.8
115.0	2.8	2.8	23.6	0.8	85.0	GGRGRCGMSAGER	1177.6	1178.6	1177.5	1178.5
312.0	2.0	2.0	16.8	2.0	99.0	AGDWCPNPQCGNQNFQWR	2233.9	2234.9	2233.9	2234.9
Q02818 NUCB1_HUMAN		Nucleobindin-1 precursor (CALNUC) - Homo sapiens (Human)								
271.0	4.1	4.1	18.2	2.0	99.0	DLAQYDAAHHEEFKR	1828.9	1829.9	1828.8	1829.9
271.0	4.1	4.1	18.2	2.0	99.0	KQQQQQQQGHKPAAHPEQLK	2464.3	2465.3	2464.3	2465.3
271.0	4.1	4.1	18.2	0.1	21.0	AQRLSQETEALGR	1460.7	1461.7	1460.7	1461.7
150.0	4.7	4.7	23.4	2.0	99.0	DLAQYDAAHHEEFKR	1828.9	1829.9	1828.8	1829.9
150.0	4.7	4.7	23.4	2.0	99.0	QFEHLDPPQNQHFEAR	1978.9	1979.9	1978.9	1979.9
150.0	4.7	4.7	23.4	0.4	58.0	DLELLIQTATR	1271.7	1272.7	1271.7	1272.7
150.0	4.7	4.7	23.4	0.1	29.0	YEMLKHEHER	1233.6	1234.6	1233.6	1234.6
150.0	4.7	4.7	23.4	0.1	26.0	EMEEERLRLR	1357.7	1358.7	1357.7	1358.7
150.0	4.7	4.7	23.4	0.0	97.0	DLAQYDAAHHEEFKR	1828.8	1829.9	1828.8	1829.9
Q02878 RL6_HUMAN		60S ribosomal protein L6 (TAX-responsive enhancer element-binding protein 107) (TREXB107) (Neoplasm-related protein C140) - Homo sapiens								
355.0	3.2	3.2	21.2	2.0	99.0	AIPOLGYLRL	1157.7	1158.7	1157.7	1158.7
355.0	3.2	3.2	21.2	1.2	94.0	YPTTEDVPR	1138.5	1139.5	1138.5	1139.5
332.0	2.0	2.0	12.8	2.0	99.0	AIPOLGYLRL	1157.7	1158.7	1157.7	1158.7
Q06033 ITIH3_HUMAN		Inter-alpha-trypsin inhibitor heavy chain H3 precursor (ITI heavy chain H3) (Inter-alpha-inhibitor heavy chain 3) (Serum-derived hyaluronan-ass								
116.0	9.7	9.7	7.3	2.0	99.0	IDFGNYIYER	1289.6	1290.6	1289.6	1290.6
116.0	9.7	9.7	7.3	2.0	99.0	FAHNIVTMR	1043.6	1044.6	1043.6	1044.6
116.0	9.7	9.7	7.3	2.0	99.0	GHSVFKPSLDOOR	1497.7	1498.7	1497.8	1498.8
116.0	9.7	9.7	7.3	1.7	98.0	VFTFLTYEELLKR	1625.9	1626.9	1625.9	1626.9
100.0	3.5	3.5	8.6	2.0	99.0	FAHNIVTMR	1043.6	1044.6	1043.6	1044.6
100.0	3.5	3.5	8.6	1.5	97.0	DYIFGNYIYER	1289.6	1290.6	1289.6	1290.6
92.0	8.1	8.1	13.8	2.0	99.0	DYIFGNYIYER	1289.6	1290.6	1289.6	1290.6
92.0	8.1	8.1	13.8	2.0	99.0	FAHNIVTMR	1043.6	1044.6	1043.6	1044.6
92.0	8.1	8.1	13.8	2.0	99.0	KGHVSFKPSLDOOR	1625.9	1626.9	1625.9	1626.9
92.0	8.1	8.1	13.8	2.0	99.0	VFTFLTYEELLKR	1639.9	1640.9	1639.9	1640.9
Q06323 PSME1_HUMAN		Proteasome activator complex subunit 1 (Proteasome activator 28-alpha subunit) (PA28alpha) (PA28a) (Activator of multicatalytic protease subu								
68.0	14.7	14.7	38.2	2.0	99.0	AAKOPHVGDYR	1240.6	1241.6	1240.6	1241.6
68.0	14.7	14.7	38.2	2.0	99.0	LEGHTQFQISK	1158.6	1159.6	1158.6	1159.6
68.0	14.7	14.7	38.2	2.0	99.0	NAYAVLYDIILK	1394.8	1395.8	1394.8	1395.8
68.0	14.7	14.7	38.2	2.0	99.0	OLVHELDEAEYRDIR	1884.9	1885.9	1884.9	1885.9
68.0	14.7	14.7	38.2	2.0	99.0	OPHVGDR	954.3	954.4	954.4	954.4
68.0	14.7	14.7	38.2	2.0	99.0	YFSERGDAVTK	1271.6	1272.6	1271.6	1272.6
68.0	14.7	14.7	38.2	1.7	98.0	LVMVMEIR	890.5	891.5	890.5	891.5
68.0	14.7	14.7	38.2	1.0	91.0	IVVLLOR	839.6	840.6	839.6	840.6
50.0	6.3	6.3	26.9	2.0	99.0	IVVLLOR	839.6	840.6	839.6	840.6
50.0	6.3	6.3	26.9	2.0	99.0	NAYAVLYDIILK	1394.8	1395.8	1394.8	1395.8
50.0	6.3	6.3	26.9	2.0	99.0	OLVHELDEAEYR	1500.7	1501.7	1500.7	1501.7
50.0	6.3	6.3	26.9	0.3	49.0	LVMVMEIR	890.5	891.5	890.5	891.5
59.0	12.9	12.9	34.1	2.0	99.0	AAKOPHVGDYR	1240.6	1241.6	1240.6	1241.6
59.0	12.9	12.9	34.1	2.0	99.0	IEDGNNGFVAVQEKF	1519.7	1520.7	1519.7	1520.7
59.0	12.9	12.9	34.1	2.0	99.0	IVVLLQR	839.6	840.6	839.6	840.6
59.0	12.9	12.9	34.1	2.0	99.0	OLVHELDEAEYRDIR	1483.7	1484.7	1483.7	1484.7
59.0	12.9	12.9	34.1	2.0	99.0	QITVNDLPVGR	1210.7	1211.7	1210.7	1211.7
48.0	18.3	18.3	55.3	2.0	99.0	TIAQDYGVKLADEGISFR	1106.6	1107.6	1106.6	1107.6
48.0	18.3	18.3	55.3	2.0	99.0	ATAVMPDGQFK	1982.0	1983.0	1982.0	1983.0
48.0	18.3	18.3	55.3	0.3	52.0	ATAVMPDGQFKDISLSDYK	1163.6	1164.6	1163.6	1164.6
25.0	12.3	12.3	52.8	2.0	99.0	ATAVMPDGQFKDISLSDYK	2085.0	2086.0	2085.0	2086.0
25.0	12.3	12.3	52.8	2.0	99.0	ATAVMPDGQFKDISLSDYK	2270.1	2271.1	2270.1	2271.1
25.0	12.3	12.3	52.8	2.0	99.0	IGHPAPNFK	979.5	980.5	979.5	980.5
25.0	12.3	12.3	52.8	2.0	99.0	KOGGLGPMNIPLVSDPKR	1906.0	1907.0	1906.0	1907.1
25.0	12.3	12.3	52.8	2.0	99.0	QITVNDLPVGR	1210.7	1211.7	1210.7	1211.7
25.0	12.3	12.3	52.8	2.0	99.0	TIAQDYGVKLADEGISFR	1982.0	1983.0	1982.0	1983.0
25.0	12.3	12.3	52.8	0.3	49.0	ATAVMPDGQFKDISLSDYK	2084.1	2085.1	2085.0	2086.0
41.0	18.0	18.0	49.7	2.0	99.0	ATAVMPDGQFK	1163.6	1164.6	1163.6	1164.6
41.0	18.0	18.0	49.7	2.0	99.0	ATAVMPDGQFKDISLSDYK	2085.0	2086.0	2085.0	2086.0
41.0	18.0	18.0	49.7	2.0	99.0	IGHPAPNFK	2270.1	2271.1	2270.1	2271.1
41.0	18.0	18.0	49.7	2.0	99.0	KOGGLGPMNIPLVSDPKR	1358.8	1359.8	1358.8	1359.8
41.0	18.0	18.0	49.7	2.0	99.0	QITVNDLPVGR	1906.0	1907.1	1906.0	1907.1
41.0	18.0	18.0	49.7	2.0	99.0	TIAQDYGVKLADEGISFR	1210.7	1211.7	1210.7	1211.7
41.0	18.0	18.0	49.7	2.0	99.0	ATAVMPDGQFK	1982.0	1983.0	1982.0	1983.0
41.0	18.0	18.0	49.7	0.0	99.0	IGHPAPNFK	979.5	980.5	979.5	980.5
41.0	18.0	18.0	49.7	0.0	99.0	QITVNDLPVGR	1210.7	1211.7	1210.7	1211.7
41.0	18.0	18.0	49.7	0.0	99.0	TIAQDYGVKLADEGISFR	1982.0	1983.0	1982.0	1983.0
41.0	18.0	18.0	49.7	0.0	99.0	ATAVMPDGQFKDISLSDYK	2084.1	2085.1	2085.0	2086.0
Q06380 LG3BP_HUMAN	Galectin-3-binding protein precursor (Lectin galactoside-binding soluble 3-binding protein) (Mac-2-binding protein) (Mac-2-BP) (MAC2BP) (Tumor)									
436.0	2.0	2.0	9.1	2.0	99.0	GOWGTVCDNLWDLTASVCR	2451.1	2452.1	2451.1	2452.1
161.0	2.0	2.0	6.3	2.0	99.0	AVDTWWSGER	1205.5	1206.6	1205.5	1206.6
276.0	2.1	2.1	7.5	2.0	99.0	YSDSYQAPSDYR	1597.7	1598.7	1597.7	1598.7
Q12906 ILF3_HUMAN		Interleukin enhancer-binding factor 3 (Nuclear factor of activated T-cells 90 kDa) (NF-AT-90) (Double-stranded RNA-binding protein 76) (DRBP76)								
60.0	16.5	16.5	21.9	2.0	99.0	AEPQAMALMIR	1327.6	1328.7	1327.6	1328.6
60.0	16.5	16.5	21.9	2.0	99.0	CLAALASLR	956.5	957.5	956.6	957.6
60.0	16.5	16.5	21.9	2.0	99.0	HSSVPTQEELEAVONMVSHTER	2670.2	2671.2	2670.2	2671.2
60.0	16.5	16.5	21.9	2.0	99.0	LAAFQGLHK	983.6	984.6	983.6	984.6
60.0	16.5	16.5	21.9	2.0	99.0	SGGNSYGGSGASYNPNGSHGGYGGGGSSQYQ	3011.2	3012.2	3011.2	3012.2
60.0	16.5	16.5	21.9	2.0	99.0	SIGTANRPMAEGEARL	1755.9	1756.9	1755.9	1756.9
60.0	16.5	16.5	21.9	2.0	99.0	VLODMGLPTGAEGR	1442.7	1443.7	1442.7	1443.7
60.0	16.5	16.5	21.9	1.7	98.0	IFVNDDRHVKMAK	1443.7	1444.7	1443.7	1444.7
60.0	16.5	16.5	21.9	0.2	30.0	WFOAR	706.4	707.4	706.4	707.4

126.0	9.3	9.3	50.7	0.3	51.0	FTTGDAMSKR	1112.5	1113.5	1112.5	1113.5
212.0	3.2	3.2	37.3	2.0	99.0	LFAFVR	751.4	752.4	751.4	752.4
212.0	3.2	3.2	37.3	0.9	86.0	ATKIDKEACR	1232.6	1233.6	1232.6	1233.6
212.0	3.2	3.2	37.3	0.4	57.0	YDGSTIVPGEQEGAQYHQFIQQCTDDVR	3112.4	3113.4	3112.4	3113.4
Q14103 HNRPD_HUMAN	Heterogeneous nuclear ribonucleoprotein D0 (hnRNP C1) (AU-rich element RNA-binding protein 1) - Homo sapiens (Human)									
85.0	12.2	12.2	35.2	2.0	99.0	FGEVVDCTKLKDPTGR	1919.0	1920.0	1919.0	1920.0
85.0	12.2	12.2	35.2	2.0	99.0	GFCFITFK	1018.5	1019.5	1018.5	1019.5
85.0	12.2	12.2	35.2	2.0	99.0	GFCFITKEEVPVK	1857.9	1858.9	1857.9	1858.9
85.0	12.2	12.2	35.2	2.0	99.0	GFGFVLFK	913.5	914.5	913.5	914.5
85.0	12.2	12.2	35.2	2.0	99.0	IFVGGLSPDTPEEK	1487.7	1488.8	1487.8	1488.8
85.0	12.2	12.2	35.2	2.0	99.0	SRGFGVFLK	1156.6	1157.6	1156.6	1157.6
85.0	12.2	12.2	35.2	0.1	21.0	IFVGGLSPDTPEEKIR	1756.9	1757.9	1756.9	1757.9
157.0	2.0	4.0	11.0	2.0	99.0	GFCFITKEEVPVK	1857.9	1858.9	1857.9	1858.9
157.0	2.0	4.0	11.0	0.0	99.0	GFGFVLFK	913.5	914.5	913.5	914.5
Q14152 IF3A_HUMAN	Eukaryotic translation initiation factor 3 subunit 10 (eIF-3 theta) (eIF3 p167) (eIF3 p180) (eIF3 p185) (eIF3a) - Homo sapiens (Human)									
137.0	8.2	8.2	16.1	2.0	99.0	RGADDPRSPWR	1329.6	1330.6	1329.6	1330.6
137.0	8.2	8.2	16.1	2.0	99.0	WGRDSEGTWR	1363.6	1364.6	1363.6	1364.6
137.0	8.2	8.2	16.1	1.7	98.0	RGLDDDRGPWR	1341.7	1342.7	1341.7	1342.7
137.0	8.2	8.2	16.1	1.5	97.0	RGMDDDRGPWR	1203.5	1204.5	1203.5	1204.5
137.0	8.2	8.2	16.1	0.8	83.0	EELREOAEALQKVR	1769.9	1770.9	1769.9	1770.9
137.0	8.2	8.2	16.1	0.1	25.0	DLRDRDRREGPPLR	1761.9	1762.9	1761.9	1762.9
137.0	8.2	8.2	16.1	0.0	96.0	WGDRDSEGTWR	1363.6	1364.6	1363.6	1364.6
404.0	1.3	1.3	16.4	1.2	94.0	WGDRDSEGTWR	1363.6	1364.6	1363.6	1364.6
Q14764 MVP_HUMAN	Major vault protein (MVP) (Lung resistance-related protein) - Homo sapiens (Human)									
122.0	9.5	9.5	13.9	2.0	99.0	ALOPEEGEDEEKVSHOAGDHWLIR	2886.4	2887.4	2886.3	2887.3
122.0	9.5	9.5	13.9	2.0	99.0	VPHAAVQVYDYR	1530.8	1531.8	1530.8	1531.8
122.0	9.5	9.5	13.9	1.3	95.0	ATEEFIR	1019.5	1020.5	1019.5	1020.5
122.0	9.5	9.5	13.9	1.3	95.0	NFRDFR	853.4	854.4	853.4	854.4
122.0	9.5	9.5	13.9	0.7	78.0	SLOPLAPR	880.5	881.5	880.5	881.5
122.0	9.5	9.5	13.9	0.6	77.0	DAOGLVLFDVTGQVR	1616.8	1617.9	1616.9	1617.9
122.0	9.5	9.5	13.9	0.2	37.0	LFSPDFVGDACK	1453.7	1454.7	1453.7	1454.7
145.0	5.1	5.1	15.8	2.0	99.0	DAQQLVLFDTVGQVR	1616.9	1617.9	1616.9	1617.9
145.0	5.1	5.1	15.8	2.0	99.0	VPHAAVQVYDYR	1530.8	1531.8	1530.8	1531.8
145.0	5.1	5.1	15.8	1.0	90.0	ATEEFIR	1019.5	1020.5	1019.5	1020.5
Q14847 LASP1_HUMAN	LIM and SH3 domain protein 1 (LASP-1) (MLN 50) - Homo sapiens (Human)									
72.0	14.1	14.1	37.9	2.0	99.0	GFSVADTPELQR	1417.7	1418.7	1417.7	1418.7
72.0	14.1	14.1	37.9	2.0	99.0	GYEKPKYCNAHYPK	1753.8	1754.8	1753.8	1754.8
72.0	14.1	14.1	37.9	2.0	99.0	KPYCNAHYPK	1276.6	1277.6	1276.6	1277.6
72.0	14.1	14.1	37.9	2.0	99.0	LKQOSSELSQSVR	1442.8	1443.8	1442.8	1443.8
72.0	14.1	14.1	37.9	2.0	99.0	NYKGEEKPKYCNAHYPK	2159.0	2160.0	2159.0	2160.0
72.0	14.1	14.1	37.9	2.0	99.0	OSFTMVAITPENLR	1590.7	1591.8	1590.7	1591.7
72.0	14.1	14.1	37.9	2.0	99.0	TODQISNIKYHEEFK	2007.9	2009.0	2008.0	2009.0
124.0	6.0	6.0	33.7	2.0	99.0	GKGFSSVADTPELQR	1602.8	1603.8	1602.8	1603.8
124.0	6.0	6.0	33.7	2.0	99.0	NYKGEEKPKYCNAHYPK	2159.0	2160.0	2159.0	2160.0
124.0	6.0	6.0	33.7	2.0	99.0	TODQISNIKYHEEFK	2008.0	2009.0	2008.0	2009.0
Q15233 NONO_HUMAN	Non-POU domain-containing octamer-binding protein (NonO protein) (54 kDa nuclear RNA- and DNA-binding protein) (p54(nrb)) (p54nrb) (55 kDa									
78.0	13.4	15.9	33.3	2.0	99.0	FACHSASLTVR	1247.6	1248.6	1247.6	1248.6
78.0	13.4	15.9	33.3	2.0	99.0	FAQPGSFEYEMAR	1694.7	1695.7	1694.7	1695.7
78.0	13.4	15.9	33.3	2.0	99.0	HEHOVMLMR	1179.6	1180.6	1179.6	1180.6
78.0	13.4	15.9	33.3	2.0	99.0	ROQEGFKGTFPDAR	1635.8	1636.8	1635.8	1636.8
78.0	13.4	15.9	33.3	1.3	95.0	FQQAATMEIGAIAGGTPPAFN	2162.0	2163.0	2162.1	2163.1
78.0	13.4	15.9	33.3	1.2	99.0	GIVEFSGKPAAR	1230.7	1231.7	1230.7	1231.7
78.0	13.4	15.9	33.3	1.2	99.0	MEEHLNOEVQKR	1539.8	1540.8	1539.7	1540.8
78.0	13.4	15.9	33.3	0.5	67.0	EQPREAOPGSFEYAMR	2302.0	2303.0	2302.0	2303.1
78.0	13.4	15.9	33.3	0.1	21.0	ALIEMEKOQODVDR	1829.9	1830.9	1829.9	1830.9
232.0	2.6	2.6	21.4	1.4	96.0	MEEHLNOEVQKR	1539.7	1540.8	1539.7	1540.8
232.0	2.6	2.6	21.4	1.2	93.0	HEHOVMLMR	1178.6	1180.6	1178.6	1180.6
Q16181 SEPT7_HUMAN	Septin-7 (CDC10 protein homolog) - Homo sapiens (Human)									
406.0	2.3	2.3	9.8	1.3	95.0	RROFEDEKANWEAQQR	2090.0	2091.0	2090.0	2091.0
406.0	2.3	2.3	9.8	0.6	74.0	OFEDEKANWEAQQR	1777.8	1778.8	1777.8	1778.8
406.0	2.3	2.3	9.8	0.3	48.0	FEDYLNRAESR	1242.6	1243.6	1242.6	1243.6
406.0	2.3	2.3	9.8	0.1	20.0	NLEYGVGFANLPQNVYR	1953.0	1954.0	1953.0	1954.0
206.0	3.5	3.5	10.3	2.0	99.0	OFEDEKANWEAQQR	1777.8	1778.8	1777.8	1778.8
206.0	3.5	3.5	10.3	1.5	97.0	NLEYGVGFANLPQNVYR	1953.0	1954.0	1953.0	1954.0
Q16555 DPYL2_HUMAN	Dihydropyrimidinase-related protein 2 (DRP-2) (Collapsin response mediator protein 2) (CRMP-2) (N2A3) - Homo sapiens (Human)									
286.0	2.0	2.0	9.8	2.0	99.0	THNSSLEYNIFEGMECR	2085.9	2086.9	2085.9	2086.9
336.0	3.5	3.5	5.9	2.0	99.0	THNSSLEYNIFEGMECR	2085.9	2086.9	2085.9	2086.9
336.0	3.5	3.5	5.9	1.5	97.0	VFNLYPR	907.5	908.5	907.5	908.5
Q16658 FSCN1_HUMAN	Fascin (Singed-like protein) (55 kDa actin-bundling protein) (p55) - Homo sapiens (Human)									
383.0	2.5	2.5	11.2	2.0	99.0	YLAQAKDGDVNCTER	1610.7	1611.7	1610.7	1611.7
383.0	2.5	2.5	11.2	0.5	66.0	QIWTLTEOPDDEAGSAVCLR	2240.1	2241.1	2240.1	2241.1
344.0	2.0	2.0	4.7	2.0	99.0	NGACNFIDIEW	1459.6	1460.6	1459.6	1460.6
Q16881 TRXR1_HUMAN	Thioredoxin reductase 1, cytoplasmic precursor (EC 1.8.1.9) (TR) (TR1) - Homo sapiens (Human)									
392.0	2.4	2.4	9.2	2.0	99.0	WGLGCTCVNGGICPK	1616.8	1617.8	1616.8	1617.8
392.0	2.4	2.4	9.2	0.4	58.0	VMLVDFVTPTPLGTR	1644.9	1645.9	1644.9	1645.9
343.0	2.0	2.0	4.6	2.0	99.0	VEETVKHDWDR	1412.7	1413.7	1412.7	1413.7
P62633 CNBP_HUMAN	Cellular nucleic acid-binding protein (CNBP) (Zinc finger protein 9) - Homo sapiens (Human)									
353.0	3.2	3.2	43.5	2.0	99.0	EOCCYNCGKPGHLAR	1848.8	1849.8	1848.8	1849.8
353.0	3.2	3.2	43.5	1.2	94.0	CGESGHLLAKDCDQEADYNCR	2697.0	2698.0	2697.0	2698.0
179.0	2.0	2.0	16.5	2.0	99.0	EOCCYNCGKPGHLAR	1848.8	1849.8	1848.8	1849.8
P19105 MLRM_HUMAN	Myosin regulatory light chain 2, noncrossover (Myosin RLC) - Homo sapiens (Human)									
151.0	8.0	8.0	29.1	2.0	99.0	ELLTMDGRFTDEEVDELYR	2431.1	2432.1	2431.1	2432.1
151.0	8.0	8.0	29.1	2.0	99.0	FTDEEVDELYR	1414.6	1415.6	1414.6	1415.6
151.0	8.0	8.0	29.1	2.0	99.0	GDNFYIEPTR	1259.6	1260.6	1259.6	1260.6
151.0	8.0	8.0	29.1	2.0	99.0	NAQACFDEATGTIOEDYLR	2349.0	2350.0	2349.0	2350.0
146.0	2.1	2.1	17.4	2.0	99.0	GDNFYIEPTR	1259.6	1260.6	1259.6	1260.6
128.0	6.0	6.0	33.9	2.0	99.0	ELLTMDGRFTDEEVDELYR	2431.2	2432.2	2431.1	2432.1
128.0	6.0	6.0	33.9	2.0	99.0	NAQACFDEATGTIOEDYLR	2349.0	2350.0	2349.0	2350.0
128.0	6.0	6.0	33.9	0.7	80.0	KLPFQQR	787.5	788.5	787.5	788.5
112.0	6.9	6.9	37.5	0.1	23.0	STELLIR	830.5	831.5	830.5	831.5
112.0	6.9	6.9	37.5	0.0	99.0	NAQACFDTDLR	1348.7	1349.7	1348.7	1349.7
112.0	6.9	6.9	37.5	0.0	53.0	NAQACFDTDLR	1362.7	1363.7	1362.7	1363.7
112.0	6.9	6.9	37.5	0.0	41.0	KLPFQQR	787.5	788.5	787.5	788.5
139.0	2.1	2.1	19.1	2.0	99.0	NAQACFDTDLR	1			

260.0	2.2	2.2	16.7	0.3	46.0	SPMDTFLLIK	1163.6	1164.6	1163.6	1164.6
092598 HS105_HUMAN			Heat-shock protein 105 kDa (Heat shock 110 kDa protein) (Antigen NY-CO-25) - Homo sapiens (Human)							
290.0	4.0	4.0	6.9	2.0	99.0	GCALQCAILSPAFK	1534.8	1535.8	1534.8	1535.8
290.0	4.0	4.0	6.9	2.0	99.0	NAVEEVYVEFR	1401.6	1402.6	1401.6	1402.6
290.0	4.0	4.0	6.9	0.0	99.0	NAVEEVYVEFR	1417.7	1418.7	1417.7	1418.7
194.0	1.7	1.7	10.7	1.7	98.0	NAVEEVYVEFR	1417.7	1418.7	1417.7	1418.7
194.0	1.7	1.7	10.7	0.0	97.0	NAVEEVYVEFR	1401.6	1402.6	1401.6	1402.6
315.0	2.0	2.0	9.6	2.0	99.0	NAVEEVYVEFR	1417.7	1418.7	1417.7	1418.7
096C23 GALM_HUMAN			Aldose 1-epimerase (EC 5.1.3.2) (Galactose mutarotase) - Homo sapiens (Human)							
148.0	8.0	8.0	19.3	2.0	99.0	FQLOSDLR	1118.6	1119.6	1118.6	1119.6
148.0	8.0	8.0	19.3	2.0	99.0	GFDKLVLWTPR	1217.7	1218.7	1217.7	1218.7
148.0	8.0	8.0	19.3	2.0	99.0	HSGFCLETONWPDAVNOPR	2255.0	2256.0	2255.0	2256.0
148.0	8.0	8.0	19.3	2.0	99.0	OPEFGAVIGR	1106.6	1107.6	1106.6	1107.6
274.0	2.1	2.1	14.0	2.0	99.0	HSGFCLETONWPDAVNOPR	2255.0	2256.0	2255.0	2256.0
096CX2 KCD12_HUMAN			BTB/POZ domain-containing protein KCTD12 (Pfeelin) (Predominantly fetal expressed T1 domain) - Homo sapiens (Human)							
474.0	2.0	2.0	7.4	2.0	99.0	EAEYFELPELVR	1493.7	1494.7	1493.7	1494.7
139.0	5.7	5.7	25.5	2.0	99.0	DLOLVLPDYFFPER	1603.8	1604.8	1603.8	1604.8
139.0	5.7	5.7	25.5	2.0	99.0	MFTQQPOELAR	1475.7	1476.7	1475.7	1476.7
139.0	5.7	5.7	25.5	1.7	98.0	EAEYFELPELVR	1493.7	1494.7	1493.7	1494.7
096EP5 DAZP1_HUMAN			DAZ-associated protein 1 (Deleted in azoospermia-associated protein 1) - Homo sapiens (Human)							
283.0	4.0	4.0	11.3	2.0	99.0	LFVGGLDWSTQETLR	1821.9	1822.9	1821.9	1822.9
283.0	4.0	4.0	11.3	2.0	99.0	SOAPGPGASQWGSR	1512.7	1513.7	1512.7	1513.7
395.0	1.5	1.5	7.6	1.4	96.0	SOAPGPGASQWGSR	1512.7	1513.7	1512.7	1513.7
096U4 ABHEB_HUMAN			Abhydrolase domain-containing protein 14B (EC 3.-.-.-) (CCG1-interacting factor B) - Homo sapiens (Human)							
308.0	4.0	4.0	11.4	2.0	99.0	FSETWTNGLTHR	1674.8	1675.8	1674.8	1675.8
308.0	4.0	4.0	11.4	2.0	99.0	FSVLLNHGIR	1153.7	1154.7	1153.7	1154.7
236.0	2.5	2.5	11.4	2.0	99.0	FSETWTNGLTHR	1674.8	1675.8	1674.8	1675.8
236.0	2.5	2.5	11.4	0.5	66.0	FSVLLNHGIR	1153.7	1154.7	1153.7	1154.7
096KP4 CNDP2_HUMAN			Cytosolic nonspecific dipeptidase (CNDP dipeptidase 2) (Glutamate carboxypeptidase-like protein 1) - Homo sapiens (Human)							
347.0	3.3	3.3	8.4	2.0	99.0	WVAIQVSAPWEKR	1655.9	1656.9	1655.9	1656.9
347.0	3.3	3.3	8.4	1.3	95.0	TGQEIPVNVR	1111.6	1112.6	1111.6	1112.6
253.0	2.2	2.2	7.4	2.0	99.0	TVGFVPEPDTR	1232.6	1233.7	1232.6	1233.6
253.0	2.2	2.2	7.4	0.1	26.0	TGQEIPVNVR	1111.6	1112.6	1111.6	1112.6
099497 PARK7_HUMAN			Protein DJ-1 (Oncogene DJ1) (Parkinson disease protein 7) - Homo sapiens (Human)							
120.0	9.6	9.6	28.6	2.0	99.0	DKMMGGHYTYSENREK	2159.0	2160.0	2158.9	2159.9
120.0	9.6	9.6	28.6	2.0	99.0	GAEMETVIPVDMVR	1674.8	1675.8	1674.8	1675.8
120.0	9.6	9.6	28.6	2.0	99.0	GAEMETVIPVDMVR	1830.9	1831.9	1830.9	1831.9
120.0	9.6	9.6	28.6	2.0	99.0	MMNGGHYTYSENREK	1559.6	1560.6	1559.6	1560.6
266.0	2.1	2.1	20.1	1.4	96.0	AKQVTVAGLAGKDPVQCSR	2026.1	2027.1	2026.1	2027.1
266.0	2.1	2.1	20.1	0.7	80.0	MMNGGHYTYSENREK	1915.8	1916.8	1915.8	1916.8
177.0	2.0	2.0	14.8	2.0	99.0	GAEMETVIPVDMVR	1674.8	1675.8	1674.8	1675.8
098RA2 TXNL5_HUMAN			Thioredoxin-like protein 5 (14 kDa thioredoxin-related protein) (TRP14) (Protein 42-9-2) - Homo sapiens (Human)							
307.0	4.0	4.0	19.5	2.0	99.0	TIAFYFTGSK	1133.6	1134.6	1133.6	1134.6
307.0	4.0	4.0	19.5	2.0	99.0	YEESVSGFEEFHR	1713.8	1714.8	1713.8	1714.8
358.0	2.0	2.0	11.4	2.0	99.0	YEESVSGFEEFHR	1713.8	1714.8	1713.8	1714.8
09H299 SH3L3_HUMAN			SH3 domain-binding glutamic acid-rich-like protein 3 (SH3 domain-binding protein 1) (SH3BP-1) - Homo sapiens (Human)							
213.0	6.0	6.0	31.2	2.0	99.0	IQYOLVDISQNALDEMR	1774.9	1775.9	1774.9	1775.9
213.0	6.0	6.0	31.2	2.0	99.0	IQYOLVDISQNALDEMR	2306.1	2307.1	2306.1	2307.1
213.0	6.0	6.0	31.2	2.0	99.0	VYSTVSGTSR	1055.5	1056.5	1055.5	1056.5
176.0	2.0	2.0	20.4	2.0	99.0	IQYOLVDISQNALDEMR	2306.1	2307.1	2306.1	2307.1
340.0	2.0	2.0	49.5	2.0	99.0	IQYOLVDISQNALDEMR	2306.1	2307.1	2306.1	2307.1
09NUV9 GIMA4_HUMAN			GT-Pase I MAP family member 4 (Immunologically associated protein 4) (Immunity-associated nucleotide 1 protein) (hAN1) - Homo sapiens (Human)							
105.0	10.4	10.4	24.9	2.0	99.0	AAQGMSFNPTPGASYGPR	2244.0	2245.0	2244.0	2245.0
105.0	10.4	10.4	24.9	2.0	99.0	AEEIQQKQTQAMQELHR	2068.0	2069.0	2068.0	2069.0
105.0	10.4	10.4	24.9	2.0	99.0	AQILLGLIQR	1010.6	1011.6	1010.6	1011.6
105.0	10.4	10.4	24.9	2.0	99.0	KLAEEQEAHYAVR	1413.7	1414.7	1413.7	1414.7
105.0	10.4	10.4	24.9	2.0	99.0	LAEQEAHYAVR	1285.6	1286.6	1285.6	1286.6
105.0	10.4	10.4	24.9	0.4	57.0	SFMILIFTR	1126.6	1127.6	1126.6	1127.6
213.0	1.3	1.3	23.1	1.3	95.0	LAQEEQAHYAVR	1285.6	1286.6	1285.6	1286.6
118.0	6.4	6.4	26.1	2.0	99.0	IREEYEEKIR	1363.7	1364.7	1363.7	1364.7
118.0	6.4	6.4	26.1	2.0	99.0	LAQEEQAHYAVR	1285.6	1286.7	1285.6	1286.6
118.0	6.4	6.4	26.1	1.3	95.0	IREEYEEKIRKLEDKVEQEKR	2771.5	2772.5	2771.5	2772.5
118.0	6.4	6.4	26.1	0.6	73.0	KLAEEQEAHYAVR	1413.7	1414.7	1413.7	1414.7
118.0	6.4	6.4	26.1	0.5	71.0	SFMILIFTR	1126.6	1127.6	1126.6	1127.6
09NY33 DPP3_HUMAN			Dipeptidyl-peptidase 3 (EC 3.4.14.4) (Dipeptidyl-peptidase III) (DPP III) (Dipeptidyl aminopeptidase III) (Dipeptidyl arylamidase III) - Homo sapien							
185.0	6.2	6.2	15.7	2.0	99.0	LEGGSDVOLLEYASAAGLIR	2133.0	2134.0	2133.1	2134.1
185.0	6.2	6.2	15.7	2.0	99.0	LFKEVGEKGPKYEV	1928.0	1929.0	1928.0	1929.0
185.0	6.2	6.2	15.7	2.0	99.0	VILGSEAAQOHPEEV	1761.9	1762.9	1761.9	1762.9
170.0	2.0	2.0	6.1	2.0	99.0	LAQDFLDGSNLNSAYNTR	1954.9	1956.0	1954.9	1955.9
171.0	4.0	4.0	11.9	2.0	99.0	LFKEVGEKGPKYEV	1928.0	1929.0	1928.0	1929.0
171.0	4.0	4.0	11.9	2.0	99.0	LYAHLRSR	1021.5	1022.5	1021.5	1022.5
09NY9 TMOD3_HUMAN			Tropomodulin-3 (Ubiquitous tropomodulin) (T-Mod) - Homo sapiens (Human)							
305.0	4.0	4.0	7.1	2.0	99.0	FGYQFTQOQPR	1327.6	1328.6	1327.6	1328.6
305.0	4.0	4.0	7.1	2.0	99.0	SNDPVTAFQAEMLK	1492.7	1493.7	1492.7	1493.7
330.0	2.0	2.0	11.6	2.0	99.0	FGYQFTQOQPR	1327.7	1328.7	1327.6	1328.6
09P258 RCC2_HUMAN			Protein RCC2 (Teloophase disk protein of 60 kDa) (RCC1-like protein TD-60) - Homo sapiens (Human)							
273.0	4.1	4.1	8.2	2.0	99.0	NLGNLNLWGPHR	1290.7	1291.7	1290.7	1291.7
273.0	4.1	4.1	8.2	2.0	99.0	VFSWCFCCGYCR	1231.6	1232.6	1231.6	1232.6
211.0	3.2	3.2	10.5	2.0	99.0	NLGNLNLWGPHR	1290.7	1291.7	1290.7	1291.7
211.0	3.2	3.2	10.5	1.2	94.0	YGLCLAGR	894.4	895.4	894.4	895.4
09UBR2 CATZ_HUMAN			Cathepsin Z precursor (EC 3.4.22.-) (Cathepsin X) (Cathepsin P) - Homo sapiens (Human)							
145.0	8.0	8.0	24.8	2.0	99.0	NOHIPQYCGSCWAHSTSAMD	2647.1	2648.1	2647.1	2648.1
145.0	8.0	8.0	24.8	2.0	99.0	NSWGEWPWER	1216.5	1217.5	1216.5	1217.5
145.0	8.0	8.0	24.8	2.0	99.0	NVDGVNVYASITR	1307.7	1308.7	1307.6	1308.7
99.0	3.7	3.7	11.6	2.0	99.0	YNLALIEHCTFGDPIV	1876.9	1877.9	1876.9	1877.9
99.0	3.7	3.7	11.6	1.7	98.0	YNLALIEHCTFGDPIV	1876.9	1877.9	1876.9	1877.9
113.0	6.8	6.8	38.9	2.0	99.0	NSWGEWPWER	1217.5	1218.5	1217.5	1218.5
113.0	6.8	6.8	38.9	2.0	99.0	NVDGVNVYASITR	1307.6	1308.7	1307.6	1308.7
113.0	6.8	6.8	38.9	0.4	58.0	DLPKSWDWR	1201.6	1202.6	1201.6	1202.6
113.0	6.8	6.8	38.9	0.2	35.0	NOHIPQYCGSCWAHSTSAMD	2647.1	2648.1	2647.1	2648.1
113.0	6.8	6.8	38.9	0.2	32.0	NSWGEWPWERGWL	1728.8	1729.8	1728.8	1729.8
113.0	6.8	6.8	38.9	0.0	99.0	YNLALIEHCTFGDPIV	1216.5	1217.5	1216.5	1217.5
113.0	8.1	8.1	26.4	2.0	99.0	ALVHDEREAAYGELR	1727.9	1728.9	1727.9	1728.9
113.0	8.1	8.1	26.4	2.0	99.0	ALVHDEREAAYGELR	1876.9	1877.9	1876.9	1877.9
95.0	8.1	8.1	26.4	2.0	99.0	IVNPKGEEKPSMY	1490.7	1491.8	1490.7	1491.8
95.0	8.1	8.1	26.4	2.0	99.0	QNLQFAEEFLYR	1685.8	1686.8	1685.8	1686.8
95.0	8.1	8.1	26.4	0.0	99.0	QNLQFAEEFLYR	1668.7	1669.8	1668.8	1669.8
09ULV4 COR1C_HUMAN			Coronin-1C (Coronin-3) (hCRNN4) - Homo sapiens (Human)							
223.0	5.7	6.0	18.1	2.0	99.0	AIFLADGNVFTGFSR	1714.9	1		

174.0	6.5	6.5	18.8	2.0	99.0	FDAMPFTLR	1096.5	1097.5	1096.5	1097.5
174.0	6.5	6.5	18.8	2.0	99.0	HELLOPFNVLYEK	1628.9	1629.9	1628.9	1629.9
174.0	6.5	6.5	18.8	2.0	99.0	LVPKGNONTOVTEAWNK	1926.0	1927.0	1926.0	1927.0
174.0	6.5	6.5	18.8	0.4	61.0	AFFSEVER	983.5	984.5	983.5	984.5
174.0	6.5	6.5	18.8	0.1	23.0	TTIYKRDPSKOYGLK	1797.0	1798.0	1797.0	1798.0
288.0	2.0	2.0	6.3	2.0	99.0	AFFSEVER	983.5	984.5	983.5	984.5
O9Y490 TLN1_HUMAN Talin-1 - Homo sapiens (Human)										
67.0	14.8	14.8	8.8	2.0	99.0	ACKEAAYHPEVAPDVR	1811.9	1812.9	1811.9	1812.9
67.0	14.8	14.8	8.8	2.0	99.0	EAAYHPEVAPDVR	1452.7	1453.7	1452.7	1453.7
67.0	14.8	14.8	8.8	2.0	99.0	IGITNHDEYSLVR	1515.8	1516.8	1515.8	1516.8
67.0	14.8	14.8	8.8	2.0	99.0	LHTTDELNWLDHGR	1719.8	1720.8	1719.8	1720.8
67.0	14.8	14.8	8.8	2.0	99.0	TMOFEPESTMVYDACR	1834.8	1835.8	1834.8	1835.8
67.0	14.8	14.8	8.8	2.0	99.0	VGAIPANALDDGQWSOGLISAAR	2309.2	2310.2	2309.2	2310.2
67.0	14.8	14.8	8.8	2.0	99.0	VVAPTISSPVCOEQLVEAGR	2139.1	2140.1	2139.1	2140.1
67.0	14.8	14.8	8.8	0.7	80.0	AVAEQIPLVQGVGR	1491.9	1492.9	1491.9	1492.9
75.0	9.8	9.8	7.6	2.0	99.0	IGITNHDEYSLVR	1515.8	1516.8	1515.8	1516.8
75.0	9.8	9.8	7.6	2.0	99.0	TMOFEPESTMVYDACR	1834.8	1835.8	1834.8	1835.8
75.0	9.8	9.8	7.6	2.0	99.0	VVAPTISSPVCOEQLVEAGR	2139.1	2140.1	2139.1	2140.1
75.0	9.8	9.8	7.6	1.7	98.0	AVAEQIPLVQGVGR	1491.9	1492.9	1491.9	1492.9
75.0	9.8	9.8	7.6	0.9	87.0	ASAGPQLLVSCK	1454.7	1455.7	1454.8	1455.8
75.0	9.8	9.8	7.6	0.5	65.0	KSTVLQQQYNR	1363.7	1364.7	1363.7	1364.7
75.0	9.8	9.8	7.6	0.4	64.0	EAAYHPEVAPDVR	1452.7	1453.7	1452.7	1453.7
75.0	9.8	9.8	7.6	0.2	32.0	ACKEAAYHPEVAPDVR	1811.9	1812.9	1811.9	1812.9
75.0	9.8	9.8	7.6	0.1	24.0	HKAGFLDLKDFLPK	1702.9	1703.9	1702.9	1703.9
O9Y5S9 RBM8A_HUMAN RNA-binding protein 8A (RNA-binding motif protein 8A) (Ribonucleoprotein RBM8A) (RNA-binding protein Y14) (Binder of OVCA1-1) (BOV-1) - Ho										
485.0	2.0	2.0	18.4	2.0	99.0	MREDYDSVEQDGDEPGPQR	2221.9	2222.9	2221.9	2222.9
328.0	2.0	2.0	27.0	2.0	99.0	MREDYDSVEQDGDEPGPQR	2221.9	2222.9	2221.9	2222.9

Online Table III. Differentially expressed proteins in CFUs compared to EPC cultures

No.	Protein identity	Swissprot Number	Theoretical MW	XC Score	Prob	Coverage (%)	Ratio*
Membrane proteins							
1	HLA class II histocompatibility antigen, DR alpha chain	P01903	28588.7	60.22	8.2E-09	15.7	-3.15
Lysosomal enzymes							
2	Cathepsin B	P07858	37796.8	50.25	5.0E-10	12.7	-5.18
3	Cathepsin H	P09668	37353.1	30.24	1.2E-06	9.0	2.49
4	Cathepsin Z	Q9UBR2	33846.2	50.19	1.8E-06	16.2	-1.62
Secreted proteins							
5	Alpha-2-macroglobulin	P01023	163174.3	40.14	1.4E-06	1.3	-11.26
6	Thymidine phosphorylase	P19971	49924.3	220.40	1.6E-14	36.7	2.62
ER proteins							
7	78 kDa glucose-regulated protein	P11021	72288.5	228.27	1.4E-09	34.3	-1.70
8	78 kDa glucose-regulated protein	P11021	72288.5	248.37	1.2E-12	28.7	-3.01
9	Endoplasmic reticulum protein ERp29	P30040	28975.2	40.18	1.2E-07	14.2	-7.49
10	Endoplasmic reticulum resident protein ERp44	Q9BS26	46941.5	40.18	3.1E-10	10.6	3.08
11	Endoplasmin	P14625	92411.2	190.26	2.0E-08	22.9	-2.60
12	Protein disulfide-isomerase A3	P30101	56746.8	408.33	2.4E-11	58.2	-1.55
13	Protein disulfide-isomerase A3	P30101	56746.8	660.38	7.1E-12	67.9	-1.46
14	Protein disulfide-isomerase A3	P30101	56746.8	428.36	2.8E-09	53.9	-1.53
Aminoacid metabolism							
15	Cytosol aminopeptidase	P28838	56130.9	220.26	2.0E-09	46.6	2.13
16	Cytosol aminopeptidase	P28838	56130.9	320.25	3.2E-10	48.7	2.95
17	Tryptophanyl-tRNA synthetase, cytoplasmic	P23381	53131.7	240.33	1.4E-11	37.6	5.19
18	Tryptophanyl-tRNA synthetase, cytoplasmic	P23381	53131.7	260.30	5.4E-11	43.3	11.15
19	Tryptophanyl-tRNA synthetase, cytoplasmic	P23381	53131.7	180.29	1.6E-11	37.8	2.34

Glucose metabolism							
20 Alpha-enolase	P06733	47139.4	158.27	8.5E-13	34.8	2.13	
21 Alpha-enolase	P06733	47139.4	146.26	4.1E-14	31.1	2.26	
22 Phosphoglycerate mutase 1	P18669	28785.9	90.31	5.1E-12	42.5	1.94	
23 Pyruvate kinase isozymes M1/M2	P14618	57900.2	136.21	6.7E-07	17.3	2.74	
24 Pyruvate kinase isozymes M1/M2	P14618	57900.2	400.32	5.2E-13	51.0	3.85	
25 Triosephosphate isomerase	P60174	26652.7	218.33	8.9E-15	76.7	2.23	
Lipid metabolism							
26 Aldehyde dehydrogenase	P05091	56345.7	360.28	1.3E-11	44.5	-1.63	
Respiratory chain							
27 ATP synthase D chain	O75947	18479.5	140.25	1.0E-06	40.4	-1.61	
28 NADH-ubiquinone oxidoreductase, 75 kDa subunit	P28331	79416.7	138.24	9.8E-10	16.8	-1.93	
29 Ubiquinol-cytochrome-c reductase complex core protein 1	P31930	52612.5	260.38	1.6E-11	51.7	-2.18	
Cytoskeletal proteins							
30 Gelsolin	P06396	85644.3	30.23	3.6E-05	5.1	-6.15	
31 Gelsolin	P06396	85644.3	40.29	7.5E-04	6.5	-6.24	
32 Gelsolin	P06396	85644.3	40.27	9.0E-07	5.1	-4.78	
33 Gelsolin	P06396	85644.3	50.21	3.2E-06	5.1	-2.16	
34 Macrophage-capping protein	P40121	38493.6	90.22	3.1E-08	16.1	6.94	
35 Major vault protein	Q14764	99266.1	210.29	1.2E-14	28.9	1.65	
36 Major vault protein	Q14764	99266.1	306.26	1.3E-13	33.7	1.91	
37 Major vault protein	Q14764	99266.1	190.25	3.6E-08	19.6	1.65	
38 Moesin	P26038	67777.9	150.37	1.7E-09	16.8	-1.49	
Annexins							
39 Annexin A1	P04083	38690.0	210.30	1.3E-09	46.8	-1.27	
Myofilament & Intermediate filament							
40 Vimentin	P08670	53619.2	410.36	3.6E-11	51.9	1.79	

Antioxidans							
41	Glutathione S-transferase P	P09211	23341.0	130.34	5.1E-13	53.8	1.66
Proteasome							
42	Proteasome subunit alpha type 3	P25788	28415.1	140.22	1.1E-06	32.5	1.89
Chaperones							
43	Prohibitin	P35232	29785.9	80.19	2.2E-07	22.4	-2.66
44	T-complex protein 1 subunit beta	P78371	57452.3	270.29	3.1E-10	37.4	1.48
45	Translationally-controlled tumor protein (TCTP)	P13693	19582.6	70.22	5.5E-09	30.2	1.93
Signalling							
46	cAMP-dependent protein kinase type I-alpha regulatory subunit	P10644	42955.0	272.26	1.1E-12	44.1	-4.45
47	Elongation factor 1-delta	P29692	31102.8	120.28	1.5E-07	39.5	-2.10
48	Elongation factor 1-delta	P29692	31102.8	130.23	6.8E-10	39.5	-2.24
49	Growth factor receptor-bound protein 2	P62993	25190.4	108.22	6.2E-07	40.6	2.11
50	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1	P62873	37353.0	60.18	2.2E-05	16.8	-1.45
	Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 2	P62879	37307.1	50.18	8.1E-07	13.8	
Protein mixtures							
51	Aldose reductase	P15121	35830.5	98.25	1.4E-07	22.5	1.99
	Annixin A2	P07355	38579.8	90.25	5.0E-06	24.5	
52	Superoxide dismutase [Mn]	P04179	24706.6	60.25	1.7E-06	21.2	-2.94
	Ferritin heavy chain	P02794	21212.3	50.16	4.7E-06	37.2	
	Adenine phosphoribosyltransferase	P07741	19595.4	48.17	5.1E-08	28.3	
53	Vimentin	P08670	53619.2	140.29	5.2E-07	33.9	-4.69
	ATP synthase subunit beta	P06576	56524.7	118.29	6.5E-08	32.5	

* A negative or positive ratio indicates a decrease or an increase CFUs compared cultured EPCs, respectively. Values are average ratios comparing CFUs vs cultured EPCs, “XC” denotes X-correlation score as calculated by the Sequest algorithm, “Prob” denotes protein probability

Online Table IV. Cytokine profiles from CFUs and cultured EPCs

Cytokine (pg/ml)	CFUs (n=15)	EPCs (n=13)	p-value
IL1beta	3.1 ± 1.1	0.1 ± 0.0	0.017
IL2Ra	159.9 ± 45.1	7.4 ± 1.4	0.004
IL2	0.3 ± 0.1	0.0 ± 0.0	0.013
IL4	2.2 ± 0.7	1.0 ± 0.2	0.113
IL5	2.5 ± 1.1	0.0 ± 0.0	0.046
IL6	616.8 ± 224.3	6.3 ± 4.5	0.017
IL7	0.4 ± 0.1	0.9 ± 0.2	0.022
IL8	76,109.3 ± 6452.1	1,415.8 ± 425.1	0.001
IL9	8.4 ± 1.1	27.3 ± 9.3	0.066
IL10	11.5 ± 6.2	9.4 ± 2.0	0.749
IL12	0.5 ± 0.3	1.3 ± 0.4	0.082
IL13	1.3 ± 0.4	0.3 ± 0.1	0.029
IL15	0.0 ± 0.0	0.0 ± 0.0	0.650
IL17	7.5 ± 4.5	0.0 ± 0.0	0.120
Eotaxin	6.3 ± 2.0	2.6 ± 0.3	0.077
FGF basic	1.9 ± 0.7	2.5 ± 0.4	0.442
GCSF	10.8 ± 3.6	0.5 ± 0.2	0.014
GMCSF	0.4 ± 0.2	0.0 ± 0.0	0.056
INFgamma	29.2 ± 9.4	4.4 ± 0.7	0.020
IP10	21,900.8 ± 7,615.8	1,339.4 ± 793.9	0.018
MCP1	4,564.0 ± 1,222.6	516.8 ± 169.3	0.065
MIP1alpha	110.1 ± 52.9	0.1 ± 0.0	0.056
MIP1beta	469.4 ± 107.5	34.2 ± 7.3	0.001
PDGFbb	1.7 ± 1.1	1161.7 ± 403.4	0.014
RANTES	215.8 ± 51.4	40.5 ± 16.0	0.005
TNF	14.5 ± 6.2	0.3 ± 0.2	0.040
VEGF	152.4 ± 85.9	607.8 ± 91.4	0.001

P-values were derived from unpaired Student's t-test. The conditioned media from 13 EPC cultures and 15 CFUs were analyzed according to the manufacturers' instructions. Depending on the cytokine, the intraplate variability of the assay measured as %CV (percent coefficient of variation) is between 2 and 13%, while the interplate %CV is between 4.3 and 21.5%. The limit of detection (LOD) ranges from 0.2 to 19.3 pg/ml.